index	event	rel	is_certain(1:certain; 0:uncertain)	gene/protein	disease	sentence
1	G. Regulate	C. Cause	1	CIB1	heart failure	In this regard, we have recently identified the calcium-binding protein CIB1 as an important regulator of pathological cardiac hypertrophy and transition to heart failure.
2	I. None	E. Associate	1	NP	heart failure	Increased plasma amino-terminal-cleavage-fragment of NP (NT-proBNP) is an established indicator for heart failure.
3	I. None	F. None	1	CD133	chf	But so far our knowledge about the number of circulating hematopoietic stem/ progenitor cells (CPC) expressing the early hematopoietic marker CD133 and CD34 in CHF is spares and therefore we determined their number and correlated them with New York Heart Association (NYHA) functional class.
4	I. None	E. Associate	1	STC1	heart failure	Because the mammalian counterpart of the fish calcium-regulating hormone stanniocalcin-1 (STC1) is expressed in the heart, we reasoned that STC1 might play a role in the adaptive-maladaptive processes that lead to the heart failure phenotype.
5	F.2 Methylation	E. Associate	1	TIMP4	heart failure	We observed that there are 7 CpG islands in the TIMP4 promoter which get methylated during the progression of heart failure which leads to its epigenetic silencing.
6	I. None	E. Associate	1	TNF	heart failure	Perhaps the most direct evidence for the role of TNF(α) in heart failure will come from the analysis of the phase I study in which a soluble recombinant human TNF receptor: Fc fusion protein was utilized in patients with moderate to severe heart failure Enrollment in that trial was recently completed; the results will soon be available for analysis.
7	F.2 Methylation	F. None	1	estrogen receptor	congestive heart failure	Known epigenetic changes contributing to CVD include hypomethylation in proliferating vascular smooth muscle cells in atherosclerosis, changes in estrogen receptor-α (ER-α) and ER-β methylation in vascular disease, decreased superoxide dismutase 2 expression in pulmonary hypertension (PH), as well as trimethylation of histones H3K4 and H3K9 in congestive heart failure.
8	I. None	E. Associate	1	SIRT1	heart failure	The purpose of this study was to investigate the functional role of SIRT1 in the heart and the potential use of SIRT1 in therapy for heart failure.
9	I. None	F. None	1	salvador homolog 1	congestive heart failure	We identified four functional categories of genes possibly involved in abnormal heart development: cardiac morphogenesis: tenascin, thioredoxin, salvador homolog 1 protein; extracellular matrix (ECM) and valvular tissue biosynthesis; placental-associated plasma protein, collagen, type I, alpha 2, fibulin-1, heparanase, procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha polypeptide II, Jumonji, AT rich interactive domain 1B RBP2-like; normal contractile activity: actinin, alpha 4, fascin homolog 1, actin-bundling protein; and congestive heart failure.
10	D.1 Mutation	E. Associate	1	dystrophin	heart failure	Thousands of different dystrophin mutations have been identified in DMD patients, who suffer from a loss of ambulation followed by respiratory insufficiency, heart failure, and death by the third decade of life.
11	A.2 Under-expression	H. Benefit	1	AQP2	chf	Long-term treatment with obestatin improves water retention in CHF by increasing urinary output through downregulation of AQP2 expression in renal IMCD cells.
12	A.1 Over-expression	E. Associate	1	angiotensin II	chronic cardiac failure	Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure.
13	I. None	F. None	1	CD4	CHRONIC HEART FAILURE	Multiple logistic regression analysis showed that CAD was independently associated with age, gender, body mass index (BMI), systolic blood pressure (SBP), chronic heart failure (CHF) and the CD4/CD8 ratio.
14	I. None	F. None	1	prothrombin	CHRONIC HEART FAILURE	In stable, optimally managed outpatients with chronic heart failure, baseline levels of prothrombin fragment F1+2, D-dimer, and tPA and PAI-1 antigens were determined.
15	I. None	F. None	1	insulin	heart failure	Atrial fibrillation was associated with indicators of a worse prognosis (age > 70 years, female sex, higher Killip class, previous myocardial infarction, treated hypertension, high systolic blood pressure at entry, insulin dependent diabetes, signs or symptoms of heart failure) and with some adverse clinical events (reinfarction, sustained ventricular tachycardia, ventricular fibrillation).
16	D.1 Mutation	C. Cause	1	lamin A/C	heart failure	Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is characterized by cardiac conduction abnormalities and left ventricular systolic dysfunction predisposing to heart failure.
17	I. None	F. None	1	insulin	heart failure	However, the imbalance of GRK2 expression and activity plays an important role in the development of IIR-related diseases, such as hypertension, heart failure, Alzheimer's disease, type 2 diabetes mellitus, insulin resistance, rheumatoid arthritis, thyroid cancer, multiple sclerosis, and liver cancer.
18	A. Expression	F. None	1	ACE2	chf	CHF and exercise training did not change skeletal muscle ACE and ACE2 activity and protein expression.
19	A.2 Under-expression	H. Benefit	1	renin	heart failure	Decreased neurohormonal activity, reflecting both the sympathetic nervous system and the renin-angiotensin system, was found 3 months after an acute myocardial infarction with heart failure treated with beta-receptor antagonists.
20	A.1 Over-expression	E. Associate	1	GRK2	heart failure	Increased cardiac G protein-coupled receptor kinase-2 (GRK2) expression has a pivotal role at inducing heart failure (HF)-related β-adrenergic receptor (βAR) dysfunction.
21	F.1 Phosphorylation	E. Associate	1	MLC2	chf	5-HT(2A)-receptor stimulation, previously studied in acute CHF, induces a positive inotropic response also in chronic CHF, probably mediated by MLC2 phosphorylation.
22	F.1 Phosphorylation	E. Associate	1	c-Jun	chf	Compared to vehicle treated CHF rabbits, Tempol significantly decreased AT1R protein expression (1.6+/-0.29 versus 0.88+/-0.16, P<0.05), phosphorylated Jnk protein (0.4+/-0.05 versus 0.2+/-0.04, P<0.05), cytosolic phosphorylated c-Jun (0.56+/-0.1 versus 0.36+/-0.05, P<0.05), and nuclear phosphorylated c-Jun (0.67+/-0.1 versus 0.3+/-0.08, P<0.01).
23	A. Expression	E. Associate	1	SERCA1	heart failure	We propose that SERCA1 expression is evidence of a natural adaptive response to the impaired Ca2+ handling thought to occur in German shepherd dogs with DCM and heart failure.
24	J. Inhibition	C. Cause	1	STAT3	heart failure	Mutation of Lys-685 inhibits this function of STAT3, providing new information on the role of U-STAT3 in augmenting the development of heart failure.
25	A.1 Over-expression	E. Associate	1	angiotensin II	congestive heart failure	Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
26	I. None	E. Associate	1	BNP	heart failure	We have elucidated a novel miR-30-GALNT1/2 axis whose dysregulation increases the proportion of inactive proBNP secreted by the heart and impairs the compensatory actions of BNP during the progression of heart failure.
27	A. Expression	E. Associate	1	MYOCD	heart failure	Further, perturbations in MYOCD gene expression are associated with an increasing number of diseases including heart failure, cancer, acute vessel disease, and diabetes.
28	H. Other	E. Associate	1	CaM	heart failure	Calmodulin (CaM) is the primary Ca2+ regulatory protein in cardiac cells, thus alterations in calmodulin would greatly influence the contractile response and may play a role in the abnormal calcium handling observed in human heart failure.
29	A.2 Under-expression	E. Associate	1	MCPT1	chf	Our results showed that the left ventricular mass index (LVMI), collagen volume fraction (CVF), and free fatty acid (FFA) concentration of CHF group rats increased when compared with sham control group, while the protein and mRNA expressions of PPARα, MCAD, and MCPT1 decreased in CHF.
30	A. Expression	E. Associate	1	CT-1	chf	This study reports differential regulation of gene expression of CT-1 and BNP in the heart during the progression of CHF, and demonstrates that ventricular CT-1 gene activation precedes ventricular BNP gene activation.
31	A. Expression	E. Associate	1	ACE	chf	These data suggest that the activation of the central RAS in animals with CHF involves an imbalance of ACE and ACE2 in regions of the brain that regulate autonomic function and that EX can reverse this imbalance.
32	A.1 Over-expression	E. Associate	1	PP2A	heart failure	We previously showed decreased cellular coupling and dephosphorylation of the gap junctional protein connexin 43 (Cx43) in left ventricular (LV) myocytes from an arrhythmogenic rabbit model of non-ischaemic heart failure (HF) that was associated with a 2.5-fold increase in the amount of protein phosphatase type 2A (PP2A) co-localized with Cx43.
33	G. Regulate	H. Benefit	1	apelin	heart failure	Our recent study shows that apelin may protect ischemic heart failure via upregulation of sirtuin 3 (Sirt3) and angiogenesis.
34	I. None	G. Marker	1	ANF	heart failure	Plasma BNP measured within 1-4 days of acute myocardial infarction is a powerful independent predictor of left ventricular function, heart failure, or death over the subsequent 14 months, and superior to ANF, N-ANF, cGMP, and plasma catecholamines.
35	L.2 Down-regulation	E. Associate	1	I-1	heart failure	I-1 was found to be down-regulated and hypo-phosphorylated in human and experimental heart failure but hyperactive in human atrial fibrillation, implicating I-1 in the pathogenesis of heart failure and arrhythmias.
36	M.2 Knock in	C. Cause	1	MLP	heart failure	We now report the generation and detailed analysis of the corresponding Mlp(W4R/+) and Mlp(W4R/W4R) knock-in animals, which develop an age- and gene dosage-dependent hypertrophic cardiomyopathy and heart failure phenotype, characterized by almost complete loss of contractile reserve under catecholamine induced stress.
37	A.2 Under-expression	H. Benefit	1	PP1alpha	heart failure	Valsartan improved cardiac function in volume and pressure overload induced heart failure rabbits possibly by upregulating expressions of myocardial SERCA2, PKA and downregulating expression of myocardial PP1alpha.
38	A. Expression	E. Associate	1	NCX1	chf	The protein expression of NCX1 and SERCA2 in the CHF-C and CHF-T groups is significantly different (both P < 0.05).
39	M.1 Knock down	C. Cause	1	MLP	heart failure	MLP (-/-) mice developed dilated cardiomyopathy with hypertrophy and heart failure after birth.
40	A.1 Over-expression	E. Associate	1	angiotensin II	CHRONIC HEART FAILURE	Elevated central angiotensin II (ANG II) plays a critical role in the sympathoexcitation of chronic heart failure (CHF) by stimulating upregulated ANG II type 1 receptors (AT(1)R) in the rostral ventrolateral medulla (RVLM).
41	M.2 Knock in	E. Associate	1	FASN	heart failure	The heart failure-like substrate metabolism was reproduced in a novel transgenic model of myocardium-specific expression of fatty acid synthase (FASN), the major palmitate-synthesizing enzyme.
42	H. Other	A. Treat	1	relaxin 2	ACUTE HEART FAILURE	We used this approach for the replacement of the A-chain intramolecular disulfide bond of human relaxin 2 (H2 relaxin), an insulin-like peptide that has important regulatory roles in cardiovascular and connective tissue homeostasis that has led to successful Phase IIIa clinical trials for the treatment of acute heart failure.
43	H. Other	C. Cause	1	T3	heart failure	These results demonstrate that SERCA2 is an important target of FOG-2 and that increased FOG-2 expression may contribute to a decline in cardiac function in end-stage heart failure by impaired T3 signaling.
44	A. Expression	E. Associate	1	ADM	chf	This study also indicates that cardiac ADM gene expression is differently regulated between atrium and ventricle in CHF.
45	A.1 Over-expression	E. Associate	1	CCK	heart failure	Isoprenaline rapidly stimulated cardiac CCK gene expression in vitro and in vivo, which suggests that the cardiac-specific truncated pro-CCK may have pathophysiological relevance as a new marker of heart failure.
46	H. Other	E. Associate	1	SR	heart failure	Using a model of tachypacing-induced heart failure, we show that there are populations of swollen and collapsed t-ts, patches of SR tangling, and disorder with rearrangement of the mitochondria.
47	G. Regulate	E. Associate	1	ZO-1	congestive heart failure	Our findings suggest that ZO-1, by interacting with Cx43, plays a role in the down-regulation and decreased size of Cx43 gap junctions in congestive heart failure.
48	A. Expression	C. Cause	1	angiotensin II	heart failure	Alterations in the expression or action of these components, which include angiotensin converting enzyme (ACE), angiotensinogen, and angiotensin II type-1 receptors, may contribute to the development of disease, such as hypertension, left ventricular hypertrophy, myocardial infarction, and end-stage heart failure.
49	J. Inhibition	H. Benefit	1	MR	heart failure	Altered expression or inappropriate activation of cardiac MR is directly linked to the development of cardiac fibrosis, and MR blockade is beneficial for the treatment of heart failure.
50	L. Be regulated	E. Associate	1	PTEN	chf	All of these findings show that miR-217 participates in cardiac hypertrophy and cardiac fibrosis processes through regulating PTEN, which suggests a promising therapeutic target for CHF.
51	A. Expression	E. Associate	1	BNP	chf	In CHF, LV-BNP increased further markedly (P<0.01 vs. CTRL, P<0.05 vs. ELVD) while atrial ANP and BNP expression as well as LV ANP expression remained unchanged (all P=n.s.
52	A.1 Over-expression	H. Benefit	1	FGF-4	heart failure	In a blinded placebo-controlled study in a pig model of pacing-induced heart failure, intracoronary delivery of human FGF-4 expressed in an adenovirus vector showed significant improvement in regional cardiac function and a reduction in the size of the heart over a 3-week study period.
53	J. Inhibition	A. Treat	1	ACE	heart failure	Patients with reduced LV function following acute MI who receive ACE inhibitors have a decreased risk of death, a lower probability of developing systematic heart failure, and fewer MI recurrences.
54	A.1 Over-expression	E. Associate	1	TNF-alpha	chf	Low concentrations of LPS induced a stepwise increase in TNF-alpha release from whole blood to concentrations well above those seen in CHF.
55	I. None	B. Target	1	G protein-coupled receptor APJ	heart failure	The G protein-coupled receptor APJ is a promising therapeutic target for heart failure.
56	I. None	A. Treat	1	albumin	Cardiac Insufficiency	[Indications for treatment of chronic cardiac insufficiency with albumin].
57	A.1 Over-expression	C. Cause	1	ACE	chronic cardiac failure	Myocardial fibrosis, associated with increased expression of angiotensin converting enzyme (ACE) and bradykinin (BK) receptor binding at sites of tissue repair, accompanies chronic elevations in circulating angiotensin II (AngII) and/or aldosterone (ALDO) that simulate chronic cardiac failure.
58	J. Inhibition	A. Treat	1	aldosterone synthase	congestive heart failure	Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
59	D.1 Mutation	E. Associate	1	LMNA	heart failure	MNA p.(Arg331Gln) carriers had a significantly better outcome regarding the composite end point (malignant ventricular arrhythmias, end-stage heart failure, or death) compared with carriers of other pathogenic LMNA mutations.
60	G. Regulate	E. Associate	1	GRK2	heart failure	The G protein-coupled receptor kinase-2 (GRK2 or beta-ARK1) regulates beta-adrenergic receptors (beta-ARs) in the heart, and its cardiac expression is elevated in human heart failure (HF).
61	I. None	B. Target	1	OMA1	heart failure	Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.
62	A.2 Under-expression	E. Associate	1	phospholamban	Cardiac Failure	We conclude that this model of pressure overload-induced cardiac failure is associated with (1) diminished LV force development, rates of pressure development, and decay; (2) depressed protein expression of the Ca(2+)-cycling proteins SR Ca(2+)-ATPase and phospholamban; and (3) decreased Vmax and affinity of the SR Ca(2+)-ATPase for Ca2+.
63	I. None	B. Target	1	arginine vasopressin	heart failure	The neurohormone arginine vasopressin (AVP) is a promising target in the treatment of heart failure because AVP promotes congestion and hyponatremia, each of which is associated with poor outcomes.
64	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Recent clinical trials have explored whether angiotensin receptor blockers (ARBs) or aldosterone blockade should be added to standard angiotensin-converting enzyme (ACE) inhibitor/beta blocker treatment in heart failure.
65	G. Regulate	A. Treat	1	STAT3	heart failure	In this review, STAT3 is highlighted as a regulator of angiogenic factors, and activation of STAT-mediated signaling in the cardiac myocyte is proposed as a novel therapeutic strategy for the prevention of heart failure.
66	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure	We sought to improve the use of aspirin and beta-blocker therapy for patients diagnosed with AMI and the use of angiotensin-converting enzyme (ACE) inhibitors for patients with congestive heart failure.
67	J. Inhibition	A. Treat	1	SGLT2	heart failure	The search of the literature revealed many possible cardioprotective mechanisms, because SGLT2 inhibitors (i) increase natriuresis and act as diuretics with unique properties leading to a reduction in preload and myocardial stretch (the diuretic hypothesis); (ii) decrease blood pressure and afterload (the blood pressure lowering hypothesis), (iii) favor the production of ketones, which can act as a 'superfuel' in the cardiac and renal tissue (the 'thrifty substrate' hypothesis), (iv) improve many metabolic variables (the metabolic effects hypothesis), (v) exert many anti-inflammatory effects (the anti-inflammatory effects hypothesis), (vi) can act through the angiotensin II type II receptors in the context of simultaneous renin-angiotensin-aldosterone-system (RAAS) blockade leading to vasodilation and positive inotropic effects (the RAAS hypothesis), (vii) directly decrease the activity of the upregulated in heart failure Na+-H+ exchanger in myocardial cells leading to restoration of mitochondrial calcium handling in cardiomyocytes (the sodium hypothesis).
68	A.2 Under-expression	C. Cause	1	JP2	heart failure	Animal models of cardiac stresses demonstrate that down-regulation of JP2 contributes to T-tubule disorganization, loss of excitation-contraction coupling, and heart failure development.
69	D.1 Mutation	C. Cause	1	SLCO1B1	heart failure	We show that SLCO1B1 LoF mutations significantly increase the risk of incident heart failure, thus implicating the metabolite in the causal pathway of disease.
70	J. Inhibition	A. Treat	1	ACE	heart failure	To compare the effect of the direct renin inhibitor aliskiren on neurohumoral activity in heart failure patients treated with low-dose and high-dose ACE inhibitor.
71	M.1 Knock down	C. Cause	1	BAG3	TAKOTSUBO CARDIOMYOPATHY	BAG3 ablation in mice results in a lethal cardiomyopathy soon after birth and mutations of this gene have been associated with different cardiomyopathies including stress-induced Takotsubo cardiomyopathy (TTC).
72	A.1 Over-expression	E. Associate	1	ANF	congestive heart failure	This atrial natriuretic factor (ANF) is secreted in normal subjects and is increased in patients with congestive heart failure.
73	M.1 Knock down	E. Associate	1	MLP	heart failure	Increased phospholamban phosphorylation limits the force-frequency response in the MLP-/- mouse with heart failure.
74	A.1 Over-expression	E. Associate	1	BNP	congestive heart failure	Expression of the BNP and ANP genes is greatly augmented in patients with congestive heart failure and animal models of ventricular hypertrophy or cardiomyopathy.
75	D.1 Mutation	C. Cause	1	OCTN2	heart failure	In conclusion, cardiomyopathy and heart failure with energy depletion may be induced by pressure overload in heterozygotes for OCTN2 mutations and could be prevented by l-carnitine supplementation.
76	A.1 Over-expression	E. Associate	1	osteoglycin	heart failure	Finally, circulating osteoglycin levels in patients with heart failure were significantly increased in the patients with a previous history of MI compared with those with nonischemic heart failure and correlated with survival, left ventricular volumes, and other markers of fibrosis.
77	I. None	G. Marker	1	ANP	heart failure	As the common diagnostic markers of heart failure, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) primarily reflect increased pressure loading, determination of soluble, heart-derived MMPs and TIMPs in plasma, as well as the determination of the emerging fibrosis marker osteopontin (OPN) might be valuable tools for detecting heart fibrosis.
78	L.1 Up-regulation	E. Associate	1	RGS4	heart failure	Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure.
79	A. Expression	E. Associate	1	MCP-1	congestive heart failure	These findings suggest that dobutamine may modulate monocyte activation, such as chemotaxis and [Ca(2+)](i), as well as MCP-1 production, during therapy for congestive heart failure.
80	D.1 Mutation	C. Cause	1	titin	heart failure	The recent discovery of heterozygous human mutations that truncate full-length titin (TTN, an abundant structural, sensory, and signaling filament in muscle) as a common cause of end-stage dilated cardiomyopathy (DCM) promises new prospects for improving heart failure management.
81	J. Inhibition	A. Treat	1	mineralocorticoid receptor	heart failure	Addition of mineralocorticoid receptor (MR) antagonists to standard therapy for heart failure, kidney disease, metabolic syndrome, and diabetes is increasing steadily in response to clinical trials demonstrating clear benefits.
82	A.2 Under-expression	H. Benefit	1	GRP78	heart failure	By down-regulating GRP78, caspase-12 and CHOP expressions in myocardial cells in rat heart failure after myocardial infarction, atorvastatin treatment decreased the apoptosis of myocardial cells, suggesting the possible mechanism by which atorvastatin functions in protecting against heart failure.
83	L.1 Up-regulation	C. Cause	1	ET	heart failure	Endothelin-1 (ET-1) and its receptor endothelin A receptor (ET[Formula: see text] have been shown to be upregulated in a high glucose environment, which increase the incidence of diabetes-related heart failure.
84	A.1 Over-expression	E. Associate	1	tyrosine hydroxylase	heart failure	Rats with heart failure treated with PVN vehicle or SN50M (inactive peptide for SN50) had increased levels of glutamate, norepinephrine (NE), tyrosine hydroxylase (TH), superoxide, gp91(phox) (a subunit of NAD(P)H oxidase), phosphorylated IKKβ and NF-κB p65 activity, and lower levels of gamma-aminobutyric acid (GABA) and the 67-kDa isoform of glutamate decarboxylase (GAD67) in the PVN compared with those of SHAM rats.
85	J. Inhibition	H. Benefit	1	GRK2	heart failure	Inhibition of GRK2 improved cardiac function and survival and diminished cardiac remodeling in various animal heart failure models.
86	A.2 Under-expression	H. Benefit	1	caspase-3	heart failure	In conclusion, Berberine can inhibit the myocardium cell apoptosis of heart failure after myocardial infarction, and its mechanism may be realized by affecting the ERS in myocardial tissue of heart failure after myocardial infarction and CHOP and caspase-12 apoptotic signaling pathway, upregulating Bcl-2/Bax expression and downregulating caspase-3 expression, thus inhibiting the cardiac remodeling and protecting the cardiac function.
87	J. Inhibition	A. Treat	1	ACE	chf	AII "reactivation" occurred in 15% and failure of aldosterone suppression in 38% of routine CHF patients taking ACE inhibitor treatment.
88	D.1 Mutation	C. Cause	1	DSP	heart failure	This novel homozygous truncating mutation in the isoform-1 specific region of the DSP C-terminus caused Carvajal syndrome comprising severe early-onset heart failure with features of non-compaction cardiomyopathy, woolly hair and an acantholytic form of palmoplantar keratoderma in our patient.
89	A.1 Over-expression	C. Cause	1	RAMP3	heart failure	It was found that the expressions of RAMP1, RAMP2 and RAMP3 mRNAs increased with the worsening of heart function, but the expressions of RAMP1 and RAMP2 mRNA decreased at level IV of heart failure.
90	D.1 Mutation	C. Cause	1	lamin A/C	heart failure	Dilated cardiomyopathy caused by lamin A/C gene (LMNA) mutation is complicated with atrioventricular (AV) conduction disturbances, malignant ventricular arrhythmias, and progressive severe heart failure.
91	A. Expression	E. Associate	1	CD4	chf	We have demonstrated expression of IFN-gamma production of CD4(+) T cells during CHF.
92	D.1 Mutation	C. Cause	1	TTN	heart failure	Human mutations that truncate the massive sarcomere protein titin [TTN-truncating variants (TTNtvs)] are the most common genetic cause for dilated cardiomyopathy (DCM), a major cause of heart failure and premature death.
93	A.2 Under-expression	E. Associate	1	ACE2	heart failure	Decreases in ACE2 expression and activity have been reported in models of hypertension, heart failure, atherosclerosis, diabetic nephropathy and others.
94	L.1 Up-regulation	C. Cause	1	PDE5A	Cardiac Failure	In disorders such as cardiac failure, PDE5A upregulation may contribute to a decline in cGMP and protein kinase G signaling, exacerbating dysfunction.
95	J. Inhibition	A. Treat	1	ACE	chf	This study assessed the effect of angiotension-converting enzyme (ACE) inhibitor therapy on cell volume and cell volume regulation in patients with CHF.
96	A.2 Under-expression	C. Cause	1	HCN4	chf	HCN4 is the dominant subunit in canine sinoatrial node and RA; strong sinus node HCN expression likely contributes to its pacemaker function; downregulation of HCN4 and HCN2 expression contribute to CHF-induced sinus node dysfunction; and upregulation of atrial HCN4 may help to promote atrial arrhythmia formation.
97	L.1 Up-regulation	E. Associate	1	PLB	chf	An activated leptin pathway was associated with downregulation of SERCA2a and upregulation of PLB in mRNA and protein expression in CHF.
98	L.2 Down-regulation	H. Benefit	1	leptin	chf	The multi-ion-channel-blocking and antioxidative effects of CPU86017 downregulate the leptin pathway and ET system, resulting in reversal of the abnormalities of expression of SERCA2a and PLB and cardiac performance in CHF.
99	A.1 Over-expression	E. Associate	1	MCP-1	chf	Northern blot analysis and real-time quantitative polymerase chain reaction demonstrated upregulation of MCP-1 mRNA expression correlating with the severity of CHF (288+/-22, 502+/-62, and 826+/-138 copies/ng total RNA for sham, compensated, and decompensated animals, respectively; n=5, P:<0.05).
100	G. Regulate	E. Associate	1	PPAR	heart failure	This article will review cardiac pathways involved in PPAR activation and their potential regulation of maladaptive pathways involved in heart failure and highlight molecular mechanisms that may contribute to adverse events and raise safety concerns.
101	A.1 Over-expression	E. Associate	1	G protein-coupled receptor kinase 2	heart failure	During heart failure, there is substantial alpha2AR dysregulation in the adrenal gland, triggered by increased expression and activity of G protein-coupled receptor kinase 2 (GRK2).
102	L.1 Up-regulation	E. Associate	1	TNF-alpha	heart failure	Heart failure due to a variety of causes is accompanied by an upregulation of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).
103	I. None	B. Target	1	GRK5	CHRONIC HEART FAILURE	Molecular modulation of the kinases that are ubiquitously expressed in the heart has proven GRK2, and also GRK5, to be promising targets for prevention and reversal of one of the most severe pathologies in man, chronic heart failure (HF).
104	L.1 Up-regulation	E. Associate	1	MMP-9	heart failure	Our findings in RHD may speculate that the long-term reduction of GH and IGF-I as well as the compensating effects of upregulated MMP-9 activity may be partially involved in the long-term pathogenesis from RHD to heart failure.
105	A.1 Over-expression	E. Associate	1	angiotensinogen	chf	The expression of angiotensinogen mRNA in failing hearts of these CHF rats was slightly higher than that of the sham-operated rats.
106	D.1 Mutation	C. Cause	1	MYL2	heart failure	Genetic studies have shown that many slow cardiac myosin regulatory light chain 2 (MYL2) gene mutations can cause hypertrophic cardiomyopathy, which is one of the most common causes of heart failure (HF).
107	A.1 Over-expression	C. Cause	1	ACE	congestive heart failure	In animal models of cardiac disease and in human congestive heart failure, expression of angiotensin-converting enzyme (ACE) is upregulated in the failing heart and has been associated with disease progression leading to cardiac failure and fibrosis.
108	J. Inhibition	A. Treat	1	neprilysin	heart failure	Because of the structural similarity with other inhibitors of neprilysin (NEP), an enzyme explored for the treatment of heart failure, we devised the synthesis of tyrosine betaine and three analogues to be subjected to in vitro NEP inhibition assays and to molecular modeling studies.
109	A.2 Under-expression	E. Associate	1	IRS1	heart failure	L-DKO mice had decreased cardiac IRS1 and IRS2 proteins and exhibited features of heart failure, with impaired cardiac energy metabolism gene expression and activation of p38α mitogen-activated protein kinase (p38).
110	I. None	E. Associate	1	ANP	heart failure	From animal experiments one may conclude that ANP may play an important role in early and moderate heart failure as a counterregulating mechanism of the renin-angiotensin-aldosterone system.
111	D.1 Mutation	E. Associate	1	SCN5A	heart failure	This late component had been shown to increase in several acquired or congenital conditions, including hypoxia, oxidative stress, and heart failure, or due to mutations in SCN5A, which encodes the α-subunit of the sodium channel, as well as in channel-interacting proteins, including multiple β subunits and anchoring proteins.
112	I. None	E. Associate	1	ANP	heart failure	Through a yeast two-hybrid screen of a cDNA library made from tissue of a failing human heart, we have discovered that the precursor of ANP, natriuretic peptide precursor (NPPA), physically interacts with the N-terminus of apoptosis signal-regulating kinase 1 (ASK1), a kinase believed to be involved in the pathogenesis of heart failure.
113	M.1 Knock down	C. Cause	1	CXCR4	heart failure	CXCR4 ablation increased susceptibility to isoproterenol-induced heart failure, by upregulating apoptotic markers and reducing mitochondrial function; cardiac function decreases whereas fibrosis increases.
114	D.1 Mutation	C. Cause	1	LMNA	heart failure	The cardiac disease of LMNA mutated patients is classically defined by conduction system and rhythm disturbances occurring early in the course of the disease, followed by dilated cardiomyopathy and heart failure.
115	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Recognition of the importance of the renin-angiotension-aldosterone system in heart failure, along with an appreciation of the hemodynamic benefits of vasodilator therapy has led to the widespread use of angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure.
116	D.1 Mutation	E. Associate	1	AMPD1	congestive heart failure	AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression.
117	A.1 Over-expression	C. Cause	1	AT2	heart failure	Recently, upregulation of AT2 expression is revealed under certain pathological conditions, such as vascular injury, myocardial infarction, and heart failure.
118	A.2 Under-expression	E. Associate	1	angiotensin II	chf	These data further suggest that the lowering of angiotensin II may contribute to the decrease in sympathetic nerve activity after EX in the CHF state.
119	A.2 Under-expression	E. Associate	1	retinoid X receptor alpha	heart failure	Studies in advanced heart failure show down-regulation of fatty acid oxidation genes, possibly due to decreased expression of the nuclear transcription factors peroxisome proliferator activated receptor alpha (PPARalpha) and retinoid X receptor alpha (RXRalpha).
120	A.1 Over-expression	H. Benefit	1	BNP	heart failure	In heart failure, cardiac expression of both ANP and BNP is augmented with increased circulating levels as a cardiac compensatory mechanism.
121	A.1 Over-expression	E. Associate	1	preproendothelin-1	congestive heart failure (CHF)	Increased myocardial expression of preproendothelin-1 (ppET-1) mRNA has been associated with congestive heart failure (CHF) in rats.
122	A.1 Over-expression	E. Associate	1	TSP-1	heart failure	In aging-associated heart failure, we linked an aging-induced increase in the ECM proteins CTGF and TSP-1 to a decreased expression of their targeting microRNAs 18a, 19a, and 19b, all members of the miR-17-92 cluster.
123	L.1 Up-regulation	E. Associate	1	PLB	chf	In CHF-C group, the left ventricular mRNA of NCX1 and PLB were significantly upregulated in comparing with PS group (RNCX1/beta-Actin: 0.51 +/- 0.12 vs 0.19 +/- 0.06, P < 0.01; RPLB/beta-Actin: 0.26 +/- 0.12 vs 0.20 +/- 0.08, P < 0.05), while SERCA2 mRNA was downregulated (0.48 +/- 0.10 vs 0.80 +/- 0.11, P < 0.01).
124	A.1 Over-expression	E. Associate	1	LIGHT	chf	Real-time quantitative RT-PCR confirmed significantly upregulated gene expression of APRIL, LIGHT, FasL and CD27L in CHF patients and showed in addition significantly enhanced gene expression of TNFalpha and TRAIL.
125	M.1 Knock down	H. Benefit	1	cyclophilin D	heart failure	Double-knockout mice lacking MCL-1 and cyclophilin D, an essential regulator of the mPTP, exhibited delayed progression to heart failure and extended survival.
126	L. Be regulated	C. Cause	1	AT1R	heart failure	Regulation of angiotensin II type 1 receptor (AT1R) has a pathophysiological role in hypertension, atherosclerosis and heart failure.
127	A.1 Over-expression	E. Associate	1	urotensin II	congestive heart failure (CHF)	Expression of urotensin II (UII) is significantly elevated in the hearts of patients with congestive heart failure (CHF).
128	A.1 Over-expression	H. Benefit	1	RAMP1	CHRONIC HEART FAILURE	The above results demonstrated in the atria of heart failure patients an up-regulation of CGRP receptor by an increase of RAMP1 in association with CRLR and an up-regulation of ADM receptor by an increase of RAMP2 expression in association with CRLR, thus suggesting that CGRP and ADM receptors be playing a functional role in compensating the chronic heart failure in human.
129	J. Inhibition	A. Treat	1	ACE	heart failure	Recent studies have found that combined inhibition of ACE and neutral endopeptidase (NEP) may have a greater beneficial effect in the treatment of heart failure than inhibition of ACE alone.
130	A.1 Over-expression	E. Associate	1	osteopontin	heart failure	Increased myocardial expression of osteopontin in patients with advanced heart failure.
131	D.1 Mutation	E. Associate	1	BAG3	heart failure	Four BAG3 genetic variants were identified; these were expressed in 42 of 402 African American individuals (10.4%) with nonischemic heart failure and 9 of 107 African American individuals (8.4%) with ischemic heart failure but were not present in a reference population of European ancestry (P < .001).
132	A.1 Over-expression	E. Associate	1	PLB	heart failure	Accordingly, inactivation of TRα1 receptor prevents reactive hypertrophy after myocardial infarction and results in heart failure with increased phospholamban (PLB) expression and marked activation of p38MAPK.
133	J. Inhibition	A. Treat	1	ACE	heart failure	There is now conclusive evidence that most patients with heart failure due to left ventricular systolic dysfunction should be treated with angiotensin converting enzyme (ACE) inhibitors and beta-blockers.
134	L.1 Up-regulation	C. Cause	1	TLR4	CHRONIC HEART FAILURE	This study suggests that upregulation of monocyte TLR4 may contribute to the pathophysiology of chronic heart failure.
135	G. Regulate	E. Associate	1	renin	congestive heart failure	The renin-angiotensin system is an important regulator of vascular resistance in many patients with hypertension and congestive heart failure.
136	L.1 Up-regulation	C. Cause	1	PYK2	heart failure	Up-regulation and activation of PYK2, a member of the FAK family of protein tyrosine kinases, is involved in the pathogenesis of left ventricular (LV) remodeling and heart failure (HF).
137	G. Regulate	E. Associate	1	eNOS	heart failure	Endothelial nitric oxide synthase (eNOS), VEGF, and hypoxia-inducible factor 1-alpha (HIF-1alpha) are important regulators of endothelial function, which plays a role in the pathophysiology of heart failure (HF).
138	A.1 Over-expression	E. Associate	1	CT-1	congestive heart failure (CHF)	Both cardiotrophin-1 (CT-1) and B-type or brain natriuretic peptide (BNP) are activated by cardiomyocyte stretch, and gene expression of CT-1 and BNP are augmented in the heart in experimental and human congestive heart failure (CHF).
139	F. Epigenetic modification	E. Associate	1	phospholamban	heart failure	The progression of human heart failure is associated with increased protein phosphatase 1 (PP1) activity, which leads to a higher dephosphorylation of cardiac regulatory proteins such as phospholamban.
140	A.2 Under-expression	H. Benefit	1	NLRP3	heart failure	Short-term treatment with colchicine successfully attenuated pro-inflammatory cytokines and NLRP3 inflammasome, and improved cardiac function, heart failure, and survival after MI.
141	J. Inhibition	A. Treat	1	ACE	heart failure	Renal reserve was explored by means of an oral protein load (2 g/kg body weight) under the form of cooked red meat in a group of 9 patients with end-stage heart failure (ESHF), class III of the New York Heart Association receiving loop diuretics and angiotensin-converting enzyme (ACE) inhibitors, and in a group of 18 healthy controls (HC) matched for age, gender, and height under an identical dietary regimen providing 40 cal/kg per day, 1 g/kg body weight of protein per day, Na 120 mmol/day, and K 50 mmol/day.
142	A.1 Over-expression	E. Associate	1	BNP	heart failure	Plasma concentrations of atrial natriuretic peptide (ANP) and its second messenger cGMP as humoral markers of heart failure as well as ventricular expression of ANP- and brain natriuretic peptide (BNP)-mRNA were significantly increased in mice with shunt compared to control mice.
143	I. None	A. Treat	1	EPO	heart failure	It thus appears that Stat-mediated reduction of inflammation and cytokine production and Akt-mediated attenuation of oxidative stress accompany the beneficial effects of late treatment with EPO on chronic post-MI heart failure.
144	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	chronic congestive heart failure	Imidapril hydrochloride (imidapril) is a long-acting, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, which has been used clinically in the treatment of hypertension, chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy.
145	I. None	A. Treat	1	ARB	CHRONIC HEART FAILURE	However, there are few reports concerning AR expression and the protective effect of angiotensin II receptor blockers (ARB) on the lung in chronic heart failure (CHF).
146	M.2 Knock in	C. Cause	0	AR	heart failure	Using a transgenic mouse model of myocardial-targeted overexpression of the wild-type alpha1B adrenergic receptor (AR) (Tg alpha43), we studied the role of the betaAR kinase (betaARK1) in the evolution of myocardial hypertrophy and its transition to heart failure (HF).
147	I. None	E. Associate	1	IK1	chf	Knockdown of endogenous microRNA-26 to mimic CHF effects unregulated IK1.
148	A. Expression	E. Associate	1	GRK6	hypertensive heart failure	In this study, we determined the expression and subcellular distribution of GRK2, GRK3, GRK5, and GRK6 in cardiac myocytes of 2- to 24-month-old spontaneously hypertensive heart failure (SHHF) rats.
149	L. Be regulated	E. Associate	0	endothelin-1	congestive heart failure	We hypothesized that increased pulmonary vascular pressure--one of the characteristics of congestive heart failure--directly regulates pulmonary endothelial vasoconstrictors (endothelin-1, urotensin II) and vasodilators (adrenomedullin, relaxin).
150	G. Regulate	E. Associate	0	COX	heart failure	It is unknown whether microsomal (m) prostaglandin (PG) E synthase (S)-1, a target downstream of COX, regulates myocardial (M) ischemia/reperfusion (I/R) injury, a key determinant of heart failure.
151	I. None	E. Associate	0	GH	CHRONIC HEART FAILURE	This study evaluated the effects of growth hormone (GH) on morphology and myogenic regulatory factors (MRF) gene expression in skeletal muscle of rats with ascending aortic stenosis (AAS) induced chronic heart failure.
152	G. Regulate	E. Associate	0	SCN5A	heart failure	Splicing factor expression profiles during human heart failure and a specific splicing pathway for SCN5A regulation were explored in this study.
153	A. Expression	E. Associate	1	Bcl-2	heart failure	Changes in the expression of Bcl-2 and Bax and their transcriptional regulator, p53, were determined by Western blot analysis in myocytes isolated from dogs affected by pacing-induced heart failure.
154	A. Expression	E. Associate	1	STIM1	heart failure	To determine the mechanistic role of STIM1 in cardiac hypertrophy and during the transition to heart failure, we manipulated STIM1 expression in mice cardiomyocytes by using in vivo gene delivery of specific short hairpin RNAs.
155	D.5 Polymorphism	E. Associate	1	ADRB1	systolic heart failure	Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.
156	I. None	E. Associate	0	renin	congestive heart failure	In this study, we investigated the role of the renin-angiotensin system in expression of the endothelin system in atrial myocardium of patients with congestive heart failure.
157	A. Expression	E. Associate	0	IL6	heart failure	The study objective was to assess the cardiac expression of interleukin-6 (IL6) and its receptor (IL6R) in advanced heart failure.
158	A. Expression	E. Associate	0	aquaporin-2	congestive heart failure (CHF)	This study investigated the effect of fosinopril (Fos), valsartan (Val), and combination of both drugs (Fos + Val) on the cardiac and renal expression of aquaporin-1 (AQP1) and aquaporin-2 (AQP2) in congestive heart failure (CHF).
159	A. Expression	E. Associate	0	HDAC9	CHRONIC HEART FAILURE	Thus, we aim to investigate the expression of HDAC 9 in patients with chronic heart failure (CHF) and the relationship among HDAC9, Tregs and CHF.
160	A. Expression	E. Associate	1	CAT-1	Acute Congestive Heart Failure	The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure.
161	A. Expression	E. Associate	0	BK	heart failure	We sought to study the expression of bradykinin type-2 receptors (BK-2Rs) in patients with heart failure (HF).
162	D.1 Mutation	E. Associate	0	LMNA	heart failure	Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening.
163	I. None	E. Associate	0	CNP	heart failure	The actions of single doses (100 ng x kg(-1) x min(-1) iv over 30 min) of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) were studied in conscious normal dogs and in dogs with pacing-induced heart failure.
164	A. Expression	E. Associate	0	TNF-alpha	CHRONIC HEART FAILURE	BACKGROUND This study investigated the expression of the BCL2 and BAX mRNA, inflammatory cytokines, interleukin-1ß (IL-1ß), IL-6, and tumor necrosis factor-alpha (TNF-alpha), and cardiac function in patients with chronic heart failure (CHF).
165	G. Regulate	E. Associate	0	SLN	heart failure	Although defects in SERCA activity are known to cause heart failure, the regulatory mechanisms imposed by PLN and SLN could have clinical implications for both heart and skeletal muscle diseases.
166	A.1 Over-expression	E. Associate	0	NOS3	heart failure	Some apparently contrasting findings may have arisen from the use of non-isoform-specific inhibitors of NO synthase isoforms (NOS) as compared to the use of mouse models genetically deficient or overexpressing the NOS thought to be responsible for the increase in NO production in heart failure (mainly NOS2 and NOS3).
167	A.1 Over-expression	E. Associate	0	myocardin	heart failure	A possible dual consequence of increased myocardin and decreased HOP expression levels on serum response factor-dependent cardiac-specific expression in the normal heart and at heart failure is discussed.
168	F.2 Methylation	E. Associate	0	LY75	heart failure	We detected methylation differences in pathways related to heart disease, but also in genes with yet unknown function in DCM or heart failure, namely Lymphocyte antigen 75 (LY75), Tyrosine kinase-type cell surface receptor HER3 (ERBB3), Homeobox B13 (HOXB13) and Adenosine receptor A2A (ADORA2A).
169	I. None	E. Associate	0	angiotensin II	congestive heart failure	The aim of the study was to investigate a possible relationship between plasma renin activity, angiotensin II, serum levels of angiotensin-converting enzyme, aldosterone and markers of immune activation in congestive heart failure (CHF).
170	A. Expression	E. Associate	0	TBP	heart failure	We assessed the expression of 16 reference genes (ACTB, B2M, GAPDH, GUSB, HMBS, HPRT1, IPO8, PGK1, POLR2A, PPIA, RPLP0, TBP, TFRC, UBC, YWHAZ, 18S) in tissues from: right and left ventricles from healthy controls and heart failure (HF) patients; right-atrial tissue from patients in sinus rhythm with (SRd) or without (SRnd) atrial dilatation, patients with paroxysmal (pAF) or chronic (cAF) atrial fibrillation or with HF; and left-atrial tissue from patients in SR or cAF.
171	I. None	E. Associate	0	TNF	heart failure	To investigate the role of leptin and regulators of apoptosis in cardiac cachexia we compared leptin concentrations and their relation to the TNF system, interleukin 1-beta (IL-1b), and soluble Fas in patients with heart failure with and without cachexia.
172	J. Inhibition	E. Associate	0	GRK2	heart failure	We tested the effects of cardiac-targeted GRK2 inhibition in vivo exclusively on β2AR signaling under normal conditions and in heart failure (HF).
173	D.1 Mutation	E. Associate	0	HFE	Cardiac Failure	The clinical, histological, and genetic findings were examined in a series of seven adult patients with marked iron accumulation in their liver explants and cardiac failure despite the absence of HFE mutations.
174	A. Expression	E. Associate	0	BMP9	heart failure	We examined BMP9 expression and signaling in human cardiac fibroblasts and human subjects with heart failure.
175	I. None	E. Associate	0	interleukin-19	heart failure	To investigate the role of interleukin-19 (IL-19) in a murine model of female-dominant heart failure (HF).
176	I. None	E. Associate	0	fractalkine	CHRONIC HEART FAILURE	Accordingly, the purpose of our study was - to evaluate the role of clusterin and fractalkine in progression of chronic heart failure in patients with postinfarction cardiosclerosis, type 2 diabetes and obesity.
177	D.1 Mutation	C. Cause	0	LMNA	heart failure	Our in vivo and in vitro results question the relationship of causality between LMNA mutations and the development of heart failure in some DCM patients and therefore, the reliability of genetic counselling.
178	I. None	E. Associate	0	tumor necrosis factor-alpha	heart failure	Using a post hoc analysis the serum biomarkers tumor necrosis factor-alpha, high-sensitivity C-reactive protein interleukin 6 and pentraxin 3 (PTX3) and clinical, demographic, echocardiographic-Doppler and clinical outcomes data were analyzed in HFpEF patients enrolled in NHLBI Heart Failure Research Network clinical trials which enrolled patients with either AD-HFpEF or S-HFpEF.
179	G. Regulate	E. Associate	1	apelin	heart failure	Modulation of the apelin/APJ system in heart failure and atherosclerosis in man.
180	A. Expression	A. Treat	0	arginine vasopressin	heart failure	Objective To investigate the association between arginine vasopressin (AVP) levels and loop diuretic (LD) therapy in patients with heart failure and to determine if AVP levels are a prognostic indicator of treatment failure.
181	A. Expression	E. Associate	0	adiponectin	chf	Expression of adiponectin and adiponectin receptors (ADIPOR1 and ADIPOR2) was studied by qPCR and immunohistochemistry in myocardial tissues of patients with end-stage CHF and control subjects.
182	A.1 Over-expression	E. Associate	1	NQO1	chf	Furthermore, CDDO-Me reduced NF-kB binding and increased Nrf2 binding to the CREB-Binding Protein (CBP), respectively, which may contribute to the selective increase of Nrf2 downstream targets, including NQO1, HO-1, Catalase, and GCLC, and the attenuation of myocardial inflammation in CHF rats.
183	F.1 Phosphorylation	E. Associate	1	phospholamban	heart failure	We further revealed that C33(S) significantly elevated intracellular cGMP levels, phosphorylation of phospholamban (PLB) and expression of SERCA2a in PE-treated NRCMs in vitro and in ISO-induced heart failure model in vivo.
184	L. Be regulated	E. Associate	1	phospholamban	ACUTE DIASTOLIC HEART FAILURE	In a time-course study of LT toxicity, echocardiography revealed acute diastolic heart failure accompanied by pulmonary regurgitation and left atrial dilation in adult Sprague-Dawley rats at time points corresponding to dysregulated JNK, phospholamban (PLB) and protein phosphatase 2A (PP2A) myocardial signaling.
185	A. Expression	E. Associate	1	CAA	heart failure	The increase in Ca(2+)-uptake and CAA expression suggests, at the cellular level, a compensatory response to LV hypertrophy, while the decline at later stages indicates the transition to heart failure.
186	I. None	A. Treat	1	ANP	heart failure	Although the potential for its therapeutic application in the treatment of hypertension and heart failure has been evaluated in several experimental and clinical investigations, no pharmacological approach directly targeted at modulation of ANP levels has ever reached the stage of being incorporated into clinical practice.
187	G. Regulate	E. Associate	1	AVP	chf	Thus, non-osmotic release of AVP in CHF upregulates AQP2 water channels, enhances water reabsorption and causes hyponatremia.
188	L. Be regulated	E. Associate	1	HO-1	Cardiac Failure	Our study demonstrates that the cardioprotective effect of Adeno-Trx-1 gene therapy in SHR is Trx-1/HO-1/Bcl-2 mediated and may represent future target to develop therapy against hypertension associated cardiac failure.
189	H. Other	B. Target	1	GLP-1	heart failure	Our findings indicate that exendin-4 protects against post-MI remodelling via preferential actions on inflammation and the extracellular matrix independently of its established actions on glycaemic control, thereby suggesting that selective targeting of GLP-1 signalling may be required to realise its clear therapeutic potential for post-MI heart failure.
190	D.1 Mutation	B. Target	1	CHIP	chf	Future studies will have to validate our findings in larger cohorts and address whether targeting specific inflammatory pathways may be valuable for precision medicine in patients with CHF carrying specific mutations encoding for CHIP.
191	G. Regulate	E. Associate	1	ANP	heart failure	The mechanisms responsible for this alteration are not clear but might involve mechanisms other than down-regulation of the ANP receptors because the increases in venous plasma cyclic GMP caused by intra-arterial ANP were comparable between patients with heart failure and normal subjects.
192	I. None	E. Associate	1	substance P	heart failure	ACE inhibitors, have been discussed in relation to the increased heart failure risk, as well as interactions with peptides regulating cardiovascular functions that are also split by DPP-4 enzymes such as BNP, substance P, and NPY.
193	I. None	E. Associate	1	ANP	heart failure	In the heart failure group, it was found that there was no significant difference in the plasma NT-proBNP and ANP between the deaths and surviving patients.
194	I. None	A. Treat	1	CNP	heart failure	Thus, CU-NP represents a novel fusion peptide of CNP and urodilatin that has the potential to be developed into a therapeutic agent to treat cardiac hypertrophy and heart failure.
195	H. Other	E. Associate	1	YY1	heart failure	The Ku protein complex interacts with YY1, is up-regulated in human heart failure, and represses alpha myosin heavy-chain gene expression.
196	L. Be regulated	E. Associate	1	LGMD2I	Cardiac Failure	LGMD2I due to FKRP mutations appears to be a relatively common cause of LGMD, with respiratory and cardiac failure as prominent complications.
197	J. Inhibition	E. Associate	1	angiotensin II	heart failure	Overexpressing superoxide dismutase 1 (SOD1; also called Cu/ZnSOD), an intracellular superoxide (O(2)(*-))-scavenging enzyme, in central neurons inhibits angiotensin II (AngII) intraneuronal signaling and normalizes cardiovascular dysfunction in diseases associated with enhanced AngII signaling in the brain, including hypertension and heart failure.
198	G. Regulate	E. Associate	1	CSK	heart failure	To further elucidate the role of CSK in heart failure, we studied the expression of its downstream target, Src, and found that Src expression and phosphorylation were markedly upregulated in failing ventricles.
199	H. Other	H. Benefit	1	JP-2	heart failure	Treatment of mice with a calpain inhibitor prevented Gαq-dependent JP-2 cleavage, T-tubule disruption, and the development of heart failure.
200	F. Epigenetic modification	E. Associate	1	LONP1	heart failure	Oxidative post-translational modifications develop LONP1 dysfunction in pressure overload heart failure.
201	J. Inhibition	A. Treat	1	SR Ca(2+)-ATPase 2	heart failure	Phospholamban (PLB) inhibits SR Ca(2+)-ATPase 2 (SERCA2) Ca(2+) uptake and is a potential therapeutic target in the context of heart failure.
202	D.1 Mutation	E. Associate	1	RyR	heart failure	In heart failure, the interaction between the N-terminal and central domains of the ryanodine receptor (RyR), the domains where many mutations have been found in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), is defective, as shown in our recent report.
203	H. Other	E. Associate	1	FXR	congestive heart failure	Thus, modulating DDAH1 activity through FXR receptor agonists such as UDCA could be a therapeutic target for treating reduced nitric oxide bioavailability in congestive heart failure and other cardiovascular diseases.
204	L. Be regulated	C. Cause	1	SERCA2	heart failure	These results demonstrate that SERCA2 is an important target of FOG-2 and that increased FOG-2 expression may contribute to a decline in cardiac function in end-stage heart failure by impaired T3 signaling.
205	A. Expression	E. Associate	1	adiponectin	heart failure	We examined changes in heart failure caused by myocarditis in mice by candesartan based on induction of cardiac adiponectin expression.
206	J. Inhibition	H. Benefit	1	TNF-alpha	chf	PBMC from CHF patients show an upregulation of A(2A)R-mediated inhibition of TNF-alpha, which may represents a mechanism of protection against inappropriate cytokine production.
207	D.1 Mutation	C. Cause	1	dystrophin	heart failure	Coupled with previous data showing that dystrophin mutations also cause dilated cardiomyopathy, these results raise the possibility that defective transmission of force in cardiac myocytes is a mechanism underlying heart failure.
208	D.1 Mutation	C. Cause	1	BAG3	heart failure	DCM caused by mutations in BAG3 is characterized by high penetrance in carriers >40 years of age and a high risk of progressive heart failure.
209	F.1 Phosphorylation	C. Cause	1	cTnI	heart failure	These results imply that PKC-mediated phosphorylation of cTnI plays a dominant role in depressing contractility, and, thus, increased PKC isozyme activity may contribute to maladaptive behavior exhibited during the progression to heart failure.
210	D.1 Mutation	C. Cause	1	MYBPC3	heart failure	Although females with MYBPC3 mutations showed later onset of the disease, female patients were more symptomatic at diagnosis and had more frequent heart failure events once they had developed hypertrophy.
211	D.1 Mutation	C. Cause	1	desmoplakin	heart failure	Mutations in desmoplakin can result in devastating skin blistering diseases and arrhythmogenic right ventricular cardiomyopathy, a heart muscle disorder associated with ventricular arrhythmias, heart failure, and sudden death.
212	D.1 Mutation	C. Cause	1	ACTC	heart failure	We propose that the ACTC E99K mutation causes higher myofibrillar Ca(2+) sensitivity that is responsible for the sudden cardiac death, apical hypertrophy, and subsequent development of heart failure in humans and mice.
213	J. Inhibition	H. Benefit	1	ACE	heart failure	It is 10 years since the CONSENSUS I study showed that ACE inhibitors improved mortality in heart failure.
214	G. Regulate	C. Cause	1	JPH2	heart failure	This demonstrates two novel and independent cellular mechanisms by which JPH2 regulates RyR2-mediated SR Ca(2+) leak and heart failure development.
215	J. Inhibition	H. Benefit	1	ACE	heart failure	To review the effects of angiotensin-converting enzyme (ACE) inhibitors on renal pathophysiology and the compensatory mechanisms involved in heart failure.
216	J. Inhibition	A. Treat	1	angiotensin I converting enzyme	congestive heart failure	Several intervention studies with angiotensin I converting enzyme (ACE) inhibitors have demonstrated a remarkable improvement in the treatment of patients with primary hypertension and congestive heart failure.
217	I. None	H. Benefit	1	hepatocyte growth factor	heart failure	Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty.
218	J. Inhibition	A. Treat	1	ACE	chf	Our data suggest that early administration of ACE inhibitors may be beneficial in patients with mild CHF and sinus rhythm, although the magnitude of improvement was less substantial than that reported for patients with more severe CHF.
219	J. Inhibition	A. Treat	1	ACE	heart failure	Nevertheless, there are convincing data for prevention of myocardial infarction with ACE inhibitors in patients with heart failure, including those with heart failure after myocardial infarction, as well as supportive evidence from studies in patients with diabetes mellitus and concomitant hypertension.
220	J. Inhibition	A. Treat	1	ACE	heart failure	Long-term reductions in MI, stroke, cardiac arrest, and heart failure, as well as improvements in mortality, were observed in this population after treatment with ACE inhibitors.
221	I. None	F. None	1	angiotensin II	chronic congestive heart failure	Neither the infusion of angiotensin II nor the acute administration of enalaprilat significantly alters the activity of the sympathetic nervous system as reflected by plasma norepinephrine or systemic venous norepinephrine spillover in patients with chronic congestive heart failure.
222	L.1 Up-regulation	H. Benefit	1	bradykinin	Decompensated heart failure	Acutely decompensated heart failure (ADHF) represents an episodic failure of cardiorenal homeostasis that may resolve with upregulation of natriuretic peptides, bradykinin, and ce+L23rtain prostacyclins.
223	J. Inhibition	A. Treat	1	PDE5	rvf	Although long-term outcome studies are currently lacking, chronic PDE5 inhibition should be considered in carefully selected LVSD patients who manifest persistent significant elevation of pulmonary hypertension or PVR or uncontrolled RVF after aggressive management with all standard current evidence-based LVSD therapies (neurohormonal antagonists, diuretics and cardiac resynchronization in appropriate candidates).
224	A. Expression	E. Associate	1	MAFbx	heart failure	Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.
225	I. None	B. Target	1	ST2	heart failure	IL-33/ST2 not only represents a promising cardiovascular biomarker but also a novel mechanism of intramyocardial fibroblast-cardiomyocyte communication that may prove to be a therapeutic target for the prevention of heart failure.
226	F.1 Phosphorylation	H. Benefit	1	eNOS	chf	Thus the complete restoration of endothelium-dependent coronary vascular relaxation during cardiac recovery from CHF was mediated by 1) a restoration of phosphorylated eNOS for partial recovery of the NO production and 2) an increase in cGMP/cGMP-dependent protein kinase-I pathway signaling activity for the enhancement of coronary vascular smooth muscle relaxation in response to NO.
227	A.1 Over-expression	E. Associate	1	GCLC	chf	Furthermore, CDDO-Me reduced NF-kB binding and increased Nrf2 binding to the CREB-Binding Protein (CBP), respectively, which may contribute to the selective increase of Nrf2 downstream targets, including NQO1, HO-1, Catalase, and GCLC, and the attenuation of myocardial inflammation in CHF rats.
228	L.2 Down-regulation	E. Associate	1	KLF2	chf	In conclusion, down-regulation of KLF2 in the carotid body increases CBC sensitivity, oscillatory breathing, RSNA and arrhythmia incidence during CHF.
229	F.2 Methylation	E. Associate	1	ASB1	heart failure	ASB1 differential methylation in ischaemic cardiomyopathy: relationship with left ventricular performance in end-stage heart failure patients.
230	J. Inhibition	A. Treat	1	ACE	heart failure	RAAS-blocking agents like angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers, have long been key components in the treatment of essential hypertension, heart failure, diabetic nephropathy, and chronic kidney disease, showing benefits well beyond blood pressure reduction.
231	J. Inhibition	C. Cause	1	PLN	heart failure	Correspondingly, the depressed contractility in experimental and human heart failure is partially attributed to increased inhibition by PLN due to: (a) increases in PLN/SERCA2; and (b) decreases in PLN phosphorylation.
232	D.1 Mutation	E. Associate	1	LMNA	heart failure	The novel LMNA nonsense mutation c.544C>T causes a severe arrhythmogenic phenotype manifesting with high incidence of SCD in most patients; and in one sub-family, a distinct phenotype with fast progressing heart failure, indicating the need for early consideration of ICD-implantation and listing for heart-transplantation.
233	A.2 Under-expression	E. Associate	1	follistatin	heart failure	Reduced myogenin and follistatin expression seems to participate in muscle atrophy while increased MRF4 protein levels can modulate myosin heavy chain isoform shift in skeletal muscle of spontaneously hypertensive rats with heart failure.
234	I. None	E. Associate	1	copeptin	ACUTE HEART FAILURE	Median copeptin value at admission was 42 (0-905) pmol/L in acute heart failure patients and 20 (0-887) pmol/L in no acute heart failure, respectively (p<0.001).
235	L.2 Down-regulation	E. Associate	1	CYP2E1	heart failure	Knockdown or downregulation of CYP2E1 might be a therapeutic strategy to control the development of DCM after mutations of cTnT(R141W) or other factors, because DCM is the third most common cause of heart failure and the most frequent cause of heart transplantation.
236	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure (CHF)	Randomized trials have shown that angiotensin-converting enzyme (ACE) inhibitors reduce mortality and morbidity, and improve symptoms and exercise tolerance in selected patients with congestive heart failure (CHF).
237	J. Inhibition	A. Treat	1	ACE	congestive heart failure	Angiotensin-convertng enzyme (ACE) inhibitors are well recognized for their benefits in treating hypertension and congestive heart failure and preventing postmyocardial infarction heart failure or left ventricular (LV) dysfunction.
238	J. Inhibition	A. Treat	1	ACE	Decompensated heart failure	The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated.
239	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	chf	We focused on the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for secondary prevention of CHF.
240	J. Inhibition	A. Treat	1	ACE	HEART FAILURE WITH PRESERVED EJECTION FRACTION	The treatment of heart failure with preserved ejection fraction lacks clear evidence of mortality reduction, diuretics are recommended to remove symptoms, ACE inhibitors or sartans and beta-blockers to improve the prognosis.
241	J. Inhibition	E. Associate	1	HMG-CoA reductase	heart failure	Although HMG-CoA reductase inhibitors (statins) prevent important causative factors for heart failure, myocardial damage and ischemia, the benefits of statins and low-density lipoprotein (LDL) lowering in heart failure patients have been questioned.
242	I. None	E. Associate	1	titin	heart failure	We will emphasize and thoroughly discuss two splicing targets including titin and CaMKII which are known to play a vital role in dilated cardiomyopathy and heart failure.
243	A.1 Over-expression	E. Associate	1	CTGF	heart failure	This is the first report of increased CTGF expression in myocardium of diabetic rodents suggesting that cardiac injury associated with PKCbeta2 activation, diabetes, or heart failure is marked by increased CTGF expression.
244	D.1 Mutation	E. Associate	1	LMNA	heart failure	They further provide proof of principle for ERK inhibition as a therapeutic option to prevent or delay heart failure in humans with Emery-Dreifuss muscular dystrophy and related disorders caused by mutations in LMNA.
245	L.2 Down-regulation	H. Benefit	1	sphingosine-1-phosphate receptor 1	heart failure	β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy.
246	D.1 Mutation	C. Cause	1	titin	heart failure	Human mutations that truncate the massive sarcomere protein titin [TTN-truncating variants (TTNtvs)] are the most common genetic cause for dilated cardiomyopathy (DCM), a major cause of heart failure and premature death.
247	J. Inhibition	E. Associate	1	ACE	congestive heart failure	Fifth, at least some portion of the cardiovascular effects of ACE inhibitors is influenced by the contributions of other systems whose physiologic effects may be of importance in some patients with congestive heart failure.
248	I. None	F. None	1	CPK	heart failure	Cardiovascular manifestations can be considered common and have been reported in France, India, Sri Lanka, Malaysia, Colombia, Venezuela and USA, including mainly, but no limited to: hypotension, shock and circulatory collapse, Raynaud phenomenon, arrhythmias, murmurs, myocarditis, dilated cardiomyopathy, congestive insufficiency, heart failure and altered function profile (Troponins, CPK).
249	G. Regulate	C. Cause	1	p8	heart failure	These findings suggest a role for p8 in regulating in vivo key signaling pathways involved in the pathogenesis of heart failure.
250	I. None	F. None	1	GAPDH	chf	ACE protein and mRNA expression in the cerebellum, medulla, hypothalamus, PVN, NTS, and RVLM were significantly upregulated in CHF rabbits (ratio of ACE to GAPDH: 0.3 +/- 0.03 to 0.8 +/- 0.10 in the RVLM, P < 0.05).
251	D.1 Mutation	E. Associate	1	cTnT	heart failure	GSK-3β(+/-) KO prevented the slow and rapid deterioration in left ventricular systolic function accompanying heart failure (HF) in DCM mice with heterozygous and homozygous ΔK210 cTnT KI mutations, respectively.
252	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	chf	Treatment of this asymptomatic phase with angiotensin-converting enzyme inhibitors can delay the progression to CHF and ameliorate its substantial morbidity and mortality.
253	A. Expression	F. None	1	PARP	heart failure	The protein expressions of fibrotic (Smad3, TGF-β), apoptotic (BAX, cleaved caspase 3, PARP), DNA damage (γ-H2AX), oxidative stress (oxidized protein), mitochondrial damage (cytosolic cytochrome-C), heart failure (brain natriuretic peptide), and hypertrophic (β-MHC) biomarkers of the LV myocardium showed an opposite pattern to the LVEF among the three groups.
254	I. None	A. Treat	1	ANP	Acute Congestive Heart Failure	Atrial natriuretic peptide (ANP) exerts beneficial pharmacological effects in the treatment of various cardiovascular disorders, such as acute congestive heart failure (ADHF).
255	A. Expression	E. Associate	1	nNOS	chf	Taken together, our data highlight the importance of altered expression and subsequent interaction of nNOS and CAPON within the PVN, leading to increased sympathoexcitation in CHF.
256	A. Expression	F. None	1	BAX	heart failure	The protein expressions of fibrotic (Smad3, TGF-β), apoptotic (BAX, cleaved caspase 3, PARP), DNA damage (γ-H2AX), oxidative stress (oxidized protein), mitochondrial damage (cytosolic cytochrome-C), heart failure (brain natriuretic peptide), and hypertrophic (β-MHC) biomarkers of the LV myocardium showed an opposite pattern to the LVEF among the three groups.
257	J. Inhibition	H. Benefit	1	angiotensin-converting enzyme	heart failure	Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression.
258	J. Inhibition	E. Associate	1	angiotensin-converting enzyme	CHRONIC HEART FAILURE	We sought to investigate the effects of mibefradil on survival, hemodynamic variables and cardiac remodeling in a rat model of chronic heart failure (HF) and to compare these effects with those of the angiotensin-converting enzyme (ACE) inhibitor cilazapril.
259	I. None	G. Marker	1	interleukin 18	heart failure	Urinary kidney injury molecule 1 (KIM-1) and interleukin 18 (IL-18) as risk markers for heart failure in older adults: the Health, Aging, and Body Composition (Health ABC) Study.
260	J. Inhibition	A. Treat	1	ACE	heart failure	Recent concepts about post-infarction left ventricular remodeling, which is the basis for heart failure in these patients, as well as its prevention by ACE inhibitors are briefly summarized.
261	J. Inhibition	A. Treat	1	AT1R	heart failure	Indeed, experimental and clinical evidence indicates that blockade of this system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin type 1 receptor (AT1R) antagonists is an effective therapy to attenuate hypertension and diabetic renal injury, and to improve heart failure.
262	A.1 Over-expression	C. Cause	1	P53	heart failure	P53 expression increases as cardiac hypertrophy worsens to heart failure, suggesting that p53 may play important role in cardiac remodeling.
263	F.1 Phosphorylation	E. Associate	1	phospholamban	heart failure	Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban.
264	A.1 Over-expression	H. Benefit	1	bradykinin	heart failure	However, despite the potential therapeutic benefit of increased natriuretic peptide and bradykinin levels, neprilysin inhibitor therapy has only modest efficacy in essential hypertension and heart failure.
265	A.1 Over-expression	H. Benefit	1	ATF3	heart failure	Furthermore, infusion of tert-butylhydroquinone (tBHQ), a selective ATF3 inducer, increased the expression of ATF3 via the nuclear factor erythroid 2-related transcriptional factor, inhibited TAB-induced cardiac dilatation, and increased left ventricular contractility, thereby rescuing heart failure.
266	I. None	B. Target	1	apelin	heart failure	The cardiovascular profile of the apelin makes it a promising therapeutic target for heart failure and ischemic heart disease.
267	L.1 Up-regulation	H. Benefit	1	FSTL1	heart failure	FSTL1 (follistatin-like protein 1) is an emerging cardiokine/myokine that is upregulated in heart failure (HF) and is found to be cardioprotective in animal models of cardiac injury.
268	J. Inhibition	A. Treat	1	ACE	chronic congestive heart failure	Although many clinical trials have evaluated the use of long-acting angiotensin-converting enzyme (ACE) inhibitors in patients with chronic congestive heart failure (CHF), there are no data regarding whether a once-daily or twice-daily regimen is preferable with respect to effects on the neuroendocrine system.
269	J. Inhibition	A. Treat	1	ribosomal S6 kinase 2	heart failure	We previously reported the discovery of a novel ribosomal S6 kinase 2 (RSK2) inhibitor, (R)-5-Methyl-1-oxo-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a] indole-8-carboxylic acid [1-(3-dimethylamino-propyl)-1H-benzoimidazol-2-yl]-amide (BIX 02565), with high potency (IC(50) = 1.1 nM) targeted for the treatment of heart failure.
270	D.1 Mutation	E. Associate	1	CASQ2	heart failure	Studies on the consequences of RyR2 and CASQ2 mutations in cellular systems and mouse models have shed new light on pathways that are also implicated in arrhythmias occurring in highly prevalent diseases, such as heart failure.
271	J. Inhibition	A. Treat	1	ACE	systolic heart failure	Systematic review of randomized clinical trials permitted comparisons between blacks and whites with systolic heart failure concerning the efficacy of angiotensin converting enzyme (ACE) inhibitors, beta blockers and a combination of hydralazine/ nitrate to reduce the risks of death and hospitalization.
272	A. Expression	E. Associate	1	angiotensinogen	heart failure	In pathologic states, such as experimental heart failure, and certain models of hypertension, such as the spontaneously hypertensive rat, expression of renal angiotensinogen mRNA levels is altered.
273	I. None	H. Benefit	1	apelin	heart failure	Apelin could have a cardioprotective effect, and the apelin-APJ system may be a new therapeutic target in myocardial injury and heart failure.
274	J. Inhibition	C. Cause	1	HIF-1	heart failure	Cardiac angiogenesis played an important role in the maintenance of cardiac function as well as the development of cardiac hypertrophy induced by pressure-overload, and upregulated p53 induced the transition from cardiac hypertrophy to heart failure through the suppression of hypoxia inducible factor-1(HIF-1), which regulates angiogenesis in the hypertrophied heart.
275	A.1 Over-expression	C. Cause	1	PDE4D	heart failure	These studies elucidate a novel mechanism by which hyperinsulinemia contributes to heart failure by increasing PDE4D expression and identify β2AR or GRK2 as plausible therapeutic targets for preventing or treating heart failure in subjects with type 2 DM.
276	I. None	B. Target	1	endoglin	heart failure	Our results identify endoglin as a critical component of TGFβ1 signaling in the cardiac fibroblast and show that targeting endoglin attenuates cardiac fibrosis, thereby providing a potentially novel therapeutic approach for individuals with heart failure.
277	I. None	E. Associate	1	FKBP12.6	Heart failure, chronic	In heart failure, chronic stimulation of the beta-adrenergic signaling pathway leads to hyperphosphorylation of RyR2 by protein kinase A, which dissociates calstabin2 (FKBP12.6) from the receptor.
278	J. Inhibition	A. Treat	1	NEP	heart failure	Thus, the combined inhibition of ACE and NEP, by attenuating excessive vasoconstriction and enhancing vasodilator substances, holds promise as a valuable option in heart failure treatment for the near future.
279	I. None	B. Target	1	GRK2	heart failure	In this review, we discuss conventional heart failure therapies and highlight new pharmacological agents targeting pathophysiological features of the failing heart, for example, non-coding RNAs, angiotensin receptor-neprilysin inhibitors, cardiac myosin activators, BGP-15 and molecules targeting GRK2 including M119, gallein and paroxetine.
280	D.1 Mutation	E. Associate	1	LMNA	heart failure	Dilated cardiomyopathy caused by lamin A/C gene (LMNA) mutation is complicated with atrioventricular (AV) conduction disturbances, malignant ventricular arrhythmias, and progressive severe heart failure.
281	F. Epigenetic modification	E. Associate	1	nNOS	chf	Angiotensin II-mediated posttranslational modification of nNOS in the PVN of rats with CHF: role for PIN.
282	J. Inhibition	A. Treat	1	ACE	congestive heart failure	This suggests that therapeutic targets in the treatment of myocardial ischemia, and potentially congestive heart failure and hypertension, should include prevention of mast cell degranulation, mast cell renin inhibition, local ACE inhibition, ANG II antagonism and H3-receptor activation.
283	J. Inhibition	A. Treat	1	ACE	congestive heart failure	The aim of the study was to compare, in a rat model of congestive heart failure, the effect of captopril, a selective angiotensin-converting enzyme (ACE; EC 3.4.15.1) inhibitor, to that of alatriopril, a mixed inhibitor of ACE and atriopeptidase (EC 3.4.24.11), an enzyme implicated in the degradation of atrial natriuretic factor (ANF).
284	A.1 Over-expression	C. Cause	1	TRPC6	heart failure	TRPC3 and TRPC6, two members in the TRPC family, are highly expressed in the heart, and participate in the pathogenesis of cardiac hypertrophy and heart failure as a pathological response to chronic mechanical stress.
285	J. Inhibition	A. Treat	1	ACE	heart failure	ACE inhibitors reduce the likelihood of symptomatic heart failure in asymptomatic patients with reduced ejection fraction.
286	D.1 Mutation	E. Associate	1	TAZ	heart failure	Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle.
287	J. Inhibition	H. Benefit	1	angiotensin-converting enzyme	heart failure	Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients.
288	I. None	B. Target	1	PLN	heart failure	Recent progress in molecular cardiology makes it possible to envision a new therapeutic approach to heart failure (HF), targeting key molecules involved in intracellular Ca(2+) handling such as RyR, SERCA2a, and PLN.
289	I. None	A. Treat	1	ADM	congestive heart failure	A decrease in the electrocardiographic limb lead QRS voltage of greater than or equal to 30% was highly correlated with the development of congestive heart failure in patients treated with adriamycin (ADM).
290	I. None	B. Target	1	stem cell factor	heart failure	Increased expression of stem cell factor and its receptor after left ventricular assist device support: a potential novel target for therapeutic interventions in heart failure.
291	J. Inhibition	H. Benefit	1	ACE	chf	Although many lines of evidence have shown beneficial effects of angiotensin-converting enzyme (ACE) inhibitors on patients with chronic heart failure (CHF) after myocardial infarction (MI), the target of ACE inhibitors still remains unclear.
292	I. None	B. Target	1	ARK1	chf	This article summarizes the advances made in the study of beta ARK1 in the heart and addresses its potential as a novel therapeutic target for CHF.
293	J. Inhibition	A. Treat	1	neprilysin	heart failure	Patients with chronic kidney disease (CKD) have a higher incidence of cardiovascular (acute and chronic) events, which in turn have an increased risk of progression to end-stage renal disease (ESRD) Inhibition of neprilysin, in addition to offering a new therapeutic target in patients with heart failure, could represent a potential improvement strategy in cardiovascular and renal outcome of patients with CKD.
294	I. None	G. Marker	1	insulin-like growth factor I	CHRONIC HEART FAILURE	Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure.
295	D.1 Mutation	E. Associate	1	LMNA	heart failure	Mutation in the lamin A/C gene (LMNA) is associated with several cardiac phenotypes, such as cardiac conduction disorders (CCD), atrial arrhythmia (AA), malignant ventricular arrhythmia (MVA) and left ventricular dysfunction (LVD), leading to sudden cardiac death (SCD) and/or end-stage heart failure.
296	D.1 Mutation	F. None	1	HFE	Cardiac Failure	This study highlights a unique set of liver transplant patients with marked iron deposition in their cirrhotic liver who developed severe cardiac failure and have iron deposits in the heart, despite the absence of major HFE gene mutations.
297	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Incidence of START was highest with omissions of statin therapy, angiotensin-converting enzyme (ACE) inhibitor with heart failure, and vitamin D in patients with osteoporosis.
298	A.1 Over-expression	E. Associate	1	SGLT1	heart failure	In cardiomyocytes, SGLT1 and SGLT2 expression is upregulated in diabetes mellitus, heart failure, and myocardial infarction.
299	A.1 Over-expression	H. Benefit	1	TIMP-1	hypertensive heart failure	Our results indicates that basic fibroblast growth factor could up-regulate TIMP-1 expression and down-regulate MMP-9 activation in CFs in perivascular spaces, leading to inhibited progression of cardiac fibrosis during hypertensive heart failure.
300	L. Be regulated	C. Cause	1	ERR	heart failure	This review describes the biologic actions of the PGC-1 and ERR cascade and summarizes the evidence that dysregulation of this transcriptional regulatory circuit contributes to heart failure.
301	A. Expression	E. Associate	1	IL-10	heart failure	Heart failure (HF) is associated with changes in the skeletal muscle (SM) which might be a consequence of the unbalanced local expression of pro- (TNF-alpha) and anti- (IL-10) inflammatory cytokines, leading to inflammation-induced myopathy, and SM wasting.
302	G. Regulate	E. Associate	1	NF-kappaB	heart failure	These findings suggest that eplerenone may have significant therapeutic potential for heart failure, and these cardioprotective mechanisms of eplerenone may be mediated in part by stimulating eNOS through Akt and inhibiting iNOS via NF-kappaB after activation of the oxidative stress-LOX-1 pathway and signal transduction pathway.
303	A.2 Under-expression	E. Associate	1	S100A1	heart failure	In cardiac disease, the expression of S100A1 is dynamically altered as it is significantly down-regulated in end stage human heart failure (HF), and it is up-regulated in compensated hypertrophy.
304	A. Expression	E. Associate	1	COX-2	chf	COX-1 and COX-2 mRNAs were abundantly expressed in the renal medulla of control and CHF rats and only minimally in the cortex.
305	A. Expression	B. Target	1	TIMP	chf	Accordingly, the control of MMP and TIMP expression and activity within the failing myocardium represents a new and potentially significant therapeutic target for CHF.
306	J. Inhibition	A. Treat	1	ECE-1	heart failure	Pharmacological inhibition of augmented ECE-1 expression might provide a new therapeutic perspective in the treatment of heart failure.
307	H. Other	C. Cause	1	RLC	heart failure	The FHC-mediated structural perturbations in RLC that affect Ca(2+) binding properties of the mutated myocardium are responsible for triggering the abnormal function of the heart that in turn might initiate a hypertrophic process and lead to heart failure.
308	C. Activation	E. Associate	1	PP1	heart failure	As the activity of PP1 is enhanced in heart failure, subsequent dephosphorylation by of, e.g., PLB may explain the impaired relaxation of the human heart.
309	A. Expression	G. Marker	1	galectin-3	heart failure	The β-galactoside-binding animal lectin galectin-3 is predominantly expressed by activated macrophages and is a promising biomarker for patients with heart failure.
310	I. None	B. Target	1	GRK2	CHRONIC HEART FAILURE	Molecular modulation of the kinases that are ubiquitously expressed in the heart has proven GRK2, and also GRK5, to be promising targets for prevention and reversal of one of the most severe pathologies in man, chronic heart failure (HF).
311	D.1 Mutation	E. Associate	1	eNOS	Chronic Systolic Heart Failure	The 894G Allele of the Endothelial Nitric Oxide Synthase 3 (eNOS) is Associated with Atrial Fibrillation in Chronic Systolic Heart Failure.
312	A.2 Under-expression	F. None	1	GLUT1	heart failure	GLUT1 deficiency in cardiomyocytes alters myocardial substrate utilization, but does not substantially exacerbate pressure-overload induced contractile dysfunction or accelerate the progression to heart failure.
313	A. Expression	E. Associate	1	TRAIL	heart failure	Previous studies have identified TNF-related apoptosis inducing ligand (TRAIL) and its receptor, DR5, as being altered in a chronic catecholamine administration model of heart failure, and suggest a role of non-canonical signaling in cardiomyocytes.
314	L. Be regulated	E. Associate	1	AT1	heart failure	With the development of subtype specific angiotensin II (Ang II) receptor antagonists and their introduction into the treatment of heart failure and hypertension, the regulation of the Ang II receptor with its subtypes AT1 and Ang T2 gains clinical importance.
315	J. Inhibition	A. Treat	1	TRPV1	heart failure	TRPV1 is a physical and regulated component of the natriuretic peptide signaling system, and TRPV1 inhibition may provide a new treatment strategy for treating, and reversing the loss of function associated with cardiac hypertrophy and heart failure.
316	A.1 Over-expression	E. Associate	1	MMP1	heart failure	Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure.
317	A.1 Over-expression	C. Cause	1	TNF-alpha	heart failure	Thus, we studied cardiac mtDNA repair mechanisms, mtDNA damage, and mitochondrial structure and function in mice with heart failure secondary to overexpression of TNF-alpha (TNF1.6 mice).
318	L.2 Down-regulation	E. Associate	1	Nav1.1	heart failure	Downregulation of neuronal sodium channel subunits Nav1.1 and Nav1.6 in the sinoatrial node from volume-overloaded heart failure rat.
319	M.3 Gene silencing	E. Associate	1	SIRT6	heart failure	A new study now identifies gene promoters that bind the transcription factor AP1 as targets for silencing by SIRT6, providing possible links between SIRT6 deficiency and dysregulation of insulin-like growth factor signaling, hypertrophic cardiomyopathy and heart failure (pages 1643-1650).
320	I. None	E. Associate	1	G protein-coupled receptor kinase 2	congestive heart failure	G protein-coupled receptor kinase 2 (GRK2), a cytosolic enzyme desensitizing G protein-couple receptors (e.g., β-adrenergic receptors [β-ARs]), is involved in regulation of hypertension, congestive heart failure, and inflammatory response.
321	H. Other	H. Benefit	1	IL-1	heart failure	Interestingly, interfering with IL-1 has proved to be also effective in other cardiovascular manifestations, such as myocarditis, arrhythmias, and heart failure.
322	I. None	C. Cause	1	angiotensin II	Cardiac Failure	Evidence for the role of angiotensin II in promoting LVH and cardiac failure as well as for abnormal regulations of the angiotensin signal transduction pathways in model systems and in humans are reviewed.
323	A.2 Under-expression	C. Cause	1	dystrophin	Cardiac Failure	Early cardiac failure in a child with Becker muscular dystrophy is due to an abnormally low amount of dystrophin transcript lacking exon 13.
324	L. Be regulated	E. Associate	1	PP2A	heart failure	Thus, PR65A phosphorylation is an in vivo mechanism for regulation of the PP2A signaling complex and increased PP2A activity in heart failure.
325	L. Be regulated	E. Associate	1	GRK2	heart failure	During heart failure, there is substantial alpha2AR dysregulation in the adrenal gland, triggered by increased expression and activity of G protein-coupled receptor kinase 2 (GRK2).
326	A.1 Over-expression	E. Associate	1	endothelin-1	heart failure	Early increase in pulmonary vascular reactivity with overexpression of endothelin-1 and vascular endothelial growth factor in canine experimental heart failure.
327	I. None	E. Associate	1	TNFR1	CHRONIC HEART FAILURE	Tumor necrosis factor alpha (TNFalpha) plays a major role in chronic heart failure, signaling through two different receptor subtypes, TNFR1 and TNFR2.
328	M.3 Gene silencing	H. Benefit	1	SOCS3	Diastolic Heart Failure	Adeno-associated virus 9-mediated RNA interference targeting SOCS3 alleviates diastolic heart failure in rats.
329	L. Be regulated	B. Target	1	CTGF	heart failure	Modulation of CCN2 (CTGF, connective tissue growth factor) and associated early ECM changes may represent a new therapeutic target in the treatment and prevention of heart failure in HCM.
330	I. None	C. Cause	1	titin	heart failure	In the present study we describe familial RCM with severe heart failure triggered by a de novo mutation in TTN, encoding the huge muscle filament protein titin.
331	A.1 Over-expression	E. Associate	1	ANP	heart failure	Previous studies have indicated that the serum level and ventricular expression of the ANP gene were augmented in patients with heart failure.
332	A. Expression	E. Associate	1	desmin	heart failure	During heart failure, the pattern of desmin, vimentin, periostin and caspase-3 expression alters in the left atrium, regardless of the cause.
333	L.2 Down-regulation	E. Associate	1	cystic fibrosis transmembrane conductance regulator	heart failure	Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure.
334	I. None	G. Marker	1	interleukin 6	CHRONIC HEART FAILURE	Plasma B-type natriuretic peptide (BNP) and interleukin 6 (IL-6) levels have recently been demonstrated as significant neurohormonal markers associated with the progression of chronic heart failure (CHF).
335	L.1 Up-regulation	E. Associate	1	fas-activated serine/threonine kinase	heart failure	Besides the reported upregulation of beta-adrenergic receptor kinase-1 in heart failure, we observed new gene expression patterns, such as the upregulation of fas-activated serine/threonine kinase (FAST) or reduced expression of desmoplakin.
336	A. Expression	C. Cause	1	leptin	heart failure	In conclusion, our findings demonstrate that cardiac leptin expression after MI could contribute to the evolution towards heart failure through autocrine and/or paracrine actions.
337	J. Inhibition	E. Associate	1	NOS2	heart failure	Some apparently contrasting findings may have arisen from the use of non-isoform-specific inhibitors of NO synthase isoforms (NOS) as compared to the use of mouse models genetically deficient or overexpressing the NOS thought to be responsible for the increase in NO production in heart failure (mainly NOS2 and NOS3).
338	A. Expression	C. Cause	1	miR-22	heart failure	Our data shows that forced expression of miR-22 induces a pro-hypertrophic gene expression program, and it elicits contractile dysfunction leading to cardiac dilation and heart failure.
339	A.2 Under-expression	E. Associate	1	nNOS	chf	Seven days after intervention, nNOS protein expression, nNOS immunostaining signaling, and diaphorase-positive stained cells were significantly decreased in the PVN of CHF rats, changes that were reversed by A-RDN.
340	L. Be regulated	E. Associate	1	CTGF	heart failure	MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure.
341	A.2 Under-expression	B. Target	1	JP2	heart failure	MiR-24-mediated suppression of JP2 expression provides a novel molecular mechanism for E-C coupling regulation in heart cells and suggests a new target against heart failure.
342	I. None	B. Target	1	miR-18	heart failure	Our results demonstrated that the p53-miR-18-HSF2-IGF-IIR axis was a critical regulatory pathway of cardiomyocyte hypertrophy in vitro and in vivo, suggesting that miR-18 could be a therapeutic target for the control of cardiac functions and the alleviation of cardiomyopathy during hypertension-induced heart failure.
343	H. Other	E. Associate	1	PLD2	heart failure	The results suggest that heart failure is associated with increased activities of both PLD2 and PAP2 in the SL membrane and the beneficial effect of imidapril on heart function may be due to its ability to prevent these changes in the phospholipid signaling molecules in the cardiac SL membrane.
344	J. Inhibition	H. Benefit	1	ACE	heart failure	These data suggest that the beneficial effect of ACE inhibitors against left cardiac remodeling and heart failure may be due at least in part to regulating MMPs activity and expression by modulation of NO pathway.
345	I. None	B. Target	1	XIST	heart failure	Collectively, these in vivo and in vitro findings identify XIST as a necessary regulator of cardiac hypertrophy due to its regulation of the miR-101/TLR2 axis, suggesting that XIST might act as a therapeutic target for the treatment of cardiac hypertrophy and heart failure.
346	A. Expression	E. Associate	1	GRK5	heart failure	Lymphocyte expression of adrenoceptors (β1 and β2) and kinases (GRK2, GRK3, and GRK5) reflects the neurohumoral changes that occur in heart failure (HF).
347	A.1 Over-expression	E. Associate	1	GRK2	heart failure	Downregulation of β(1)- adrenergic receptors (β(1)-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established.
348	A. Expression	C. Cause	1	ACE	heart failure	Alterations in the expression or action of these components, which include angiotensin converting enzyme (ACE), angiotensinogen, and angiotensin II type-1 receptors, may contribute to the development of disease, such as hypertension, left ventricular hypertrophy, myocardial infarction, and end-stage heart failure.
349	A.1 Over-expression	H. Benefit	1	TFAM	MYOCARDIAL FAILURE	Therefore, the activation of TFAM expression could ameliorate the pathophysiological processes seen in myocardial failure.
350	A.2 Under-expression	E. Associate	1	phospholamban	heart failure	Decreased phospholamban expression within the heart during heart failure has also been observed.
351	F.1 Phosphorylation	B. Target	1	ALDH2	congestive heart failure	These recently discovered protective pathways indicate that activation of mast-cell Gicoupled receptors and subsequent ALDH2 phosphorylation/activation represent a novel therapeutic target for the alleviation of RAS-induced cardiac dysfunctions, including ischemic heart disease and congestive heart failure.
352	A. Expression	E. Associate	1	NKCC2	chf	These results indicate that the renal sympathetic nerves have an effect on NKCC2 expression in the mTAL and might have an effect on cAMP formation in the TAL in CHF.
353	J. Inhibition	A. Treat	1	neprilysin	heart failure	Simultaneous angiotensin receptor (AT1) blockade and neprilysin inhibition with sacubitril/valsartan has been recently approved to treat patients with heart failure (HF).
354	J. Inhibition	A. Treat	1	ACE	heart failure	Based on strong clinical trial data, low-dose aldosterone receptor blockers are recommended to improve morbidity and mortality in patients with severe chronic heart failure due to left ventricular systolic dysfunction and in patients with heart failure associated with left ventricular systolic dysfunction after acute myocardial infarction, and in patients already on standard therapy including ACE inhibitors (or angiotensin receptor blockers) and beta blockers.
355	F.1 Phosphorylation	E. Associate	1	cTnI	heart failure	In human heart failure, Ser199 (equivalent to Ser200 in mouse) of cTnI (cardiac troponin I) is significantly hyperphosphorylated, and in vitro studies suggest that it enhances myofilament calcium sensitivity and alters calpain-mediated cTnI proteolysis.
356	D.1 Mutation	C. Cause	1	vinculin	Cardiac Failure	Humans bearing familial or sporadic mutations in vinculin suffer from chronic, progressively debilitating DCM that ultimately leads to cardiac failure and death, whereas autosomal dominant mutations in vinculin can also provoke HCM, causing acute cardiac failure.
357	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure	All nonfatal events contributed to the composite score according to their severity: recurrent myocardial infarction (weight 0.5), congestive heart failure that required the use of open-label angiotensin-converting enzyme (ACE) inhibitors (weight 0.2), and hospitalization to treat congestive heart failure (weight 0.5).
358	I. None	B. Target	1	GRK2	heart failure	We will focus on the G protein-coupled receptor kinase GRK2, an increasing target for heart failure therapy, based on its important role in disease progression and the therapeutic potential of GRK2 inhibitors.
359	I. None	B. Target	1	PLM	heart failure	The unique role of PLM in regulation of Na(+)-K(+)-ATPase, Na(+)/Ca(2+) exchanger, and potentially L-type Ca(2+) channel in the heart, together with the changes in its expression and phosphorylation in heart failure, make PLM a rational and novel target for development of drugs in our armamentarium against heart failure.
360	J. Inhibition	A. Treat	1	ACE	heart failure	Advanced heart failure, also be defined as stage D heart failure, characterized by advanced structural heart disease and marked symptoms of heart failure at rest despite dietary modification, salt restriction and maximal medical therapy including ACE inhibitors, angiotensin II receptor blockers, digitalics, diuretics and beta blockers.
361	J. Inhibition	A. Treat	1	ACE	heart failure	Toborinone did not aggravate adverse effects such as arrhythmias, and can be combined with ACE inhibitors, nitrates and diuretics for the treatment of heart failure [175268].
362	A.2 Under-expression	E. Associate	1	IL-10	chf	Our present study demonstrates significantly decreased serum levels of IL-10 in patients with advanced CHF.
363	J. Inhibition	A. Treat	1	ACE	systolic heart failure	Some dihydropyridine calcium antagonists may be useful as alternatives to ACE inhibitors in patients with hypertension and systolic heart failure.
364	J. Inhibition	H. Benefit	1	NHE1	heart failure	Although the clinical trials of the NHE1 inhibitors in ischemia and reperfusion have been disappointing to date, evidence was presented in the sodium-hydrogen exchanger symposium that these agents might be beneficial in hypertrophy and heart failure.
365	I. None	B. Target	1	CARD3	heart failure	Thus, CARD3 may be a promising therapeutic target for the treatment of heart failure after MI.
366	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
367	I. None	E. Associate	1	NCX1	heart failure	The Na+-Ca2+ exchanger (NCX1) is involved in altered calcium handling in cardiac myocytes during cardiac remodeling associated with heart failure, however, its role in cardiac myofibroblast cell function is unexplored.
368	D.1 Mutation	C. Cause	1	LMNA	heart failure	LMNA mutations are an important cause of cardiomyopathy often leading to cardiac arrhythmias, heart failure and even heart transplantation.
369	J. Inhibition	H. Benefit	1	AVP	heart failure	We conclude that inhibition of AVP with a specific V1 antagonist had no effect on the venous or arterial circulations in normal rats, but in rats with left ventricular dysfunction and heart failure after chronic myocardial infarction, AVP inhibition decreased arterial pressure and caused venodilatation.
370	J. Inhibition	A. Treat	1	SGLT2	heart failure	Recent major trials demonstrated sodium-glucose co-transporter-2 (SGLT2) inhibitors improve prognosis of T2DM patients through prevention of heart failure.
371	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	left ventricular failure	In other patients, if serial studies reveal progressive left ventricular failure and dilation late after reperfusion, despite therapy with an angiotensin-converting enzyme (ACE) inhibitor, and if repeat coronary angiography identifies significant coronary stenoses and areas of hibernating or stunned myocardium, revascularization may limit progression of dilation and improve left ventricular function.
372	L.2 Down-regulation	E. Associate	1	Nav1.6	heart failure	Downregulation of neuronal sodium channel subunits Nav1.1 and Nav1.6 in the sinoatrial node from volume-overloaded heart failure rat.
373	F.1 Phosphorylation	E. Associate	1	RLC	heart failure	Although information is limited, RLC phosphorylation appears compromised in human heart failure which is consistent with data from mouse studies.
374	A.2 Under-expression	E. Associate	1	PLN	heart failure	The reduced PLN and HAX-1 expressions were highly correlated with the severity of heart failure (P<.001), vertebral heart score (P<.05), and left atrium to aortic root ratio (P<.05).
375	D.1 Mutation	E. Associate	1	urotensin II receptor	congestive heart failure	A stop‑gain mutation in urotensin II receptor (UTS2R) (p.S241X), which is associated with congestive heart failure, was identified in the proband and in one other affected family member.
376	I. None	B. Target	1	CAD	heart failure	Our study suggests that CAD might be a novel target for the treatment of pathological cardiac hypertrophy and heart failure.
377	I. None	E. Associate	1	NPPB	heart failure	Importantly, adenoviral overexpression of glypican-6 in cultured cardiomyocytes increased protein synthesis and induced mRNA levels of the pro-hypertrophic signature gene ACTA1 and the hypertrophy and heart failure signature genes encoding natriuretic peptides, NPPA and NPPB.
378	I. None	G. Marker	1	galectin-3	heart failure	Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
379	I. None	B. Target	1	PI16	heart failure	PI16 might represent a novel therapeutic target in heart failure.
380	D.1 Mutation	E. Associate	1	SCN5A	heart failure	Recently, SCN5A mutations have been associated with heart failure combined with variable atrial and ventricular arrhythmia.
381	L.2 Down-regulation	E. Associate	1	PLB	chf	Western blots showed that while SR Ca2+ ATPase (SERCA) expression was unaltered in CHF, phospholamban (PLB) was downregulated (60+/-11% of SHAM values, P<0.05).
382	A.2 Under-expression	E. Associate	1	fibronectin	congestive heart failure	Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure.
383	J. Inhibition	E. Associate	1	ACE	chf	The accurate diagnosis of mild CHF became imperative with the advent of angiotensin converting enzyme (ACE) inhibitors.
384	I. None	E. Associate	1	myoregulin	heart failure	We propose that (i) this partially-protonated intermediate serves as the consensus mechanism for SERCA inhibition by other members of the SERCA regulatory subunit family including myoregulin and sarcolamban, and (ii) this consensus mechanism is utilized to regulate Ca(2+) transport in skeletal and cardiac muscle, with important implications for therapeutic approaches to muscle dystrophy and heart failure.
385	F.1 Phosphorylation	E. Associate	1	PLB	chf	We found that compared to CTR, (1) both INH-1 (10.2+/-2 versus 57.5+/-1; p < 0.05) and INH-2 activity (3.8+/-0.4 versus 36.2+/-4; p < 0.05) were reduced, (2) total and phosphorylated PLB amount reduced, (3) protein level of phosphorylated INH-1 was reduced (2.32+/-0.1 versus 0.73+/-0.04; p < 0.05) whereas that of phosphorylated INH-2 increased (3.05+/-0.3 versus 1.42+/-0.1; p < 0.05), and (4) PP1 activity was increased approximately 2.6-fold in rats with CHF (1.59+/-0.05 versus 0.61+/-0.01; p < 0.05) while protein level of the catalytic subunit of PP1 (PP1C) increased 3.85-fold (0.77+/-0.05 versus 0.20+/-0.02; p < 0.05).
386	D.1 Mutation	E. Associate	1	BAG3	heart failure	Mutations in the BAG3 gene, which encodes a co-chaperone protein, have been associated with heart failure due to both inherited and sporadic dilated cardiomyopathy.
387	I. None	B. Target	1	TNNI3K	heart failure	TNNI3K could be a potential therapeutic target for preventing from heart failure.
388	I. None	E. Associate	1	NEP	heart failure	NPs play central roles in regulation of heart failure (HF), and are inactivated through not only NP receptor-C, but also neutral endopeptidase (NEP), dipeptidyl peptidase-4 and insulin degrading enzyme.
389	G. Regulate	E. Associate	1	angiotensin II	heart failure	Angiotensin II (ANG II)-induced mitogen-activated protein kinase (MAPK) signaling upregulates angiotensin II type-1 receptors (AT(1)R) in hypothalamic paraventricular nucleus (PVN) and contributes to AT(1)R-mediated sympathetic excitation in heart failure.
390	I. None	A. Treat	1	CPT	chronic congestive heart failure	The effects of long-term therapy with captopril (CPT) were studied in 11 patients with severe chronic congestive heart failure (CHF).
391	A. Expression	F. None	1	ANP	chf	In CHF, LV-BNP increased further markedly (P<0.01 vs. CTRL, P<0.05 vs. ELVD) while atrial ANP and BNP expression as well as LV ANP expression remained unchanged (all P=n.s.
392	I. None	B. Target	1	ET	heart failure	Therefore, ET may be an important therapeutic target for the prevention of heart failure in postmenopausal women affected by MI.
393	I. None	B. Target	1	BRD4	heart failure	Bromodomain-containing protein 4 (BRD4), an epigenetic reader of acetyl lysine, has emerged as a promising therapeutic target for many diseases including cancer, inflammation and heart failure.
394	A.1 Over-expression	E. Associate	1	PI3Kgamma	chf	The expression of PI3Kgamma was increased four-fold in CHF, but returned to control levels in CR.
395	A.1 Over-expression	E. Associate	1	GRK5	heart failure	G protein-coupled receptor kinase 5 (GRK5) plays a key role in cardiac signaling regulation, and its expression is increased in heart failure.
396	D.1 Mutation	E. Associate	1	desmoplakin	heart failure	Early-onset heart failure, alopecia, and cutaneous abnormalities associated with a novel compound heterozygous mutation in desmoplakin.
397	J. Inhibition	A. Treat	1	ACE	heart failure	Management of myocarditis requires avoidance of agents that exacerbate myocarditis or depress myocardial function, and conventional therapy for heart failure (diuretics, ACE inhibitors and, if indicated, digoxin) and arrhythmias.
398	A.1 Over-expression	E. Associate	1	BNIP3	heart failure	BNIP3 expression gradually increased in the first weeks after pressure overload and peaked at the heart failure stage.
399	J. Inhibition	H. Benefit	1	ACE	chronic congestive heart failure	Chronic congestive heart failure (CHF) is a common disease responsible for a high mortality and morbidity whose clinical course can be improved by angiotensin-converting-enzyme (ACE) inhibition.
400	J. Inhibition	A. Treat	1	ACE	heart failure	[Dosage of ACE inhibitors in heart failure].
401	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Together with angiotensin-converting enzyme inhibitors, beta blockers have emerged as standard therapy for heart failure, especially for patients with mild to moderate heart failure.
402	D.1 Mutation	C. Cause	1	nexilin	heart failure	Mutations in genes encoding different Z-disc proteins such as integrin-linked kinase (ILK) and nexilin have recently been shown to cause heart failure by distinct mechanisms such as disturbed mechanosensing, altered mechanotransduction or mechanical Z-disc destabilization.
403	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Omapatrilat, a novel vasopeptidase inhibitor, is a highly potent and selective inhibitor of neutral endopeptidase and angiotensin-converting enzyme; its therapeutic potential is being investigated for treatment of hypertension and heart failure.
404	G. Regulate	E. Associate	1	apelin	heart failure	Emerging data suggest that the cardiovascular system is the main target of apelin, which exerts an overall neuroprotective role, and is a positive regulator of angiotensin-converting enzyme 2 (ACE2) in heart failure.
405	J. Inhibition	A. Treat	1	ACE	chf	These results suggest that the brain is a possible target for ACE inhibitors in the treatment of CHF after MI.
406	G. Regulate	B. Target	1	PI3Kgamma	heart failure	As a whole, PI3Kgamma appears to negatively control cardiac contractility through different signalling mechanisms, thus becoming a possible drug target for the treatment of critical human cardiac pathologies, such as infarction or heart failure.
407	J. Inhibition	A. Treat	1	ACE	heart failure	Angiotensin converting enzyme (ACE)-inhibitors are established in the treatment of arterial hypertension and heart failure.
408	J. Inhibition	A. Treat	1	ACE	congestive heart failure	Sampatrilat is a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) under development for the treatment of hypertension and congestive heart failure.
409	J. Inhibition	H. Benefit	1	aldosterone receptor	CHRONIC HEART FAILURE	In clinical studies, aldosterone receptor antagonism is associated with decreased hospitalization, symptomatology, and mortality, and improvement of endothelial dysfunction in patients with chronic heart failure.
410	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	CHRONIC HEART FAILURE	The level of inhibition of the angiotensin-converting enzyme (ACE) provided by standard doses of ACE inhibitors may only be partial during long-term treatment in patients with severe chronic heart failure (CHF).
411	I. None	B. Target	1	SGK1	heart failure	These results suggest that SGK1 may play a critical role in the inflammatory cascade of cardiac fibroblasts triggered by mechanical stretch; SGK1 could be used as a potential target for treatment of cardiac fibrosis and heart failure.
412	J. Inhibition	A. Treat	1	ACE	heart failure	We evaluated the interaction of angiotensin-converting enzyme (ACE) inhibitor therapy with the effect of the ACE D/I polymorphism on heart failure survival.
413	D.1 Mutation	C. Cause	1	MYBPC3	heart failure	Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy.
414	A.1 Over-expression	G. Marker	1	OLF	heart failure	Increased concentrations of OLF were observed in patients with left ventricular dysfunction due to dilated cardiomyopathy, before the occurrence of overt heart failure, suggesting that OLF may be an early marker of the disease.
415	A.1 Over-expression	E. Associate	1	fractalkine	CHRONIC HEART FAILURE	Concentrations of the chemokine fractalkine (FKN) are increased in patients with chronic heart failure, and our previous studies show that aged mice lacking the prostaglandin E2 EP4 receptor subtype (EP4-KO) have increased cardiac FKN, with a phenotype of dilated cardiomyopathy.
416	A.1 Over-expression	E. Associate	1	APJ receptor	heart failure	Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression.
417	J. Inhibition	A. Treat	1	ACE	heart failure	Despite this, there has been very little examination of its effects in humans and none in heart failure patients or in other patients treated with ACE inhibitors.
418	D.1 Mutation	C. Cause	1	PLN	heart failure	Mutations and post-translational modifications of PLN may lead to dilated cardiomyopathy (DCM) and heart failure.
419	G. Regulate	E. Associate	1	AWD	heart failure	Nucleoside diphosphate kinase (NDPK, NM23, AWD): recent regulatory advances in endocytosis, metastasis, psoriasis, insulin release, fetal erythroid lineage and heart failure; translational medicine exemplified.
420	L.1 Up-regulation	H. Benefit	1	eNOS	chf	The results of the present study suggest that Ato upregulates eNOS by inhibiting RhoA/Rho kinase overexpression in the myocardial tissue of rats with CHF, thus improving left ventricular remodeling and cardiac function.
421	D.1 Mutation	E. Associate	1	TNNC1	heart failure	This association between restrictive cardiomyopathy and TNNC1 mutations was strengthened by prospective observations on the second pregnancy in the family which revealed, in the presence of the same TNNC1 genotype, prenatally diagnosed hypertrophic cardiomyopathy which evolved into restrictive cardiomyopathy, heart failure and death at the age of 9 months.
422	D.1 Mutation	E. Associate	1	LMNA	heart failure	This seems to be mainly attributable to a high prevalence of malignant ventricular arrhythmias and end-stage heart failure in LMNA and PLN mutation carriers.
423	A.2 Under-expression	E. Associate	1	elastin	heart failure	Since collagen was induced in SHR with heart failure, decorin and elastin were decreased and the ratios of gelatinase A and elastase to tissue inhibitor of metalloproteinase-4 were increased, we conclude that heart failure is associated with adverse extracellular matrix remodeling.
424	A. Expression	E. Associate	1	MCP-1	chf	To determine the involvement of proinflammatory cytokine in cardiac hypertrophy and CHF induced by mechanical overload, we investigated the expression of interleukin (IL)-1 beta and monocyte chemotactic and activating factor (MCAF)/monocyte chemoattractant protein-1 (MCP-1) in the left ventricle (LV) of Dahl salt-sensitive (DS) rats that showed hypertrophy of the LV induced by hypertension and subsequently developed CHF.
425	L.2 Down-regulation	C. Cause	1	titin	congestive heart failure	These results suggest that the down-regulation of titin and up-regulation of microtubule and desmin filaments may contribute to myocyte lengthening and malfunction in pressure overload congestive heart failure.
426	J. Inhibition	A. Treat	1	MPO	heart failure	Thus, MPO inhibitors have been developed for the treatment of heart failure and acute coronary syndrome in humans.
427	I. None	E. Associate	1	TRPV4	heart failure	Recent studies have shown that transient receptor potential vanilloid 4 (TRPV4), an ion channel expressed in pulmonary tissues, is a crucial mediator of pressure-induced damage associated with ventilator-induced lung injury, heart failure, and infarction.
428	J. Inhibition	A. Treat	1	ACE	chf	One factor that has fueled the hesitancy to use ACE inhibitors in CHF has been the concern that renal function might worsen upon their receipt.
429	G. Regulate	E. Associate	1	RKIP	heart failure	We also describe how RKIP's role as key signaling modulator of many cell fate decisions leads to the fact that fine control of RKIP activity and regulation is crucial to avoid pathological processes, such as metastasis, pulmonary arterial hypertension, and heart failure.
430	A.1 Over-expression	E. Associate	1	UCN	heart failure	UCN has potent cardiostimulatory, cardioprotective, vasodilator and diuretic/natriuretic effects, and cardiac UCN expression is increased in heart failure (HF).
431	L.1 Up-regulation	E. Associate	1	LUC7L3	heart failure	Of the 17 mRNA splicing factors upregulated in heart failure, RBM25 and LUC7L3 were sufficient to explain the increase in truncated forms and the reduction in full-length Na+ channel transcript.
432	L.1 Up-regulation	H. Benefit	1	DHPR	heart failure	Our results suggest that sophoridine could improve heart failure by ameliorating cardiac Ca(2+) induced Ca(2+) transients, and that this amelioration is associated with upregulation of DHPR.
433	A.2 Under-expression	E. Associate	1	apelin	rvf	Moreover, two models of RVF were associated with fibrosis, capillary rarefaction, the decreased expression of genes encoding the angiogenesis factors vascular endothelial growth factor, insulin-like growth factor 1, apelin, and angiopoeitin-1, and the increased expression of genes encoding a set of glycolytic enzymes.
434	J. Inhibition	C. Cause	1	TNF-alpha	heart failure	Large phase II and III trials with TNF-alpha antagonists in advanced heart failure have shown trends towards a worse prognosis, and should therefore be avoided in this population.
435	A.2 Under-expression	C. Cause	1	dystrophin	Cardiac Failure	Duchenne muscular dystrophy (DMD), a degenerative pathology of skeletal muscle, also induces cardiac failure and arrhythmias due to a mutation leading to the lack of the protein dystrophin.
436	I. None	B. Target	1	USP18	heart failure	Thus, USP18 is a potent therapeutic target for heart failure treatment.
437	J. Inhibition	H. Benefit	1	angiotensin-converting enzyme	heart failure	Although the beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in patients with heart failure are well recognized, there are theoretical advantages in combining ACE inhibition with angiotensin (AT)1 receptor antagonism.
438	I. None	B. Target	1	PI3Kgamma	heart failure	Thus, PI3Kgamma may represent a novel therapeutic target for the treatment of decreased cardiac function in heart failure.
439	I. None	B. Target	1	TNF-alpha	heart failure	The results suggest a critical role of TNF-alpha and MMPs in myocardial matrix remodeling and functional regulation and support the hypothesis that both TNF-alpha and MMPs may serve as potential therapeutic targets in the treatment of heart failure.
440	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure (CHF)	In a double-blind, placebo-controlled, randomized, multicenter study, 225 patients with mild to moderate congestive heart failure (CHF) due to arterial hypertension and ischemic heart disease received quinapril, a new non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, in addition to maintenance therapy with digitalis and/or diuretics.
441	D.1 Mutation	C. Cause	1	BAG3	heart failure	Earlier studies have ascribed a role for BAG3 in the development of cardiomyopathy in experimental animals leading to the identification of BAG3 mutations in patients with heart failure which may play a part in the onset of disease development and progression.
442	J. Inhibition	E. Associate	1	ACE	congestive heart failure (CHF)	Independent of their symptomatic benefits, diuretics, digitalis, ACE inhibitors, PDE inhibitors and dopamine agonists exert specific influences on factors that retard or accelerate progression of congestive heart failure (CHF).
443	F.1 Phosphorylation	E. Associate	1	HSP27	chf	The phosphorylation status of HSP27 was significantly decreased in the CHF canine model when compared to control (p < 0.0111) and it tended towards a decrease in the ATP canine model when compared to control (p=0.0923).
444	J. Inhibition	H. Benefit	1	angiotensin-converting enzyme	heart failure	Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors improves outcomes and symptoms in patients with heart failure (HF).
445	A. Expression	E. Associate	1	IL6	heart failure	In summary, in end-stage heart failure, IL6 mRNA is consistently expressed in the myocardium.
446	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure.
447	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	ACUTE HEART FAILURE	The angiotensin-converting enzyme inhibitors (ACEI) captopril and enalapril were also administered in the same manner to compare the therapeutic effects of these three drugs on the degree of myocarditis, acute heart failure, and left ventricular (LV) hypertrophy.
448	J. Inhibition	A. Treat	1	ACE	chf	The long-term treatment of CHF in children includes digoxin, diuretics and afterload reduction with angiotensin-converting enzyme (ACE) inhibitors.
449	J. Inhibition	H. Benefit	1	NEP	heart failure	Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.
450	G. Regulate	B. Target	1	NDUFAB1	heart failure	Together, our findings identify that NDUFAB1 is a crucial regulator of mitochondrial energy and ROS metabolism through coordinating the assembly of respiratory complexes and supercomplexes, and thus provide a potential therapeutic target for the prevention and treatment of heart failure.
451	D.1 Mutation	C. Cause	1	TNNT2	heart failure	TNNT2 mutations can also lead to dilated cardiomyopathy, a leading cause of heart failure.
452	A.1 Over-expression	E. Associate	1	COL1A1	chf	Expression of miR29b extracellular matrix target genes collagen-1A1 (COL1A1), collagen-3A1 (COL3A1), and fibrillin increased significantly in CHF fibroblasts.
453	L.1 Up-regulation	E. Associate	1	NCX	heart failure	In heart failure, the Na+-Ca²+ exchanger (NCX) is upregulated and mediates Ca²+ influx (instead of efflux) during the cardiac action potential.
454	J. Inhibition	A. Treat	1	ACE	heart failure	Although heart failure in cats is treated with angiotensin converting enzyme (ACE) inhibitors, data on the effects of different doses of enalapril on hemodynamics and the inhibition of ACE activity have not been published.
455	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	All patients with heart failure should be taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker.
456	J. Inhibition	H. Benefit	1	SGLT2	heart failure	For the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, the DECLARE-TIMI 58 study (of dapagliflozin) clearly indicates strong protection for heart failure in those with CVD, and probably in those with no prior CVD.
457	H. Other	E. Associate	1	leptin	chf	An activated leptin pathway was associated with downregulation of SERCA2a and upregulation of PLB in mRNA and protein expression in CHF.
458	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	This favorable effect on the pulsatile component of afterload may contribute to the improvement in left ventricular performance that occurs in patients with heart failure treated with angiotensin-converting enzyme inhibitors.
459	J. Inhibition	H. Benefit	1	ACE	congestive heart failure	ACE inhibitors have been shown to improve the longevity and quality of life of patients with congestive heart failure.
460	J. Inhibition	H. Benefit	1	aldosterone receptor	CHRONIC HEART FAILURE	In chronic heart failure and post myocardial infarction patients, aldosterone receptor blockade benefit was associated with decreased serum levels of collagen synthesis marker PIIINP (procollagen type III amino-terminal peptide), without affecting collagen degradation.
461	J. Inhibition	A. Treat	1	TNF-alpha	heart failure	For these reasons, inhibition of TNF-alpha appears to be a valid target for the improvement of heart failure therapy beyond the current practice of inhibiting neurohormonal activation with beta-blockade, angiotensin-converting enzyme (ACE) inhibition and aldosterone antagonism.
462	A.2 Under-expression	E. Associate	1	BAG3	heart failure	To simulate decreased BAG3 protein levels observed in human heart failure, we targeted BAG3 by shRNA (shBAG3) in adult LV myocytes.
463	I. None	B. Target	1	GRK2	heart failure	GRK2 as a therapeutic target for heart failure.
464	L. Be regulated	E. Associate	1	angiotensin-converting enzyme 2	heart failure	Emerging data suggest that the cardiovascular system is the main target of apelin, which exerts an overall neuroprotective role, and is a positive regulator of angiotensin-converting enzyme 2 (ACE2) in heart failure.
465	J. Inhibition	H. Benefit	1	ACE	heart failure	Beta-blockers and calcium channel blockers are effective antianginals; diuretics, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are useful for heart failure; ACE inhibitors and angiotensin receptor blockers are especially effective in preserving renal function.
466	G. Regulate	B. Target	1	HDAC4	heart failure	We conclude that HDAC4 plays a central role for rapid modifications of histone methylation in response to variations in cardiac load and may represent a target for pharmacological interventions to prevent maladaptive remodeling in patients with heart failure.
467	D.1 Mutation	E. Associate	1	SCN5A	heart failure	Mutations in the SCN5A gene encoding NaV1.5 have been linked to changes in the Na current leading to a variety of arrhythmogenic phenotypes, and alterations in the NaV1.5 expression level, Na current density, and/or gating have been observed in acquired cardiac disorders, including heart failure.
468	A.1 Over-expression	E. Associate	1	nerve growth factor receptor	chf	In CHF hearts, the expression of the muscarinic m4 (Chrm4) and nicotinic alpha4 (Chrna4) acetylcholin receptors, the ATP receptor P2rx4, nerve growth factor receptor (Ngfr), discoidin domain receptor 1 (Ddr1), neuronal pentraxin receptor (Nptxr), peripheral myelin protein Pmp-22, leukocyte type 12-lipoxygenase (Alox15), cytochrome P450 4F5 (Cyp4F5) and cardiac Kcne1 were all increased (range 1.6-6.0-fold, P < 0.01 for all genes).
469	I. None	B. Target	1	RyR	heart failure	Recent progress in molecular cardiology makes it possible to envision a new therapeutic approach to heart failure (HF), targeting key molecules involved in intracellular Ca(2+) handling such as RyR, SERCA2a, and PLN.
470	A.2 Under-expression	E. Associate	1	myostatin	heart failure	Another study showed that the expression of myostatin in skeletal muscle, a negative regulator of muscle growth that is essential for normal regulation of muscle mass, is decreased in spontaneously hypertensive rats with heart failure compared with control animals.
471	D.1 Mutation	C. Cause	1	transthyretin	Cardiac Failure	Cardiac failure in transthyretin (TTR) amyloidosis patients has been shown to be caused by different mutations in the TTR gene.
472	H. Other	A. Treat	1	eNOS	heart failure	In addition to such continuous eNOS activation for treating chronic ischemic heart failure, rapid eNOS activation in the setting of acute ischemic events upon chronic myocardial ischemia by new strategies such as postconditioning seems to be also essential for developing further effective anti-heart-failure therapies.
473	L.1 Up-regulation	E. Associate	1	AT1R	chf	HR increased with the severity of CHF reaching its maximum by 12 weeks post-MI; loss of circadian HR and BRS rhythms were observed as early as 4 weeks post-MI in conjunction with a significant blunting of the BRS and an upregulation in the AT1R and gp91(phox) proteins in the brainstem.
474	A. Expression	E. Associate	1	SERCA2	Diastolic Heart Failure	Sarcoplasmic reticulum Ca²⁺-ATPase 2 (SERCA2) gene expression in HL-1 cardiomyocytes was used as a molecular phenotype of diastolic heart failure.
475	D.1 Mutation	C. Cause	1	titin	heart failure	The recent discovery of titin mutations being a major cause of dilated cardiomyopathy (DCM) also underpins the importance of mechanosensation and mechanotransduction in the pathogenesis of heart failure.
476	A.2 Under-expression	E. Associate	1	AT1R	chf	Compared to vehicle treated CHF rabbits, Tempol significantly decreased AT1R protein expression (1.6+/-0.29 versus 0.88+/-0.16, P<0.05), phosphorylated Jnk protein (0.4+/-0.05 versus 0.2+/-0.04, P<0.05), cytosolic phosphorylated c-Jun (0.56+/-0.1 versus 0.36+/-0.05, P<0.05), and nuclear phosphorylated c-Jun (0.67+/-0.1 versus 0.3+/-0.08, P<0.01).
477	A.1 Over-expression	E. Associate	1	NKCC2	chf	Rats with CHF display increased expression of the Na-K-2Cl cotransporter (NKCC2) in the renal medullary thick ascending limb of the loop of Henle (mTAL), and arginine vasopressin (AVP)-stimulated cAMP formation in mTAL segments is increased in rats with CHF.
478	D.1 Mutation	E. Associate	1	MYBPC3	heart failure	MYBPC3 mutations can be associated with cardiac events such as progressive heart failure, stroke and sudden death even at younger age.
479	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	CHRONIC HEART FAILURE	The reported incidence of hypotension also differs: 5-10% in acute heart failure, 20% in chronic heart failure, 9% in unstable angina and < 1-48% in acute myocardial infarction, with the incidence being much higher with concomitant nitrate therapy plus angiotensin-converting enzyme inhibitors.
480	G. Regulate	B. Target	1	GRK5	heart failure	G protein-coupled receptor kinase 5 (GRK5) is a regulator of cardiac performance and a potential therapeutic target in heart failure in the adult.
481	D.1 Mutation	H. Benefit	1	AMPD1	ACUTE HEART FAILURE	The presence of the C34T mutation in AMPD1 gene appears to be protective against acute heart failure in cardiac donors.
482	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	CHRONIC HEART FAILURE	This was a randomized, standard treatment-controlled, 2-center pilot trial of 102 patients (52 receiving adjunctive therapy with enoxaparin at a dosage of 1.5 mg/kg daily for 3 months and 50 receiving standard therapy with angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics alone) with stable chronic heart failure secondary to dilated cardiomyopathy (New York Heart Association [NYHA] class II and III; left ventricular [LV] ejection fraction, < or = 40%).
483	A.1 Over-expression	E. Associate	1	FGF23	heart failure	Recent studies indicate that FGF23 is also expressed in the heart, and markedly enhanced in various clinical and experimental settings of cardiac remodeling and heart failure independent of preserved or reduced renal function.
484	J. Inhibition	A. Treat	1	ACE	heart failure	In clinical trials that enrolled patients with heart failure, post-MI, diabetes, and hypertension, ARBs did not prevent MI or prolong survival compared with ACE inhibitors, other antihypertensives, or placebo.
485	D.1 Mutation	C. Cause	1	RAF1	heart failure	Hypertrophic cardiomyopathy associated with RAF1 "RASopathy" mutations is a major risk factor for heart failure and death in NS and has been attributed to activation of MEK1/2-ERK1/2 mitogen-activated protein kinases.
486	L. Be regulated	E. Associate	1	TNF	heart failure	Androgenic hormones also regulate pathologic levels of inflammatory cytokines as 11-6 or TNF, in advanced heart failure.
487	L.1 Up-regulation	E. Associate	1	leptin receptor	chf	CHF rats showed hyperleptinemia and excessive ROS in the serum, and the upregulation of MMP-2/9, TNF-alpha, and leptin receptor mRNA and downregulation of TIMP-1/2 mRNA in the myocardium compared with the sham operation group.
488	H. Other	E. Associate	1	caspase-3	heart failure	Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy.
489	J. Inhibition	A. Treat	1	ACE	congestive heart failure	ACE inhibitors have since gained widespread use in the treatment of mild to moderate hypertension, congestive heart failure, myocardial infarction, and diabetic nephropathy.
490	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	The proportion of patients with heart failure (HF) treated with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) is frequently used as quality indicator.
491	D.1 Mutation	E. Associate	1	MYBPC3	heart failure	Myosin binding protein C gene (MYBPC3) mutation was associated with 2 cases of sudden cardiac death and 3 cases of heart failure among 7 affected members.
492	J. Inhibition	A. Treat	1	vasopressin V2 receptor	heart failure	Lixivaptan (VPA-985), being developed by Biogen Idec and Cardiokine, under license from Wyeth (now part of Pfizer), is a non-peptide, selective vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia associated with heart failure.
493	J. Inhibition	H. Benefit	1	ACE	heart failure	Thus prolonged beta blockade and ACE inhibition after infarction may decrease myocardial oxidative stress and thereby could be beneficial in heart failure.
494	J. Inhibition	A. Treat	1	CYP11B2	congestive heart failure	Recently, we proposed inhibition of aldosterone synthase (CYP11B2) as a novel strategy for the treatment of congestive heart failure and myocardial fibrosis and synthesized a large number of inhibitors.
495	I. None	B. Target	1	apelin receptor	heart failure	The apelin receptor (APJ) belongs to family A of the G protein-coupled receptors (GPCRs) and is a potential pharmacotherapeutic target for heart failure, hypertension, and other cardiovascular diseases.
496	D.1 Mutation	C. Cause	1	SMYD1	Cardiac Failure	We describe here the care of an infant suffering from cardiac failure due to an SMYD1 mutation requiring biventricular assist devices as a bridge to successful heart transplantation.
497	F.1 Phosphorylation	E. Associate	1	cTnI	heart failure	The phosphorylation of cardiac troponin I (cTnI) plays an important role in the contractile dysfunction associated with heart failure.
498	G. Regulate	B. Target	1	beta-2 adrenergic receptor	Cardiac Failure	The beta-2 adrenergic receptor (β2AR), a member of GPCR, can activate multiple signaling pathways and is an important treatment target for cardiac failure.
499	J. Inhibition	H. Benefit	1	aldosterone receptor	heart failure	The benefits of aldosterone receptor antagonists (spironolactone and eplerenone) for patients with heart failure were shown in 2 recent randomized controlled trials.
500	J. Inhibition	A. Treat	1	ACE	heart failure	New preliminary insights include exposition of the 'low tech' approach to heart failure diagnosis across Europe: doctors report the use of symptoms and signs alone; the lack of direct (open) access to objective investigations, such as echocardiography, which almost guarantees that misdiagnoses will occur; and the under-utilization and under-dosing with ACE inhibitors.
501	J. Inhibition	A. Treat	1	ACE	heart failure	Beta-blocking agents have proved to be the greatest gain in the treatment of heart failure in recent years, in addition to ACE inhibitors, diuretics and digoxin.
502	D.1 Mutation	C. Cause	1	MYBPC3	systolic heart failure	Homozygous or compound heterozygous frameshift mutations in MYBPC3 encoding cardiac myosin-binding protein C (cMyBP-C) cause neonatal hypertrophic cardiomyopathy (HCM), which rapidly evolves into systolic heart failure and death within the first year of life.
503	J. Inhibition	A. Treat	1	ACE	chf	Angiotensin-converting enzyme (ACE) inhibition constitutes a major advance in the treatment of chronic heart failure (CHF).
504	F.1 Phosphorylation	B. Target	1	Hsp20	heart failure	These findings suggest that phosphorylated Hsp20 may be a potential therapeutic target in heart failure.
505	I. None	B. Target	1	galectin-3	heart failure	In this review we discuss how galectin-3 could be a target for therapy in heart failure.
506	J. Inhibition	H. Benefit	1	angiotensin-converting enzyme	heart failure	Clinical studies indicate that treatment of symptomless left ventricular dysfunction with angiotensin-converting enzyme inhibition at greater than or equal to 1 week following myocardial infarction may prevent further ventricular dilation and reduce the probability of progression to heart failure.
507	J. Inhibition	A. Treat	1	ACE	heart failure	However, unfortunately, very few data are available concerning the combination therapy of ACE inhibitors and nitrates in heart failure and following acute myocardial infarction.
508	A.1 Over-expression	B. Target	1	arginine vasopressin	heart failure	In patients with heart failure (HF), increased arginine vasopressin concentrations are associated with more severe disease, making arginine vasopressin an attractive target for therapy.
509	J. Inhibition	H. Benefit	1	angiotensin-converting enzyme	congestive heart failure	Although angiotensin-converting enzyme inhibitors are beneficial for patients with congestive heart failure, the appropriate timing and dosage in acute myocardial infarction are still controversial.
510	L.1 Up-regulation	E. Associate	1	UCP2	heart failure	Northern blot analysis revealed that UCP2 mRNA level was significantly upregulated in rat heart failure along with BNIP3 protein level.
511	A.1 Over-expression	E. Associate	1	cystatin C	heart failure	High concentrations of cystatin C and low estimated glomerular filtration rate were each associated with heart failure, but the magnitude was greater for blacks than for whites (cystatin C concentration: adjusted hazard ratio for quintile 5 [> or =1.18 mg/dL] vs quintile 1 [<0.84 mg/dL] was 3.0 [95% confidence interval 1.4-6.5] in blacks and 1.4 [95% confidence interval, 0.8-2.5] in whites; estimated glomerular filtration rate: adjusted hazard ratio for quintile 5 (<59.2 mL/min) vs quintile 1 (>86.7 mL/min) was 2.7 [95% confidence interval, 1.4-4.9] in blacks and 1.8 [95% confidence interval, 0.9-3.6] in whites).
512	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	There is good evidence to show that treatment with angiotensin-converting enzyme (ACE) inhibitors in patients with left ventricular systolic dysfunction improves symptoms and signs, slows progression of heart failure, reduces hospitalisation rates, and improves survival.
513	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	chf	A shift in this paradigm has allowed alterations in therapy of CHF such that agents that target the neurohormonal axis and specifically the renin-angiotensin-aldosterone system, with drugs such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers, are utilized.
514	D.1 Mutation	C. Cause	1	LMNA	heart failure	Many LMNA mutation carriers have a poor prognosis, because of a high frequency of MVA and progression to end-stage heart failure.
515	A. Expression	H. Benefit	1	Bcl-2	heart failure	Monocyte-specific Bcl-2 expression attenuates inflammation and heart failure in monocyte chemoattractant protein-1 (MCP-1)-induced cardiomyopathy.
516	A.2 Under-expression	C. Cause	1	dystrophin	heart failure	Duchenne muscular dystrophy (DMD) is caused by an X-linked mutation that leads to the absence of dystrophin, resulting in life-threatening arrhythmogenesis and associated heart failure.
517	H. Other	E. Associate	1	MMP-9	chf	Preformed MMP-2 and MMP-9 were probably activated in CHF, because neither their gene expression nor protein levels were altered (P > 0.05).
518	H. Other	B. Target	1	APJ	heart failure	APJ agonism represents a novel potential therapeutic target for patients with heart failure.
519	J. Inhibition	A. Treat	1	ACE	CHRONIC HEART FAILURE	We report the findings in 31 patients with stable chronic heart failure (CHF) who were treated with spironolactone (50-100 mg/day) or placebo in addition to diuretics and angiotensin converting enzyme (ACE) inhibition.
520	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Advances in the treatment of heart failure may require manipulation of neurohumoral responses to cardiac impairment in addition to the established strategy of angiotensin-converting enzyme (ACE) inhibition.
521	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure	This syndrome responds well to conventional therapy for congestive heart failure with angiotensin-converting enzyme inhibitors, digoxin, and diuretics.
522	J. Inhibition	A. Treat	1	ACE	heart failure	According to these guidelines, all heart failure patients regardless of etiology (with rare exceptions such as obstructive valvular heart disease) should be treated with an angiotensin-converting enzyme (ACE) inhibitor as first-line treatment of the heart failure.
523	J. Inhibition	A. Treat	1	ACE	Decompensated heart failure	The physiologic effects of ACE inhibitors often result in symptomatic relief in patients with heart failure and prevention of episodes of decompensated heart failure and ischemic events in some patients.
524	F.1 Phosphorylation	E. Associate	1	CREB	Cardiac Failure	Cardiac failure is associated with diminished activation of the transcription factor cyclic nucleotide regulatory element binding-protein (CREB), and heart-specific expression of a phosphorylation-deficient CREB mutant in transgenic mice [dominant negative CREB (dnCREB) mice] recapitulates the contractile phenotypes of cardiac failure (Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM.
525	J. Inhibition	H. Benefit	1	ACE	heart failure	Large clinical trials have demonstrated that angiotensin-converting-enzyme (ACE) inhibitors are associated with beneficial outcomes in patients with arterial hypertension, heart failure, coronary artery disease, or a combination of these conditions.
526	J. Inhibition	A. Treat	1	ACE	heart failure	Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely prescribed for the treatment of hypertension and heart failure, as well as for kidney disease prevention in patients with diabetes mellitus and the management of patients after myocardial infarction.
527	G. Regulate	E. Associate	1	ASK1	heart failure	We conclude that ASK1 plays an important role in regulation of cardiac contractile function by phosphorylating cTnT and may participate in cytokine/ROS-induced pathogenesis of cardiomyopathy and heart failure.
528	A. Expression	E. Associate	1	IL-10	chf	The expression of the IL-10 receptor estimated by flow cytometry of mononuclear leukocytes was higher in the CHF patients than in the normal subjects.
529	D.1 Mutation	C. Cause	1	GTPBP3	heart failure	Mutations in MTO1 or GTPBP3 impair the modification of the wobble uridine at position 5 of the pyrimidine ring and cause heart failure.
530	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure	Some studies report that inhibition of angiotensin-converting enzyme (ACE) improves renal function in patients with congestive heart failure, whereas others report that renal deterioration is a frequent complication of treatment with ACE inhibitors.
531	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Patients with symptomatic left ventricular dysfunction should be treated with conventional heart failure therapy, including angiotensin-converting enzyme (ACE) inhibitors, digitalis, diuretics, and beta-blockers.
532	A.2 Under-expression	H. Benefit	1	ICER	heart failure	Valsartan can ameliorate ventricular remodeling and heart failure by inhibiting the expression of ICER and increasing the expression of phosphodiesterase 3A.
533	L.1 Up-regulation	B. Target	1	eNOS	heart failure	Upregulation of eNOS by inhibiting Rho may provide a new pharmacologic target for the treatment of arteriosclerosis, pulmonary hypertension, and heart failure.
534	G. Regulate	E. Associate	1	angiotensin II	heart failure	The results show that under these study conditions, angiotensin II is more potent than potassium in regulating aldosterone in patients with heart failure.
535	J. Inhibition	E. Associate	1	ACE	chf	In parallel, ACE inhibition prevented the reduction of endothelial NO synthase mRNA by CHF.
536	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) guidelines consider angiotensin-converting enzyme (ACE) inhibitors as one of the mainstay therapies in the management of heart failure.
537	A. Expression	E. Associate	1	periostin	heart failure	However, only the coadministration of eplerenone with standard heart failure therapy normalized the expression of matricellular proteins thrombospondin 1, tenascin C, periostin, and secreted protein acidic rich in cysteine/osteonectin to values comparable to normotensive rats.
538	A.2 Under-expression	E. Associate	1	IL-6	heart failure	Moreover, heart failure patients with high plasma Nampt levels showed suppressed cardiac TNF-α and IL-6 mRNA expression after 6 months' follow-up as well as lower B-type natriuretic peptide levels compared with heart failure patients with low Nampt plasma concentrations.
539	J. Inhibition	A. Treat	1	ACE	chf	Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme (ACE) inhibitors in the treatment of chronic heart failure (CHF).
540	H. Other	B. Target	1	XO	heart failure	These studies establish an early interplay between cardiomyocyte XO activation and bioenergetic dysfunction that may provide a new target that prevents progression to heart failure in VO.
541	D.1 Mutation	E. Associate	1	BAG3	heart failure	Mutation and downregulation of the co-chaperone protein BCL-2-associated athanogene 3 (BAG3) are associated with cardiac myopathy and heart failure, and a BAG3 E455K mutation leads to dilated cardiomyopathy (DCM).
542	J. Inhibition	A. Treat	1	ACE	chf	In a series of 202 consecutive HD patients, we combined optimized CHF therapy, including beta-blockers (BB), ACE inhibitors and angiotensin receptor blockers (ARBs), to target doses with full anemia correction by epoetin beta (hemoglobin (Hb) target males 14.5 g/dl, females 13.5 g/dl).
543	J. Inhibition	A. Treat	1	ATGL	heart failure	Overall, this work demonstrates that specifically targeting the adipocyte to inhibit ATGL is a potential treatment for heart failure.
544	J. Inhibition	C. Cause	1	TCTP	heart failure	Dihydroartemisinin, a pharmacological TCTP inhibitor, induced development of heart failure and cardiomyocyte death in control mice, but not in mice with cardiomyocyte-specific TCTP overexpression.
545	D.1 Mutation	C. Cause	1	SHP2	heart failure	Importantly, certain SHP2 mutations such as Q510E can cause a particularly severe form of HCM with heart failure in infancy.
546	A.1 Over-expression	E. Associate	1	MMP-2	heart failure	Matrix metalloproteinase-2 (MMP-2) is prominently overexpressed both after myocardial infarction (MI) and in heart failure.
547	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure	Risk-factor modification has been targeted in the secondary prevention of cardiovascular disease, including lipid management, smoking cessation, improved control of blood pressure, physical activity, weight management, the use of antiplatelet agents/anticoagulants, angiotensin-converting enzyme (ACE) inhibitors in congestive heart failure, beta blockers after myocardial infarction, and estrogen replacement therapy.
548	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	chf	HGF levels in serum and the culture medium were not notably different between CHF patients regularly treated with and without angiotensin-converting enzyme inhibitors.
549	A.1 Over-expression	E. Associate	1	arginine vasopressin	chf	Non-osmotic arginine vasopressin (AVP) release and biosynthesis have been shown to be increased during chronic cardiac failure (CHF) and baroreceptors pathways have been demonstrated to play a major role in this non-osmotic stimulation of AVP.
550	J. Inhibition	A. Treat	1	GSNOR	heart failure	GSNOR ablation is protective in models of asthma and heart failure, raising the idea that GSNOR inhibitors might hold therapeutic value.
551	J. Inhibition	A. Treat	1	AII	congestive heart failure	A large number of compounds known as "AII (Angiotensin II) antagonists" have been developed for the treatment of various heart diseases such as hypertension, congestive heart failure, and chronic renal failure.
552	I. None	E. Associate	1	angiotensin II	chf	We found that (1) although AT(1)R expression in the RVLM was upregulated, the AT(2)R was significantly downregulated (CHF: 0.06+/-0.02 versus sham: 0.15+/-0.02, P<0.05); (2) simultaneously stimulating RVLM AT(1)R and AT(2)R by angiotensin II evoked sympathoexcitation, hypertension, and tachycardia in both sham and CHF rats with greater responses in CHF; (3) stimulating RVLM AT1R with angiotensin II plus the specific AT(2)R antagonist PD123319 induced a larger sympathoexcitatory response than simultaneously stimulating AT(1)R and AT(2)R in sham rats, but not in CHF; (4) activating RVLM AT(2)R with CGP42112 induced a sympathoinhibition, hypotension, and bradycardia only in sham rats (renal sympathetic nerve activity: 36.4+/-5.1% of baseline versus 102+/-3.9% of baseline in artificial cerebrospinal fluid, P<0.05); (5) pretreatment with 5,8,11,14-eicosatetraynoic acid, a general inhibitor of arachidonic acid metabolism, into the RVLM attenuates the CGP42112-induced sympathoinhibition.
553	D.1 Mutation	C. Cause	1	ACTC1	heart failure	A combined phenotype of ASD and late-onset heart failure was caused by a heterozygous, nonsynonymous ACTC1 mutation.
554	J. Inhibition	A. Treat	1	ACE	heart failure	Although medical therapy, particularly with angiotensin-converting enzyme (ACE) inhibitors, has been demonstrated to prolong life in patients with chronic heart failure, the effect of standard medical therapy on sudden unexpected death in patients with heart failure is less well understood.
555	J. Inhibition	H. Benefit	1	ACE	heart failure	ACE inhibitors (ACEIs) and angiotensin II type 1 (AT(1)) receptor blockers are effective in reducing left ventricular mass in hypertension and heart failure.
556	J. Inhibition	H. Benefit	1	ACE	heart failure	The Consensus trial in patients with class IV heart failure suggested that ACE inhibitors were effective in improving survival.
557	D.1 Mutation	C. Cause	1	myocardin	heart failure	Mice harboring a cardiomyocyte-restricted null mutation in the myocardin gene (Myocd) develop dilated cardiomyopathy and succumb from heart failure within a year.
558	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	congestive heart failure	Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure.
559	D.1 Mutation	H. Benefit	1	AMPD1	CHRONIC HEART FAILURE	We tested the hypothesis that possession of the C34T nonsense mutation in AMPD1 gene, which is known to improve survival in chronic heart failure, protects against cardiac dysfunction in donors.
560	G. Regulate	B. Target	1	CCN2	heart failure	Modulation of CCN2 (CTGF, connective tissue growth factor) and associated early ECM changes may represent a new therapeutic target in the treatment and prevention of heart failure in HCM.
561	D.1 Mutation	C. Cause	1	XIRP2	heart failure	The synergistic effects of TNNT2 and XIRP2 mutations, resulting in perturbed sarcomeric force generation and transmission, respectively, would account for an early-onset heart failure phenotype.
562	J. Inhibition	A. Treat	1	ACE	Cardiac Failure	Angiotensin Converting Enzyme (ACE) inhibitors represent a major advance in the treatment of: hypertension, and generally speaking, in cardiovascular prevention; myocardial infarction; cardiac failure.
563	J. Inhibition	A. Treat	1	ACE	CHRONIC HEART FAILURE	1 Characteristics of cyclic GMP- and cyclic AMP-mediated relaxation in aortic segments of rats with chronic heart failure (CHF) and the effects of chronic treatment with an angiotensin I converting enzyme (ACE) inhibitor, trandolapril, were examined 8 weeks after coronary artery ligation.
564	I. None	B. Target	1	GRK2	systolic heart failure	GRK2 appears a promising target, given its established role in insulin resistance and in systolic heart failure.
565	A.2 Under-expression	E. Associate	1	SCN5A	heart failure	To support the clinical relevance of this mechanism, BRG1/BRM occupancy was diminished at the same target genes in human heart failure cases compared to controls, and this correlated with increased c-MYC expression and decreased CX43 and SCN5A expression.
566	A.1 Over-expression	E. Associate	1	NCX1	heart failure	The expression of the sodium/calcium exchanger NCX1 increases during cardiac hypertrophy and heart failure, playing an important role in Ca(2+) extrusion.
567	I. None	A. Treat	1	ANP	Acute Congestive Heart Failure	On the basis of these findings, we prepared a fusion protein carrying human atrial natriuretic peptide (ANP), a drug for acute congestive heart failure.
568	I. None	H. Benefit	1	EC-SOD	heart failure	Extracellular superoxide dismutase (EC-SOD) is of particular interest, as it demonstrates in vivo the protective action against development of atherosclerosis, hypertension, heart failure, diabetes mellitus.
569	F.1 Phosphorylation	E. Associate	1	cTnI	heart failure	Protein kinase C (PKC)-mediated phosphorylation of troponin I (cTnI) at Ser42/44 is increased in heart failure.
570	J. Inhibition	A. Treat	1	ACE	CONGESTIVE CARDIAC FAILURE	ACE inhibitors and beta blockers in chronic congestive cardiac failure: therapeutic basis.
571	D.1 Mutation	C. Cause	1	LMNA	congestive heart failure	On the other hand, affected subjects from three FPLD pedigrees with heterozygous R28W, R60G and R62G LMNA mutations in the amino-terminal had associated cardiomyopathy presenting as premature onset of congestive heart failure, dilated cardiomyopathy and conduction system disturbances.
572	F.1 Phosphorylation	E. Associate	1	eNOS	heart failure	Thus, increased VCAM-1 and PAI-1, and decreased eNOS phosphorylation through the TLR4/NFκB/p38 pathway, may be associated with atrial thrombogenesis in the heart failure mice model.
573	J. Inhibition	A. Treat	1	ACE	congestive heart failure	The role of ACE inhibitors has been established in the treatment of hypertension and congestive heart failure.
574	I. None	B. Target	1	LOXL2	heart failure	Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment.
575	I. None	B. Target	1	APJ	CHRONIC HEART FAILURE	In combination with its interaction with the renin-angiotensin system, APJ agonism may provide a new therapeutic target in the treatment of acute and chronic heart failure.
576	J. Inhibition	A. Treat	1	ACE	heart failure	Short-term improvement in submaximal exercise capacity by optimized therapy with ACE inhibitors and beta blockers in heart failure patients is associated with restoration of peripheral endothelial function.
577	I. None	G. Marker	1	NRON	heart failure	Circulating long non-coding RNAs NRON and MHRT as novel predictive biomarkers of heart failure.
578	J. Inhibition	A. Treat	1	ACE	heart failure	Given the dramatic decline in quality of life with heart failure, this end-point should be a much more important target for healthcare interventions, especially treatments such as ACE inhibitors and beta-blockers that are shown to improve quality of life.
579	J. Inhibition	A. Treat	1	angiotensin-converting enzyme	heart failure	Accordingly, blockade of this system by angiotensin-converting enzyme (ACE) inhibitors has assumed a central role in the treatment of heart failure.
580	J. Inhibition	A. Treat	1	ACE	congestive heart failure	Overall, the evidence does not support the use of ACE inhibitors as first-line drugs in the management of most patients with hypertension, although they have proven benefit as second-line drugs for the treatment of congestive heart failure and left ventricular dysfunction secondary to myocardial infarction.
581	J. Inhibition	E. Associate	1	ACE	chf	Nevertheless, ACE inhibitors can impair renal function in CHF, leading to an actual increase in plasma concentrations.
582	D.1 Mutation	E. Associate	1	GPX4	cardiorespiratory failure	Mutations in GPX4 were linked to Sedaghatian disease, characterized by bone and brain anomalies and cardiorespiratory failure.
583	D.1 Mutation	C. Cause	1	LDB3	Cardiac Failure	Additional cardiac stress, such as that caused by AVR and/or KD might have triggered cardiac failure in the form of LVNC due to LDB3 mutation.
584	G. Regulate	E. Associate	1	AVP	chf	A number of studies have shown that rats with congestive heart failure (CHF) have increased protein levels of the vasopressin (AVP)-regulated water channel aquaporin-2 (AQP2) even during conditions with unchanged circulating levels of AVP, suggesting an increase in the sensitivity of the AVP type 2 (V2) receptor in experimental CHF.
585	A.2 Under-expression	C. Cause	0	MMP-2	heart failure	We hypothesize that genetic ablation of TIMP-2 exacerbates the adverse cardiac matrix remodelling due to lack of pro-angiogenic MMP-2 and increase in anti-angiogenic factors during pressure overload stress and results in severe heart failure.
586	A.2 Under-expression	E. Associate	0	ANP	heart failure	This study was aimed to clone and sequence corin in the rat and to analyze corin mRNA expression in heart failure when ANP release upon stretch is blunted.
587	A. Expression	E. Associate	0	ST2	heart failure	The aim of this study was (1) to investigate myocardial expression of the IL-33/ST2 pathway in relation to myocardial fibrosis in end-stage heart failure patients and (2) to study whether plasma sST2 is associated with histologically determined cardiac fibrosis.
588	C. Activation	E. Associate	0	glucagon-like peptide 1 receptor	heart failure	There appears to be growing evidence for the benefit of sodium-glucose cotransporter-2 inhibitors, and there are still not enough data to fully support the safety of glucagon-like peptide 1 receptor agonists in heart failure.
589	D.1 Mutation	E. Associate	1	KCNT1	heart failure	Herein we describe 3 infants with malignant migrating partial seizures with KCNT1 mutations accompanied by massive systemic to pulmonary collateral arteries with life-threatening hemoptysis and heart failure.
590	F.1 Phosphorylation	E. Associate	1	cTnI	chf	The relative percentages of the total phosphorylated cTnI forms over the entire cTnI populations (%P(total)) were 56.4 ± 3.5%, 36.9 ± 1.6%, 6.1 ± 2.4%, and 1.0 ± 0.6% for postmortem hearts with normal cardiac function (n = 7), early stage of mild hypertrophy (n = 5), severe hypertrophy/dilation (n = 4), and end-stage CHF (n = 6), respectively.
591	J. Inhibition	E. Associate	1	ACE	heart failure	In patients with stable coronary artery disease (CAD) without overt heart failure, ACE inhibitors are among the most commonly used drugs as these agents have been proven effective in reducing the risk of cardiovascular events.
592	D.1 Mutation	E. Associate	1	RyR	heart failure	Pathological desynchronization of the clocks may explain sinus node dysfunction in heart failure and RyR mutations.
593	I. None	E. Associate	0	OPN	heart failure	In this review, we will discuss diverse roles of OPN related to cardiovascular diseases, including atherosclerosis, valvular stenosis, hypertrophy, myocardial infarction and heart failure.
594	I. None	E. Associate	0	erythropoietin	CHRONIC HEART FAILURE	Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.".
595	A. Expression	E. Associate	1	AVP	CONGESTIVE CARDIAC FAILURE	The extraction and assay procedures were validated by observing the changes in plasma AVP and ANP concentrations in normal subjects at different stages of hydration and in elderly patients during treatment for congestive cardiac failure.
596	J. Inhibition	E. Associate	0	ECE	chf	We therefore investigated the effects of endothelin-converting enzyme (ECE) inhibition and endothelin ETA receptor blockade in CHF patients treated with ACE inhibitors.
597	L.1 Up-regulation	E. Associate	0	APJ	Cardiac Failure	In cardiac failure, endothelial apelin expression correlates with other hypoxia-responsive genes, and in healthy animals both apelin and APJ are markedly upregulated in various tissues following systemic hypoxic exposure.
598	I. None	E. Associate	0	CPT	congestive heart failure (CHF)	In a group of 10 patients (9 male, 1 female, aged 16 to 56, mean 43 years) with severe congestive heart failure (CHF), due to ischemic heart disease (8 cases) or dilatative cardiomyopathy (2 cases), the acute hemodynamic response to captopril (CPT) (90 min after 50 mg po) was evaluated.
599	A. Expression	E. Associate	1	aquaporin-2	CHRONIC HEART FAILURE	[Effects of perindopril on expression of kidney aquaporin-2 and urine aquaporin-2 excretion in chronic heart failure rats].
600	A. Expression	E. Associate	1	AR	CHRONIC HEART FAILURE	However, there are few reports concerning AR expression and the protective effect of angiotensin II receptor blockers (ARB) on the lung in chronic heart failure (CHF).
601	I. None	E. Associate	0	YKL-40	congestive heart failure (CHF)	The concentrations of serum and pleural fluid YKL-40 and conventional pleural marker levels were measured in 80 subjects with pleural effusions, including 23 transudates caused by congestive heart failure (CHF), and 57 exudates including 23 parapneumonic, 22 malignant and 12 tuberculous pleural effusions (TBPEs).
602	A. Expression	E. Associate	1	NCX	heart failure	hemodynamics) on the regulation of NKA isoform and NCX expression in heart failure by comparing the pattern of change in right atrial myocardium during heart failure with that previously determined for LV.
603	I. None	H. Benefit	0	CD30	heart failure	Here, we hypothesized that brentuximab vedotin, which targets CD30, induces apoptosis in tumourigenic cells, thus increasing the safety of iPSC therapy for heart failure.
604	I. None	E. Associate	0	osteopontin	Diastolic Heart Failure	Plasma concentration of 17 biomarkers (matrix metalloproteinase [MMP]-1, -2, -3, -7, -8, and -9; tissue inhibitors -1, -2, -3, and -4; N-terminal propeptide of brain natriuretic peptide (NT-proBNP); cardiotrophin; osteopontin; soluble receptor for advanced glycation end products; collagen I teleopeptide; collagen I NT-proBNP; and collagen III N-terminal propetide [PIIINP]), an echocardiogram, and 6-minute hall walk were performed on 241 referent control subjects, 144 patients with LVH but no evidence of heart failure, and 61 patients with LVH and diastolic heart failure (DHF).
605	L. Be regulated	E. Associate	0	S100A1	heart failure	We hypothesized that S100A1 is regulated during human hypertrophy and heart failure and that it may be implicated in remodeling after left ventricular assist device.
606	I. None	E. Associate	1	RyR	heart failure	But that is expected given the large number of participating proteins, the relevance of phosphorylation in heart failure and inherited arrhythmic diseases, and the frustrations of predicting relationships between structure and function before the advent of a high resolution structure of RyR.
607	G. Regulate	E. Associate	1	TNF	congestive heart failure	Although patients with advanced congestive heart failure express elevated circulating levels of tumour necrosis factor-alpha (TNFalpha), little is known about the prognostic importance and regulation of TNF in the heart in cardiac disease states.
608	D.1 Mutation	E. Associate	0	NOS1AP	chf	A total of 1,428 patients with CHF and 480 control subjects were genotyped for 6 SNPs of NOS1AP, and the genetic associations with mortality as well as QTc interval were analyzed.
609	F.2 Methylation	E. Associate	0	ERBB3	heart failure	We detected methylation differences in pathways related to heart disease, but also in genes with yet unknown function in DCM or heart failure, namely Lymphocyte antigen 75 (LY75), Tyrosine kinase-type cell surface receptor HER3 (ERBB3), Homeobox B13 (HOXB13) and Adenosine receptor A2A (ADORA2A).
610	A. Expression	E. Associate	0	GPR35	Cardiac Failure	Since mechanisms controlling GPR35 expression are not known, we investigated the regulation of GPR35 gene and protein expression in cardiac myocytes and in the mouse models of cardiac failure.
611	F.1 Phosphorylation	E. Associate	0	phospholamban	heart failure	Inotropic and lusitropic responses were measured in left ventricular muscle strips and cyclic nucleotide levels, PDE activity and phospholamban (PLB) and troponin I (TnI) phosphorylation were measured in ventricular cardiomyocytes from Wistar rats with heart failure 6 weeks after myocardial infarction.
612	A.2 Under-expression	E. Associate	1	angiotensin II	chf	In addition, EPI-ext significantly inhibited the serum levels of tumor necrosis factor alpha, norepinephrine, angiotensin II and brain natriuretic peptide in rats with CHF and improved the histological changes including cadiocyte hypertrophy, cadiocyte degeneration, inflammatory infiltration, and cardiac desmoplasia.
613	A.1 Over-expression	E. Associate	0	angiotensin II	CHRONIC HEART FAILURE	Since 1) dilated cardiomyopathy (DCM) causes chronic heart failure (CHF), and 2) augmentation of neurohumoral factors such as angiotensin II impairs glucose metabolism, we examined the rate of abnormal glucose metabolism in patients having both DCM and CHF and whether correction of the impairment of glucose metabolism would improve the pathophysiology of CHF in DCM patients.
614	L. Be regulated	E. Associate	0	ANP	heart failure	Although both hormones exert almost identical biological actions, the differential regulation of cardiac ANP and BNP mRNA in compensated and overt heart failure is not known.
615	A. Expression	E. Associate	1	DDAH-1	Acute Congestive Heart Failure	The biological effect of pharmacological treatment on dimethylaminohydrolases (DDAH-1) and cationic amino acid transporter-1 (CAT-1) expression in patients with acute congestive heart failure.
616	F.2 Methylation	E. Associate	0	HER3	heart failure	We detected methylation differences in pathways related to heart disease, but also in genes with yet unknown function in DCM or heart failure, namely Lymphocyte antigen 75 (LY75), Tyrosine kinase-type cell surface receptor HER3 (ERBB3), Homeobox B13 (HOXB13) and Adenosine receptor A2A (ADORA2A).
617	M.2 Knock in	E. Associate	0	inhibitor-1	heart failure	Aim of our study was to assess the effects of adeno-associated virus serotype 9 (AAV9) - mediated cardiac-specific expression of constitutively active inhibitor-1 (I-1c) and to investigate whether I-1c is able to attenuate the development of heart failure in mice subjected to transverse aortic constriction (TAC).
618	I. None	E. Associate	0	CML	chf	We evaluated whether the AGE/RAGE system is activated in stable CHF and COPD, and whether plasma sRAGE and CML levels are affected by clinical and functional parameters.
619	J. Inhibition	E. Associate	0	dipeptidyl peptidase 4	heart failure	We assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database.
620	I. None	E. Associate	1	IGF-I	heart failure	Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study.
621	I. None	E. Associate	0	galectin-3	heart failure	Moreover, though not specifically investigated in diabetic cohorts, plasma levels of galectin-3 correlated with the prevalence of diabetes and related metabolic conditions, thus suggesting that pharmacological blockade of this lectin might be successful for treating heart failure especially in subjects suffering from these disorders.
622	I. None	E. Associate	1	ET	chf	Conflicting data exist about the endothelin-1 (ET) level in patients with mild to moderate CHF and the effect of maximal exercise on plasma ET levels.
623	I. None	E. Associate	0	TNF-alpha	chf	At baseline, 125 patients with CHF were assessed for kidney dysfunction and Type D. Serum levels of proinflammatory cytokines (TNF-alpha, sTNFR1, sTNFR2, IL-6), the anti-inflammatory cytokines IL-10, and IL-1 receptor antagonist were measured at 1-year follow-up.
624	A. Expression	E. Associate	0	TIMP-1	congestive heart failure	To study the changes of matrix metalloproteinase-3 (MMP-3) and tissue inhibitor of matrix metalloproteinase-1(TIMP-1) expression during congestive heart failure.
625	J. Inhibition	E. Associate	0	angiotensin-converting enzyme	heart failure	The mechanisms of action of omapatrilat, an agent that inhibits both neutral endopeptidase 24.11 and angiotensin-converting enzyme, on arterial function in patients with heart failure have not been previously reported.
626	A.1 Over-expression	A. Treat	0	ANP	chf	However, it is still unknown whether such elevation of the ANP and BNP may offer a therapeutic benefit to the progression of chronic heart failure (CHF).
627	A. Expression	E. Associate	0	proliferating cell nuclear antigen	chf	In 20 myocardial samples from patients with terminal CHF (before and after LVAD), the protein expression of survivin, cyclin D1, cdk4, p16(INK4a), and proliferating cell nuclear antigen (PCNA) was immunohistochemically investigated and morphometrically quantified by calculating the percentage of positive cardiomyocytes per visual field.
628	I. None	H. Benefit	0	apelin	heart failure	The present study investigates whether apelin, a newly described inotropic peptide with important cardiovascular regulatory properties, contributes to the functional improvement in patients with severe heart failure after cell transplantation.
629	D.1 Mutation	E. Associate	0	PTPN11	congestive heart failure	We report on a woman with LS and a novel Gln510His mutation in PTPN11, who had progressive HCM with congestive heart failure and nonsustained ventricular tachycardia, successfully treated with implantable cardioverter defibrillator (ICD).
630	L. Be regulated	E. Associate	1	LIMK1	chf	Thus, we determined to probe into the effects of miR-93 in rats with CHF by targeting LIMK1 through regulating RhoA/ROCK pathway.
631	F.2 Methylation	E. Associate	0	ASC	heart failure	Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure.
632	I. None	E. Associate	0	adrenomedullin	heart failure	We have developed a specific radioimmunoassay and measured the immunoreactivity of human adrenomedullin in the plasma of 58 male subjects: eight with essential hypertension, 12 with heart failure, 10 with ascites due to cirrhosis, 12 with chronic renal failure, four with hypoxia due to chronic obstructive pulmonary disease and 12 control subjects.
633	I. None	E. Associate	0	IL-17	chf	Since VD expresses anti-inflammatory properties, we investigated its impact on cytokines implicated in CHF, such as TNFα and IL-17, in patients suffering from CHF.
634	I. None	H. Benefit	0	GHRP	chf	However, whether GHRP have a beneficial effect on chronic heart failure (CHF) is unclear, and the present work aims to clarify this issue.
635	I. None	E. Associate	0	guanine nucleotide regulatory protein	congestive heart failure	We have examined another hypothesis, one that states the stimulatory guanine nucleotide regulatory protein (Gs) that couples the beta-adrenergic receptor to adenylate cyclase activity is also decreased in congestive heart failure.
636	I. None	E. Associate	0	GRK2	heart failure	Although the canonical role of GRKs is to desensitize G protein-coupled receptors via phosphorylation, it has been demonstrated that GRK5, unlike GRK2, can reside in the nucleus of myocytes and exert G protein-coupled receptor-independent effects that promote maladaptive cardiac hypertrophy and heart failure.
637	L. Be regulated	H. Benefit	0	AC6	heart failure	Therefore, in the present study, we aimed to explore whether HSF1 can play its role in ameliorating heart failure by regulating AC6, and how the potential internal mechanisms work.
638	A. Expression	E. Associate	0	PLB	heart failure	These data also show that the altered SR function in human heart failure cannot be explained by altered protein levels of PLB and SERCA2.
639	I. None	E. Associate	0	DBP	heart failure	This study sought to determine if low serum 25-hydroxyvitamin D (25[OH]D) is associated with incident heart failure (HF) and if the association is: 1) partly mediated by traditional cardiovascular risk factors; 2) stronger among whites than blacks; and 3) stronger among those genetically predisposed to having high levels of vitamin D binding protein (DBP).
640	J. Inhibition	H. Benefit	0	angiotensin-converting enzyme	congestive heart failure (CHF)	This study aimed to examine whether angiotensin-converting enzyme (ACE) inhibition improved cardiac fatty acid metabolism in patients with congestive heart failure (CHF).
641	I. None	E. Associate	0	antidiuretic hormone	congestive heart failure (CHF)	Plasma antidiuretic hormone (ADH), PRA, plasma osmolality, and the parameters of renal water excretion were measured after overnight dehydration and for 5 h after an oral load in 14 patients with congestive heart failure (CHF) treated with diuretics (group 1), 8 hypertensive patients without CHF also treated with diuretics (group 2), and 11 patients with coronary artery disease but without CHF who were not treated with diuretics (group 3).
642	D.1 Mutation	E. Associate	0	LMNA	heart failure	Limb-girdle muscular dystrophy with severe heart failure overlapping with lipodystrophy in a patient with LMNA mutation p.Ser334del.
643	F.2 Methylation	E. Associate	0	norepinephrine transporter	heart failure	To explore the methylation status in promoter region of norepinephrine transporter gene (NET, SLC6A2) in heart failure ( HF) patients and its correlation with qi deficiency/blood stasis syndrome (QDS/BSS).
644	F.1 Phosphorylation	E. Associate	0	MLCK	heart failure	In order to determine changes in MLC phosphorylation in cardiac hypertrophy and heart failure, the relative content of MLCK and MLC phosphorylation in the cardiac muscle from both sham control and experimental rats were assessed at 4 and 8 weeks following ligation of the left coronary artery.
645	A. Expression	E. Associate	0	titin	heart failure	We tested whether changes in titin isoform expression occur in the diastolic dysfunction that accompanies heart failure.
646	A.1 Over-expression	E. Associate	0	GLP-1	heart failure	To elucidate the effect of increased endogenous GLP-1 during heart failure progression, the DPP4 inhibitor saxagliptin or vehicle was administered by daily oral gavage to female TG9 mice, a transgenic model of dilated cardiomyopathy, starting at day of life 42, just prior to the development of detectable contractile dysfunction.
647	L. Be regulated	E. Associate	0	TIMP4	heart failure	To validate this hypothesis, we created heart failure model by creating AV fistula in C57BL/6 mice and looked into the promoter methylation (methylation specific PCR, high resolution melting, methylation sensitive restriction enzyme and Na bisulphite treatment followed by sequencing), histone modification (ChIP assay) and microRNAs that regulate TIMP4 (mir122a) and MMP9 (mir29b and mir455-5p).
648	I. None	E. Associate	0	von Willebrand factor	chf	We hypothesized that acute and chronic CHF may manifest different degrees of endothelial damage/dysfunction and activation, as reflected by different plasma endothelial markers, such as von Willebrand factor (vWF) and soluble thrombomodulin (both are indexes of endothelial damage/dysfunction) and soluble E-selectin (an index of endothelial activation).
649	J. Inhibition	E. Associate	0	ACE	heart failure	Can angiotensin converting enzyme (ACE) inhibitors influence the risk of sudden cardiac death in patients with heart failure?
650	F.1 Phosphorylation	E. Associate	0	phospholamban	heart failure	We therefore investigated whether alterations in cAMP-dependent phosphorylation of phospholamban may be responsible for the reduced SR Ca2+-ATPase activity in human heart failure.
651	I. None	E. Associate	0	VASP	heart failure	In platelets from patients with heart failure due to idiopathic dilated cardiomyopathy (n= 16) and healthy control subjects (n= 23), NO synthase (NOS) activity was evaluated by L-[(3)H]-arginine to l-[(3)H]-citrulline conversion, cGMP was determined by radioimmunoassay, vasodilator-stimulated phosphoprotein (VASP: total and serine-239-phosphorylated) was assessed by western blotting, and O(2)(-) production and O(2)(-) scavenging capacity were measured by pholasin-enhanced chemiluminescence.
652	A. Expression	E. Associate	0	eNOS	CHRONIC HEART FAILURE	Endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) gene expression in the skeletal muscle, peak oxygen consumption (VO2) and calf peak reactive hyperemia were measured before and after 12 weeks of supervised physical training in 10 patients with chronic heart failure.
653	A. Expression	E. Associate	0	dynamin-related protein 1	heart failure with reduced ejection fraction	We sought to investigate the expression of this pathway along with the expression of mitochondrial biogenesis (PGC-1α [peroxisome proliferator-activated receptor-γ coactivator-1α]), dynamics (DRP-1 [dynamin-related protein 1], OPA-1 [optic atrophy 1], and MFN 2 [mitofusin 2]), and oxidative phosphorylation (citrate synthase and electron transport chain complexes) markers and COX IV (cytochrome C oxidase) activity in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
654	I. None	E. Associate	0	erythropoietin	chf	Serum hepcidin-25, erythropoietin (EPO), ferritin and IL-6 concentrations were measured in 61 CHF patients.
655	A. Expression	E. Associate	0	PACAP	heart failure	Therefore, the aim of the present study was to measure the alterations of blood PACAP levels in chronic heart failure caused by primary dilated cardiomyopathy or ischemic cardiomyopathy and to examine the possible relationship between serum levels of PACAP, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and systolic left ventricular function, the most reliable biomarkers of heart failure.
656	I. None	E. Associate	0	LD	heart failure	Papillary muscles from 20 patients with heart failure during mitral valves replacement and 6 control subjects died of non-cardiac accidents were obtained and free fat acid (FFA), lactic acid (LD) and the activity of Na(+)K(+)-ATPase and Ca(2+)Mg(2+)-ATPase, protein and mRNA expressions of beta(3)-adrenergic receptor and PPARalpha were measured.
657	D.1 Mutation	C. Cause	0	ACTC	heart failure	To test the hypothesis that actin dysfunction leads to heart failure, patients with hereditary idiopathic dilated cardiomyopathy (IDC) were examined for mutations in the cardiac actin gene (ACTC).
658	A. Expression	E. Associate	0	titin	heart failure	This study examined the effects of long-term monotherapy with the aldosterone receptor blocker eplerenone on mRNA and protein expression of the cytoskeletal proteins titin, tubulin, fibronectin and vimentin, the matrix metalloproteinases (MMPs)-1, -2 and -9, and the tissue inhibitors of MMPs (TIMPs)-1 and -2 in left ventricular (LV) myocardium of dogs with heart failure (HF).
659	A. Expression	E. Associate	0	dynamin-related protein 1	HEART FAILURE WITH PRESERVED EJECTION FRACTION	We sought to investigate the expression of this pathway along with the expression of mitochondrial biogenesis (PGC-1α [peroxisome proliferator-activated receptor-γ coactivator-1α]), dynamics (DRP-1 [dynamin-related protein 1], OPA-1 [optic atrophy 1], and MFN 2 [mitofusin 2]), and oxidative phosphorylation (citrate synthase and electron transport chain complexes) markers and COX IV (cytochrome C oxidase) activity in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
660	A. Expression	E. Associate	0	aromatase	systolic heart failure	Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure.
661	I. None	E. Associate	0	parathyroid hormone-related protein	chf	Blood samples from the patients with chronic heart failure (CHF) caused by ischaemic disease (coronary artery disease) (NYHA class I-IV) were used to analyze the levels of calcium, inorganic phosphate, sodium, potassium, parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP).
662	A. Expression	E. Associate	0	DRP-1	HEART FAILURE WITH PRESERVED EJECTION FRACTION	We sought to investigate the expression of this pathway along with the expression of mitochondrial biogenesis (PGC-1α [peroxisome proliferator-activated receptor-γ coactivator-1α]), dynamics (DRP-1 [dynamin-related protein 1], OPA-1 [optic atrophy 1], and MFN 2 [mitofusin 2]), and oxidative phosphorylation (citrate synthase and electron transport chain complexes) markers and COX IV (cytochrome C oxidase) activity in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
663	A. Expression	E. Associate	0	inducible NOS	hypertensive heart failure	To elucidate the relationship between renin-angiotensin system and nitric oxide in hypertensive heart failure, we evaluated the effects of long-term treatment with imidapril, angiotensin-converting enzyme inhibitor, on endothelial-cell nitric oxide synthase (eNOS) and inducible NOS (iNOS) expression in the left ventricle (LV) and its relation to myocardial remodelling in failing heart of Dahl salt-sensitive hypertensive rats (DS) fed a high-salt diet.
664	J. Inhibition	E. Associate	0	NEP	chf	We studied CGRP-like immunoreactivity (CGRP-ir) in rat plasma in a coronary artery-ligation model of CHF with and without NEP inhibition.
665	F.1 Phosphorylation	E. Associate	0	eNOS	CHRONIC HEART FAILURE	Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure.
666	J. Inhibition	E. Associate	0	AVP	heart failure	The purpose of this study was to examine the renal effects of a V2 receptor arginine vasopressin (AVP) antagonist in heart failure.
667	A. Expression	E. Associate	0	RPLP0	heart failure	We assessed the expression of 16 reference genes (ACTB, B2M, GAPDH, GUSB, HMBS, HPRT1, IPO8, PGK1, POLR2A, PPIA, RPLP0, TBP, TFRC, UBC, YWHAZ, 18S) in tissues from: right and left ventricles from healthy controls and heart failure (HF) patients; right-atrial tissue from patients in sinus rhythm with (SRd) or without (SRnd) atrial dilatation, patients with paroxysmal (pAF) or chronic (cAF) atrial fibrillation or with HF; and left-atrial tissue from patients in SR or cAF.
668	A.1 Over-expression	E. Associate	1	HER2	breast cancer	Neoadjuvant chemotherapy plus trastuzumab results in a 30% to 50% pathologic complete response (pCR) rate in human epidermal growth factor receptor 2 (HER2)-positive breast cancer and has been associated with improved therapeutic outcomes.
669	A.1 Over-expression	E. Associate	1	progesterone receptor	breast cancer	Evidence suggests hormonal factors may be more strongly associated with estrogen receptor+progesterone receptor+ (ER+PR+) than ER-PR- breast cancer risk.
670	I. None	B. Target	1	estrogen receptor	Triple-negative breast cancer	Triple-negative breast cancer (TNBC) is insensitive to endocrine therapy and targeted therapy to human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER) and progesterone receptor (PR).
671	H. Other	B. Target	1	FGFR1	GASTRIC CANCER	It also displays an outstanding anti-tumor activity in a gastric cancer xenograft tumor model by targeting FGFR1 signaling.
672	I. None	E. Associate	1	EGFR	NSCLC	In Thailand, the first-line treatment for advanced NSCLC with TKIs conditional on EGFR test results was not cost-effective as compared with platinum doublets for all.
673	L. Be regulated	E. Associate	1	STAT3	lung cancer	MiR-218 acts as a tumor suppressor in lung cancer via IL-6/STAT3 signaling pathway regulation.
674	A. Expression	E. Associate	1	PD-L1	non-small cell lung cancer	The PD-1 inhibitor pembrolizumab may be a better first-line treatment than chemotherapy for many patients with advanced non-small cell lung cancer: In a phase III trial, patients with PD-L1 expression of 1% or higher treated with the drug had better overall survival, a longer duration of response, and fewer side effects than patients who received chemotherapy alone.
675	A.2 Under-expression	E. Associate	1	MMP1	lung metastasis	Therapeutic inhibition of miR-181a decreased expression of VEGF and MMP1 in vitro, and angiogenesis, MMP1 activity, tumor growth, and lung metastasis, all by more than 50%, in a xenograft mouse model.
676	J. Inhibition	A. Treat	1	ALK	non-small cell lung cancer	Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
677	J. Inhibition	A. Treat	1	ALK	NSCLC	ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment.
678	L. Be regulated	C. Cause	1	VIM	lung cancer	The target genes of 13 deregulated miRNAs including CRK, NR2F2, VIM, RASSF1, CCND2, PRKCA, SIRT1, CDK6, MAP3K7, HIF1A, UBE2V2, ATG10, BAX, E2F1, RASSF5 and CTNNB1, could involve in the pathway of lung cancer developing.
679	D.1 Mutation	E. Associate	1	RET	MEN2A	In the interests of simplifying genetic molecular diagnosis, I suggest the following guidelines: 1) only in cases of total colonic aganglionosis (TCA) is it advisable to carry out full RET mutation screening (the mutation rate is up to 70 %); and 2) all HSCR patients should be tested only for standard MEN2A and MTC mutations.
680	I. None	F. None	1	EGFR	breast cancer	These trials were designed to determine if patients with advanced malignancies would derive benefit from the addition of seribantumab to standard-of-care drugs in platinum-resistant/refractory ovarian cancer, hormone receptor-positive HER2-negative breast cancer, and EGFR wild-type non-small cell lung cancer (NSCLC).
681	I. None	E. Associate	1	MMP9	breast cancer	Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.
682	D.1 Mutation	C. Cause	1	BRCA2	familial breast cancer	Less than 20% of familial breast cancer patients who undergo genetic testing for BRCA1 and BRCA2 carry a pathogenic mutation in one of these two genes.
683	F.1 Phosphorylation	E. Associate	1	4EBP1	breast cancer	Here, we undertook an effort to uncover the mechanisms underlying the limited efficacy of rapamycin, and found that the transit suppression of 4EBP1 phosphorylation led to cap-dependent translation and cell proliferation in breast cancer cells.
684	I. None	C. Cause	1	GALNT14	breast cancer	These findings indicate that GALNT14 contributes to breast cancer invasion by altering the cell proliferation, motility, expression levels of EMT genes, and by stimulating MMP-2 activity, suggesting GALNT14 may be a potential target for breast cancer treatment.
685	A. Expression	H. Benefit	1	BRCA1	breast cancer	These preliminary results on the effects of lycopene on the expression of BRCA1 and BRCA2 oncosuppressor genes in breast cancer may reflect cross-talk between the oestrogen and retinoic acid receptor (RAR) pathways.
686	A.2 Under-expression	E. Associate	1	EBP50	breast cancer	In this study, we investigate the potential function of EBP50 through over-expression in the breast cancer cell line, MDA-MB-231, which has low EBP50 protein expression levels.
687	A.2 Under-expression	E. Associate	1	estrogen receptor	Triple-negative breast cancer	Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer.
688	A.2 Under-expression	E. Associate	1	HER2	breast cancer	EGFR, p53 and vimentin were highly expressed in ER(-)/HER2(-) breast cancer cells (p<0.01).
689	A.1 Over-expression	E. Associate	1	ER	breast cancers	Although many estrogen receptor-positive (ER+) breast cancers are effectively treated with selective estrogen receptor modulators and down-regulators (SERM/SERD), some are highly resistant.
690	A. Expression	C. Cause	1	COX-2	breast cancer	These data provide impetus to investigate how baseline COX-2 expression is regulated in premenopausal breast tissue because COX-2 levels in normal breast epithelium may prove to be an indicator of breast cancer risk in young women, and predict the chemopreventive and therapeutic efficacy of COX-2 inhibitors in this population.
691	I. None	C. Cause	1	HNE	breast cancer	Given the growing evidence supporting the role of HNE in breast cancer progression and metastasis, we assessed the cellular effects of compounds 3 and 4 in the context of targeting invasive breast cancer.
692	I. None	B. Target	1	E2F-1	GASTRIC CANCER	E2F-1 gene silencing can enhance cisplatin chemosensitivity of gastric cancer SGC-7901/DDP cells possibly by down-regulating survivin and Bcl-2 expressions, suggesting the value of E2F-1 as a new chemotherapeutic target for gastric cancer.
693	G. Regulate	E. Associate	1	EGF	GASTRIC CANCER	The identification of miR-610 as a novel miRNA regulated by EGF that targets VASP in gastric cancer cells suggests that EGF-miR610-VASP axis may be exploited for therapeutic intervention to inhibit gastric cancer progression and metastasis.
694	A. Expression	C. Cause	1	IL-18	Gastric carcinoma	The positive expressions of IL-12 and IL-18 can play an important role in progression and metastasis of gastric cancer, and IL-12 might be an independent factor of poor prognosis in gastric carcinoma.
695	G. Regulate	C. Cause	1	B7-H3	HEPATOMA	Consistently in experiments performed in vitro, B7-H3 was able to stimulate the wound healing, metastasis and invasion of hepatoma cells by targeting epithelial-to-mesenchymal transition (EMT) via JAK2/Stat3/Slug signaling pathway, while no obvious influence on cell growth and apoptosis.
696	L. Be regulated	H. Benefit	1	SEMA4C	hepatocellular carcinoma	MiR-205 suppresses tumor growth, invasion, and epithelial-mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma.
697	L. Be regulated	C. Cause	1	PTEN	hepatocellular carcinoma	MicroRNA-20b promotes proliferation of H22 hepatocellular carcinoma cells by targeting PTEN.
698	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	non-small cell lung cancer	The epidermal growth factor receptor (EGFR) mutation status has become one of the most important factors in the treatment of non-small cell lung cancer.
699	J. Inhibition	C. Cause	1	MMP9	NSCLC	Furthermore, the demethylation of SFRP2 gene appeared to inhibit Zinc Finger E-Box Binding Homeobox 1 (ZEB1) and matrix metallopeptidase 9 (MMP9), two key factors that enhance NSCLC cell invasion.
700	I. None	F. None	1	GATA3	lung adenocarcinoma	In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
701	A.1 Over-expression	G. Marker	1	c-Met	lung adenocarcinoma	Therefore, c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion can coexist in lung adenocarcinoma and may become a potential biomarker of cancer refractory to crizotinib, chemotherapy, and radiotherapy as well as of a relatively poor prognosis.
702	L. Be regulated	C. Cause	1	STAT3	lung metastasis	PLOD3 promotes lung metastasis via regulation of STAT3.
703	D.1 Mutation	E. Associate	1	EGFR	NSCLC	Recent phase one data and our case indicate osimertinib should be viewed as a best practice for treatment of LM disease in epidermal growth factor receptor (EGFR) mutated NSCLC regardless of T790M status.
704	D.1 Mutation	C. Cause	1	ALK	NSCLC	Crizotinib is an oral tyrosine kinase inhibitor approved in 2011 as a first-line therapy for patients with metastatic ALK mutation-driven NSCLC.
705	I. None	B. Target	1	EGFR	NSCLC	Small-molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) pathways are used clinically for patients with non-small cell lung cancer (NSCLC).
706	A.1 Over-expression	E. Associate	1	NBR2	NSCLC	Simultaneous overexpression of NBR2 and Notch1 could reverse the inhibitory effect of NBR2 on proliferation and migration of NSCLC cells.
707	L. Be regulated	E. Associate	1	TP53	lung cancer	These results demonstrate that miR-1269 promotes cell survival and proliferation by targeting TP53 and caspase-9 in lung cancer.
708	D.1 Mutation	G. Marker	1	EGFR	lung cancer	Circulating tumor DNA (ctDNA) is an approved noninvasive biomarker to test for the presence of EGFR mutations at diagnosis or recurrence of lung cancer.
709	A.1 Over-expression	E. Associate	1	BMI1	lung adenocarcinoma	High expression of HectH9 and six stemness-related genes (BMI1, SOX2, OCT4, NANOG, NOTCH1, and NOTCH2) predicted poor survival in patients with head and neck squamous cell carcinoma and lung adenocarcinoma.
710	D.1 Mutation	E. Associate	1	EGFR	lung cancer	The European Commision (EC) recently approved osimertinib for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR T790M mutations.
711	D.1 Mutation	F. None	1	BRAF	lung cancers	The recent FDA approvals of crizotinib, an ALK kinase inhibitor that has yielded significant clinical benefit in ALK-translocated lung cancers, and vemurafenib, a BRAF-selective kinase inhibitor that has demonstrated dramatic clinical efficacy in BRAF mutant melanoma patients, define the new landscape for tailored cancer drug therapy.
712	A.1 Over-expression	G. Marker	1	EGFR	non-small cell lung cancer	The overexpression of epidermal growth factor receptor (EGFR) is closely associated with a poor outcome in non-small cell lung cancer (NSCLC), and EGFR is an ideal biomarker for the targeted therapy of NSCLC.
713	D.1 Mutation	E. Associate	1	EGFR	lung adenocarcinoma	We here describe a patient with EGFR mutation-positive lung adenocarcinoma who developed severe hepatotoxicity during treatment first with gefitinib and then with erlotinib, but who was subsequently able to continue treatment with afatinib for at least 44 weeks with no evidence of hepatotoxicity or disease progression.
714	D.1 Mutation	E. Associate	1	BRAF	thyroid cancer	AICAR inhibited the proliferation of BRAF V600E-mutant thyroid cancer cell lines more strongly than was the case with wild-type cell lines.
715	D.1 Mutation	F. None	1	VHL	MEN 2	In 166 patients (25.9%) the disease was familial and caused by germline mutations in VHL (56), SDHB (34), SDHD (31), RET (31) or NF1 (14), causing von Hippel-Lindau disease, SDHB- or SDHD-PH/FPGL syndromes, multiple endocrine neoplasia type 2 (MEN 2) and type 1 neurofibromatosis (NF1), respectively.
716	L.1 Up-regulation	E. Associate	1	CD25	breast cancer	The culture supernatant of ASCs isolated from breast cancer patients with pathological stage III induced upregulation of the mRNA expression levels of IL-4, TGF-β1, IL-10, CCR4 and CD25 in PBLs.
717	A.2 Under-expression	E. Associate	1	HER2	breast cancers	They are represented with 15% of all breast cancers, characterized with lack of hormone receptor as well as with negative expression of HER2 test.
718	L.1 Up-regulation	C. Cause	1	LRH-1	breast cancer	Recent studies have demonstrated that the liver receptor homolog-1 (LRH-1), another nuclear receptor, regulates breast cancer cell proliferation and promotes motility and invasion.
719	G. Regulate	E. Associate	1	caspase 8	breast cancer	Normally inactive in breast cancer, caspase 8 can cleave Vps34 at residue D285, which directly abolished its lipid kinase activity and dramatically altered cell invasion potential, colony formation, as well as tumorigenesis in orthotopic engraftments in mice.
720	D.1 Mutation	E. Associate	1	cofilin	breast cancer	In vivo findings confirmed that erucin-mediated inhibition of tumor growth in a breast cancer cell xenograft mouse model is associated with the mitochondrial translocation of cofilin and Drp1, fission and apoptosis.
721	J. Inhibition	H. Benefit	1	ADAM17	breast cancer	Targeting this protease, TNF-alpha-converting enzyme (TACE; also referred to as a disintegrin and metalloproteinase 17 [ADAM17]), with small molecular inhibitors or siRNAs reverted the malignant phenotype in a breast cancer cell line by preventing mobilization of 2 crucial growth factors, TGF-alpha and amphiregulin.
722	G. Regulate	E. Associate	1	ER	breast cancer	Regarding the article "The p160 ER co-regulators predict outcome in ER negative breast cancer" by Spears, Oesterreich, Migliaccio et al. published in Breast Cancer Res Treat, March 2011.
723	A. Expression	E. Associate	1	ER	breast cancer	Taken together, our results suggest that lapatinib induces p27 expression via both transcriptional and post-translational upregulations, leading to cell cycle arrest and cell proliferation inhibition, and that its effect on breast cancer cells may be modified by ER expression status.
724	A.1 Over-expression	E. Associate	1	PTX3	metastatic breast cancer	PTX3 expression was also up-regulated in a bone metastatic breast cancer cell line and further enhanced by pro-inflammatory cytokine TNFα.
725	H. Other	E. Associate	1	MCPH1	BREAST CARCINOMA	To understand the importance of MCPH1 and ATM in deregulation of DNA damage response pathway in breast carcinoma, we studied m-RNA expression and genetic/epigenetic alterations of these genes in primary breast carcinoma samples.
726	D.5 Polymorphism	E. Associate	1	GSTT1	breast cancer	GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene.
727	A.1 Over-expression	E. Associate	1	HER2	breast cancers	A limitation of trastuzumab is that its activity is largely restricted to breast cancers with the highest level of HER2 overexpression or HER2 gene amplification.
728	H. Other	C. Cause	1	BRCA2	breast cancer	There is abundant evidence, that alterations in the breast cancer susceptibility genes, BRCA1 and BRCA2, are present in a large proportion of families with multiple cases of breast and ovarian cancer.
729	A.1 Over-expression	E. Associate	1	CXorf61	breast cancer	For example, HORMAD1, CXorf61, ACTL8, and PRAME are highly enriched in the basal subtype of breast cancer; MAGE and CSAG are most frequently activated in the magnoid subtype of lung adenocarcinoma; and PRAME is highly upregulated in the ccB subtype of clear cell renal cell carcinoma.
730	A.1 Over-expression	E. Associate	1	CaM	breast cancer	Calmodulin (CaM) that is overexpressed in breast cancer plays a critical role in regulating DR5-mediated apoptosis.
731	A.1 Over-expression	E. Associate	1	hormone receptor	breast cancer	Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial.
732	L. Be regulated	E. Associate	1	miR-29b	Invasive Breast Cancer	The differential regulation of miR-29b by S100A7 in ER-positive and ER-negative breast cancer is supported by the gene expression analysis of TCGA invasive breast cancer dataset.
733	H. Other	H. Benefit	1	NRF2	GASTRIC CANCER	Nuclear factor erythroid 2-related factor 2 (NRF2) signaling is regarded as an important way to mitigate the effects of reactive oxygen species (ROS) damage and inhibit gastric cancer progress.
734	A.2 Under-expression	E. Associate	1	15-PGDH	GASTRIC CANCER	In a gastric cancer cell line with a very low 15-PGDH expression (TMK-1), the 15-PGDH promoter was methylated and treatment with a demethylating agent 5-aza-2'-deoxycytidine restored 15-PGDH expression.
735	A.1 Over-expression	E. Associate	1	MMP-9	GASTRIC CANCER	Plasma MMP-9 level was significantly elevated in gastric cancer patients when compared with control subjects (P < 0.001).
736	A.1 Over-expression	H. Benefit	1	FOXA2	GASTRIC CANCER	Over-expression of FOXA2 in MKN-45 cells up-regulates E-cadherin expression and inhibits gastric cancer cell migration and invasion.
737	A. Expression	E. Associate	1	MYC	GASTRIC CANCER	Our findings suggest that the measurement of plasma HER2 and MYC gene levels could improve the screening of gastric cancer.
738	A.1 Over-expression	E. Associate	1	HER2	GASTRIC CANCER	The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence in situ hybridisation, respectively.
739	L.1 Up-regulation	C. Cause	1	CCL26	hepatocellular carcinoma	Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells.
740	H. Other	A. Treat	1	interleukin-2	hepatocellular carcinoma	Immunotherapy using Freund's adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma.
741	A.2 Under-expression	E. Associate	1	ACSS2	hepatocellular carcinoma	Despite exhibiting no gross deficits in growth or development, adult mice lacking ACSS2 exhibit a significant reduction in tumor burden in two different models of hepatocellular carcinoma.
742	A.1 Over-expression	E. Associate	1	CCL18	NSCLC	Our results showed that the median serum concentration of CCL18 was significantly elevated to 436.11 ng/mL in NSCLC patients compared to 41.97 ng/ml in healthy people ( P<0.01), which was also positively related to the expression of lung cancer biomarkers carcinoma-embryonic antigen and cytokeratin fragment antigen 21-1.
743	A. Expression	E. Associate	1	Arp11	lung adenocarcinoma	Expression of the Arp11 gene may regulate the metastatic potential of PC-14 human lung adenocarcinoma.
744	A.1 Over-expression	E. Associate	1	E2	NSCLC	The expression levels of E2, CEA, NSE, and CYFRA21-1 in patients with NSCLC were significantly higher than those in patients with BPL ( P < .05); E2 was positively correlated with tumor markers ( P < .01).
745	L. Be regulated	E. Associate	1	HIF-1	non-small cell lung cancer	We demonstrate that in non-small cell lung cancer (NSCLC), p53 mutants exert a gain-of-function (GOF) effect on HIF-1, thus regulating a selective gene expression signature involved in protumorigenic functions.
746	A.1 Over-expression	B. Target	1	XIAP	lung cancer	X-linked inhibitor of apoptosis protein (XIAP) has been shown to be highly expressed in lung cancer, but not in normal lung tissue, which makes it an attractive target for lung cancer treatment.
747	A.1 Over-expression	E. Associate	1	TCTP	lung cancer	DHA could inhibit A549 lung cancer cell proliferation, and simultaneously up-regulate the expression of TCTP mRNA, but down-regulate its protein expression in A549 cells.
748	A.1 Over-expression	E. Associate	1	ALK	NSCLC	Patients in cohort 1 had EGFR+/ALK+ NSCLC with at least 25%, or less than 25%, of tumour cells with PD-L1 expression.
749	J. Inhibition	A. Treat	1	EGFR	lung cancer	cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer.
750	I. None	B. Target	1	STAT3	lung cancer	Together, we showed that STAT3 and STAT1 could be valuable chemopreventive and therapeutic targets within the lung tumor microenvironment in addition to being targets within tumor itself, and that silibinin inhibits their activation as a plausible mechanism of its efficacy against lung cancer.
751	L.1 Up-regulation	E. Associate	1	AKR1B10	lung cancer	The present study observed the upregulation of Aldo‑keto reductase family 1 member Bio10 (AKR1B10) lung cancer tissues by analyzing two public lung cancer gene expression datasets.
752	I. None	C. Cause	1	rearranged during transfection	MEN2A	Four major forms of MEN, which are autosomal dominant disorders, are recognized and referred to as: MEN type 1 (MEN1), due to menin mutations; MEN2 (previously MEN2A) due to mutations of a tyrosine kinase receptor encoded by the rearranged during transfection (RET) protoncogene; MEN3 (previously MEN2B) due to RET mutations; and MEN4 due to cyclin-dependent kinase inhibitor (CDNK1B) mutations.
753	G. Regulate	E. Associate	1	leukemia inhibitory factor	MTC	Previously, we reported that expression of activated Ras or Raf in the human MTC cell lines, TT and MZ-CRC-1, can induce growth arrest and RET downregulation via a leukemia inhibitory factor (LIF)-mediated autocrine/paracrine loop.
754	D.3 Fusion	F. None	1	TPM3	Medullary Carcinoma	ALK is rendered oncogenic as a result of its fusion to NPM1 in anaplastic large cell lymphoma, to TPM3 or TPM4 in inflammatory myofibroblastic tumor, to EML4 in non-small cell lung carcinoma, and to VCL in renal medullary carcinoma.
755	L.2 Down-regulation	E. Associate	1	TPIS	lobular carcinoma	ACTB, ACTG, TPM3, TBA1A, TBA1B, VIME, TPIS, PDIA3, PDIA6, and VTDB were upregulated in ductal carcinoma compared to in lobular carcinoma samples.
756	A.1 Over-expression	E. Associate	1	COX-2	breast cancer	COX-2 overexpression has been observed in colon, head and neck, lung, prostate, stomach, and breast cancer.
757	A. Expression	E. Associate	1	p21	breast cancer	Treatment with bisphenol A and methoxychlor results in the growth of human breast cancer cells and alteration of the expression of cell cycle-related genes, cyclin D1 and p21, via an estrogen receptor-dependent signaling pathway.
758	D.1 Mutation	E. Associate	1	breast cancer resistance protein	breast cancer	The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein.
759	D.1 Mutation	E. Associate	1	PIK3CA	breast cancer	Human epidermal growth factor receptor 2 (HER2; ERBB2) amplification and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations often co-occur in breast cancer.
760	I. None	E. Associate	1	MRP1	BREAST CARCINOMA	P-glycoprotein (P-gp) / MDR1, MRP1 and LRP may play more important roles than BCRP in chemotherapy of human breast carcinoma.
761	I. None	E. Associate	1	TNF-alpha	breast cancer	S468 phosphorylation occurred rapidly after TNF-alpha and IL-1beta in T cell, B cell, cervix carcinoma, hepatoma, breast cancer, and astrocytoma lines and in primary hepatic stellate cells as well as peripheral blood mononuclear cells.
762	I. None	B. Target	1	ER	breast cancer	The ER has been a highly successful target for breast cancer treatment.
763	G. Regulate	E. Associate	1	KISS1R	breast cancer	KISS1R signaling promotes drug resistance by increasing the expression of efflux drug transporter, breast cancer resistance protein (BCRP) and by inducing the activity and transcription of the receptor tyrosine kinase, AXL.
764	J. Inhibition	H. Benefit	1	RANKL	breast cancer	Experimental data show that RANKL inhibitors can play a role in reducing tumor-induced lesions of bone in multiple myeloma, breast cancer, prostate cancer and lung cancer.
765	I. None	C. Cause	1	WT1	breast cancer	The results indicate that the wild-type WT1 gene plays an important role in the tumorigenesis of primary breast cancer.
766	D.1 Mutation	E. Associate	1	TP53	breast cancer	These patches can be recognized on the basis of mutations in TP53, and have been reported for head and neck, lung, skin, and breast cancer.
767	D.1 Mutation	C. Cause	1	BRCA2	breast cancer	BRCA1 and BRCA2 mutation carriers with breast cancer have a high risk of ipsilateral breast cancer tumor recurrence (IBTR) and a high lifetime risk of contralateral breast cancer (CBC).
768	D.1 Mutation	E. Associate	1	CDC2	breast cancer	Two variants in EIF3A (rs10787899 and rs3824830; P < 0.01) and four variants in SART1 (rs660118, rs679581, rs754532, and rs735942; P(trend) < or = 0.02) were significantly associated with an altered risk of breast cancer along with single variants in RRM2, PSCD3, C11orf51, CDC16, SNW1, MFAP1, and CDC2 (P < 0.05).
769	L.1 Up-regulation	E. Associate	1	IDO1	breast cancer	DOX induced immunogenic cell death of murine breast cancer cells 4T1 as well as the upregulation of IDO1.
770	A.1 Over-expression	E. Associate	1	HER2	breast cancer	While signaling cascades downstream of HER2 and HER3 have been studied extensively at the level of post-translational modification, little is known about the effects of HER2/HER3 overexpression and activation on gene expression in breast cancer.
771	D.1 Mutation	C. Cause	1	BRCA2	breast cancers	Approximately 5% of all breast cancers can be attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2.
772	A.2 Under-expression	E. Associate	1	TPD52	breast cancer	Finally, miR-107 could further reduce the decreased expression of TPD52, Wnt1, β-catenin and cyclin D1 that was induced by PTX in both mRNA and protein levels, which were rescued by pcDNA3.1-TPD52 indicating that miR-107 regulated breast cancer cell sensitivity to PTX may be targeting TPD52 through Wnt/β-catenin signaling pathway.
773	G. Regulate	E. Associate	1	transferrin	breast cancer	To evaluate the role of the 5-lipoxygenase (5-LO) pathway on breast cancer growth regulation, we exposed cells to insulinlike growth factor-1 or transferrin, which increased the levels of the 5-LO metabolite, 5(S)-hydrooxyeicosa-6E,8C,11Z,14Z-tetraenoic acid (5-HETE), by radioimmunoassay and high-performance liquid chromatography.
774	H. Other	B. Target	1	CTCF	breast cancer	The present study provides a new insight into the tumor suppressor roles of CTCF in breast cancer development and suggests that the CTCF/NF-κB pathway is a potential target for breast cancer therapy.
775	A.2 Under-expression	E. Associate	1	DC-SCRIPT	breast cancer	We have previously identified the loss of expression of the transcription regulator DC-SCRIPT (Zfp366) as a prominent prognostic event in estrogen receptor positive breast cancer patients.
776	A.1 Over-expression	E. Associate	1	IGFBP-3	GASTRIC CANCER	Overexpression of IGFBP-3 resulted in significant inhibition of total and phosphorylated p65 NF-κB and IκB proteins in gastric cancer cells.
777	L. Be regulated	E. Associate	1	p21	GASTRIC CANCER	Effects of microRNA-106 on proliferation of gastric cancer cell through regulating p21 and E2F5.
778	J. Inhibition	H. Benefit	1	DNA topoisomerase I	GASTRIC CANCER	DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
779	D.1 Mutation	E. Associate	1	IL-17F	GASTRIC CANCER	Additionally, the variant genotypes of IL-17F T7488C could alter the risk of gastric cancer under the following comparisons (C vs T OR = 1.29, 95 % CI, 1.13-1.47, POR < 0.001; TC vs TT OR = 1.35, 95 % CI, 1.14-1.60, POR < 0.001; CC + TC vs TT OR = 1.35, 95 % CI, 1.15-1.58, POR < 0.001).
780	D.1 Mutation	E. Associate	1	BRAF	gists	Secondary resistance to IM in GISTs typically occurs due to several mechanisms that include hemi- or homo-zygous deletion of the wild-type KIT allele, overexpression of focal adhesion kinase (FAK) and insulin-like growth factor receptor I (IGF-1R) amplification, BRAF mutation, a RTK switch (loss of c-KIT and gain of c-MET/AXL), etc.
781	A.1 Over-expression	E. Associate	1	gastrokine 1	GASTRIC CANCER	Overexpression of gastrokine 1 in gastric cancer cells induces Fas-mediated apoptosis.
782	I. None	E. Associate	1	ER	GASTRIC CANCER	A steroid specificity study of ER showed the presence of an binder in gastric cancer tissue.
783	A.2 Under-expression	E. Associate	1	KLF6	Gastric carcinoma	Decreased expression of KLF6 in gastric carcinoma was significantly associated with histological differentiation (P<0.01), TNM stage (P<0.05), lymph node metastasis (P<0.01) and distant metastasis (P<0.05).
784	D.1 Mutation	E. Associate	1	SDHD	gists	In a separate condition, in which the association (or dyad) of GISTs with PGLs is inherited in an autosomal dominant manner (Carney-Stratakis syndrome, CSS), germline mutations of the SDHB, SDHC and SDHD genes (but not KIT or PDFGRA) were found; GISTs in this condition were caused by SDH deficiency.
785	A.1 Over-expression	E. Associate	1	DEK	hepatocellular carcinoma	Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma.
786	L.1 Up-regulation	E. Associate	1	CYPA	hepatocellular carcinoma	Up-regulation of CYPA has been found to be a common phenomenon in several tumor types, including in hepatocellular carcinoma (HCC).
787	F.2 Methylation	E. Associate	1	CTGF	HEPATOMA	In conclusion, aberrant methylation of COL1A2, IGFBP2, CTGF and fibronectin 1 genes were detected in hepatoma cell lines.
788	J. Inhibition	E. Associate	1	cytochrome P450 2E1	liver tumors	However, competitive inhibition of cytochrome P450 2E1, which metabolizes DENA, by its other substrate, isopropanol, does not weaken, but enhances the toxicity of DENA effect on mice and reduces the number of preneoplastic nodules and liver tumors induced by it.
789	C. Activation	E. Associate	1	SLC25A12	hepatocellular carcinoma	Here, we demonstrate that SLC25A12 gene is reactivated in hepatocellular carcinoma (HCC) HepG2 cell line through histone acetylation and CREB recruitment.
790	I. None	B. Target	1	epidermal growth factor receptor	lung cancer	One molecular target for lung cancer is the epidermal growth factor receptor (EGFR).
791	D.1 Mutation	E. Associate	1	EGFR	lung cancer	Here, we observed that a high level of FOXO3a was correlated with EGFR mutation-independent EGFR-TKI sensitivity, the suppression of cancer stemness, and better progression-free survival in lung cancer patients.
792	J. Inhibition	A. Treat	1	EGFR	lung cancer	We suggest concomitant EGFR and TNF inhibition as a potentially new treatment approach that could be beneficial for a majority of lung cancer patients.
793	J. Inhibition	H. Benefit	1	aromatase	lung cancer	We previously showed that the aromatase inhibitor (AI) anastrozole decreased development of tobacco carcinogen-induced lung tumors in a murine lung cancer prevention model and that aromatase and estrogen receptor were expressed in pulmonary inflammatory cells.
794	L.1 Up-regulation	E. Associate	1	ALDH1A1	NSCLC	Furthermore, the levels of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) were observed to be upregulated in resistant cells and PLAC8-overexpressing parent cells, suggesting that ALDH1A1 may be involved in the association between the overexpression of PLAC8 and AZD9291 resistance in NSCLC.
795	D.1 Mutation	E. Associate	1	EGFR	NSCLC	To address this challenge, in the last years the therapeutic algorithm of NSCLC has become much more complex and articulated, with different kinds of drugs, including chemotherapy, targeted-based agents, angiogenesis inhibitors and immunotherapy, and multiple lines of treatments, for patients with squamous and non-squamous hystology, EGFR mutation and ALK rearrangement.
796	A. Expression	E. Associate	1	FAK	SCLC	Focal Adhesion Kinase (FAK), one of the central genes represented in this pathway, was commonly expressed in SCLC tumors and constitutively phosphorylated in SCLC cell lines.
797	D.1 Mutation	E. Associate	1	EGFR	NSCLC	Preclinical in vitro experiments demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) might have synergistic effect in combination with radiotherapy on Non-small cell lung cancer (NSCLC), but the clinical trials showed inconsistence results in NSCLC patients with EGFR status unknow or mutations.
798	A. Expression	E. Associate	1	PI3K	NSCLC	Survival was significantly improved in advanced NSCLC with PI3K- and p-Akt-negative expression compared with PI3K- and p-Akt-positive expression [P13K: 17.70 months (95% confidence interval (CI), 15.11-20.28 months) vs. 13.43 months (95% CI, 11.83-15.02 months); P=0.004; and p-Akt: 17.13 months (95% CI, 14.93-19.34 months) vs. 13.07 months (95% CI, 11.32-14.82 months); P=0.007].
799	A. Expression	E. Associate	1	p63	lung adenocarcinoma	Chromosomal rearrangements and copy number abnormalities of TP63 correlate with p63 protein expression in lung adenocarcinoma.
800	L. Be regulated	H. Benefit	1	JAK2	Non-Small-Cell Lung Carcinoma	miR-204 suppresses non-small-cell lung carcinoma (NSCLC) invasion and migration by targeting JAK2.
801	D.2 Rearrangement	E. Associate	1	ALK	NSCLC	Search for similar cases in the literature reveals that concomitant K-RAS mutations and ALK rearrangement occur in a subset of NSCLC and seems to lead to resistance to crizotinib.
802	A. Expression	G. Marker	1	CK	SCLC	These data suggest that the biological characteristics of LCNEC and SCLC may be different and the expression of CK may serve as differential diagnostic markers.
803	I. None	G. Marker	1	KL-6	lung adenocarcinoma	Human serum Krebs von den Lungen-6 (KL-6) antigen, a high-molecular-weight glycoprotein classified as a polymorphic epithelial mucin (MUC1), is a biomarker of diseases such as interstitial pneumonia, lung adenocarcinoma, breast cancer, colorectal adenocarcinoma, and hepatocellular carcinoma.
804	D.1 Mutation	E. Associate	1	EGFR	lung adenocarcinoma	Quantitative analysis of DESCT could help detect solid lung adenocarcinoma harboring EGFR or KRAS mutation, or ALK rearrangement.
805	A. Expression	E. Associate	1	CD137L	NSCLC	Positive CD137L expression was observed in 53/102 (52.0%) of the NSCLC samples and correlated with early TNM stage (P = 0.046), well-differentiated tumors (P = 0.009) and better overall survival (P = 0.004).
806	A.1 Over-expression	E. Associate	1	MSLN	lung cancer	MSLN overexpression was found in human lung tumors, lung cancer cell lines, and BSW cells.
807	I. None	H. Benefit	1	CCL21	lung cancer	Here we describe that vault nanocapsule platform for CCL21 delivery elicits antitumor activity with inhibition of lung cancer growth.
808	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	non-small cell lung cancer	Drug resistance of non-small cell lung cancer (NSCLC) is highly correlated to the mutation of the epidermal growth factor receptor (EGFR).
809	A. Expression	E. Associate	1	ERCC1	NSCLC	Our study found that panobinostat, an HDAC inhibitor, increased the cisplatin sensitivity of several NSCLC cell lines with low ERCC1 expression but not those with high ERCC1 expression or gain-of-function (GOF) p53 mutation despite of ERCC1 expression level.
810	A. Expression	E. Associate	1	EGFR	NSCLC	We therefore suggest that combination treatment with ZD1839 and trastuzumab might have improved therapeutic efficacy against NSCLC cells expressing both EGFR and HER2.
811	A. Expression	E. Associate	1	HMGB1	lung cancer	The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and the p53 status.
812	D.1 Mutation	E. Associate	1	EGFR	lung adenocarcinoma	Herein, we describe a novel mutation in EGFR exon 20 in a female non-smoker bearing a lung adenocarcinoma, characterized by the insertion of a nucleotide triplet GTT, which translates into a protein with an additional Valine between Proline 772 and Histidine 773 (p.P772_H773insV-c.2316_2317insGTT).
813	I. None	G. Marker	1	MMP-9	lung cancer	In conclusion MMP-9 can serve as a marker for metastasis and can be valuable in the follow-up of lung cancer patients.
814	G. Regulate	E. Associate	1	FOXO1	NSCLC	Together, FOXO1 plays dual roles in TKI resistance through posttranslational modifications in NSCLC and this study provides a possible strategy for treatment of TKI-resistant NSCLC patients.
815	I. None	B. Target	1	BCL2	lung cancer	BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
816	D.1 Mutation	E. Associate	1	EGFR	lung cancer	Non-small-cell lung cancer (NSCLC) is associated with diverse genetic alterations including mutation of epidermal growth factor receptor (EGFR).
817	A.2 Under-expression	C. Cause	1	TERT	lung adenocarcinoma	The high risk variant of rs2853677 disrupts the Snail1 binding site and derepresses TERT expression in response to Snail1 upregulation, thus increasing lung adenocarcinoma susceptibility.
818	I. None	B. Target	1	CXCR2	lung adenocarcinoma	The CXCR2 axis may be an important target in smoking-related lung adenocarcinoma.
819	D.1 Mutation	C. Cause	1	RET	MEN 2a	The RET C611Y mutation causes MEN 2A and associated cutaneous
820	G. Regulate	H. Benefit	1	papillary thyroid carcinoma susceptibility candidate 3	papillary thyroid carcinoma	Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits proliferation and invasion of glioma cells by suppressing the Wnt/β-catenin signaling pathway.
821	D.1 Mutation	E. Associate	1	BRAF	thyroid cancers	TERT promoter mutations are highly prevalent in advanced thyroid cancers, particularly those harboring BRAF or RAS mutations, whereas PTCs with BRAF or RAS mutations are most often TERT promoter wild type.
822	J. Inhibition	E. Associate	1	VEGFR1	cancer of the thyroid	In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT).
823	I. None	E. Associate	0	ADAM10	HER2 Positive Breast Cancer	Therefore, we studied the role of ADAM10 in relation to trastuzumab treatment and resistance in HER2 positive breast cancer.
824	D.5 Polymorphism	E. Associate	0	APOE	breast cancer	The primary purpose of this study was to compare the neuropsychological performance of long-term survivors of breast cancer and lymphoma treated with standard dose chemotherapy who carried the epsilon 4 allele of the Apolipoprotein E (APOE) gene to those who carry other APOE alleles.
825	H. Other	E. Associate	0	PHB2	breast cancer	Here, we focus on whether XN directly binds to the tumour suppressor protein prohibitin 2 (PHB2), forming a novel natural antitumour compound targeting the BIG3-PHB2 complex and acting as a pivotal modulator of E2/ERα signalling in breast cancer cells.
826	J. Inhibition	A. Treat	0	Bcl-2	breast cancer	We examined the effect of antisense (AS) Bcl-2 in combination with anticancer drug for targeting therapy against Bcl-2 in gastric and breast cancer cells.
827	A. Expression	E. Associate	0	RIZ1	Gastric carcinoma	Mutation status of the p53 gene was not associated with methylation status or RIZ1 expression in gastric carcinoma.
828	I. None	E. Associate	0	IL-6	NSCLC	Individual concentrations of thymus and activation-regulated cytokine (C-C motif chemokine ligand 17), Gro-b (C-X-C motif chemokine ligand 2 (CXCL2)), CXCL13, interleukin (IL)-1ra, IL-6, IL-8 (CXCL8), IL-16, IL-17A, macrophage migration inhibitory factor (MIF), granulocyte colony-stimulating factor, platelet-derived growth factor subunit B, MMP-2, MMP-8 and MMP-12 were significantly different in serum from NSCLC and COPD patients.
829	F.2 Methylation	E. Associate	0	RASSF1A	lung cancer	The aims of our study were to i) determine the methylation profile of RASGRF2 and ii) compare the methylation profiles of RASGRF2 with RASSF1A in lung cancer.
830	D.1 Mutation	E. Associate	0	BRCA1	breast cancer	We did a prospective multicentre cohort study in 649 women aged 35-49 years with a strong family history of breast cancer or a high probability of a BRCA1, BRCA2, or TP53 mutation.
831	J. Inhibition	H. Benefit	0	mammalian target of rapamycin	breast cancer	The PI3K catalytic subunit inhibitor BKM120, the mammalian target of rapamycin (mTOR) inhibitor RAD001 and the dual PI3K/mTOR inhibitor BGT226 were tested against ER-positive breast cancer cell lines before and after long-term estrogen deprivation (LTED).
832	F.2 Methylation	E. Associate	0	RASSF1A	breast cancer	Promoter hypermethylation of 8 tumor suppressor genes (RASSF1A, APC, HIN1, BRCA1, CYCLIND2, RARbeta, CDH1 and TWIST1) and DNA methylation for three repetitive elements (LINE1, Sat2 and Alu) were analyzed in invasive ductal carcinoma of the breast, paired adjacent normal tissue and WBC from 40 breast cancer patients by the MethyLight assay.
833	J. Inhibition	E. Associate	0	IGF-I	breast cancer	The aim of this study was to determine the relationship between inhibition of IGF-I responsiveness and induction of apoptosis by vitamin D analogues in breast cancer cells.
834	D.1 Mutation	E. Associate	0	FOXO1	HEPATOMA	In the present study we mutated Leu375 to alanine in the nuclear export signal of Foxo1 (mouse FOXO1), so that it would remain in the nucleus of H4IIE rat hepatoma cells after insulin treatment, and determined whether insulin could still inhibit transcription stimulated by the Foxo1 mutant.
835	D.1 Mutation	E. Associate	0	WWOX	non-small cell lung cancer	Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer.
836	D.2 Rearrangement	E. Associate	0	ROS1	lung cancer	Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
837	F.2 Methylation	E. Associate	0	MGMT	lung cancers	We determined the frequency of aberrant promoter methylation (referred to as methylation) of the genes retinoic acid receptor beta-2 (RARbeta), tissue inhibitor of metalloproteinase 3 (TIMP-3), p16INK4a, O6-methylguanine-DNA-methyltransferase (MGMT), death-associated protein kinase (DAPK), E-cadherin (ECAD), p14ARF, and glutathione S-transferase P1 (GSTP1) in 107 resected primary non-small cell lung cancers (NSCLCs) and in 104 corresponding nonmalignant lung tissues by methylation-specific PCR.
838	D.1 Mutation	E. Associate	0	RET	Medullary thyroid cancer (MTC)	A comprehensive assessment has not been undertaken of long-term outcomes in children carrying germline RET mutations and undergoing prophylactic thyroidectomy with the aim of preventing medullary thyroid cancer (MTC).
839	A. Expression	E. Associate	0	EHD1	PTC	The objective of the present study was to determine the protein expression levels and clinical significance of EHD1, EGFR, caveolin-1 (CAV-1) and RAB11 family interacting protein 3 (RAB11FIP3) in PTC.
840	A. Expression	E. Associate	0	ABCG2	GASTRIC CANCER	This study aimed to investigate whether spheroid body-forming cells in human gastric cancer cell were enriched for CSC properties, and to assess the expression of candidate CSC markers, cluster of differentiation 44 (CD44) and adenosine triphosphate binding cassette transporter G 2 (ABCG2) in the MKN45 spheroid body cells.
841	D.1 Mutation	E. Associate	0	XRCC2	familial breast cancer	The coding regions and exon-intron boundaries of XRCC2 were scanned for mutations in an international cohort of 3548 non-BRCA1/2 familial breast cancer cases and 1435 healthy controls using various mutation scanning methods.
842	A. Expression	E. Associate	0	breast cancer resistance protein	breast cancer	The aim of our study was to investigate the effect of biochanin A on the accumulation and transport of mitoxantrone in breast cancer resistance protein (BCRP)-expressing normal cells and its impact on the pharmacokinetics (PK) and tissue distribution of mitoxantrone.
843	D.1 Mutation	E. Associate	0	BRCA1	breast cancer	We undertook BRCA1 mutation analysis in 308 individuals with TN breast cancer, 159 individuals from unselected series of breast cancer and 149 individuals from series ascertained on the basis of young age and/or family history.
844	A. Expression	E. Associate	0	DDC	breast cancer	The purpose of the present study was to investigate the effect of chemotherapeutic agents on the expression of human DDC in human prostate and human breast cancer cell lines.
845	I. None	E. Associate	0	EGF	BREAST CARCINOMA	To address this question, we analyzed the migration and invasion of MDA-MB-231 breast carcinoma cell line in response to various stimuli including lysophosphatidic acid (LPA), hepatocyte growth factor (HGF) and epidermal growth factor (EGF) and determined the involvement of select signaling pathways that impact myosin light chain phosphorylation.
846	D.1 Mutation	E. Associate	0	BRCA1	breast cancer	A total of 130 patients with (N = 66) and without (N = 64) a family history of breast cancer, 70 unaffected individuals with a family history of breast cancer and 40 control subjects were analysed for BRCA1 mutations.
847	A. Expression	E. Associate	0	NPR-A	GASTRIC CANCER	Impact of NPR-A expression in gastric cancer cells.
848	A. Expression	E. Associate	0	HGF	GASTRIC CANCER	The expression of HGF, SP1, VEGF and CD34 were detected in 80 gastric cancer specimens with serosal invasion by immunohistochemistry.
849	A. Expression	E. Associate	0	macrophage migration inhibitory factor	non-small cell lung cancer	To investigate the expression of macrophage migration inhibitory factor (MIF) and extracellular matrix metalloproteinase inducer (CD147) in non-small cell lung cancer (NSCLC) and its metastatic lymph node with tissue microarray technique, and to reveal clinical significance of these two molecules expression in NSCLC.
850	I. None	E. Associate	0	miR-21	non-small cell lung cancer	This study aimed at exploring the role of microRNA-21 (miR-21) in predicting brain metastases (BM) from non-small cell lung cancer (NSCLC).
851	D.2 Rearrangement	E. Associate	0	ALK	NSCLC	We enrolled 201 patients with primary NSCLC who had undergone molecular testing for both ALK gene rearrangement and EGFR mutation.
852	A. Expression	E. Associate	0	CXCL12	SCLC	We performed immunohistochemical analysis for the expression of CXCR4 and CXCL12 in metastatic tumor tissue of a 69-year-old Caucasian male with extensive SCLC metastatic to a renal oncocytoma.
853	D.1 Mutation	E. Associate	0	GFRA1	Medullary Thyroid Cancer	Evaluation of germline sequence variants of GFRA1, GFRA2, and GFRA3 genes in a cohort of Spanish patients with sporadic medullary thyroid cancer.
854	J. Inhibition	A. Treat	1	ALK	NSCLC	This case report focuses mainly on several controversial clinical aspects, that is, the sequence of treatment in ALK-positive NSCLC, the ALK inhibitors' efficacy on brain disease and beyond progression, the management of LC, and the role of WBRT despite the risk of cognitive impairment.
855	H. Other	E. Associate	1	ARHGEF39	NSCLC	Although ARHGEF39 has been proven to regulate tumor progression in hepatocellular carcinoma, the downstream signaling pathway of ARHGEF39 and its clinical associations in non-small cell lung cancer (NSCLC) are currently unknown.
856	J. Inhibition	A. Treat	1	BRAF	NSCLC	We tested two different options to enhance the efficacy of vemurafenib (BRAF V600E inhibitor) in BRAF mutated NSCLC.
857	A. Expression	E. Associate	1	ZIC1	GASTRIC CANCER	The regulation of sonic hedgehog (Shh), phosphoinositide 3-kinase (PI(3)K) and mitogen-activated protein kinase (MAPK) signaling pathways after ectopic expression of ZIC1 in gastric cancer cells were evaluated.
858	M.2 Knock in	H. Benefit	0	tumor necrosis factor	lung adenocarcinoma	The aim of this study is to investigate the electrophysiological properties of human lung adenocarcinoma cell line A-549 and the role of K+ channel in inhibition of cell proliferation by the recombinant mutant human tumor necrosis factor (rmhTNF).
859	J. Inhibition	A. Treat	1	CD73	breast cancer	Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.
860	A.2 Under-expression	E. Associate	1	HER-2	breast cancers	Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.
861	J. Inhibition	E. Associate	1	mammalian target of rapamycin	GASTRIC CANCER	miR‑140 significantly prevented mammalian target of rapamycin signaling in gastric cancer cells.
862	A. Expression	H. Benefit	0	IL-10	breast cancer	Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response?
863	A.1 Over-expression	C. Cause	1	interleukin-11	breast cancer	The released factors then stimulate tumor cell signaling, which causes breast cancer cells to make increased amounts of osteolytic factors, such as parathyroid hormone-related protein (PTHrP), interleukin-11 (IL-11), and vascular endothelial growth factor (VEGF).
864	I. None	B. Target	0	AGPS	Hepatic Carcinoma	Benzyl isothiocyanate (BITC) showed the inhibitory effect of tumor and AGPS activity, therefore, we screened a group of small molecular compound based on BITC by computer-aid design targeting AGPS and the results showed that the derivants could suppress the proliferation, the expression of tumor related genes such as survivin and Bcl-2, and the level of ether lipids such as lysophosphatidic acid ether (LPAe) and platelet activating factor ether (PAFe); however, the activity of caspase-3/8 was improved in glioma U87MG and hepatic carcinoma HepG2 cells in vitro.
865	I. None	B. Target	0	MTA2	breast cancer	A short-hairpin RNA targeting MTA2 was chemically synthesized and transfected into a lentivirus to construct Lv-shMTA2 for infection into the MDA-MB231 human breast cancer cell line.
866	J. Inhibition	A. Treat	1	HER2	breast cancer	HER2 is currently the only validated marker to select breast cancer patients for anti-HER2 treatment; however, it is becoming evident that HER2-positive breast cancer is a heterogeneous disease.
867	H. Other	H. Benefit	1	PTEN	lung cancer	Collectively, these results provide mechanistic insight into the anti-NSCLC of FMG by enhancing the phosphatase activity of PTEN, and suggest that FMG could be as a potential option for lung cancer treatment.
868	A.1 Over-expression	E. Associate	1	CT120	lung cancer	The expression of CT120 was higher in lung cancer tissues and A549 cells.
869	A. Expression	C. Cause	1	SOX4	small cell lung cancer	Novel transcriptional targets of the SRY-HMG box transcription factor SOX4 link its expression to the development of small cell lung cancer.
870	A.1 Over-expression	E. Associate	1	OPN	NSCLC	OPN expression in NSCLC was significantly higher in lung adenocarcinomas (AC) then in squamous cell carcinomas (p<0.001).
871	L. Be regulated	H. Benefit	1	CCNE2	breast cancer	The expression of shrimp miR-34 in breast cancer cells and in mice suppressed the growth and metastasis of breast cancer by targeting human CCND1, CDK6, CCNE2, E2F3, FOSL1, and MET genes in a cross-phylum manner.
872	F.2 Methylation	E. Associate	1	VPS13B	breast carcinomas	Here, an integrative genomics screen (DNA copy number, transcriptional and DNA methylation profiling) performed in 229 primary invasive breast carcinomas identified substantial coamplification of the 8p11-p12 genomic region and the MYC oncogene (8q24.21), as well as aberrant methylation and transcriptional patterns for several genes spanning the 8q12.1-q24.22 genomic region (ENPP2, FABP5, IMPAD1, NDRG1, PLEKHF2, RRM2B, SQLE, TAF2, TATDN1, TRPS1, VPS13B).
873	D.3 Fusion	B. Target	1	ALK	NSCLC	Personalized targeted therapy of non-small-cell lung cancer (NSCLC) is based on the mutation status of epithelial growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog, B-Raf proto-oncogene and anaplastic lymphoma kinase (ALK) fusion gene, with different mutations requiring different treatment.
874	D.1 Mutation	C. Cause	1	NHERF1	breast cancer	Truncation and mutation of the PDZ-I domain of NHERF1 increased the nuclear distribution of the NHERF1 protein, and this redistribution was associated with the malignant phenotype of breast cancer cells, including growth, migration, and adhesion.
875	A. Expression	C. Cause	1	LRH-1	breast cancer	Alterations in LRH-1 expression and/or activity in adipose tissue could therefore have considerable effects on local estrogen production and breast cancer development.
876	D.1 Mutation	E. Associate	1	EGFR	NSCLC	We show that higher concentrations of the irreversible EGFR inhibitor CL-387,785 are required to inhibit EGFR phosphorylation in T790M-expressing cells compared with EGFR mutant NSCLC cells without T790M.
877	H. Other	B. Target	1	EGFR	NSCLC	The upregulation of the epidermal growth factor receptor (EGFR) due to mutations has been observed in a number of cancers, and tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, which specifically target EGFR signaling, have been used to treat NSCLC patients.
878	I. None	B. Target	1	programmed cell death protein 1	non-small cell lung cancer	Immunotherapy targeting the checkpoint PD1 (programmed cell death protein 1) or PDL1 (programmed death ligand 1) has led to advances in the treatment of melanoma and non-small cell lung cancer (NSCLC).
879	L.2 Down-regulation	E. Associate	1	LEF1	breast cancer	In breast cancer Hs578T and MDA-MB-231 cells, micromolar concentrations of longdaysin attenuated the phosphorylation of LRP6 and DVL2 and reduced the expression of active β-catenin and total β-catenin, leading to the downregulation of Wnt target genes Axin2, DKK1, LEF1, and Survivin.
880	I. None	E. Associate	1	alpha-fetoprotein	hepatocellular carcinoma	This study showed that the presence of a halo and an intratumoral echo pattern on ultrasonography were useful predictors for local recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma, and that a high serum alpha-fetoprotein level was associated with a higher frequency of new nodular recurrences.
881	H. Other	E. Associate	1	ALK	Lung Adenocarcinomas	Using FISH as the gold standard, this assay has a sensitivity of 88.46% and a specificity of 95.83% for the detection of fusion transcripts involving ALK, RET, and ROS1 in lung adenocarcinomas.
882	I. None	B. Target	1	LRS	NSCLC	These results provide a new therapeutic strategy for NSCLC and warrant future clinical development by targeting LRS.
883	I. None	B. Target	0	glyceraldehyde-3-phosphate dehydrogenase	hepatocellular carcinoma	This was accomplished by demonstrating their ability to perform molecular targeting of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in human hepatocellular carcinoma (HCC) by using percutaneous injection of either inhibitor--3-bromopyruvate (3-BrPA) or short hairpin RNA (shRNA).
884	H. Other	E. Associate	1	ALK	NSCLC	Among 4064 patients with NSCLC (median age, 66.0 years; 51.9% female), 3183 (78.3%) had a history of smoking, 3153 (77.6%) had nonsquamous cancer, and 871 (21.4%) had an alteration in EGFR, ALK, or ROS1 (701 [17.2%] with EGFR, 128 [3.1%] with ALK, and 42 [1.0%] with ROS1 alterations).
885	D.5 Polymorphism	H. Benefit	1	MGMT	lung cancer	These results suggest that the R allele may protect against lung cancer, specifically in heavy smokers, an effect that may result from this polymorphism affecting the function of the MGMT protein and/or levels in MGMT activity.
886	H. Other	A. Treat	1	EGFR	non-small cell lung cancer	Tyrosine kinase inhibitors for epidermal growth factor receptor (EGFR TKIs) greatly improved clinical outcomes of patients with non-small cell lung cancer (NSCLC).
887	I. None	E. Associate	1	MMP10	breast cancer	HRG induction of MMP10 (matrix metalloproteinase 10) was found to be highly sensitive both to P-Rex1 depletion and inhibition of Rac1 function by the GTPase Activating Protein (GAP) β2-chimaerin, suggesting the dependence of the P-Rex1/Rac1 pathway for the induction of genes critical for breast cancer invasiveness.
888	A. Expression	E. Associate	1	IGF2	Gist	Of the 445 GIST cases with clinical information, those with high expression of IGF2 had a significantly worse outcome than those with low or no expression.
889	F.2 Methylation	E. Associate	1	HOXC10	GASTRIC CANCER	Bisulfite sequencing revealed that CpG sites in the HOXC10 first intronic region were hypomethylated in three gastric cancer tissues, and HOXC10 expression was increased in gastric cancer cell lines (AGS and SNU620) in response to 5‑azacytidine treatment.
890	H. Other	E. Associate	1	LSD1	lung cancer	Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells.
891	I. None	B. Target	0	PTN	small cell lung cancer	To construct a siRNA lentiviral expressing vector targeting PTN (pleiotrophin) gene in human small cell lung cancer H446 cells and to study the RNAi effect on tumor growth and apoptosis.
892	L. Be regulated	H. Benefit	1	PTEN	GASTRIC CANCER	In conclusion, miR-147 suppressed the proliferation and enhanced the chemosensitivity of gastric cancer cells to 5-FU by promoting cell apoptosis through directly targeting PTEN and regulating the PI3K/AKT signaling pathway.
893	A.2 Under-expression	E. Associate	0	ER	breast cancer	Research into mechanisms that explain these findings, especially the association with ER- breast cancer, is needed.
894	A.1 Over-expression	E. Associate	1	HER-2	breast cancer	Since about 20% of human breast cancers overexpress HER-2 and some of breast cancer cell lines overexpress both HER-2 and HER-4, cell-specific targeting of retroviral vectors may provide a different approach for in vivo gene therapy of this type of breast cancer.
895	J. Inhibition	A. Treat	0	PD-L1	NSCLC	The combination of PD-1/PD-L1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but requires a careful approach if considered in the future.
896	I. None	B. Target	1	ER	breast cancer	A further docking study of these compounds with ERα elucidates their structure-activity relationships, which provides guidance to design new PROTAC degrons targeting ER for breast cancer therapy.
897	D.1 Mutation	E. Associate	1	ER	breast cancer	In addition, we find that the ER isolated from the human breast cancer cell line MCF-7 contains a Gly-400----Val mutation present in the hormone-binding domain.
898	A. Expression	E. Associate	1	PCNA	lung cancer	In these estrogen receptor-α (ERα)-positive lung cancer cells, thyroid hormone (T(4)>T(3)) caused phosphorylation of ERα; the specific ERα antagonist ICI 182,780 blocked T(4)-induced, but not T(3)-induced ERK1/2 activation, as well as ERα phosphorylation, proliferating-cell nuclear antigen (PCNA) expression and hormone-dependent thymidine uptake by tumor cells.
899	A. Expression	G. Marker	1	CHFR	NSCLC	We also revealed that CHFR expression was predominantly impaired in smoking-related squamous cell carcinoma and might be a useful prognostic marker in NSCLC.
900	A. Expression	E. Associate	1	ERCC1	lung cancer	The expression levels of excision repair cross-complementation group 1 (ERCC1), replication protein A (RPA) and xeroderma pigmentosum group F (XPF) nucleotide excision repair proteins may be important in the response to platin-based therapy in lung cancer patients.
901	F.1 Phosphorylation	E. Associate	1	STAT3	LIVER CANCER	In addition, IFNγ inhibited liver cancer xenograft growth and impaired IL-6-induced STAT3 phosphorylation by inducing SOCS1/3 expression.
902	A.1 Over-expression	E. Associate	1	CD133	hepatocellular carcinoma	Liver functions in patients with ETV treatment improved in general, but one liver cirrhosis patient with high expression of CD133 in liver tissue developed hepatocellular carcinoma (HCC).
903	L.1 Up-regulation	E. Associate	1	NEK4	lung cancer	Interestingly, NEK4 was highly upregulated in tumor tissues derived from patients with lung cancer and colon cancer.
904	A. Expression	E. Associate	0	PD-L1	lung cancer	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
905	D.1 Mutation	E. Associate	1	HER2	metastatic breast cancer	We retrospectively screened patients with metastatic breast cancer in whom molecular profiling had been performed using next-generation sequencing from 2012 to 2015; we identified 18 patients with HER2 mutation.
906	A.1 Over-expression	E. Associate	1	EPOR	breast cancer	Our previous study demonstrated that overexpression of EPOR altered the cell growth and the sensitivity of RAMA 37 breast cancer cells to tamoxifen.
907	A.1 Over-expression	E. Associate	1	EGFR	NSCLC	It is found that the EGFR is overexpressed in NSCLC cells.
908	A.1 Over-expression	E. Associate	1	neu	breast cancer	Overexpression/amplification of the Her-2/neu has been associated with a worse outcome in patients with breast cancer.
909	A. Expression	E. Associate	1	CYP1B1	breast cancer	To synthesise a series of chalcone derivatives based on the chemopreventative agent DMU-135 and investigate their antiproliferative activities in human breast cancer cell lines which express CYP1B1 and CYP1A1.
910	J. Inhibition	H. Benefit	0	COMT	breast cancer	In the current study, we hypothesized that suppression of COMT activity in human breast cancer cells could increase the proteasome-inhibitory potency of (-)-EGCG and therefore enhance its tumor cell growth-inhibitory activity.
911	D.1 Mutation	E. Associate	1	EGFR	NSCLC	Gefitinib is currently used as a first-line therapy in patients of advanced non-small cell lung cancer (NSCLC) with susceptible epidermal growth factor receptor (EGFR) mutations.
912	D.1 Mutation	B. Target	1	EGFR	lung cancer	Targeting the EGFR T790M mutation in non-small-cell lung cancer.
913	A.1 Over-expression	E. Associate	1	HER2	breast cancer	We performed MethyLight analysis of the methylation status of 15 promoter CpG island loci involved in breast cancer progression (APC, DLEC1, GRIN2B, GSTP1, HOXA1, HOXA10, IGF2, MT1G, RARB, RASSF1A, RUNX3, SCGB3A1, SFRP1, SFRP4, and TMEFF2) and determined cancer stem cell phenotype by CD44/CD24 and ALDH1 immunohistochemistry in 36 luminal A, 33 luminal B, 30 luminal-HER2, 40 HER2 enriched, and 40 basal-like subtypes of breast cancer.
914	A.1 Over-expression	E. Associate	1	neu	breast cancer	These data suggest that the combination of Ad-mda7 with Herceptin may be a novel therapy for breast cancer patients whose tumors overexpress Her-2/neu.
915	D.1 Mutation	E. Associate	1	CHEK2	metastatic breast cancer	Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
916	A. Expression	E. Associate	1	ALK3	non-small cell lung cancer	AMH signaling regulates expression of BMPR2, ALK2, and ALK3, supports protein kinase B-nuclear factor κB (AKT-NF-κB) and SMAD survival signaling, and influences BMP-dependent signaling in non-small cell lung cancer (NSCLC).
917	I. None	B. Target	1	PD-1	hepatocellular carcinoma	Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC).
918	F.2 Methylation	E. Associate	1	CDH1	LCIS	Nineteen of the 20 LBCs had a hypermethylated CDH1 promoter, including 13/14 ILCs and 13/13 ALHs or LCIS.
919	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	Lung Adenocarcinomas	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
920	A. Expression	E. Associate	0	estrogen receptor	lung cancer	We previously showed that the aromatase inhibitor (AI) anastrozole decreased development of tobacco carcinogen-induced lung tumors in a murine lung cancer prevention model and that aromatase and estrogen receptor were expressed in pulmonary inflammatory cells.
921	L.1 Up-regulation	E. Associate	1	caspase-9	breast cancer	We demonstrated that AdVING4/p53-mediated p53 and ING4 co-expression induced synergistic growth inhibition and apoptosis as well as enhanced effects on upregulation of acetylated p53, P21, Bax, PUMA, Noxa, cleaved caspase-9, cleaved caspase-3 and cleaved PARP, and downregulation of Bcl-2, CD31 and microvessel density (MVD) in MDA-MB-231 breast cancer in vitro and/or in vivo subcutaneous (s.c.) xenografted tumors.
922	I. None	C. Cause	1	GAB2	Breast cancer metastatic	This work highlights a pivotal role for GAB2 and its transcriptional targets in anchorage-independent growth and breast cancer metastatic progression.
923	A. Expression	E. Associate	1	epidermal growth factor receptor	breast carcinomas	Most BRCA1 carcinomas have the basal-like phenotype and are high-grade, highly proliferating, estrogen receptor-negative and HER2-negative breast carcinomas, characterized by the expression of basal markers such as basal keratins, P-cadherin and epidermal growth factor receptor.
924	A. Expression	E. Associate	0	EPO	NSCLC	Functional significance of co-expressed erythropoietin (EPO) and its receptor (EPOR) in non-small cell lung cancer (NSCLC) had been under debate.
925	I. None	B. Target	1	S100A7	INTRAHEPATIC CHOLANGIOCARCINOMA	MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7.
926	D.1 Mutation	E. Associate	1	EGFR	NSCLC	These findings should assist clinicians in assessing the likelihood of EML4-ALK rearrangements and EGFR mutations and understanding their biological implications in NSCLC.
927	F.2 Methylation	E. Associate	1	GJB2	breast cancer	CGI in 5' upstream regions of 20 genes, TSPAN-2, AK5, LOC284999, HOXD11, FLJ25161, XT3, PCDH10, PCDHGB6, SIM1, LOC346978, COE2, TDH (FLJ25033), LOC346419, FLJ33790, GJB2, AMN, LOC201164, DLX4, DCC and FOXA2, were found to be methylated in at least one of 8 breast cancer cell lines.
928	A. Expression	E. Associate	1	FRA	Triple-Negative Breast Cancers	Our data demonstrate that a significant subgroup of ER/PR-negative and triple-negative breast cancers express FRA, and its expression is associated with worse clinical outcome.
929	A. Expression	E. Associate	1	NGF	breast cancer	In patient samples, the expression of NGF and NGFR [the p75(NTR) gene] mRNA are positively correlated in several subtypes of breast cancer, including basal-like breast cancer.
930	I. None	C. Cause	1	CSN5	NSCLC	Overall, our data suggested that CSN5 functions as an oncogenic gene in NSCLC, which could be a potential diagnostic and therapeutic target for NSCLC.
931	I. None	E. Associate	0	TPA	SCLC	In this study we compared the diagnostic utility of: (1) neuron-specific enolase (NSE); (2) squamous cell carcinoma antigen (SCC); (3) carcinoembryonic antigen (CEA); and (4) cytokeratin markers (CYFRA 21-1, TPA, TPM, TPS) in patients with small-cell lung cancer (SCLC) (21 cases) and non-small-cell lung cancer (94 cases).
932	I. None	E. Associate	1	IGF-II	breast cancer	Extensive data are available on the importance of the insulin-like growth factor (IGF) system in growth regulation of breast cancer cell lines in vitro, indicating that the IGF-I receptor (IGF-IR), IGF-I (and IGF-II) function as survival factors, while IGF binding protein (IGFBP)-3 may act as a growth inhibitor.
933	I. None	B. Target	1	IGF1R	HER2-positive breast cancer	Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
934	D.1 Mutation	H. Benefit	1	PIK3CA	breast cancer	Upon evaluation of 2587 breast cancer cases from 12 independent studies, we showed that patients with tumors harboring a PIK3CA mutation have a better clinical outcome than those with a wild-type PIK3CA gene.
935	J. Inhibition	A. Treat	1	ALK	NSCLC	Ceritinib is a highly selective ALK inhibitor and shows promising efficacy in non-small cell lung cancers (NSCLC) harboring the ALK gene rearrangement.
936	J. Inhibition	A. Treat	1	PDL1	breast cancers	The combinations of nanoscale MEK- and PI3K-targeting supramolecular therapeutics with checkpoint PDL1 and PD1 inhibitors exert enhanced antitumor outcome in melanoma and breast cancers in vivo, respectively.
937	D.1 Mutation	E. Associate	1	ALK	non-small cell lung cancer	The identification of driver mutations in non-small cell lung cancer (NSCLC), most prominently epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), has expanded treatment options for a significant cohort of patients.
938	D.1 Mutation	E. Associate	1	BRCA2	breast cancer	A prospective study on predictive factors linked to the presence of BRCA1 and BRCA2 mutations in breast cancer patients.
939	A.1 Over-expression	E. Associate	1	DYRK2	Lung Adenocarcinomas	DYRK2 mRNA overexpression occurs more frequently than gene amplification in both esophageal and lung adenocarcinomas.
940	A.2 Under-expression	G. Marker	1	VEGFR1	breast cancer	In addition, reduced or lost VEGFR1 expression may serve as a marker for poor prognosis in patients with breast cancer, who might not optimally benefit from endocrine therapy.
941	L.1 Up-regulation	C. Cause	1	HAS2	metastatic breast cancer	Here, we report that upregulation of hyaluronan synthase 2 (HAS2) occurs in highly metastatic breast cancer stem-like cells (CSC) defined by CD44(+)/CD24(-)/ESA(+) phenotype, where it plays a critical role in the generation of a prometastatic microenvironment in breast cancer.
942	J. Inhibition	A. Treat	1	epidermal growth factor receptor	NSCLC	Targeted therapeutics, including the epidermal growth factor receptor (EGFR) inhibitor erlotinib, have recently emerged as clinical alternatives for the treatment of non-small cell lung cancer (NSCLC).
943	J. Inhibition	H. Benefit	1	EGFR	lung cancer	EGFR inhibitors, such as gefitinib, have previously been shown to preferentially benefit distinct subgroups of advanced non-small-cell lung cancer patients, and strategies to prospectively identify these subgroups are under active investigation.
944	J. Inhibition	H. Benefit	1	AR	Triple-negative breast cancer	Early data from clinical trials evaluating AR antagonists in invasive/metastatic triple-negative breast cancer suggest that some patients may benefit from androgen blockade.
945	A. Expression	G. Marker	1	p63	BREAST CARCINOMA	On the other hand, we examine the expression of six immunohistochemical markers (ER, PR, p63, mammaglobin, CK5÷6 and D2-40) in 30 cases of cutaneous metastases from breast carcinoma, ductal type.
946	A. Expression	C. Cause	1	cyclin D1	hepatocellular carcinoma	The data suggest that URG4 may play an important role in the development of hepatocellular carcinoma by partially regulating the expression of cyclin D1 and has potential for use as a therapeutic target for hepatocellular carcinoma.
947	J. Inhibition	E. Associate	0	ER	breast cancer	Tamoxifen (TMX), an estrogen receptor (ER) antagonist, incorporated at surface of liposomes loaded with Doxorubicin (DOX), was hypothesized to serve as ligand for targeting overexpressed ERs on surface and cytosol of breast cancer cells, in addition to its synergism with DOX in killing MCF-7 cells.
948	I. None	C. Cause	1	furin	breast cancer	Opposing function of the proprotein convertases furin and PACE4 on breast cancer cells' malignant phenotypes: role of tissue inhibitors of metalloproteinase-1.
949	I. None	E. Associate	1	claudin-6	breast cancer	In our previous work, apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase (MAPK) kinase family has been proved to be associated with the pro-apoptosis effect of tight junction protein claudin-6 in breast cancer.
950	A. Expression	B. Target	1	ROCK1	breast cancer	miR-202 regulated proliferation, migration, invasion, and expression of related proteins in breast cancer cells by targeting ROCK1 expression.
951	I. None	B. Target	1	MET	lung cancer	The concept of using information from a patient's tumor to make therapeutic and treatment decisions has revolutionized the landscape for cancer care and research in general.Management of non-small-cell lung cancer, in particular, has seen several of these advances, with the understanding of activating mutations in EGFR, fusion genes involving ALK, rearrangements in ROS-1, and ongoing research in targeted therapies for K-RAS and MET.
952	D.1 Mutation	B. Target	1	epidermal growth factor receptor	non-small cell lung cancer	Targeting these driver mutations, such as sensitizing epidermal growth factor receptor (EGFR) mutations, has dramatically improved the prognosis of advanced non-small cell lung cancer (NSCLC).
953	I. None	C. Cause	1	BCAT1	breast cancer	Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.
954	J. Inhibition	A. Treat	1	NDUFA4	GASTRIC CANCER	Taken together, our present study implicates that inhibition of lncMIF-AS1/miR-212-5p/NDUFA4 signal transduction may provide a promising therapeutic target for the treatment of gastric cancer.
955	J. Inhibition	E. Associate	0	EGFR	GASTRIC CANCER	We have designed an adenovirus-expressing antisense EGFR and have investigated its effect on the growth of gastric cancer in vitro and in vivo.
956	A.2 Under-expression	F. None	1	TOP2A	lung cancer	DRZ depleted TOP2A also from fibrosarcoma-derived cells, but not from lung cancer-derived and human embryo-derived cells.
957	A. Expression	E. Associate	1	estrogen receptor	breast cancer	Sp1, Sp3, and Sp4 are expressed in a panel of estrogen receptor (ER)-positive and ER-negative breast cancer cell lines, and we hypothesized that regulation of their expression may be due to microRNA-27a (miR-27a), which is also expressed in these cell lines and has been reported to regulate the zinc finger ZBTB10 gene, a putative Sp repressor.
958	M.1 Knock down	H. Benefit	1	JMJD1A	GASTRIC CANCER	In addition, in vitro experiment revealed that knockdown of JMJD1A expression inhibited the gastric cancer cell proliferation, and further study suggested that JMJD1A knockdown suppressed MAPK pathway via transcriptional downregulation the expression of long noncoding RNA MALAT1.
959	H. Other	E. Associate	0	EGFR	lung adenocarcinoma	This study investigated the roles of YAP1 in lung adenocarcinoma by exploring its regulation and functions mediated by EGFR signaling.
960	D.1 Mutation	E. Associate	1	KRAS	NSCLC	We recently identified epiregulin (EREG) as one of several putative transcriptional targets of oncogenic KRAS signaling in both KRAS-mutant NSCLC cells and immortalized bronchial epithelial cells expressing ectopic mutant KRAS.
961	D.2 Rearrangement	E. Associate	1	ALK	NSCLC	In the nonsquamous cohort, 105 (81%) and 25 (19%) of patients were tested for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement, respectively; 44 (42%) had EGFR-positive NSCLC and 2 (8%) had ALK-positive NSCLC, including 26/46 (57%) women and 21/46 (46%) never-smokers.
962	A.1 Over-expression	E. Associate	1	YB-1	Gastric carcinoma	The expressions of FOXC-2,YB-1,Vimentin and MMP-2 in gastric carcinoma were significantly higher than those in normal and intraepithelial neoplasia while the expression of E-cadherin was significantly lower (P<0.05).The expressions of FOXC-2,YB-1 were significantly correlated with low expression of E-cadherin and high expression of Vimentin and MMP-2 (P<0.05).
963	A.1 Over-expression	E. Associate	1	ER	infiltrating lobular carcinoma	We compared gene copy number changes in the tumors based on histologic subtype and estrogen receptor (ER) status, i.e., ER-negative infiltrating ductal carcinoma, ER-positive infiltrating ductal carcinoma, and ER-positive infiltrating lobular carcinoma.
964	H. Other	E. Associate	0	hepatocyte growth factor	HEPATOMA	The effect of recombinant human hepatocyte growth factor (HGF) on low density lipoprotein (LDL) receptor gene expression was studied in the human hepatoma cell line HepG2.
965	D.1 Mutation	C. Cause	1	CHEK2	breast cancer	Both protein-truncating variants and some missense substitutions in CHEK2 confer increased risk of breast cancer.
966	J. Inhibition	A. Treat	1	HER-2	breast cancer	Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
967	A. Expression	E. Associate	1	ER	breast cancer	Although both isoforms are similarly regulated by RUNX1 in estrogen-stimulated ER+ breast cancer cells, the higher v2/v1 ratio in ER- disease is expected to weaken the tumor suppressor activity of AXIN1 in these tumors.
968	J. Inhibition	A. Treat	1	CTLA-4	lung cancers	The introduction of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) immune checkpoint inhibitors and their subsequent listing on the Pharmaceutical Benefits Scheme for use in metastatic melanomas, renal cell carcinomas and non-small-cell lung cancers has resulted in routine use of these agents in oncology practices, including in regional areas.
969	L. Be regulated	H. Benefit	1	maspin	breast cancer	Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen.
970	H. Other	E. Associate	1	DCLK1	HEPATOMA	The drug caused bundling of DCLK1 with microtubules and blocked cell-cycle progression at G2-M phase in hepatoma cells via downregulation of CDK1, induction of p21(cip1/waf1) expression, and inhibition of Akt (Ser(473)) phosphorylation.
971	M.2 Knock in	E. Associate	0	phenylalanine hydroxylase	HEPATOMA	We investigated the effect of p-chlorophenylalanine on production of human phenylalanine hydroxylase in human hepatoma cells and cells transformed with the recombinant human phenylalanine hydroxylase gene.
972	H. Other	H. Benefit	1	Raf-1	MTC	Importantly, activation of the Raf-1/ MEK/ERK pathway and the associated decrease in essential cell-cell contact molecules dramatically inhibited the abilities of adhesion and migration in MTC cells.
973	L.2 Down-regulation	H. Benefit	1	DTWD1	GASTRIC CANCER	In summary, as the new p53 target gene, DTWD1 was downregulated in gastric cancer by HDAC3 and acted as a novel tumor suppressor gene.
974	H. Other	E. Associate	1	ER	breast cancer	Recent data have suggested that HER2 overexpression is associated with resistance to hormonal therapy and there is considerable preclinical evidence to support the existence of interaction or 'cross talk' between HER2 and estrogen-receptor (ER) signalling pathways in breast cancer.
975	C. Activation	H. Benefit	1	E2F1	NSCLC	These studies suggest that nicotine might be promoting NSCLC growth and metastasis by inducing the secretion of SCF, and raise the possibility that targeting signalling cascades that activate E2F1 might be an effective way to combat NSCLC.
976	A. Expression	E. Associate	0	EGFR	PTC	The purpose of this study was to examine GPER1, EGFR and CXCR1 expression in PTC and to assess the association of their expression with clinicopathological indicators.
977	A. Expression	E. Associate	0	PD-L1	non-small cell lung cancer	Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
978	A.2 Under-expression	E. Associate	1	ER	BREAST CARCINOMA	The statistically significantly higher prevalence of "ER(-)/PR(-), HER2(- )" phenotype in African American women potentially is the attributing factor to observed lack of an association between the risk of HER2/neu positive breast carcinoma with advanced stages and poorly differentiated grade.
979	I. None	B. Target	1	estrogen receptor	breast cancer	The estrogen receptor (ER), of which there are two forms, ERalpha and ERbeta, is a ligand-modulated transcription factor important in both normal biology and as a target for agents to prevent and treat breast cancer.
980	I. None	C. Cause	0	MGMT	thyroid cancer	Further investigation is needed to decipher the functional properties of the methyltransferase encoded by MGMT and to understand how alteration of such functions may lead to the development of the most common type of thyroid cancer.
981	A. Expression	E. Associate	0	epidermal growth factor receptor	BREAST CARCINOMA	We examined epidermal growth factor receptor (EGFR) and/or c-erbB-2 expression, clinicopathological variables, silver-stained nuclear organizer region (Ag-NOR) counts, and their prognostic values in 93 patients with operable breast carcinoma.
982	D.1 Mutation	E. Associate	1	RET	Multiple Endocrine Neoplasia Type 2	RET gene rearrangements, which lead to the generation of chimeric RET/papillary thyroid carcinoma (PTC) oncogenes, occur in PTC, whereas RET point mutations occur in familial multiple endocrine neoplasia type 2 (MEN2) and sporadic medullary thyroid carcinomas (MTC).
983	A.2 Under-expression	E. Associate	1	HER2	Triple-negative breast cancer	Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks the expression of hormone receptors and human epidermal growth factor receptor 2 (HER2).
984	D.5 Polymorphism	E. Associate	0	XRCC3	metastatic breast cancer	Polymorphisms in XRCC1, XRCC3, and CCND1 and survival after treatment for metastatic breast cancer.
985	I. None	B. Target	1	HER2	breast cancer	Two approved therapies targeting HER2, the monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib, are clinically active against this type of breast cancer.
986	I. None	C. Cause	1	LMO1	lung cancer	Our in vitro investigations indicated that LMO1 had the general property of promoting cell proliferation in lung cancer cells representing different histological subtypes, suggesting a general oncogenic function of LMO1 in lung cancer.
987	I. None	B. Target	1	LINC00673	breast cancer	In this study, we identified the role of LINC00673 in inducing proliferation and metastasis of breast cancer cell lines and it might act as an underlying therapeutic target for breast cancer.
988	I. None	G. Marker	1	CDH17	Gastric carcinoma	Following previous studies that identified the adhesion molecule Cadherin-17(CDH17) as a potential marker for gastric carcinoma, we performed proof-of-principle studies to develop rational therapeutic approaches targeting CDH17 for treating this disease.
989	L.1 Up-regulation	C. Cause	1	MUC1	Triple-negative breast cancer	The immune checkpoint ligand PD-L1 and the transmembrane mucin MUC1 are upregulated in triple-negative breast cancer (TNBC), where they contribute to its aggressive pathogenesis.
990	I. None	B. Target	1	PCBP1	NSCLC	These findings suggested that PCBP1 might play an important role in preventing the process of EMT in NSCLC, thus be a promising therapeutic target to inhibit NSCLC metastasis.
991	I. None	C. Cause	1	EGFR	NSCLC	The EGFR gene and ALK rearrangements are two genetic drivers of non-small cell lung cancer (NSCLC).
992	J. Inhibition	H. Benefit	1	epidermal growth factor receptor	NSCLC	Previous trials of adjuvant targeted therapy in unselected early stage NSCLC patients showed no benefit versus placebo, however retrospective data suggests improved disease free survival (DFS) with epidermal growth factor receptor (EGFR) inhibitors in patients with appropriate molecular alterations.
993	D.1 Mutation	E. Associate	1	RET	Multiple Endocrine Neoplasia Type 2	Genetic testing revealed a pathogenic heterozygous RET mutation associated with multiple endocrine neoplasia type 2 (MEN2).
994	A.1 Over-expression	E. Associate	1	ER	breast cancer	This study suggests that AC-3E extracts can be employed as a double-barreled approach to treat human ER+ breast cancer by attacking both cancer cells and tumor-associated blood vessel cells.
995	G. Regulate	H. Benefit	1	RASSF1A	GASTRIC CANCER	RASSF1A inhibits gastric cancer cell proliferation by miR-711- mediated downregulation of CDK4 expression.
996	A.1 Over-expression	E. Associate	1	ER	breast cancer	CDK4/6 inhibitors have transited rapidly from preclinical studies to the clinical arena, and three have already been approved for the treatment of advanced, estrogen receptor (ER)-positive breast cancer patients on account of striking clinical trial results demonstrating substantial improvements in progression-free survival.
997	D.1 Mutation	E. Associate	0	MUTYH	Papillary Breast Carcinoma	Germline MUTYH gene mutations are not frequently found in unselected patients with papillary breast carcinoma.
998	F.1 Phosphorylation	C. Cause	1	ribosomal protein S6	non-small cell lung cancer	Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
999	J. Inhibition	A. Treat	1	IKK2	lung cancer	Our results thus suggest the possible application of IKK2 and Timp-1 inhibitors in treating lung cancer.
1000	A.1 Over-expression	E. Associate	1	ER	breast cancer	Everolimus enhanced the anti-proliferative effect of both tamoxifen (TAM) and fulvestrant (FUL) in ER+ breast cancer cell lines, as well as trastuzumab in HER2+ cell lines.
1001	I. None	B. Target	1	insulin-like growth factor 1 receptor	Gist	Recently, expression profiling of a limited number of pediatric and adult WT GISTs and more in depth study of a single pediatric WT GIST implicated the insulin-like growth factor 1 receptor (IGF1R) as a potential therapeutic target in pediatric WT GIST.
1002	F.2 Methylation	E. Associate	0	G0S2	lung cancer	We investigated the effect of G0S2 methylation levels on cell growth, mRNA expression, and chromatin structure using squamous lung cancer cell lines and normal human bronchial epithelial cells.
1003	D.1 Mutation	E. Associate	1	HRAS	medullary thyroid carcinoma	Medullary thyroid carcinoma (MTC), a neuroendocrine tumor originating from thyroid parafollicular cells, has been demonstrated to be associated with mutations in RET, HRAS, KRAS and NRAS.
1004	D.1 Mutation	E. Associate	1	RUNX3	Gastric Cancers	In addition to gene mutation and promoter hypermethylation, cytoplasmic mislocalization has emerged as another major manifestation of RUNX3 dysfunction in malignancies including breast, colorectal and gastric cancers.
1005	D.1 Mutation	E. Associate	0	BRAF	papillary thyroid cancer	This study investigated the utility of BRAF mutation testing of thyroid fine-needle aspiration biopsy (FNAB) specimens for preoperative risk stratification in papillary thyroid cancer (PTC).
1006	J. Inhibition	H. Benefit	1	MNK1	Ductal Carcinoma In Situ	SIGNIFICANCE: These findings provide new mechanistic insight into progression of ductal carcinoma and support clinical application of MNK1 inhibitors to delay progression of indolent ductal carcinoma in situ to invasive ductal carcinoma.
1007	D.1 Mutation	E. Associate	1	EGFR	lung adenocarcinoma	Somatic mutations of EGFR were found in lung adenocarcinoma that lead to exquisite dependency on EGFR signaling; thus patients with EGFR-mutant tumors are at high chance of response to EGFR inhibitors.
1008	D.2 Rearrangement	E. Associate	1	ALK	NSCLC	Key Messages: Next-generation ALK-TKIs are now replacing crizotinib as first-line treatment in ALKi-naïve ALK rearrangement NSCLC patients with brain metastasis, and they alone might have a strong efficacy against intracranial tumors in crizotinib-refractory situations in which occasion radiotherapy might be omitted.
1009	L. Be regulated	H. Benefit	1	PBX3	HEPATOMA	In conclusion, miR-302a inhibited proliferation and promoted apoptosis in human hepatoma cells by targeting MAP3K2 and PBX3.
1010	A. Expression	E. Associate	1	BRCA1	Hereditary Breast Cancer	Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
1011	A. Expression	E. Associate	0	erythropoietin	NSCLC	This study investigates the prognostic value of erythropoietin (EPO) and EPO receptor (EPO-R) expression of tumor cells for locoregional control and survival in non-small-cell lung cancer (NSCLC) patients.
1012	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	non-small cell lung cancer	Recent studies have reported that mutations of the epidermal growth factor receptor (EGFR) gene are associated with the responsiveness of tyrosine kinase inhibitors (TKIs), which are molecular targets for non-small cell lung cancer (NSCLC).
1013	I. None	G. Marker	1	SPOCK1	lung cancer	Taken together, our study showed that SPOCK1 is a novel metastasis related biomarker in lung cancer and may be new diagnostic and therapeutic target for lung cancer.
1014	A. Expression	G. Marker	1	PD-L1	non-small cell lung cancer	PD-L1 expression has shown a positive association with response to PD-1 inhibition in noncentral nervous system (CNS) tumors, e.g., melanoma or non-small cell lung cancer, and is discussed as a potential predictive biomarker for patient selection in these tumor types.
1015	J. Inhibition	A. Treat	0	Hsp90	of lung adenocarcinoma	A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma.
1016	A. Expression	C. Cause	1	PTEN	hepatocellular carcinoma	The aberrant expressions of PTEN and phosphorylated Smad2 and their interaction may play an important role in the pathogenesis of hepatocellular carcinoma.
1017	G. Regulate	C. Cause	1	G protein-coupled receptor kinase 2	hepatocellular carcinoma	G protein-coupled receptor kinase 2 regulating β2-adrenergic receptor signaling in M2-polarized macrophages contributes to hepatocellular carcinoma progression.
1018	A. Expression	E. Associate	1	ER	Invasive ductal breast cancer	Lymphovascular invasion but not microvessel density was independently associated with poorer survival in patients with ER positive but not ER negative invasive ductal breast cancer.
1019	A. Expression	E. Associate	0	EGFR	breast cancer	Expression of epidermal growth factor receptor (EGFR) and estrogen receptor (ER) was examined by an immunocytochemical assay (ICA) using serial cross-sections of human breast cancer tissues.
1020	A. Expression	E. Associate	0	MT	breast cancer	Expression of the hormone-related proteins hsp27, pS2, and also of cathepsin D (CD) and metallothionein (MT) was studied by immunohistochemistry and analyzed against clinical data in breast cancer.
1021	D.1 Mutation	E. Associate	1	EGFR	NSCLC	The current study has demonstrated that osimertinib reduces c-FLIP levels via facilitating its degradation and enhances apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) primarily in NSCLC with activating EGFR mutations.
1022	A.1 Over-expression	E. Associate	1	ER	breast cancers	In this review we have tried to (a) describe the specific cellular signals initiated following alterations in the cell cycle pathway genes and the PI3K pathway genes, (b) interrogate how these alterations/co-alterations influence the action of PI3K and cell cycle pathway-targeted drugs in different clinical trials and (c) understand the role of co-alterations towards the development of cell cycle inhibitors induced drug-resistance in ER+ breast cancers.
1023	A. Expression	E. Associate	0	PD-L1	NSCLC	We used multiplexed quantitative immunofluorescence (QIF) to investigate PD-L1 expression and to characterize Tumor Infiltrating Lymphocyte (TIL) populations and their activation status in over 150 Non-Small Cell Lung Cancer (NSCLC) patients with known mutation status.
1024	A. Expression	E. Associate	0	NY-ESO-1	Non-Small-Cell Lung Carcinomas	Expression of cancer-testis antigens MAGE-A3/6 and NY-ESO-1 in non-small-cell lung carcinomas and their relationship with immune cell infiltration.
1025	I. None	B. Target	1	HER-2	breast cancer	HER-2 is the target for antibody based treatment of breast cancer (Herceptin).
1026	I. None	G. Marker	1	FOXM1	GASTRIC CANCER	FOXM1 can be a useful marker for predicting patients' prognosis and monitoring docetaxel response, and might be a new therapeutic target in docetaxel resistant gastric cancer.
1027	I. None	B. Target	1	stromal cell-derived factor 1	breast cancer	In the current study, we report that the growth stimulatory cytokine stromal cell-derived factor 1 (SDF-1) is a bona fide target of estrogen action in ERalpha-positive human ovarian and breast cancer cells.
1028	D.1 Mutation	C. Cause	1	BRCA1	breast cancer	In this study by Hedenfalk et al., the authors attempted to identify discrete gene expression profiles for patients with known hereditary breast cancers caused by mutations in BRCA1 and BRCA2, both of which increase the lifetime risk of developing breast cancer.
1029	A. Expression	E. Associate	0	epidermal growth factor receptor	Invasive Breast Cancer	This study aimed to evaluate correlations between lymphovascular invasion (LVI) and the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, CK5/6, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), E-cadherin, BCL11A and P53 in invasive breast cancer and to identify predictors of LVI based on these pathological factors.
1030	A. Expression	E. Associate	0	XIAP	breast cancer	Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients.
1031	D.1 Mutation	C. Cause	0	NF1	Hereditary Breast Cancer	We evaluated whether the concomitance of NF1 and early-onset breast cancer could be due to disease-causing mutations in both NF1 and BRCA1 gene in a Korean family with clinical features of both NF1 and hereditary breast cancer.
1032	D.1 Mutation	E. Associate	0	PIK3CA	lung cancers	Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
1033	A.2 Under-expression	E. Associate	1	ER	breast cancer	The purpose of this study was to evaluate the usefulness of 22-oxacalcitriol (OCT) in the treatment of estrogen receptor (ER)-negative breast cancer.
1034	G. Regulate	E. Associate	1	ADIPOR1	breast cancer	We conclude that ADIPOR1 negatively regulates EMT in breast cancer and provides an additional node by which miR-221/222 induces the EMT.
1035	D.1 Mutation	E. Associate	0	BRCA2	familial breast cancer	Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource.
1036	J. Inhibition	A. Treat	1	EGFR	NSCLC	Among these agents, inhibitors of the epidermal growth factor receptor (EGFR) have demonstrated significant activity in the first-, second- or third-line treatment of NSCLC.
1037	I. None	B. Target	1	CHEK1	breast cancer	Using a library of siRNAs against cell cycle proteins, we identified cell division cycle protein 20 (CDC20), a recombinase RAD51, and serine-threonine protein kinase CHEK1 as effective targets for breast cancer therapy, and demonstrated their therapeutic potential in breast cancer MDA-MB-435, MDA-MB-231, and MCF7 cells with respect to another well-studied cell cycle protein, kinesin spindle protein.
1038	C. Activation	E. Associate	1	ER	breast cancer	These findings uncover a mechanism that controls the activation of ER by the posttranslational modification of epigenetic regulators, providing a rationale for epigenetic therapy in ER-positive breast cancer.
1039	I. None	E. Associate	0	macrophage migration inhibitory factor	GASTRIC CANCER	To investigate the effects of macrophage migration inhibitory factor (MIF) on proliferation of human gastric cancer MGC-803 cells and expression of cyclin D1 and p27(Kip1) in them, and further determine whether the effects are related to the PI3K/Akt signal transduction pathway.
1040	I. None	B. Target	1	EIF5A2	LIVER CANCER	In conclusion, our findings demonstrate that EIF5A2 has a critical role in HCC cell metabolic reprogramming and may serve as a prominent novel therapeutic target for liver cancer treatment.
1041	A. Expression	E. Associate	0	CCND1	breast cancer	In this study, we investigated the relationships of pathological response after neoadjuvant chemo-endocrine therapy with alterations in the Ki67 labeling index (LI), expression of cyclin D1 (CCND1) and progesterone receptor (PgR), and estrogen receptor (ER) activity in breast cancer.
1042	J. Inhibition	A. Treat	1	PD-1	lung cancers	The introduction of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) immune checkpoint inhibitors and their subsequent listing on the Pharmaceutical Benefits Scheme for use in metastatic melanomas, renal cell carcinomas and non-small-cell lung cancers has resulted in routine use of these agents in oncology practices, including in regional areas.
1043	A.1 Over-expression	C. Cause	1	PD-L1	breast cancer	These results demonstrate that IFN-γ could up-regulate the expression of PD-L1, promote cell migration and transmission, and facilitate epithelial-mesenchymal transformation of breast cancer cells and this process may be related with ERK and Jak2-STAT signaling pathways.
1044	M.3 Gene silencing	H. Benefit	1	PARG	lung cancer	Our work provides initial evidence that PARG silencing suppresses BaP induced lung cancer and stabilizes the expression of Wnt ligands, PARG gene and Wnt ligands may provide new options for the diagnosis and treatment of lung cancer.
1045	L. Be regulated	E. Associate	1	BRCA1	breast cancer	We screened two genes, MIR146A and MIR146B, producing miR-146a and miR-146b-5p, respectively, that regulate BRCA1, and the 3'- untranslated regions (3'-UTRs) of BRCA1 and BRCA2 in the GENESIS French national case/control study (BRCA1- and BRCA2-negative breast cancer cases with at least one sister with breast cancer and matched controls).
1046	J. Inhibition	A. Treat	1	MYB	breast cancer	Taken together, these data imply that MYB and its targets play an important role in the response of ER+ breast cancer cells to DNA damage, and suggest that induction of DNA damage along with inhibition of MYB activity could offer therapeutic benefits for ER+ breast cancer and possibly other cancer types.
1047	I. None	B. Target	1	MT-SP1	breast cancer	However, the significant correlation between MT-SP1 and uPAR transcript levels in this initial study suggests further work to establish the role of MT-SP1 as a possible prognostic, diagnostic or therapeutic target for breast cancer.
1048	A. Expression	E. Associate	0	THTR2	breast cancer	To further understand the biological effects of the alteration of THTR2 expression, we conducted a DNA microarray study of gene expression in THTR2-transfected breast cancer cells and found that, in addition to increased expression of THTR2 attributable to the transgene, three other genes were up-regulated >2.5-fold in the transfected cells: cytochrome P450 isoform CYP4B1, 15-hydroxyprostaglandin dehydrogenase (15-PGDH), and transcription factor CRIP1.
1049	H. Other	E. Associate	1	ER	breast cancer	Several key regulators of early cell cycle progression such as Btg2 and cyclin D1, as well as regulators of mitosis, including cyclin B, Plk1, survivin, and aurora kinase A, were identified as novel targets for FGF-8b, some of which were additionally shown to correlate with prognosis and ER status in human breast cancer.
1050	J. Inhibition	A. Treat	1	EGFR	non-small cell lung cancer	Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations.
1051	A.1 Over-expression	C. Cause	1	SMARCD1	GASTRIC CANCER	Knockdown of SMARCD1 significantly attenuated the protumorigenic effects of miR-490-3p inhibitor, whereas enforced expression of SMARCD1 promoted in vitro and in vivo oncogenic phenotypes of gastric cancer cells.
1052	D.1 Mutation	E. Associate	1	BRAF	thyroid cancers	An integral component of this pathway, BRAF, is also activated by mutation, especially in melanoma and thyroid cancers.
1053	A. Expression	A. Treat	1	OSM	lung cancer	To improve the efficacy and selectivity of gene therapy for lung cancer through inducing oncostatin M (OSM) gene expression by radiation via the early growth response gene-1 (Egr-1) promoter.
1054	J. Inhibition	H. Benefit	1	EGFR	NSCLC	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC).
1055	A.1 Over-expression	H. Benefit	1	TOP2A	HER2-positive breast cancer	TOP2A gene amplification may define a subset of HER2-amplified breast cancers that are responsible for the markedly improved chemosensitivity seen in HER2-positive breast cancer.
1056	H. Other	E. Associate	1	BRCA1	breast cancer	These findings indicate that the products of BRCA1, neu, and erbB breast cancer genes participate in a common or shared signaling pathway important in cell growth and its regulation.
1057	D.5 Polymorphism	F. None	1	ERBB2	breast cancer	These study results suggest that Ile655Val polymorphism of the ERBB2 gene do not alter its activity and may not be associated with increased breast cancer risk among Chinese women.
1058	F.2 Methylation	E. Associate	1	VDR	breast cancer	Thus, promoter methylation-mediated silencing of expression of the functional variants of VDR may contribute to reduced expression of downstream effectors of the VDR pathway and subsequent Calcitriol insensitivity in breast cancer.
1059	H. Other	E. Associate	0	EPO	breast cancers	STAT3, HIF-1alpha, EPO and EPOR - signaling proteins in human primary ductal breast cancers.
1060	A.1 Over-expression	C. Cause	1	DEPDC1	breast cancer	Therefore, the increased DEPDC1 expression in breast cancer is correlated with disease progression and poor survival, which suggested that DEPDC1 might be a potential therapeutic target against this disease.
1061	D.1 Mutation	E. Associate	1	K-Ras	non-small cell lung cancer	Human non-small cell lung cancer (NSCLC) displays activated MEK/ERK signaling due to a high frequency of K-Ras mutation and is thus a potential candidate for MEK-targeted therapy.
1062	I. None	B. Target	1	CXCR4	breast cancer	To construct human phage single-chain antibody (scFv) library against breast cancer, and to identify anti-HER2 specific antibodies from the human phage display scFv library to offer a stronger affinity sequence targeting HER2 for fusion protein targeting HER2 and CXCR4.
1063	A.2 Under-expression	E. Associate	1	FOXA1	breast cancer	Further, we demonstrated that FOXA1 attenuation was involved in transcriptional downregulation of proapoptotic Bim and thus suppressed breast cancer cell apoptosis.
1064	A. Expression	E. Associate	1	MDM2	breast cancer	In contrast, in breast cancer cells that acquired resistance to lapatinib, the abundance of MDM2 was not decreased and HUWE1 was degraded, which inhibited apoptosis, regardless of p53 status.
1065	J. Inhibition	H. Benefit	1	E2	breast cancer	Conversely, DIM and a CXCR4 antagonist (AMD3100) decreased CXCR4 protein expression, which led to inhibition of the EMT process, indicating that DIM may suppress E2, TCS or BPA-induced EMT, migration, and invasion of MCF-7 breast cancer cells by suppressing CXCR4 protein expression.
1066	L.2 Down-regulation	H. Benefit	1	HER2	breast cancer	Expression of the Adenovirus Early Gene 1A Transcription-Repression Domain Alone Downregulates HER2 and Results in the Death of Human Breast Cancer Cells Upregulated for the HER2 Proto-Oncogene.
1067	I. None	B. Target	1	MERTK	NSCLC	We previously identified MERTK tyrosine kinase as a potential therapeutic target in NSCLC and developed MRX-2843, a novel MERTK-selective inhibitor with favorable properties for clinical translation.
1068	I. None	B. Target	1	ANXA11	GASTRIC CANCER	CONCLUSIONS ANXA11 plays a critical role in regulating GC proliferation, migration, and invasion via the AKT/GSK-3β pathway, and can potentially be used as a prognostic factor and therapeutic target for gastric cancer patients.
1069	D.1 Mutation	E. Associate	1	RET	medullary thyroid carcinoma	In this study, we have shown that familial medullary thyroid carcinoma (FMTC) mutants RET(Y791F) and RET(S891A) induced, in addition to Tyr(705) phosphorylation, constitutive STAT3 Ser(727) phosphorylation.
1070	L. Be regulated	C. Cause	1	NEDD9	lung cancer	Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer.
1071	A.1 Over-expression	E. Associate	1	ER	breast cancer	Increase in ERα+/ERβ+ coexpression, ERα expression and ERβcx expression in breast cancer progression indicates an enhancement in ER expressions or an alteration in expression patterns of different ER variants during mammary carcinogenesis.
1072	J. Inhibition	H. Benefit	1	CDK4	breast cancer	Moreover, we found that blocking CDK4 expression or kinase activity, using a pharmacological inhibitor prevented breast cancer stem cell self-renewal.
1073	J. Inhibition	A. Treat	1	PD-L1	breast cancer	IMPLICATIONS FOR PRACTICE: In the light of the promising results coming from trials of immune checkpoint inhibitors for breast cancer treatment, the potential predictive and/or prognostic role of programmed cell death ligand 1 (PD-L1) in breast cancer has gained increasing interest.
1074	L. Be regulated	E. Associate	1	sphingosine-1-phosphate receptor 1	breast cancer	miR-542-3p targets sphingosine-1-phosphate receptor 1 and regulates cell proliferation and invasion of breast cancer cells.
1075	L.1 Up-regulation	H. Benefit	1	c-Met	SCLC	PAX5 has been shown to upregulate c-Met in small cell lung carcinoma (SCLC), and coinhibiting PAX5 and c-Met had a synergic effect in killing tumor cells.
1076	D.1 Mutation	C. Cause	1	ROS1	NSCLC	For the former two alterations, many inhibitors are already available, whereas for ROS1 and other driving mutations the evidence is sparse due to the rare occurrence of these mutations in NSCLC.
1077	L. Be regulated	E. Associate	0	ARHGAP1	breast cancer	One of these miRNAs, hsa-miR-940, significantly promoted the osteogenic differentiation of human mesenchymal stem cells in vitro by targeting ARHGAP1 and FAM134A Interestingly, although MDA-MB-231 breast cancer cells are commonly known as an osteolytic phenotype-inducing cancer cell line, the implantation of miR-940-overexpressing MDA-MB-231 cells induced extensive osteoblastic lesions in the resulting tumors by facilitating the osteogenic differentiation of host mesenchymal cells.
1078	D.1 Mutation	E. Associate	0	PDGFRA	gists	Succinate dehydrogenase (SDH)-deficient GISTs are a unique class of GIST defined by loss of immunohistochemical expression of SDHB, indicating dysfunction of the mitochondrial complex 2; lack of driver mutations in KIT and PDGFRA; and distinctive morphologic features and natural history.
1079	D.5 Polymorphism	H. Benefit	1	SOD2	lung adenocarcinoma	This study suggests that subjects with the SOD2 TCG haplotype may be at decreased risk for lung adenocarcinoma and that this association may depend on smoking amount.
1080	A.1 Over-expression	C. Cause	1	CD133	lung cancer	Importantly, microenvironment stimuli eliciting epithelial-to-mesenchymal transition, including signals from cancer-associated fibroblasts, are able to increase the dissemination potential of lung cancer cells through the generation of the CD133(+)/CXCR4(+)/EpCAM(-) subset.
1081	F.1 Phosphorylation	H. Benefit	1	epidermal growth factor receptor	lung cancer	Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.
1082	I. None	C. Cause	1	VASH2	NSCLC	We further showed that downregulation of AKT signaling activity by using AKT inhibitor LY294002 markedly inhibited NSCLC cell proliferation and resistance to doxorubicin induced by VASH2.
1083	A.1 Over-expression	C. Cause	1	LGR5	PTC	Our results reveal that LGR5 and its ligand, RSPO, are overexpressed in human PTC, whereby Wnt/β-catenin signaling regulates LGR5 expression and promotes cellular migration.
1084	I. None	B. Target	1	PKD1	breast cancer	Thus, our study defines PKD1 as a novel attractive prognostic factor and a potential therapeutic target in breast cancer.
1085	A. Expression	C. Cause	1	RANTES	breast cancer	Here, we identified the impact of TNF-α and IL-1β on the inflammatory phenotype of CAFs and MSCs by determining the expression of inflammatory chemokines that are well-characterized as pro-tumorigenic in breast cancer: CCL2 (MCP-1), CXCL8 (IL-8) and CCL5 (RANTES).
1086	D.1 Mutation	B. Target	1	epidermal growth factor receptor	NSCLC	ALK rearrangements are present in 3-5% of patients with non-small cell lung cancer (NSCLC) and after epidermal growth factor receptor (EGFR) mutations represent the second molecular target in NSCLC to be validated through phase III clinical trials.
1087	A.2 Under-expression	E. Associate	1	PARP1	non-small cell lung cancer	Patients with ERCC1 or PARP1 negative non-small cell lung cancer appear to benefit from platinum-based postoperative adjuvant chemotherapy.
1088	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	non-small cell lung cancer	Determining the somatic mutations of epidermal growth factor receptor (EGFR)-pathway networks is the key to effective treatment for non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitors (TKIs).The somatic mutation frequencies and their association with gender, smoking history and histology was analysed and reported in this study.
1089	A.1 Over-expression	E. Associate	0	endothelin-1	lung cancer	In order to study endothelin-1 (ET-1) positive expression in lung cancer and the relationship between the ET-1 quantitative analysis and the types, grades of lung cancer.
1090	G. Regulate	E. Associate	1	FOXE1	lung cancer	These results implicated that FOXE1 may be an important regulator by targeting autophagy and MMPs pathways in lung cancer development.
1091	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	Non-small cell lung carcinoma	Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: A review of cytologic series.
1092	J. Inhibition	E. Associate	0	CYP11B2	breast cancer	Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.
1093	J. Inhibition	H. Benefit	1	cofilin	breast cancer	Furthermore, our results suggest that inhibitors of dephosphorylated cofilin expression may provide therapeutic benefits in patients with breast cancer.
1094	F.2 Methylation	E. Associate	0	hMLH1	Gastric carcinoma	This study was designed to investigate the relationship of hMLH1 gene promoter methylation status to MSI in gastric carcinoma, and analyze its action as a risk factor of carcinogenesis.
1095	D.1 Mutation	E. Associate	0	BRCA1	breast cancer	We evaluated the effectiveness of breast cancer screening by clinical breast examination (CBE), mammography, and MRI in a population of 88 BRCA1 and 51 BRCA2 mutation carriers who had RRSO before the age of 52.
1096	G. Regulate	E. Associate	1	PRL	breast cancer	These results indicated that PRL inhibited BCL6 expression and regulated breast cancer progression through a miR-339-5p-dependent pathway.
1097	D.5 Polymorphism	E. Associate	0	CDA	non-small cell lung cancer	Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
1098	G. Regulate	C. Cause	0	CXCL9	hepatocellular carcinoma	The effect of CXCL9 on the invasion ability of hepatocellular carcinoma through up-regulation of PREX2.
1099	I. None	C. Cause	1	ACK1	NSCLC	Our study demonstrated that ACK1 played an oncogenic role in the progression of NSCLC and ACK1 might be a promising target for the treatment of NSCLC.
1100	I. None	G. Marker	1	estrogen receptor	breast cancer	The discovery of estrogen receptor (ER) gave us not only a powerful predictive and prognostic marker, but also an efficient target for the treatment of hormone-dependent breast cancer with various estrogen ligands.
1101	D.1 Mutation	C. Cause	1	BRCA2	breast cancer	Epithelial ovarian cancer is composed of distinct histological subtypes with unique genomic characteristics, which are improving the precision and effectiveness of therapy, allowing discovery of predictors of response such as mutations in breast cancer susceptibility genes BRCA1 and BRCA2, and homologous recombination deficiency for DNA damage response pathway inhibitors or resistance (cyclin E1).
1102	F.1 Phosphorylation	E. Associate	0	EGFR	breast cancer	We observed hypo-phosphorylation of EGFR in HER2+ PIK3CA H1047R breast cancer versus HER2+PIK3CAwild-type (PIK3CA WT).
1103	J. Inhibition	A. Treat	1	epidermal growth factor receptor	lung cancer	Recent studies have reported that clinical response to epidermal growth factor receptor (EGFR) inhibitors is associated with somatic changes of EGFR in the advanced stage of lung cancer.
1104	A.1 Over-expression	E. Associate	1	ER	breast cancer	The study of ER+ IBC samples might reveal biomarkers for endocrine resistant breast cancer.
1105	F.2 Methylation	E. Associate	0	INK4	hepatocellular carcinoma	Promoter hypermethylation of p14 (ARF) , RB, and INK4 gene family in hepatocellular carcinoma with hepatitis B virus infection.
1106	A. Expression	G. Marker	1	CD44	lung adenocarcinoma	Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma--their prognostic significance.
1107	H. Other	A. Treat	1	EGF	breast cancer	Combined vaccination with EGF and VEGF from shuffling showed better immunotherapy on EGF-EGFR signaling-dependent epithelial tumors such as breast cancer than the single-agent EGF vaccination.
1108	L. Be regulated	E. Associate	0	PTEN	NSCLC	We identified the role of miR-21 in non-small cell lung cancer (NSCLC) and to clarify the regulation of PTEN by miR-21 and determine mechanisms of this regulation.
1109	D.1 Mutation	E. Associate	0	BRCA1	breast cancer	With Affymetrix GeneChip arrays, we genotyped 8,576 polymorphisms in three sets of Ashkenazi Jewish breast cancer cases: a "validation" set of 27 breast cancer cases, all of whom carried the BRCA2*6174delT founder mutation; a "field" set of 19 breast cancer cases from male breast cancer kindreds, which simulated conditions for finding new genes; and a "test" set of 57 probands from breast cancer kindreds (4 or more cases/kindred), in which mutations in BRCA1 and BRCA2 had been excluded.
1110	I. None	E. Associate	0	thyroglobulin	thyroid cancer	Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer.
1111	D.1 Mutation	E. Associate	0	TP53	breast cancer	Here we describe TP53 germline mutations found in French Canadian cancer families provided from hereditary cancer clinics; investigate 37 new BRCA1 and BRCA2 mutation-negative HBC/HBOC families for the TP53 mutations; and assess the frequency of TP53 mutations in a 1235 French Canadian breast cancer cases not selected for family history of cancer.
1112	D.1 Mutation	C. Cause	1	EGFR	NSCLC	The discovery of Epidermal Growth Factor Receptor (EGFR) mutations as a driving mutation in non-small cell lung cancer (NSCLC) and the subsequent success of the tyrosine kinase inhibitors (TKI) have led the way for NSCLC to be at the forefront of biomarker-based drug development.
1113	D.1 Mutation	E. Associate	0	CDH1	GASTRIC CANCER	Error in Byline. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.
1114	A. Expression	E. Associate	0	ARNT2	non-small cell lung cancer	The present study aims to investigate the expression pattern of aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) protein and its clinical significance in human non-small cell lung cancer (NSCLC).
1115	D.1 Mutation	C. Cause	1	RET	MTC	More recent studies revealed that the RET proto-oncogene is involved in the oncogenesis of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) by activation of its tyrosine kinase either by point mutation or rearrangement.
1116	J. Inhibition	A. Treat	1	ALK	lung cancer	EML4-ALK is a lung cancer oncogene, and ALK inhibitors show marked therapeutic efficacy for tumors harboring this fusion gene.
1117	H. Other	E. Associate	0	AR	breast cancer	To investigate the anti-angiogenic effect of amphiregulin (AR) antisense RNA expression in breast cancer.
1118	I. None	B. Target	1	ADAR	Lung Adenocarcinomas	One promising target, ADAR, is amplified in 13% of lung adenocarcinomas and in-vitro studies have demonstrated the potential of its therapeutic inhibition to inhibit tumor growth.
1119	A. Expression	E. Associate	1	galectin 4	hepatocellular carcinoma	Eight cDNAs encoding galectin 4 (Gal-4), UGT2B4 (UDP-glucuronosyltransferase), ribosomal phosphoprotein P0 (rpP0), dek, insulin-like growth factor binding protein (IGFBP) 1, vitronectin, retinoic acid-induced gene E (RIG-E), and CYP3A4 (cytochrome P450 nifedipine oxidase) were identified as differentially expressed genes between human hepatocellular carcinoma (HCC) and matched nontumorous liver tissues.
1120	A.1 Over-expression	E. Associate	1	SOX4	breast cancers	Our in silico analyses identified SOX4 amplification as a novel modulator of PI3K/Akt signaling in breast cancers and in vitro studies confirmed its role in regulating Akt phosphorylation.
1121	G. Regulate	E. Associate	1	HOTAIRM1	breast cancer	This review aims to comprehensively present the updated TGFβ-induced EMT in breast cancer, including the regulatory role of the non-coding RNAs with focus on the miR-200 family and newly discovered lncRNAs such as HOTAIRM1.
1122	I. None	B. Target	1	phosphoglycerate dehydrogenase	breast cancer	Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer.
1123	A.2 Under-expression	E. Associate	1	DNPEP	breast cancer	Importantly, we verify that DNPEP expression is frequently downregulated in breast cancer tissues and is negatively correlated with PAK5 and USP4 expression.
1124	A. Expression	E. Associate	0	SIRT1	GASTRIC CANCER	Towards this, we used patient tissues representing different stages of gastric cancer including gastric pre-cancerous lesions, early gastric cancer, and advanced gastric cancer, and probed SIRT1, STAT3 and phosphorylated STAT3 (pSTAT3) levels using immunohistochemistry.
1125	J. Inhibition	A. Treat	1	EGFR	lung cancer	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been demonstrated to improve responses and clinical outcomes significantly in patients with advanced non-small-cell lung cancer (NSCLC).
1126	A.2 Under-expression	C. Cause	1	parafibromin	lung cancers	Downregulated parafibromin expression is involved in the pathogenesis and progression of parathyroid, breast, gastric, colorectal, and lung cancers.
1127	H. Other	E. Associate	0	IFN-gamma	Pulmonary metastases	We examined the activities of activated lymphocytes, interferon-gamma (IFN-gamma), and interleukin 2 (IL-2) in adoptive immunotherapy of pulmonary metastases.
1128	H. Other	E. Associate	1	RAR	breast cancer	Five lines of evidence suggest that melatonin works via epigenetic processes: (1) melatonin influences transcriptional activity of nuclear receptors (ERalpha, GR and RAR) involved in the regulation of breast cancer cell growth; (2) melatonin down-regulates the expression of genes responsible for the local synthesis or activation of estrogens including aromatase, an effect which may be mediated by methylation of the CYP19 gene or deacetylation of CYP19 histones; (3) melatonin inhibits telomerase activity and expression induced by either natural estrogens or xenoestrogens; (4) melatonin modulates the cell cycle through the inhibition of cyclin D1 expression; (5) melatonin influences circadian rhythm disturbances dependent on alterations of the light/dark cycle (i.e., light at night) with the subsequent deregulation of PER2 which acts as a tumor suppressor gene.
1129	A.2 Under-expression	E. Associate	1	ER	breast cancer	Triple negative breast cancer lacking estrogen receptor (ER), progesterone receptor and Her2 account for account for the majority of the breast cancer deaths, due to the lack of specific gene targeted therapy.
1130	A.1 Over-expression	E. Associate	1	GABRB2	thyroid cancer	Results showed that GABRB2 expression was significantly upregulated in thyroid cancer.
1131	J. Inhibition	A. Treat	1	epidermal growth factor receptor	NSCLC	Erlotinib is an oral tyrosine kinase inhibitor, targeting the human epidermal receptor type 1/ epidermal growth factor receptor, recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) after the failure of more than 1 or 2 previous chemotherapeutic regimens.
1132	H. Other	E. Associate	1	AVP	siadh	Either hypervolemia or hypotonicity may diminish the post-receptor signaling of AVP in renal collecting duct cells, under the chronic AVP excess state found in SIADH.
1133	I. None	G. Marker	1	MALAT1	lung cancer	MALAT1 was discovered as a prognostic marker for lung cancer metastasis and has been found upregulated in many types of tumor, but its transcriptional regulation mechanism in tumors remains unclear.
1134	L. Be regulated	E. Associate	1	estrogen receptor beta	breast cancer	AKT regulation of estrogen receptor beta transcriptional activity in breast cancer.
1135	M.3 Gene silencing	E. Associate	1	SRA	breast cancer	Here we report that in breast cancer cells, the unliganded progesterone receptor (PR) binds genomic sites and targets a repressive complex containing HP1γ (heterochromatin protein 1γ), LSD1 (lysine-specific demethylase 1), HDAC1/2, CoREST (corepressor for REST [RE1 {neuronal repressor element 1} silencing transcription factor]), KDM5B, and the RNA SRA (steroid receptor RNA activator) to 20% of hormone-inducible genes, keeping these genes silenced prior to hormone treatment.
1136	F.2 Methylation	E. Associate	1	SFRP1	breast cancer	In breast cancer, frequent methylation and silencing of SFRP1 was recently documented; however, altered expression of other Wnt antagonist genes is largely unknown.
1137	G. Regulate	B. Target	1	linc-ITGB1	hepatocellular carcinoma	The results indicate that linc-ITGB1, a novel oncogene in tumorigenesis, could promote the metastasis and EMT via ZEB1, which may offer a possible therapeutic target in hepatocellular carcinoma.
1138	D.1 Mutation	E. Associate	1	NKX2-1	Lung Adenocarcinomas	Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
1139	L.2 Down-regulation	C. Cause	1	TSHR	thyroid cancer	TSHR was significantly downregulated in well-differentiated thyroid cancer cells and tissues, and a lack of TSHR promoted thyroid cancer cell invasion and metastasis by inhibiting the EMT of thyroid cancer cells.
1140	D.1 Mutation	E. Associate	1	PIK3CA	breast cancer	Targeting PIK3CA mutant tumors with a PI3K pathway inhibitor and fulvestrant is therefore a feasible strategy for aromatase-inhibitor-resistant ER-positive relapsed breast cancer.
1141	D.1 Mutation	C. Cause	1	K-Ras	Gastric Cancers	Nonetheless, a high incidence of mutations of K-Ras was found within the MSI gastric group of tumors (P=0.0005), suggesting that the activation of K-Ras-dependent pathways contributes to the tumorigenesis of gastric cancers with MMR deficiency.
1142	A. Expression	F. None	1	PSA	BREAST CARCINOMA	The present study, using indirect immunohistochemistry on 75 formalin-fixed, paraffin-embedded breast cancers shows PSA immunoreactivity in only seven of 75 cases (9%), suggesting that PSA positivity in breast carcinoma is not useful as a prognostic or tumor marker with hospital-based methods.
1143	H. Other	E. Associate	1	AKT	breast cancer	Wogonin increases doxorubicin sensitivity by down-regulation of IGF-1R/AKT signaling pathway in human breast cancer.
1144	D.1 Mutation	E. Associate	0	RET	medullary thyroid carcinoma	The frequency and prognostic relevance of RET proto-oncogene somatic mutations in sporadic medullary thyroid carcinoma (MTC) remain controversial.
1145	A.2 Under-expression	E. Associate	1	N-CoR	breast cancer	We have found that estrogen markedly down-regulates N-CoR protein levels in estrogen receptor (ER)-positive breast cancer cells without affecting N-CoR mRNA levels, whereas levels of the related corepressor SMRT are unaffected.
1146	G. Regulate	H. Benefit	1	KDM5A	breast cancer	Genome-Wide Methylation Analysis Identifies NOX4 and KDM5A as Key Regulators in Inhibiting Breast Cancer Cell Proliferation by Ginsenoside Rg3.
1147	A.1 Over-expression	E. Associate	1	TFDP1	of lung adenocarcinoma	Our results suggest that overexpression of HMGA1, E2F6, IRF1, and TFDP1 and downregulation or no expression of SUV39H1, RBL1, and HNRPD in blood is suitable for diagnosis of lung adenocarcinoma and squamous cell carcinoma sub-types of NSCLC.
1148	L. Be regulated	E. Associate	1	TXNRD1	non-small cell lung cancer	MicroRNA-124 regulates the radiosensitivity of non-small cell lung cancer cells by targeting TXNRD1.
1149	M.1 Knock down	E. Associate	0	MDM2	lung cancer	This study tested the efficacy of MI-219 against a panel of lung cancer cell lines alone or in combination with MDM2 knockdown, an X-linked inhibitor of apoptosis protein (XIAP) inhibitor, or a chemotherapeutic drug, etoposide.
1150	I. None	B. Target	1	IL-17RB	lung cancer	IL-17RB may therefore serve as an independent prognostic factor and a therapeutic target for lung cancer.
1151	D.1 Mutation	E. Associate	0	AKT1	Lung Adenocarcinomas	Thirty-six resected lung adenocarcinomas from young patients under 40 years old were analyzed concurrently for mutations in EGFR, KRAS, HER2, BRAF, AKT1, ALK, RET, TP53 and LKB1 and enrolled as the younger group.
1152	L. Be regulated	E. Associate	1	profilin 1	Triple-negative breast cancer	Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
1153	A.1 Over-expression	E. Associate	1	death receptor 5	NSCLC	Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line.
1154	A. Expression	E. Associate	1	retinoic acid receptor alpha	breast cancer	Expression of estrogen receptor alpha, retinoic acid receptor alpha and cellular retinoic acid binding protein II genes is coordinately regulated in human breast cancer cells.
1155	I. None	E. Associate	0	multidrug resistance-associated protein 2	breast cancer	The glycoprotein-P (Pgp, ABCB1), multidrug resistance-associated protein 2 (MRP2, ABCC2), and breast cancer resistance protein (BCRP, ABCG2) located in the apical membrane of enterocytes were investigated using specific inhibitors.
1156	A.1 Over-expression	E. Associate	1	YY1	breast cancer	In human breast cancer tissues, FAM3C, YY1 and HSF1 protein expressions were increased.
1157	I. None	E. Associate	0	interleukin-10	breast cancer	Role of interleukin-10 in breast cancer.
1158	A. Expression	E. Associate	0	CD31	NSCLC	The expression of lymphatic vessel endothelium markers podoplanin, VEGFR-3 and vascular endothelium marker CD31 was detected in paraffin sections from 68 cases of NSCLC and 8 cases of pulmonary inflammatory myofibroblastic tumor (PIMT) by immunohistochemistry (SP).
1159	D.1 Mutation	C. Cause	1	BRCA1	breast cancer	Overall, the availability of MRI as an adjunct to mammography and ultrasound offers clear clinical benefit to women at increased risk of breast cancer development due to BRCA1 and BRCA2 mutations, and to women presenting with axillary adenopathy and an occult primary breast tumor.
1160	A. Expression	E. Associate	1	estrogen receptor	breast cancers	The estrogen receptor (ER) is expressed on the vast majority of newly diagnosed breast cancers, yet not all ER-positive tumors will respond to endocrine therapy.
1161	F.1 Phosphorylation	E. Associate	1	PDH	hepatocellular carcinoma	In this study, we show in two hepatocellular carcinoma cell lines (HepG2 and JHH-4) that, during the adaptation to hypoxia, PDH is already phosphorylated at time points preceding HIF-1-mediated transcriptional events and PDK1 protein upregulation.
1162	A.2 Under-expression	E. Associate	1	SMAGP	lung cancer	Immunohistochemical data obtained using human breast, colon and lung cancer samples sustain this hypothesis since they showed that, in both primary tumours and metastases, reduced expression and/or cytoplasmic redistribution of SMAGP is superimposable with low histological tumour differentiation features, namely a lack of epithelial cell polarity and disorganized tissue phenotype.
1163	A.2 Under-expression	E. Associate	1	ER	breast cancer	Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER-) cancers, by reducing rates of recurrences.
1164	A. Expression	E. Associate	0	VEGFR-3	NSCLC	The expression of VEGF-C and VEGFR-3 in 77 specimens of NSCLC were detected by immunohistochemistry; their correlations to lymphatic vessel density (LVD), tumor size, histological type, differentiation, lymphatic metastasis, clinical recurrence, and survival time of the patients were analyzed.
1165	D.2 Rearrangement	E. Associate	1	ALK	lung cancer	The aim of this study was to investigate the response to crizotinib in patients of advanced non-small-cell lung cancer (NSCLC) with ALK rearrangements detected by RT-PCR.
1166	D.5 Polymorphism	E. Associate	1	ERCC2	lung cancer	Several studies have associated polymorphisms in ERCC2 with response to platinum therapy, lung cancer risk, and DNA repair capacity.
1167	L. Be regulated	E. Associate	1	EGFR	breast cancers	These data implicate RME-8 in sorting decisions influencing EGFR at the level of endosomes and point to RME-8 as a potential regulatory target in ErbB2-positive breast cancers.
1168	C. Activation	E. Associate	1	F7	HEPATOMA	Reporter gene assays in hepatoma cells identified a sgRNA (sgRNAF7.5) triggering a ~35-fold increase in the activity of F7 promoter, either wild-type, or defective due to the c.-61T>G mutation.
1169	A. Expression	E. Associate	1	COX-2	hepatocellular carcinoma	Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma.
1170	L.1 Up-regulation	E. Associate	1	GDH1	lung cancer	Here we report that a glutaminolytic enzyme, glutamate dehydrogenase 1 (GDH1), upregulated upon detachment via pleomorphic adenoma gene 1 (PLAG1), provides anti-anoikis and pro-metastatic signals in LKB1-deficient lung cancer.
1171	D.1 Mutation	E. Associate	1	EGFR	NSCLC	In conclusion, this study examined whether the inhibition of glucose metabolism using 2DG enhances sensitivity to afatinib in NSCLC cells with EGFR T790M through the regulation of the AMPK/mTOR/Mcl-1 signaling pathway.
1172	A. Expression	E. Associate	1	PD-L1	NSCLC	AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells.
1173	A. Expression	E. Associate	0	ZO-1	breast cancer	In order to evaluate the relevance of the MEK1 pathway in tight junction regulation in breast cancer cells, we investigated the effect ofMEK1 inhibition on expression of claudin-1, occludin and ZO-1 in natively claudin-1 expressing T47-D cells (low Ras activity), claudin-1 negative MCF-7 cells (elevated Ras activity) as well as two retroviral claudin-1 transduced MCF-7 daughter cell lines with prominent membrane and cytoplasmic claudin-1 dominant homing, respectively.
1174	D.1 Mutation	C. Cause	1	BRCA2	breast cancer	Breast cancer due to mutations in BRCA1 and BRCA2 genes appears to be a heterogeneous syndrome in the Greek population.
1175	I. None	A. Treat	1	ADR	Gastric adenocarcinoma	A metabolomics approach using proton nuclear magnetic resonance (NMR) was applied to investigate metabolic alterations following adriamycin (ADR) treatment for gastric adenocarcinoma.
1176	D.1 Mutation	E. Associate	1	EGFR	non-small cell lung cancer	The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene resulting from an inversion within chromosome 2p occurs in approximately 5% of non-small cell lung cancer and is mutually exclusive with Ras and EGFR mutations.
1177	I. None	E. Associate	1	RGS11	lung cancer	However, trace levels of RGS11 (in the range of pg/mL) in serum samples make it difficult to quantify using currently available Enzyme-Linked ImmunoSorbent Assay (ELISA) kits and, therefore, this hinders progress in the discovery of new approaches for treating lung cancer.
1178	L. Be regulated	H. Benefit	1	YAP1	hepatocellular carcinoma	microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma.
1179	I. None	B. Target	1	IL-1	breast cancer	The increased IL-1β in breast cancers of women strongly suggests IL-1 as a potential therapeutic target in breast cancer treatment and prevention.
1180	A.1 Over-expression	E. Associate	1	IGF-II	Hepatocellular Carcinomas	N-myc2 and insulin-like growth factor II (IGF-II) are coordinately overexpressed in the great majority of altered hepatic foci, which are the earliest precancerous lesions observed in the liver of woodchuck hepatitis virus carrier woodchucks, and these genes continue to be overexpressed in hepatocellular carcinomas (HCCs).
1181	A.1 Over-expression	E. Associate	1	cytokeratin-8	liver tumors	Arsenic/TPA treatment resulted in increased expression of alpha-fetoprotein, k-ras, c-myc, estrogen receptor-alpha, cyclin D1, cdk2na, plasminogen activator inhibitor-1, cytokeratin-8, cytokeratin-18, glutathione S-transferases and insulin-like growth factor binding proteins in liver and liver tumors from both male and female mice.
1182	A. Expression	E. Associate	0	MMP-2	breast cancer	Hypoxia-inducible factor-2α (HIF-2α) may upregulate MMP-2 expression; however, little is known about the correlation between HIF-2α and MMP-2 expressions in breast cancer.
1183	D.1 Mutation	E. Associate	1	TP53	papillary thyroid cancer	Exclusion of mutations in TP53 and the TERT promoter could be considered as an adjunct tool when assessing papillary thyroid cancer with focal pleomorphism.
1184	J. Inhibition	A. Treat	1	programmed cell death protein 1	small cell lung cancer	The recent emergence of immunotherapy treatment options, such as the use of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors, has also led to a paradigm shift in the treatment of non-small cell lung cancer, and has provided promising directions for the treatment of small cell lung cancer.
1185	G. Regulate	E. Associate	1	AT1	breast cancer	These results indicate that in human primary cultured breast cancer cells AT1 regulates mitogenic signaling pathways by two simultaneous mechanisms, one involving conventional PKCs and the other EGFR transactivation.
1186	A. Expression	E. Associate	0	COX-2	breast cancers	Flow cytometry was used to analyze the expression level of MTS1 and COX-2 in cancer tissues and corresponding para-cancer tissues from 66 cases of primary invasive breast cancers.
1187	J. Inhibition	A. Treat	1	MDK	lung cancers	Inhibition of MDK with iMDK provides a potential therapeutic approach for the treatment of lung cancers that are driven by MDK.
1188	I. None	B. Target	1	EGFR	breast cancer	A growing body of work (including recent preclinical and clinical data) support targeting the HER family [epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor (HER) 1 or ErbB1) and HER2, HER3, and HER4] for preventing ER-negative and possibly ER-positive breast cancer.
1189	D.1 Mutation	E. Associate	1	ER	breast cancer	Breast cancer tissue has been shown to contain alternatively spliced estrogen receptor (ER) mRNA variants which may result in alternate ER proteins.
1190	L. Be regulated	H. Benefit	1	CTNND1	GASTRIC CANCER	Enforced expression of miR-29s in gastric cancer cells inhibited cell invasion in vitro and in vivo by directly targeting catenin-δ (CTNND1).
1191	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	NSCLC	Previous studies have shown that certain non-small cell lung cancer (NSCLC) patients harbor gain-of-function mutations in the epidermal growth factor receptor gene (EGFR).
1192	C. Activation	H. Benefit	1	caspase-3	LIVER TUMOR	Here we show that blockage of this pathway by the tyrphostin 4-(3-chloroanilino)-6,7-dimethoxyquinazoline (AG1478) in different liver tumor cell lines promotes both inhibition of cell proliferation and induction of cell death, which are coincident with arrest in the G1 phase of the cell cycle, caspase-3 activation and DNA fragmentation.
1193	H. Other	E. Associate	1	RET	Medullary Thyroid Cancer	We have previously shown that RET signals through focal adhesion kinase (FAK) in medullary thyroid cancer cells and that extracellular signal-regulated kinase (ERK) activity can be blocked by pp2, an inhibitor of both Src and RET.
1194	A.2 Under-expression	E. Associate	1	ER	breast cancer	The effect of a kinase inhibitor Go6796 on growth of epidermal growth factor (EGF)-stimulated estrogen receptor negative (ER-) breast cancer cells in vivo and role of nuclear factor kappa B (NF-kappaB) on tumorogenesis have been investigated.
1195	I. None	E. Associate	1	alpha-fetoprotein	Gastric carcinoma	A complex of measurements of alpha-fetoprotein, alkaline phosphatase, gamma-glutamyl transpeptidase and aspartate aminotransferase detected gastric carcinoma metastases to the liver in 84.6% of cases as against 61.5% detected by measurements of alpha-fetoprotein alone.
1196	D.1 Mutation	E. Associate	1	EGFR	lung cancer	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations.
1197	D.1 Mutation	E. Associate	1	RAD52	lung cancer	Several other genetic regions including variants of CHEK2 (22q12), TP53BP1 (15q15) and RAD52 (12p13) have been demonstrated to influence lung cancer risk in candidate- or pathway-based analyses.
1198	A. Expression	E. Associate	1	CXCR7	GASTRIC CANCER	The expression levels of TLR4, MD-2 and CXCR7 were closely related to gastric cancer TNM stage and lymph node metastasis.
1199	L.1 Up-regulation	E. Associate	1	miR-100	GASTRIC CANCER	Here, we showed that miR-100 was specifically upregulated in human epithelium-derived gastric cancer cells and that silencing miR-100 expression in human gastric epithelial cancer cells initiated a robust apoptotic response in vitro.
1200	I. None	C. Cause	1	HBXIP	breast cancer	The oncoprotein hepatitis B X-interacting protein (HBXIP) results in the dysregulation of lipid metabolism to enhance the development of breast cancer.
1201	I. None	E. Associate	0	CTCF	LIVER CANCER	Here we aligned the ChIP-seq data of histone modification markers and CTCF to the human genome assembly which contains a single rDNA repeat in human liver cancer cell and validated their distribution with ChIP-QPCR.
1202	F.1 Phosphorylation	E. Associate	1	IRS-1	HEPATOMA	In addition, it was also shown that HCV-NS5A-expressing hepatoma cells show serine phosphorylation of IRS-1, thereby hampering metabolic activity and contributing to insulin resistance.
1203	J. Inhibition	A. Treat	1	programmed cell death 1	NSCLC	The programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) pathway has emerged as a critical inhibitory pathway regulating T-cell response in non-small-cell lung cancer (NSCLC), and the development of PD-1/PD-L1 inhibitors has changed the landscape of NSCLC therapy.
1204	A.1 Over-expression	C. Cause	1	TAK1	GASTRIC CANCER	In conclusion, these findings suggest that increased TAK1 expression may be involved in the progression of gastric cancer; therefore, TAK1 may be used as a future therapeutic target for gastric cancer treatment.
1205	A.1 Over-expression	E. Associate	1	CK19	breast cancer	Seven breast cancer-associated genes (mam, mamB, PIP, CK19, muc1, PSE, and CEA) known to be overexpressed in metastatic breast cancer compared with control lymph nodes were used.
1206	D.1 Mutation	C. Cause	1	RET	MEN 2	Although inherited mutations of RET lead to tumor formation in patients with MEN 2, it is not understood why only selected cells develop into tumors.
1207	D.1 Mutation	E. Associate	1	PIK3CA	ATC	In addition, activation of Akt was observed in most of the ATC harboring PIK3CA mutations.
1208	L. Be regulated	E. Associate	1	c-Jun	Hepatocarcinoma	ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun.
1209	L.1 Up-regulation	E. Associate	1	neutral sphingomyelinase	breast cancer	We found that functional inhibition of endogenous RARalpha in breast cancer cells by using either RARalpha specific antagonists or a dominant negative RARalpha mutant hampers on one hand the RA-induced upregulation of neutral sphingomyelinase (nSMase)-mediated CER synthesis, and on the other hand the RA-induced downregulation of sphingosine kinase 1, SK1, pivotal for S1P synthesis.
1210	L. Be regulated	E. Associate	1	PTEN	breast cancer	We applied the Dual-luciferase Reporter assay to expose the direct interaction between miR-93 and PTEN, which suggested that miR-93 contributes to inducing EMT and drug resistance of breast cancer cells by targeting PTEN.
1211	D.1 Mutation	E. Associate	1	EGFR	NSCLC	Somatic mutations in EGFR and KRAS genes are routinely analyzed to predict response to tyrosine kinase inhibitors (TKIs), used in the treatment of NSCLC patients, whose efficacy depend on the presence or the absence of specific mutations.
1212	I. None	B. Target	1	TBK1	non-small cell lung cancer	Previous reports demonstrated synthetic lethality of TBK1 with mutant KRAS in non-small cell lung cancer (NSCLC); thus, TBK1 could be a novel target for treatment of KRAS-mutant NSCLC.
1213	D.1 Mutation	F. None	1	MSH6	breast cancer	The several occurrences of breast cancer are not due to the MSH6 mutations.
1214	A. Expression	E. Associate	0	p27	BREAST CARCINOMA	A possible association between the expression of p27 and the prognosis of breast carcinoma remains to be elucidated.
1215	I. None	E. Associate	1	prolactin	breast cancer	The acknowledged gaps in our understanding concerning progesterone, estrogen and prolactin hormones involvement in human breast cancer has exposed the need to conduct this study for better understanding of the role played by these hormones in breast cancer during pre and post menopause status in order to influence prevention and treatment of breast cancer.
1216	G. Regulate	E. Associate	1	MORC2	GASTRIC CANCER	HSF1, in association with MORC2, downregulates ArgBP2 via the PRC2 family in gastric cancer cells.
1217	L.2 Down-regulation	E. Associate	1	GAS5	lung cancer	RESULTS The results indicated that GAS5 was drastically downregulated in lung cancer cell lines.
1218	I. None	B. Target	1	HER2	Lung Adenocarcinomas	Genotype-directed therapies have changed treatment paradigms of patients with EGFR-mutant and ALK/ROS1-rearranged lung adenocarcinomas, and the list of druggable targets with demonstrated clinical actionability (BRAF, MET, RET, NTRK1 and HER2) continues to expand.
1219	I. None	B. Target	1	KDM2A	NSCLC	These findings uncover an unexpected role for a histone methylation modifier in activating ERK1/2 in lung tumorigenesis and metastasis, suggesting that KDM2A may be a promising therapeutic target in NSCLC.
1220	D.1 Mutation	C. Cause	1	RET	Multiple endocrine neoplasia type 2A	Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
1221	I. None	H. Benefit	1	DAX-1	breast cancer	DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation.
1222	D.1 Mutation	E. Associate	1	BRAF	PTC	Larger tumor size and higher lymph node metastasis frequency were observed, significant in BRAF (+), compared to the BRAF (-) PTC group (P = 0.039 and P = 0.03, respectively).
1223	A.1 Over-expression	E. Associate	1	ER	breast cancer	The induction of Pol III genes caused by alcohol in ER+ breast cancer lines or liver tumor lines are significantly higher than in their non-tumor cell lines.
1224	D.1 Mutation	E. Associate	0	ATM	BREAST CARCINOMA	Genomic DNA samples from 258 individuals were screened for mutations of all types in each of the 62 coding exons of the ATM gene; 142 of these were from breast carcinoma cases with a first-degree family history or early age at diagnosis, 35 were from cases selected for the presence of either known disease-related mutations (n = 25) or missense alterations of unknown consequences (n = 10) in BRCA1 or BRCA2, and 81 were from matched controls.
1225	G. Regulate	E. Associate	1	QKI	non-small cell lung cancer	Interestingly, a substantial fraction of the altered genes found in our analysis were targets of the protein quaking (QKI), pointing to this factor as one of the most relevant regulators of alternative splicing in non-small cell lung cancer.
1226	I. None	H. Benefit	1	AIM	hepatocellular carcinoma	Tissue macrophage-derived apoptosis inhibitor of macrophage (AIM, encoded by cd5l gene) is a circulating protein that has suppressive functions in a broad range of diseases including obesity, liver steatosis, hepatocellular carcinoma (HCC), and acute kidney injury (AKI).
1227	D.1 Mutation	E. Associate	1	K-Ras	lung cancer	We determined the expression levels of DGKη in a mouse models of mutant EGFR and K-Ras lung cancer and in human lung cancer cell lines with activating mutations in either EGFR or K-Ras.
1228	I. None	E. Associate	0	CD34	Invasive Ductal Carcinoma of the Breast	Immunohistochemical investigation of the angiogenic proteins VEGF, HIF-1α and CD34 in invasive ductal carcinoma of the breast.
1229	A.2 Under-expression	E. Associate	1	CTGF	lung cancer	Reduced expression of CTGF in lung cancer specimens was statistically significantly associated with the risk of more advanced-stage disease (stages III and IV versus stages I and II; P=.001), lymph node metastasis (P =.014), and shorter survival (median survival with high levels of CTGF = 66.7 months and median survival for low levels = 18.2 months; difference = 48.5 months, 95% CI = 33.5 to 63.5 months; P =.02).
1230	D.1 Mutation	C. Cause	1	BRCA1	breast cancer	However, the large majority of families with early-onset breast cancer and with two or more cases of ovarian cancer are likely to be due to BRCA1 mutations.
1231	A.1 Over-expression	E. Associate	1	AKIP1	breast cancer	In the breast cancer cell line, MDA-MB231 cells and MCF7 cells, where the endogenous AKIP1 is abundant, the PKA signal was found to be synergized with NF-kappaB activation; PKA-activating agents enhanced NF-kappaB-dependent transcriptional activity and the interaction between p65 and PKAc and augmented the phosphorylation of p65 on Ser-276.
1232	D.1 Mutation	E. Associate	1	EGFR	NSCLC	Antiangiogenic agents in combination with an EGFR TKI might provide additional benefit in patients with EGFR-mutant NSCLC.
1233	C. Activation	H. Benefit	1	maspin	breast cancer	This finding indicates that one of the pathways for cancer prevention and tumor inhibition by TAM is mediated through the activation of tumor suppressor gene maspin in breast cancer.
1234	H. Other	H. Benefit	1	TR3	breast cancer	Mitochondrial targeting of TR3 is involved in TPA induced apoptosis in breast cancer cells.
1235	L. Be regulated	E. Associate	1	mitochondrial transcription factor A	colon cancer	[Expression and proliferative regulation of miR-204 related to mitochondrial transcription factor A in colon cancer].
1236	L. Be regulated	C. Cause	1	ROR1	lung adenocarcinoma	We previously identified receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a transcriptional target of the NKX2-1/TTF-1 lineage-survival oncogene in lung adenocarcinoma.
1237	C. Activation	A. Treat	1	vitamin D receptor	breast cancer	Efficacy of hybrid vitamin D receptor agonist/histone deacetylase inhibitors in vitamin D-resistant triple-negative 4T1 breast cancer.
1238	I. None	B. Target	0	BRD4	prostate cancer	Because c-MYC and AR signaling are essential for prostate cancer initiation and progression, we aim to test whether targeting Plk1 and BRD4 at the same time is an effective approach to treat prostate cancer.
1239	M.1 Knock down	C. Cause	1	SPARC	gastric cancer	The 3D tumour growth and 5-FU resistance abilities of gastric cancer cells were elevated after treatment with GCAFs with SPARC knockdown relative to these abilities in negative control cells.
1240	J. Inhibition	A. Treat	1	FOLR1	ovarian cancer	Both conventional and chemically programmed CD3 × FOLR1 biAbs warrant further investigation for ovarian cancer immunotherapy.
1241	J. Inhibition	A. Treat	1	HER2	breast cancer	Key examples include two monoclonal antibodies, each engaging a distinct site of human epidermal growth factor receptor 2 (HER2), in the treatment of breast cancer and a combination of antibodies to two distinct T-cell antigens for the treatment of melanoma.
1242	A.1 Over-expression	E. Associate	1	HER3	breast cancer	Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, which may attenuate antitumor efficacy.
1243	G. Regulate	E. Associate	1	ARID3B	ovarian cancer	ARID3A and ARID3B induce stem promoting pathways in ovarian cancer cells.
1244	D.1 Mutation	B. Target	0	retinoblastoma	lung cancer	To determine whether the retinoblastoma gene (Rb) localized at 13q14, might be the target of recessive mutations in lung cancer, eight primary SCLC tumors and 50 cell lines representing all major histologic types of lung cancer were examined with the Rb complementary DNA probe.
1245	G. Regulate	E. Associate	0	PF4	invasive breast carcinoma	To elucidate the role of rapamycin and PF4 on apoptosis regulation via Bax (pro-apoptosis), Bcl-2 (anti-apoptosis) and survivin activation on the growth in the 1-methyl-1-nitrosourea -induced invasive breast carcinoma model.
1246	H. Other	E. Associate	1	TOPK	skin cancer	Strategies with research focusing on the TOPK signaling pathway and targeted therapy in skin carcinogenesis may helpful for the discovery of additional treatments against skin cancer.
1247	I. None	B. Target	1	ANKRD1	ovarian cancer	Taken together, these results suggest that ANKRD1 has a significant role in the regulation of apoptosis in human ovarian cancer cells, and is a potential molecular target to enhance sensitivity of ovarian cancer to chemotherapy.
1248	F.1 Phosphorylation	G. Marker	0	STAT5	lung cancer	OBJECTIVES    The aim of the study was to analyze the immunoexpression levels of 3 STAT proteins: STAT3, STAT5, and STAT6 in their phosphorylated forms (pSTATs), STAT inhibitors PIAS3 and SOCS3, and additionally cyclooxygenase 2 (COX‑2), as potential diagnostic and prognostic markers in lung cancer.
1249	H. Other	E. Associate	0	IGF	breast cancer	This is the first study to investigate the role of genetic variation in IGF signaling and breast cancer risk in women carrying deleterious mutations in BRCA1 and BRCA2.
1250	H. Other	B. Target	1	RB	triple-negative breast cancer	Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.
1251	I. None	E. Associate	0	CA125	cervical cancer	Routine CA125 surveillance was performed for ovarian cancer in 27 % and cervical or vault cytology for cervical cancer in 9 %.
1252	D.1 Mutation	E. Associate	1	KRAS	colorectal cancer	Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.
1253	D.1 Mutation	E. Associate	1	KRAS	adenocarcinoma	Mutational status of EGFR and KRAS may be advocated as a diagnostic criteria of synchronous lung cancer rather metastasis mainly in case of adenocarcinoma histology.
1254	D.1 Mutation	E. Associate	0	CTNNB1	adenocarcinomas	Activation of the wnt pathway through accumulation of beta-catenin may have a role in a subset of small intestinal adenocarcinomas but in contrast to colorectal carcinoma, accumulation of beta-catenin is generally not caused by inactivating APC or activating CTNNB1 mutations.
1255	D.1 Mutation	G. Marker	1	FGFR4	breast cancer	This study screened large cohorts of node-positive and node-negative breast cancer patients to determine whether the G388R mutation of the FGFR4 gene is a useful prognostic marker for breast cancer as reported by Bange et al in 2002.
1256	J. Inhibition	A. Treat	1	ALK	non-small cell lung cancer	Crizotinib, a dual ALK and cMET inhibitor, can induce responses in patients with EGFR mutation positive non-small cell lung cancer (NSCLC) that acquire cMET amplification after EGFR TKI treatment.
1257	A. Expression	E. Associate	1	estrogen receptor	breast cancer	Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: an immunochemical study with clinical, pathobiological, and histologic correlations.
1258	F.2 Methylation	E. Associate	1	HOXA9	lung cancer	In study group #2, HOXA9 and RASSF1A displayed higher methylation levels in small-cell lung cancer (SCLC) than in non-small-cell lung cancer (NSCLC).
1259	L. Be regulated	H. Benefit	1	ETS1	colorectal cancer	LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
1260	I. None	F. None	1	KLF5	bladder cancer	Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer.
1261	I. None	G. Marker	1	prostate specific antigen	prostate cancer	Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
1262	A. Expression	E. Associate	0	CRBP1	non-small-cell lung carcinoma	[Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
1263	D.1 Mutation	C. Cause	1	APC	colon cancer	Fearon and Vogelstein (1990) have described a series of molecular changes during the progression of human colon cancer, beginning with mutations in APC.
1264	C. Activation	H. Benefit	1	BAK	non-small-cell lung cancer	Re: Ling Y-H, Lin R, and Perez-Soler R (2008) Erlotinib Induces Mitochondrial-Mediated Apoptosis in Human H3255 Non-Small-Cell Lung Cancer Cells with Epidermal Growth Factor ReceptorL858R Mutation through Mitochondrial Oxidative Phosphorylation-Dependent Activation of BAX and BAK Mol Pharmacol 74:793-806; doi:10.1124/mol.107.044396.
1265	I. None	A. Treat	1	interferon alpha	breast cancer	Because the anti-endothelial effects of agents such as interferon alpha, endostatin, and various chemotherapeutic drugs appear to be optimal after protracted, frequent dosing, both in vitro and in vivo, using low concentrations/doses of drugs, we tested the geranylgeranyl transferase inhibitor BAL-9504 ((E,E,E) [2-oxo-2-[[(3,7,11,15-tetramethyl-2,6,10,14 hexadecatetraenyl)-oxy]amino]ethyl] phosphonic acid) in this manner on different human cell types, including endothelial, breast cancer cells and fibroblasts.
1266	A. Expression	E. Associate	1	ABCG2	cervical cancer	There was a positive correlation between NOS1 and ABCG2 mRNA expression levels in cervical cancer tissues (r=1.246, P=0.014).
1267	A. Expression	H. Benefit	1	osteopontin	pancreatic adenocarcinoma	Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma.
1268	I. None	E. Associate	0	hsp70	metastatic breast cancer	Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
1269	D.1 Mutation	C. Cause	1	RET	medullary thyroid cancer	The RET gene mutation is 100% predictive for the ultimate development of medullary thyroid cancer.
1270	D.1 Mutation	E. Associate	1	KRAS	colorectal cancer	Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
1271	A.1 Over-expression	E. Associate	1	LSD1	triple negative breast cancer	Interestingly, we note that overexpression of LSD1 correlates with down-regulation of BRCA1 in triple negative breast cancer.
1272	I. None	E. Associate	1	neurotensin	prostate cancer	This study aimed to determine the mechanism(s) by which 1,4-dihydropyridine Ca2+ channel blockers (DHPs) enhance the binding of neurotensin (NT) to prostate cancer PC3 cells and inhibit NT-induced inositol phosphate formation.
1273	A. Expression	H. Benefit	0	RASSF1A	adenocarcinoma	Therefore, we checked-in the control condition as well as after short-term pharmacological treatment with either docetaxel or gemcitabine-the expression of genes such as tumor suppressor genes (CDKN2A, DAPK, FHIT, GSTP1, MGMT, RARβ2, RASSF1A, and TIMP3), genes associated with drug resistance (BRCA1, COX2, ERCC1, IGFBP3, RRM1, and TUBB3), and stemness-related genes (CD133, OCT4, and SLUG) in two cellular models of squamous carcinoma (CAEP) and adenocarcinoma (RAL) of the lung originally established.
1274	D.1 Mutation	E. Associate	1	TP53	colorectal cancer	Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
1275	A. Expression	E. Associate	1	fatty acid synthase	pancreatic cancer	Also, we show that fatty acid synthase expression is inversely correlated with microRNA-195 expression in pancreatic cancer tissues.
1276	L. Be regulated	E. Associate	0	EDNRB	bladder cancer	The aim of this study was to investigate the role of miR-124-3p in bladder cancer (BC) and to determine whether miR-124-3p regulates cell proliferation by targeting EDNRB.
1277	A. Expression	E. Associate	1	CYP3A4	breast cancer	Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.
1278	A.1 Over-expression	E. Associate	1	MMP11	ductal carcinomas	Although this is a pilot study, our findings indicate that luminal A invasive ductal carcinomas commonly express high MMP2 and MMP11 levels in premenopausal breast cancer patients and suggest a co-regulation of MMP2-MMP10 and MMP8-MMP9.
1279	I. None	B. Target	1	PSMA	metastatic castration-resistant prostate cancer	Recent successes in the treatment of metastatic castration-resistant prostate cancer (mCRPCa) by systemic endoradiotherapy has sparked renewed interest in developing small molecule ligands targeting prostate-specific membrane antigen (PSMA) and chelators capable of stable complexation of metal radionuclides for imaging and therapy.
1280	H. Other	E. Associate	0	DPD	advanced gastric cancer	In this study, the relationship between immunoreactivity to TS and DPD in biopsy specimens and the effects of chemotherapy was investigated in 41 patients treated with S-1 therapy for advanced gastric cancer.
1281	D.1 Mutation	E. Associate	1	BRCA1	ovarian cancer	We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05-1.29; P = 3.8 × 10(-4)) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10-1.52; P = 1.8 × 10(-3)).
1282	I. None	C. Cause	1	androgen receptor	prostate cancer	The Androgen Receptor (AR) plays a key role in prostate biology and in the progression of prostate cancer (PCa) to castration resistance.
1283	A.1 Over-expression	C. Cause	1	overexpressed in lung cancer 1	malignant tumor	Overexpressed in lung cancer 1 (OLC1) is a potential oncogene overexpressed in human lung cancer and in other types of malignant tumor.
1284	G. Regulate	C. Cause	0	PCAF	hepatocellular carcinoma	Is the regulatory effect of PCAF and sirtuin 7 on phosphoglycerate kinase 1 acetylation a universal mechanism underlying hepatocellular carcinoma progression?
1285	A.1 Over-expression	E. Associate	1	RAD50	oral cancer	For western blotting, DSB signaling proteins such as γH2AX and MRN complex (MRE11, RAD50, and NBS1) were overexpressed in 4βHWE-treated oral cancer cells in different concentrations and treatment time.
1286	A. Expression	E. Associate	1	VEGF	head and neck squamous cell carcinoma	Histogram Analysis Parameters Derived from Conventional T1- and T2-Weighted Images Can Predict Different Histopathological Features Including Expression of Ki67, EGFR, VEGF, HIF-1α, and p53 and Cell Count in Head and Neck Squamous Cell Carcinoma.
1287	F.2 Methylation	E. Associate	1	PRDM5	lung cancer	Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.
1288	D.1 Mutation	C. Cause	1	androgen receptor	prostate cancer	A consistent finding is that androgen receptor (AR) gene mutations, present in metastatic prostate cancer and in human prostate cancer cell lines as well as in xenograft and other animal models, result in decreased specificity of ligand-binding and inappropriate receptor activation by estrogens, progestins, adrenal androgens, glucocorticoids and/or AR antagonists.
1289	L.2 Down-regulation	E. Associate	1	FASN	prostate cancer	Furthermore, citral suppressed lipogenesis of prostate cancer cells through the activation of AMPK phosphorylation and downregulation of fatty acid synthase (FASN), acetyl coA carboxylase (ACC), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR), and sterol regulatory element-binding protein (SREBP1) and apoptosis of PC3 cells by upregulating BAX and downregulating Bcl-2 expression.
1290	C. Activation	A. Treat	1	dopamine D1 receptor	breast cancer	In conclusion, dopamine D1 receptor agonists FEN and l-SPD showed efficacy in inhibiting metastasis along with good safety in breast cancer, thus providing an alternative for anti-metastasis therapy in the future.
1291	I. None	G. Marker	1	KRAS	colon cancer	The enrichment of miRNA revealed that particularly hsa-miR-424-5p, hsa-miR-96-5p, hsa-miR-1290, hsa-miR-224, hsa-miR-133a and has-miR-363-3p present possible targets for colon cancer hallmark genes, including BRAF, KRAS, EGFR, APC, amongst others.
1292	D.1 Mutation	E. Associate	1	p300	colorectal carcinomas	Likewise, the p300 gene has been recently implicated in leukemia and mutations in both alleles have been observed in gastric and colorectal carcinomas.
1293	I. None	G. Marker	1	GATA6	pancreatic cancer	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer.
1294	D.1 Mutation	E. Associate	1	epidermal growth factor receptor	adenocarcinoma	As a result of mutation analyses in 21 patients (28.5% of all adenocarcinoma patients), epidermal growth factor receptor mutation was determined in at least one exon in six patients.
1295	A.2 Under-expression	C. Cause	1	CD44	lung adenocarcinoma	Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma.
1296	D.1 Mutation	E. Associate	1	STCH	stomach cancer	In this study, we searched somatic mutations of STCH in human stomach cancer and identified the 668del12bp mutation in exon 4, resulting in a four amino acid deletion (del223V-226L) in the conserved ATP-binding domain.
1297	A.2 Under-expression	H. Benefit	1	PLK1	thyroid cancer	We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27.
1298	L.2 Down-regulation	H. Benefit	1	TFF3	prostate cancer	Exosomes Derived from miR-143-Overexpressing MSCs Inhibit Cell Migration and Invasion in Human Prostate Cancer by Downregulating TFF3.
1299	J. Inhibition	A. Treat	1	XRCC1	advanced gastric cancer	Irinotecan, another chemotherapeutic agent to induce DNA damaging used to treat patients with advanced gastric cancer that progressed on cisplatin, was found to inhibit the expression of XRCC1 effectively, and leading to an increase in the sensitivity of resistant cells to cisplatin.
1300	G. Regulate	B. Target	1	SURF4	ovarian cancer	Our findings suggest that SURF4 possesses the ability to maintain stemness of OCSCs via BIRC3, and may serve as a potential target in stem cell-targeted therapy for ovarian cancer.
1301	L.1 Up-regulation	E. Associate	1	glutamate pyruvate transaminase 2	colorectal cancer	Here we show that PIK3CA mutations reprogram glutamine metabolism by upregulating glutamate pyruvate transaminase 2 (GPT2) in colorectal cancer (CRC) cells, making them more dependent on glutamine.
1302	D.1 Mutation	E. Associate	0	FGFR1	non-small cell lung cancer	We aimed to investigate the prevalence and prognostic significance of alterations in FGFR1 copy number in non-small cell lung cancer (NSCLC).
1303	A.2 Under-expression	E. Associate	1	MUC5AC	adenocarcinomas	Moreover, for the first time, we indicated that mucin production was an independent prognostic factor for EGFR-mutated adenocarcinomas and the mucin-staining pattern of negative MUC5AC and positive MUC5B was characteristic in these adenocarcinomas.
1304	G. Regulate	E. Associate	1	OCT1	prostate cancer	We have previously reported that OCT1, an AR collaborative factor, facilitated the AR genomic bindings to regulate diverse programs of gene expression in AR-dependent prostate cancer cells.
1305	A.1 Over-expression	E. Associate	0	endostatin	colon carcinoma	To investigate whether expression of an angiogenesis inhibitor by cancer cells could alter this balance and prevent tumor formation in different organ environments, we engineered stable transfectants from RenCa mouse renal carcinoma cells and SW620 human colon carcinoma cells to constitutively secrete a mouse endostatin protein with c-myc and polyhistidine (His) tags.
1306	A.2 Under-expression	H. Benefit	1	ATM	lung cancer	Collectively, these results indicate that miR-18a-5p increases the radiosensitivity in lung cancer cells and CD133+ stem-like cells via downregulating ATM and HIF-1α expressions.
1307	H. Other	C. Cause	1	VHL	clear cell renal cell carcinoma	Clear cell Renal Cell Carcinoma (ccRCC) is due to loss of von Hippel-Lindau (VHL) gene and at least one out of three chromatin regulating genes BRCA1-associated protein-1 (BAP1), Polybromo-1 (PBRM1) and Set domain-containing 2 (SETD2).
1308	E. Pathway	E. Associate	1	FAK	prostate cancer	Maclurin exerts anti-cancer effects on PC3 human prostate cancer cells via activation of p38 and inhibitions of JNK, FAK, AKT, and c-Myc signaling pathways.
1309	F.1 Phosphorylation	B. Target	1	retinoblastoma	pancreatic cancer	Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
1310	A.2 Under-expression	H. Benefit	1	ASNS	lymphoma	Here, we report that p53 suppresses asparagine synthesis through the transcriptional downregulation of ASNS expression and disrupts asparagine-aspartate homeostasis, leading to lymphoma and colon tumour growth inhibition in vivo and in vitro.
1311	A.2 Under-expression	E. Associate	1	BRCA1	breast cancers	The promoter methylation status of this gene was also tested by methylation specific PCR as BRCA1 expression is also known to be lost by this mechanism in some sporadic breast cancers.
1312	L. Be regulated	C. Cause	1	EPAS1	lung adenocarcinoma	PDK4 is the most up-regulated kinase encoding gene in Cisplatin resistant lung adenocarcinoma and PDK4-dependent Cisplatin-resistance promotes tumor growth of lung adenocarcinoma mainly through transcriptional regulation of EPAS1.
1313	A. Expression	E. Associate	1	SIAH2	ductal carcinoma	The data showed that SIAH2 protein was overexpressed in invasive breast cancer (IBC) compared to the expression noted in normal or ductal carcinoma in situ (DCIS) tissues, expression of which is associated with malignant behaviors.
1314	A.2 Under-expression	E. Associate	1	progesterone receptor	triple-negative breast cancers	Triple-negative breast cancers (TNBC) are a subtype of breast cancer lacking of estrogen receptor (ER), progesterone receptor (PR), and human EGF-like receptor 2 (HER2).
1315	H. Other	E. Associate	1	CEACAM1	prostate cancers	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion positive prostate cancers.
1316	A. Expression	E. Associate	1	CD133	ovarian cancer	We report that human ovarian cancer is frequently associated with cells expressing the stem cell surface marker CD133.
1317	H. Other	E. Associate	0	PTEN	metastatic prostate cancer	On the basis of our previous work defining the molecular rationale for combined targeting of the PI3K and AR pathways in PTEN loss prostate cancer, the first clinical trial was recently reported demonstrating a significant benefit for combination therapy in patients with metastatic prostate cancer.
1318	L.2 Down-regulation	E. Associate	1	PCDH17	breast cancer	Downregulation of PCDH17 in breast cancer was mainly due to the methylation of its promoter.
1319	J. Inhibition	H. Benefit	1	epidermal growth factor	lung cancer	Recently, SP-D has been shown to suppress lung cancer progression via interference with the epidermal growth factor signaling.
1320	G. Regulate	C. Cause	1	SNHG7	hepatocellular carcinoma	Long noncoding RNA SNHG7 represses the expression of RBM5 to strengthen metastasis of hepatocellular carcinoma.
1321	D.1 Mutation	E. Associate	0	BARD1	familial breast cancer	Thus, in the present study, we have conducted mutational analysis of BARD1 in familial breast cancer patients (n=60) who were tested negative for both BRCA1 and BRCA2 germline mutations.
1322	D.1 Mutation	E. Associate	1	BRAF	colorectal cancer	A subgroup of colorectal cancer (CRC) shows non-random accumulation of aberrant DNA methylation, so-called CpG island methylator phenotype (CIMP), which was associated with microsatellite instability and BRAF mutation.
1323	L.2 Down-regulation	H. Benefit	1	MAP2K1	hepatocarcinoma	Down-regulation of MAP2K1 by miR-539 inhibits hepatocarcinoma progression.
1324	H. Other	E. Associate	0	EGFR	ampullary carcinoma	Our objective was to explore alteration of the epidermal growth factor receptor (EGFR) signaling pathway in ampullary carcinoma.
1325	A. Expression	H. Benefit	1	NDRG2	renal cancer	Retraction. Up-regulation of pVHL along with down-regulation of HIF-1α by NDRG2 expression attenuates proliferation and invasion in renal cancer cells.
1326	I. None	B. Target	1	TIPE2	adenocarcinoma	TIPE2 is a potential therapeutic target for the treatment of rectal adenocarcinoma.
1327	A.1 Over-expression	C. Cause	1	TPX2	hepatocellular carcinoma	Overexpression of CDCA5, KIF4A, TPX2, and FOXM1 Coregulated Cell Cycle and Promoted Hepatocellular Carcinoma Development.
1328	A. Expression	E. Associate	1	SMCT1	colorectal cancer	Fermentation of the dietary fiber by intestinal microflora results in production of butyrate.Butyrate possesses anticarcinogenic effect at the colonic level.Three transporters (MCT1, SMCT1 and BCRP) regulate the intracellular concentration of BT in colonic epithelial cells.Changes in the expression of these transporters occur in colorectal cancer.
1329	A.1 Over-expression	E. Associate	1	LMO4	breast carcinomas	LMO4, a member of the LIM-only family of zinc-finger proteins, is overexpressed in a significant proportion of breast carcinomas and acts as a negative regulator of mammary epithelial differentiation.
1330	L. Be regulated	H. Benefit	1	AGK	squamous cell carcinoma	MiR-610 functions as a tumor suppressor in oral squamous cell carcinoma by directly targeting AGK.
1331	A. Expression	E. Associate	1	SOX9	breast cancer	Chemotherapy induced breast cancer cells to secrete multiple EV miRNAs, including miR-9-5p, miR-195-5p, and miR-203a-3p, which simultaneously targeted the transcription factor One Cut Homeobox 2 (ONECUT2), leading to induction of CSC traits and expression of stemness-associated genes, including NOTCH1, SOX9, NANOG, OCT4, and SOX2.
1332	A. Expression	C. Cause	0	androgen receptor	laryngeal carcinoma	To study the expressions of androgen receptor (AR) and estrogen receptor (ER) in the pathogenesis of laryngeal carcinoma.
1333	J. Inhibition	A. Treat	1	EGFR	non-small cell lung cancer	Tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), such as erlotinib are used for the treatment of patients with advanced non-small cell lung cancer (NSCLC).
1334	A. Expression	E. Associate	0	TYMS	non-small cell lung cancer	Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
1335	A.1 Over-expression	E. Associate	1	CAIX	colorectal cancer	We demonstrated that melanoma, breast, and colorectal cancer cells transiently and chronically exposed to acidified medium (pH 6.7 ± 0.1) showed a significantly increased CAIX expression compared to those grown in standard conditions (pH 7.4 ± 0.1).
1336	D.5 Polymorphism	E. Associate	1	MPO	lung cancer	A-463 bp G/A polymorphism is located in the promoter region of myeloperoxidase (MPO) gene was found to be associated with lung cancer susceptibility; however, this association in Chinese population remained unclear.
1337	I. None	F. None	1	thyroglobulin	ovarian cancer	Some recent findings are: CA125 is elevated several months prior to diagnosis of ovarian cancer; serum thyroglobulin may be a preclinical tumour marker in subgroups of thyroid cancer; low level of selenium in serum reflects increased risk of thyroid cancer; and raised antibodies in serum against Epstein-Barr virus is a risk factor for development of Hodgkin's disease.
1338	A. Expression	E. Associate	0	S100A9	non-small cell lung cancer	The purpose of this study was to evaluate the correlation between calcium-binding protein S100A8 and S100A9 expression in non-small cell lung cancer (NSCLC) and patients' clinical features.
1339	M.1 Knock down	H. Benefit	1	CD18	renal cell carcinoma	CD18-/- down-regulates Treg cells and inhibits the pathogenesis of renal cell carcinoma.
1340	J. Inhibition	H. Benefit	1	FAK	ovary cancer	In conclusion, the compound 5a inhibited ovary cancer cell viability and induced apoptosis through decrease in expression of vWF and metalloproteinase, suppression of FAK activation and decrease in infiltration of macrophages.
1341	J. Inhibition	A. Treat	0	gastrin receptor	gastrointestinal cancer	To assess the potential of gastrin receptor antagonists in the treatment of gastrointestinal cancer, the presence of an autocrine loop involving progastrin-derived peptides has been investigated in two colorectal and one gastric carcinoma cell lines.
1342	A. Expression	E. Associate	0	HMGB3	hepatocellular carcinoma	However, the expression and the role of HMGB3 in human hepatocellular carcinoma remain unknown.
1343	F.2 Methylation	E. Associate	1	PLAGL1	gastric adenocarcinoma	Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil.
1344	L.1 Up-regulation	C. Cause	1	OGFRP1	endometrial cancer	Our experiments revealed that upregulation of OGFRP1 may enhance the progression of endometrial cancer by regulating miR-124-3p/SIRT1 axis and by activating PI3K/AKT/GSK-3β pathway.
1345	I. None	E. Associate	1	COX2	cervical cancer	These results indicate that COX2 is a novel resistance factor of DCA, and combination of celecoxib with DCA may be beneficial to the treatment of cervical cancer.
1346	I. None	E. Associate	0	IMP3	prostate cancers	Immunohistochemical stainings for IMP3 were performed on tissue microarray (TMA) organized samples from 507 patients: 31 normal prostate tissues, 425 primary carcinomas and 51 prostate cancer metastases or castration-resistant prostate cancers (CRPC).
1347	D.1 Mutation	E. Associate	1	EGFR	adenocarcinoma of the lung	Adenocarcinoma of the lung with EGFR gene mutation and subsequent resistance mechanisms exploration: case report.
1348	D.1 Mutation	E. Associate	1	BRAF	anaplastic thyroid cancer	MEK inhibition is cytostatic in papillary thyroid cancer and anaplastic thyroid cancer cells bearing a BRAF mutation and may have less impact on thyroid cancer cells lacking this mutation.
1349	I. None	B. Target	1	PHB	urothelial carcinoma	Prohibitin 1 (PHB) is a potential target for the treatment of urothelial carcinoma of the bladder (UCB).
1350	J. Inhibition	H. Benefit	1	NAIP	colon cancer	Additionally, in order to examine the function of miR-145 and miR-1 in human colon cancer, we transiently transfected a human colon cancer cell line with miR-145 and miR-1 mimics or inhibitors, and the results of MTT assay revealed that the re-expression of miR-145 and miR-1 inhibited the survival of colon cancer cells, which may be attributed to the inhibition of the anti-apoptotic activity of NAIP.
1351	G. Regulate	E. Associate	1	ARHGAP25	colorectal cancer	ARHGAP25: A negative regulator of colorectal cancer (CRC) metastasis via the Wnt/β-catenin pathway.
1352	A.1 Over-expression	E. Associate	1	ATAD2	stomach adenocarcinoma	Stomach adenocarcinoma and metastatic tissues with high HIF1α level also show enhanced ATAD2 expression.
1353	D.1 Mutation	C. Cause	1	APC	colorectal cancer	The quarter century from its´ first cloning, APC became one of the most frequently mutated, known driver genes in colorectal cancer.
1354	F.2 Methylation	C. Cause	1	forkhead box protein A1	breast cancer	Forkhead box protein A1 (FOXA1) promotes luminal differentiation, and hypermethylation of the gene can be a mechanism of developing estrogen receptor-negative (ER-) breast cancer.
1355	I. None	H. Benefit	1	pis	gastric cancer	These observations point to the potential of PIs as effective chemoprotectors against gastric cancer in animals and, possibly, in humans as well.
1356	D.2 Rearrangement	E. Associate	1	ROS1	lung adenocarcinoma	Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures.
1357	C. Activation	A. Treat	1	TLR7	skin cancer	Their effector cell function could be restored by additional peritumoral treatment with the TLR7 agonist imiquimod, a clinically approved agent for nonmelanoma skin cancer.
1358	L. Be regulated	H. Benefit	1	MEKK1	breast cancer	MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1).
1359	D.1 Mutation	C. Cause	1	APC	colorectal cancer	While the I1307K APC mutation clearly confers an increased lifetime risk for colorectal cancer, there is a paucity of data on the natural history of colonic neoplasia in symptomatic and asymptomatic mutation carriers.
1360	A. Expression	E. Associate	0	epidermal growth factor receptor	adenocarcinoma	Analysis of epidermal growth factor receptor mRNA expression by polymerase chain reaction assay in 94 human breast adenocarcinoma tumors.
1361	D.1 Mutation	C. Cause	1	PTEN	endometrial carcinoma	Germ-line and sporadic mutations in the tumor suppressor gene PTEN (also known as MMAC or TEP1), which encodes a dual-specificity phosphatase, cause a variety of cancers such as Cowden disease, glioblastoma, endometrial carcinoma and prostatic cancer.
1362	J. Inhibition	E. Associate	1	p38	non-small-cell lung carcinoma	Then, we found that p38 inhibition upregulated special AT-rich sequence-binding protein 2 expression and reversed epithelial-mesenchymal transition in non-small-cell lung carcinoma cells.
1363	I. None	E. Associate	0	NEDD4L	non-small cell lung cancer	However, the role of NEDD4L in non-small cell lung cancer (NSCLC) has not been fully elucidated.
1364	L. Be regulated	H. Benefit	1	SOCS5	cervical cancer	MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5.
1365	A. Expression	E. Associate	1	APC	colorectal cancer	Truncated APC proteins were expressed in all of the colorectal cancer cell lines studied.
1366	D.1 Mutation	C. Cause	1	BRCA1	hereditary breast and ovarian cancer	Hereditary breast and ovarian cancer (HBOC) syndrome is an important women's health condition characterized by an increased susceptibility to the development of cancer, in particular breast and ovarian neoplasms, and is caused by an inherited germline genetic mutation in one or both tumor suppressor genes named BRCA1 and BRCA2.
1367	H. Other	E. Associate	0	APRT	teratocarcinoma	Mouse teratocarcinoma stem cells deficient in activity of adenine phosphoribosyltransferase (APRT; EC 2.4.2.7) were obtained in order to have this marker in developmentally versatile cells.
1368	I. None	B. Target	1	EGFR	colorectal cancer	Epidermal growth factor receptor (EGFR) is a therapeutic target in colorectal cancer (CRC).
1369	A. Expression	E. Associate	1	CRY2	colon cancer	Altered CRY1 and CRY2 expression patterns and the interplay with the genetic landscape in colon cancer cells may underlie phenotypic divergence that could influence disease behavior as well as CRC patients survival and response to chemotherapy.
1370	I. None	B. Target	1	CCND1	epithelial ovarian cancer	This study demonstrated that CCND1 is a potential therapeutic target for epithelial ovarian cancer treatment.
1371	D.1 Mutation	E. Associate	1	CUL3	esophageal squamous cell carcinoma	Mutations in the genes encoding nuclear factor (erythroid-derived 2)-like 2 (NRF2), Kelch-like ECH-associated protein 1 (KEAP1), and cullin 3 (CUL3) are commonly observed in human esophageal squamous cell carcinoma (ESCC) and result in activation of the NRF2 signaling pathway.
1372	D.1 Mutation	C. Cause	1	POLE	colon cancers	10%-15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) or POLE exonuclease domain mutations, and are characterised by high tumour mutational burden and increased lymphocytic infiltrate.
1373	I. None	E. Associate	0	hepatocyte growth factor	liver cancer	Our results show that some pro-inflammatory molecules are significantly up-regulated, and play a role as immunological markers in the intermediate steps towards liver cancer, and that hepatocyte growth factor (HGF) is a specific marker of liver cirrhosis.
1374	D.1 Mutation	E. Associate	0	KRAS	pancreatic cancer	Hyperinsulinemia is a risk factor for pancreatic cancer, but the function of insulin in carcinogenesis is unclear, so this study aimed to elucidate the carcinogenic effects of insulin and the synergistic effect with the KRAS mutation in the early stage of pancreatic cancer.
1375	A.1 Over-expression	E. Associate	0	MIF	prostate cancer	Therefore, we hypothesized that increased expression or surface localization of CD74 and MIF overexpression by prostate cancer cells regulated tumor cell viability.
1376	A.1 Over-expression	E. Associate	1	STAT4	gastric cancer	For the first time, the present study found that STAT4 over-expression in gastric cancer cells induced NFs to obtain CAF-like features via activating wnt/β-catenin pathway.
1377	L. Be regulated	H. Benefit	1	cullin 4B	esophageal squamous cell carcinoma	MicroRNA-133b inhibits cell proliferation and promotes apoptosis by targeting cullin 4B in esophageal squamous cell carcinoma.
1378	L.1 Up-regulation	E. Associate	1	RHBDD1	breast cancer	RHBDD1 was highly up-regulated in breast cancer tissue compared with that in normal tissue and associated with pathological tumor (pT) stage, pathological tumor-node-metastasis (pTNM) stage and estrogen receptor (ER) expression.
1379	D.1 Mutation	E. Associate	1	EGFR	lung cancer	Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
1380	A.1 Over-expression	C. Cause	1	LINC01605	bladder cancer	High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer.
1381	L.2 Down-regulation	H. Benefit	1	CD133	colon cancer	TIPE1 overexpression significantly inhibits colon cancer cell growth both in vitro and in vivo through impairing stemness, accompanied with downregulation of the stemness-related markers, ALDH, CD133, CD44, and SOX-9.
1382	D.1 Mutation	C. Cause	1	STK11	breast cancer	Up to 25% of hereditary cases are due to a mutation in one of the few identified rare, but highly penetrant genes (BRCA1, BRCA2, PTEN, TP53, CDH1, and STK11), which confer up to an 80% lifetime risk of breast cancer.
1383	J. Inhibition	A. Treat	1	epidermal growth factor receptor	of lung adenocarcinoma	A 69-year-old man with post-operative recurrence of lung adenocarcinoma was treated with multiple chemotherapies, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.
1384	J. Inhibition	E. Associate	1	TLR2	gastric adenocarcinoma	Finally, the pre-incubation of the human gastric adenocarcinoma cell line AGS with blocking antibodies against Toll-like receptor-2 (TLR2), but not TLR4, prevented HIF-1α induction.
1385	G. Regulate	C. Cause	1	NEAT1	breast cancer	To conclude, we uncovered that NEAT1 participated in breast cancer progression by regulating miR-448 and ZEB1.
1386	L. Be regulated	H. Benefit	1	SP1	esophageal squamous cell carcinoma	MicroRNA-375 inhibits esophageal squamous cell carcinoma proliferation through direct targeting of SP1.
1387	I. None	E. Associate	0	BHLHE40	breast cancer	Orthotopic xenograft and experimental metastasis (tail vein injection) mouse models were used to analyze the role of BHLHE40 in lung metastasis of breast cancer.
1388	A. Expression	E. Associate	0	53BP1	colorectal cancer	This study aimed to investigate the influence of the expression of P53-binding protein 1 (53BP1), a key component in DNA damage repair pathways, on the radiosensitizing effect of icotinib hydrochloride in colorectal cancer and to elucidate the mechanisms underlying this influence.
1389	I. None	B. Target	1	TRIM65	lung cancer	Collectively, our findings provide the rationale for developing strategies to target TRIM65 for lung cancer intervention, potentially in combination with MDM2 inhibition.
1390	I. None	B. Target	1	PDK1	lung cancer	Thus, targeting PDK1 pinpoints a potential in the lung cancer treatment.
1391	A. Expression	C. Cause	1	ASIC1	gastric cancer	Results:Our results showed a significant association between expression of ASIC1 and elevated risk of gastric cancer (p<0.001).
1392	J. Inhibition	A. Treat	1	SET	pancreatic cancer	Moreover, treatment with a novel SET inhibitor, OP449, pharmacologically recapitulates the phenotypes and significantly reduces proliferation and tumorigenic potential of several pancreatic cancer cell lines, with an accompanying attenuation of cell growth and survival signaling.
1393	C. Activation	E. Associate	1	mammalian target of rapamycin	colon cancers	The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to mutations in the phosphatidylinositol 3-kinase (PI3K) pathway.
1394	A. Expression	E. Associate	0	AMACR	adenocarcinomas	In the current study, 59 surgically resected primary small intestinal adenocarcinomas (34 ampullary and 25 non-ampullary) were immunohistochemically examined for AMACR expression and compared with 66 colorectal adenocarcinomas (including 24 secondary tumors involving the small intestine by direct extension or metastasis).
1395	I. None	E. Associate	1	p63	cervical cancer	Importantly, we have shown for the first time a critical role for p63 in response to DNA damage in cervical cancer cells.
1396	D.2 Rearrangement	E. Associate	1	BCL2	lymphoma	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, mostly known as double-hit lymphoma (DHL), is a rare entity characterized by morphologic and molecular features between Burkitt lymphoma and the clinically manageable diffuse large B-cell lymphoma (DLBCL).
1397	D.1 Mutation	E. Associate	1	CD79B	lymphoma	In summary, the present case was diagnosed as PC-DLBCL, ABC subtype by the Hans algorithm and double expression lymphoma, with co-occurrence of the MYD88L265P and CD79B mutations (MCD) subtype by genetic alteration analysis.
1398	I. None	B. Target	1	epidermal growth factor receptor	non-small-cell lung cancer	Afatinib-loaded Immunoliposomes Functionalized with Cetuximab: a Novel Strategy Targeting the Epidermal Growth Factor Receptor for Treatment of Non-small-cell Lung Cancer.
1399	J. Inhibition	A. Treat	1	PDL1	esophageal cancer	We will conduct a systematic review and meta-analysis on the comparison of the efficacy of immunotherapy (PD1 and PDL1 inhibitors) alone and traditional platinum-based chemotherapy, so as to provide a reliable basis for clinicians to formulate the best chemotherapy regimen for patients with esophageal cancer after esophagectomy.
1400	I. None	B. Target	1	prolactin	pancreatic cancer	These findings suggest that targeting prolactin together with IL6, a known major activator of STAT3, could represent a novel therapeutic strategy for treating pancreatic cancer.
1401	L.1 Up-regulation	C. Cause	1	SOX4	lung adenocarcinoma	And the upregulation of SOX4 impaired the inhibitory effect of miR-204 on lung adenocarcinoma metastasis.
1402	I. None	A. Treat	1	TNF	superficial bladder cancer	Twenty patients with histologically documented superficial bladder cancer (Ta, T1, Tis) were treated with intravesical administration of TNF 400-1800 micrograms.
1403	J. Inhibition	A. Treat	1	fibroblast growth factor receptor 1	gastric cancer	Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
1404	A.1 Over-expression	E. Associate	1	FGFR3	bladder cancer	The results indicated that immunoliposomes can specifically deliver the fluorescent molecules, Dio into bladder cancer cells highly expressing FGFR3.
1405	I. None	B. Target	1	FOXO3	liver cancer	Therapeutic targeting of SIRT6 and/or FOXO3 may offer novel strategies for treatment of liver cancer.
1406	A. Expression	E. Associate	1	cyclin D1	endometrial cancer	Altered expression of DACH1 and cyclin D1 in endometrial cancer.
1407	J. Inhibition	A. Treat	1	CYP17	prostate cancer	Compounds that inhibit CYP17 activity are of pharmacological interest as they could be used for the treatment of prostate cancer.
1408	I. None	B. Target	1	EGFR	breast cancer	A number of therapeutic strategies targeting epidermal growth factor receptor (EGFR) have not always led to success in the present state of breast cancer therapy.
1409	A.2 Under-expression	H. Benefit	1	biliverdin reductase B	hepatocellular carcinoma	MicroRNA-127-5p inhibited the growth and colony formation of hepatocellular carcinoma (HCC) cells and decreased biliverdin reductase B (BLVRB) expression by directly binding to its 3'-UTR.
1410	F.2 Methylation	H. Benefit	1	KCNQ1	hepatocellular carcinoma	Hypermethylated KCNQ1 acts as a tumor suppressor in hepatocellular carcinoma.
1411	A.1 Over-expression	C. Cause	1	MUC5AC	lung cancer	CONCLUSIONS: The high frequency of both MUC1 and MUC5AC cytoplasmic expression, coupled with a lack of MUC2 and MUC6 expression in ALK + lung cancer may contribute to the biologically aggressive behavior of ALK + cancer.
1412	L. Be regulated	C. Cause	1	AKT2	esophageal cancer	In summary, these data displayed the crucial role of circRAD23B/miR-5095 regulating PARP2 and AKT2 in esophageal cancer, and provided a novel mechanism in the pathogenesis of esophageal cancer.
1413	I. None	B. Target	1	HPGD	prostate cancer	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
1414	I. None	B. Target	1	HER2	breast cancer	Human epidermal growth factor receptor 2 (HER2) is a validated breast cancer drug target for small molecule inhibitors that target the ATP-binding pocket of the kinase domain.
1415	A. Expression	E. Associate	0	STAT5A	skin cancer	Increased expression of STAT3 in human nonmelanoma skin cancer (NMSC) has been confirmed in a few studies, but to our knowledge, expression of STAT5A, STAT5B and STAT6 in BCC has not been previously evaluated.
1416	I. None	B. Target	1	ASK1	ovarian cancer	Since transcoelomic metastasis is also associated with many other cancers, such as pancreatic and colon cancers, our study provides ASK1 as a therapeutic target for the treatment of ovarian cancer and other transcoelomic metastasis cancers.
1417	L. Be regulated	C. Cause	1	PTEN	lung cancer	Exosomal miR-106b serves as a novel marker for lung cancer and promotes cancer metastasis via targeting PTEN.
1418	D.1 Mutation	E. Associate	1	EGFR	non-small cell lung cancer	[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
1419	A.1 Over-expression	E. Associate	0	CYP11B2	adrenocortical carcinoma	Human adrenocortical carcinoma cells stimulation with IgG purified from sera of APA patients increased both CYP11B2 expression and aldosterone release (+40% and +76%, respectively, versus healthy subjects).
1420	D.1 Mutation	E. Associate	0	methylenetetrahydrofolate reductase	coronary artery disease	Methylenetetrahydrofolate reductase (MTHFR) mutation, homocyst(e)ine, and coronary artery disease.
1421	I. None	E. Associate	1	RAN guanine nucleotide release factor	cardiac arrhythmia	RAN guanine nucleotide release factor (RANGRF) encoding protein MOG1 plays an important role in cardiac arrhythmia, so we intended to investigate the regulatory miRNA of RANGRF and explore its potential regulatory mechanism in arrhythmogenesis.
1422	J. Inhibition	A. Treat	1	renin	heart failure	Inhibition of neurohumoural pathways such as the renin angiotensin aldosterone and sympathetic nervous systems is central to the understanding and treatment of heart failure (HF).
1423	D.1 Mutation	H. Benefit	1	fibrinogen	ischemic stroke	With the effects of improving hemorheology, decreasing acute phase reactive proteins such as CRP and fibrinogen, ameliorating endothelial cell function, HELP system may be a novel therapy for acute ischemic stroke.
1424	D.1 Mutation	C. Cause	0	APOB	cardiovascular disease	We focus on two generations in the Framingham Heart Study, the original (FHS) and offspring (FHSO) cohorts, to determine whether aging-related processes in changing environments can substantially impact the role of lipid-related genes discovered in candidate gene (the apolipoprotein E (APOE) e2/3/4 polymorphism) and genome-wide (the APOB rs1042034 (C/T)) studies, in regulation of total cholesterol (TC) and onset of cardiovascular disease (CVD).
1425	I. None	E. Associate	0	HDL	coronary artery disease	Does simultaneous determination of LDL and HDL particle size improve prediction of coronary artery disease risk?
1426	A.1 Over-expression	E. Associate	1	c-reactive protein	cardiovascular morbidity	Among the possible mediators for the association between CRI and cardiovascular morbidity are inflammatory (C-reactive protein, fibrinogen, and interleukin-6) and hemostatic (factor VII, factor VIII, plasmin-antiplasmin product, and D-dimer) biomarkers, all of which were significantly elevated in Cardiovascular Health Study participants with CRI.
1427	F.1 Phosphorylation	C. Cause	1	annexin A7	intracerebral hemorrhage	Critical role for Annexin A7 in secondary brain injury mediated by its phosphorylation after experimental intracerebral hemorrhage in rats.
1428	I. None	E. Associate	0	tissue plasminogen activator	stroke	Infiltration of tissue plasminogen activator through cerebral vessels: evaluation using a rat thromboembolic stroke model.
1429	I. None	F. None	1	insulin	heart failure	Obesity is a state of metabolic dysregulation that can lead to maladaptive changes in heart and skeletal muscle, including insulin resistance and heart failure.
1430	A. Expression	E. Associate	0	phosphodiesterase 4D	arrhythmia	Comparative analysis of changes in the status of expression of genes in the heart of rats induced by P-11 against the simulated in vivo arrhythmia identified 16 genes that reproducibly alter the level of expression.These genes encode the extracellular matrix proteins (glypican 1, Gpc1; tissue inhibitor of metalloproteinase 2, 3, Timp2, Timp 3); intracellular signaling molecules (rho GTPase activating protein 7, Dlc1; protein tyrosine phosphatase 4a1, Ptp4a1; phosphodiesterase 4D, PDE4D; PI3-kinase regulatory subunit alpha, PIK3R1; guanine nucleotide binding protein alpha 12, Gna12) and protein of intermediate junctions (junction plakoglobin, Jup), proteins involved in glycolysis (phosphofructokinase I, Pfk1) and hemostasis (tissue plasminogen activator, Plat), plasma membrane transporters (Solute carrier family 16, member 1, Slc16a1; ATPase, Na+/K+ transporting, Atp1a), and ets.
1431	I. None	G. Marker	0	ANP	hypertensive heart disease	[Atrial natriuretic peptide (ANP) in essential hypertension: a humoral marker for salt sensitivity and hypertensive heart disease at a clinically asymptomatic stage?].
1432	J. Inhibition	A. Treat	1	angiotensin II	heart failure	Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.
1433	A.1 Over-expression	H. Benefit	1	doublecortin	stroke	Compared with control, systemic administration of ADSCs-derived exosomes significantly increased the expression of von Willebrand factor (an endothelia cell marker) and doublecortin (a neuroblasts marker) and improved functional recovery in stroke rats.
1434	A.1 Over-expression	H. Benefit	1	connexin 43	acute myocardial infarction	Ischemic postconditioning improves the expression of cellular membrane connexin 43 and attenuates the reperfusion injury in rat acute myocardial infarction.
1435	I. None	F. None	0	thrombin	myocardial infarction	In 12 patients with angiographically documented CAD without myocardial infarction within the preceding 6 months (male, age 55+/-9 years [SD]) and in 12 healthy controls (male, 52+/-7 years), molecular markers of thrombin, fibrin, and plasmin formation were determined before and after a rehabilitative group exercise session lasting 1 hour.
1436	I. None	G. Marker	0	growth differentiation factor-15	rheumatic heart disease	Growth differentiation factor-15 (GDF-15) has been identified as a strong biomarker of cardiovascular diseases; however, no evidence are available concerning the relationship of GDF-15 and atrial fibrosis in patients with atrial fibrillation (AF) and rheumatic heart disease (RHD).
1437	L. Be regulated	H. Benefit	0	CB1R	cerebral ischemia	Therefore, we investigated whether STAT3 is involved in EA pretreatment-induced neuroprotection via cannabinoid CB1 receptors (CB1R) after transient focal cerebral ischemia in rats.
1438	A. Expression	G. Marker	1	SERPINH1	stroke	For example, the expression changing of SERPINH1 only appeared in the acute phase of stroke showing its targeting role in the combined biomarker.
1439	A. Expression	C. Cause	1	GRK2	cardiovascular disease	Altered expression of GRKs (particularly of GRK2 and GRK5) occurs during pathological conditions characterized by impaired GPCR signaling including inflammatory syndromes, cardiovascular disease, and tumor contexts.
1440	A.1 Over-expression	C. Cause	1	ACE2	heart attack	And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition.
1441	L. Be regulated	A. Treat	1	NLRP3	intracerebral hemorrhage	Therapeutic effect of dexmedetomidine on intracerebral hemorrhage via regulating NLRP3.
1442	J. Inhibition	A. Treat	1	angiotensin converting enzyme	heart failure	Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
1443	L.1 Up-regulation	E. Associate	1	annexin A3	cerebral ischemia	Proteomic identification of an upregulated isoform of annexin A3 in the rat brain following reversible cerebral ischemia.
1444	D.1 Mutation	C. Cause	1	LMNA	dilated cardiomyopathy	Autosomal dominant Emery-Dreifuss muscular dystrophy is caused by mutations in the LMNA gene, which encodes lamin A and lamin C. Mutations in this gene also give rise to limb girdle muscular dystrophy type 1B, dilated cardiomyopathy with atrioventricular conduction defect and Dunnigan-type partial lipodystrophy.
1445	A. Expression	E. Associate	0	HE4	chronic heart failure	We measured HE4 levels in patients with chronic heart failure (CHF) and correlated them to HF severity, kidney function, and HF biomarkers, and determined its predictive value.
1446	J. Inhibition	E. Associate	0	angiotensin converting enzyme	left ventricular failure	Effects of a new angiotensin converting enzyme inhibitor, enalapril, in acute and chronic left ventricular failure in dogs.
1447	D.1 Mutation	E. Associate	0	GJA1	heart disease	However, as these clinical findings were not replicated in subsequent studies, the question remains about the contribution of GJA1 mutations in human congenital heart disease (CHD).
1448	I. None	F. None	0	fibrinogen	cerebrovascular disease	In logistic regression analysis, independent variables that correlated with over the cut-off point SCr values were: age >75 years [odds ratio (OR) = 2.2; 95% confidence interval (CI) = 1.5-3.4], atherosclerosis of the lower limbs (OR = 2.0; 95% CI = 1.2-3.3), cerebrovascular disease (OR = 1.9; 95% CI = 1.2-3.3), angiotensin-converting enzyme (ACE) inhibitor medication (OR = 1.8; 95% CI = 1.2-2.8), fibrinogen values >3.5 g/l (OR = 1.2; 95% CI = 1.2-2.7) and diuretic treatment (OR = 1.6; 95% CI = 1.1-2.4).
1449	J. Inhibition	A. Treat	1	thrombin	ischemic stroke	Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation.
1450	J. Inhibition	A. Treat	1	ACE	myocardial infarction	Blockade of this system with inhibitors of angiotensin-converting enzyme (ACE) has been shown to benefit several groups of patients, including those with essential hypertension, congestive heart failure, and post myocardial infarction.
1451	J. Inhibition	A. Treat	1	factor xa	stroke	Apixaban, a factor Xa (FXa) inhibitor, is a new oral anticoagulant for stroke prevention in atrial fibrillation (AF).
1452	D.1 Mutation	E. Associate	1	NRAS	congenital heart disease	Recently, germline mutations of NRAS have been shown to be associated with Noonan syndrome (NS), a relatively common developmental disorder characterized by short stature, congenital heart disease, and distinctive facial features.
1453	A.1 Over-expression	G. Marker	1	c-reactive protein	cardiovascular disease	Elevated C-reactive protein (CRP) is a suggested risk marker for cardiovascular disease.
1454	A.1 Over-expression	H. Benefit	1	BNP	coronary artery disease	An elevated level of BNP in plasma is related to the development of good collateral circulation in coronary artery disease.
1455	J. Inhibition	A. Treat	1	ACE	stroke	Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key.
1456	J. Inhibition	H. Benefit	1	PP1	heart failure	Indeed inhibition of PP1 by transgenic overexpression or gene-transfer of constitutively active inhibitor-1 improved Ca-cycling, preserved function and decreased fibrosis in small and large animal models of heart failure, suggesting that inhibitor-1 may represent a potential therapeutic target.
1457	J. Inhibition	A. Treat	1	ang II	heart failure	In addition to inhibition of the circulating renin-angiotensin system, specific inhibition of the cardiac effects of angiotensin II (Ang II) represents an important therapeutic goal in the treatment of clinical heart failure.
1458	J. Inhibition	E. Associate	0	ACE	chronic heart failure	Despite the clinical relevance of angiotensin I-converting enzyme (ACE) inhibitors, their effects on impaired vascular function in patients and animals with chronic heart failure (CHF) have not been fully understood.
1459	L. Be regulated	C. Cause	1	VEZF1	ischemic stroke	MiR-191 inhibit angiogenesis after acute ischemic stroke targeting VEZF1.
1460	I. None	F. None	0	albumin	stroke	Age, gender, social problems, education, body mass index (BMI), comorbidities, history of stroke, use vitamin K antagonists, inadequate fatty fish intake, serum thyroid-stimulating hormone (TSH), vitamin B12, albumin, and estimated glomerular filtration rate were used as confounders.
1461	D.1 Mutation	E. Associate	0	NOTCH3	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	Spectrum of NOTCH3 mutations in Korean patients with clinically suspicious cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
1462	A.1 Over-expression	E. Associate	0	HSP72	stroke	Future strategies aimed at enhancing HSP72 expression after clinical stroke may be worth pursuing.
1463	J. Inhibition	E. Associate	0	angiotensin converting enzyme	hypertensive heart failure	Determine the effect of a matrix metalloproteinase inhibitor (MMPi) and angiotensin converting enzyme inhibitor (ACEi) on collagen, MMP, tissue inhibitors of MMPs (TIMPs) expression in the spontaneously hypertensive heart failure (SHHF) rat.
1464	F.2 Methylation	C. Cause	0	ITPR3	cerebral ischemia	Correlation between altered DNA methylation of intergenic regions of ITPR3 and development of delayed cerebral ischemia in subarachnoid hemorrhage patients.
1465	A. Expression	E. Associate	0	SENP1	cardiomyopathy	We investigated whether alteration in SENP1 expression affects cardiomyopathy and the underlying mechanism.
1466	I. None	E. Associate	0	fibrinogen	myocardial infarction	Eighty-five Indian patients (age < 45 years) presenting ischemic stroke (n = 48) or myocardial infarction (n = 37) and 50 controls were studied for seven thrombophilia markers including antithrombin (AT), factor V, protein C, protein S, activated protein C resistance (APC-R), fibrinogen and Lp(a).
1467	I. None	H. Benefit	1	CD21	ischemic stroke	These results suggest that CD21 may exert neuroprotective and anti-inflammatory effects with a wide time window for the treatment of ischemic stroke.
1468	I. None	A. Treat	1	TPA	ischemic stroke	Consecutive acute ischemic stroke patients receiving intravenous tissue plasminogen activator (TPA) were studied.
1469	A.1 Over-expression	C. Cause	1	RANTES	cardiovascular disease	Patients with dyslipidemia associated with HIV-1 infection and highly active antiretroviral therapy (HAART) have elevated levels of Lp-PLA2 and CCL5/regulated on activation, normal T-cell expressed and secreted (RANTES), which may increase the risk of cardiovascular disease.
1470	L.1 Up-regulation	H. Benefit	1	APE1	stroke	Defective DNA repair is tightly correlated with worse neurological outcomes after stroke, whereas upregulation of DNA repair enzymes, such as APE1, OGG1, and XRCC1, improves long-term functional recovery following stroke.
1471	I. None	E. Associate	1	VPS4B	cerebral ischemia	Vacuolar protein sorting 4B (VPS4B), a member of ATPase family proteins, reportedly possesses multiple biological functions, such as regulating the development of breast cancer and non-small-cell lung cancer, participating in Parkinson's disease, and modulating neuronal apoptosis after cerebral ischemia.
1472	M.2 Knock in	C. Cause	1	HSP60	heart failure	Neonatal Death and Heart Failure in Mouse with Transgenic HSP60 Expression.
1473	I. None	G. Marker	1	b-type natriuretic peptide	congestive heart failure	In conclusion, it was found that B-type natriuretic peptide is an important biomarker for differentiating congestive heart failure from lung disease in patients presenting with dyspnea.
1474	A. Expression	E. Associate	1	SPARC	myocardial infarction	Fibroblast migration after myocardial infarction is regulated by transient SPARC expression.
1475	J. Inhibition	H. Benefit	1	tpa	stroke	We demonstrate that tissue plasminogen activator (tPA) and its inhibitors contribute to neurite outgrowth in the central nervous system (CNS) after treatment of stroke with multipotent mesenchymal stromal cells (MSCs).
1476	A. Expression	E. Associate	0	fibrinogen	cerebral infarction	Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction.
1477	A. Expression	E. Associate	0	BDNF	stroke	This study aimed to clarify whether ischemia-induced early growth response 1 (EGR1) influenced the outcomes of experimental stroke by regulating brain-derived neurotrophic factor (BDNF) expression.
1478	I. None	B. Target	1	thrombin	stroke	These results indicated that thrombin preferentially activated astrocytic autophagy after ICH, and therefore provided novel insights into the pathophysiological mechanisms and therapeutic targets for hemorrhage stroke and brain trauma.
1479	A. Expression	E. Associate	0	synapsin I	cerebral ischemia	The purpose of the present study was to determine whether nefiracetam has an effect on the expression of brain-derived neurotrophic factor (BDNF) and synapsin I mRNAs that are believed to be produced via CREB, and the alteration in their protein contents in the hippocampus after cerebral ischemia.
1480	A. Expression	E. Associate	0	MAP2	transient cerebral ischemia	Changes in drebrin, MAP2 (postsynaptic marker) and synaptophysin (presynaptic marker) in rat brains were examined after 20 min of transient cerebral ischemia.
1481	D.1 Mutation	C. Cause	1	MTHFR	stroke	Coexistent atrial septal aneurysm, size of PFO, degree of the shunt, shunt at rest, pelvic deep vein thrombosis, and prothrombotic states (G20210A prothrombin gene mutation, Factor V Leiden mutation, MTHFR: C677T, basal homocystine, recent surgery, trauma, or use of contraceptives) could enhance stroke risk in subjects with PFO.
1482	I. None	G. Marker	1	gelsolin	acute rheumatic carditis	Plasma gelsolin as a biomarker of acute rheumatic carditis.
1483	D.1 Mutation	E. Associate	1	apolipoprotein A5	coronary artery disease	The association between -1131T>C single nucleotide polymorphism (SNP) of the apolipoprotein A5 gene (APOA5) and hypertriglyceridemia raised the possibility that this SNP could be related to coronary artery disease (CAD) risk.
1484	D.1 Mutation	E. Associate	0	desmoplakin	carvajal syndrome	As similar phenotypes have been described in Naxos disease and Carvajal syndrome, respectively, the genes for plakoglobin (JUP) and desmoplakin (DSP) were screened for mutations using direct genomic sequencing.
1485	D.1 Mutation	C. Cause	1	CTC1	coats plus syndrome	Mutations in CTC1, which encodes a key telomere component, have been identified as the cause of Coats plus syndrome.
1486	I. None	B. Target	1	NOX2	stroke	A profound body of literature suggests NOX2 to be a major therapeutic target in stroke.
1487	J. Inhibition	A. Treat	1	angiotensin converting enzyme	heart failure with reduced ejection fraction	Current guideline-based therapies for heart failure with reduced ejection fraction, including beta blockers, angiotensin converting enzyme (ACE) inhibitors, and aldosterone antagonists aim to interrupt deleterious neurohormonal pathways and have shown significant success in reducing morbidity and mortality associated with heart failure.
1488	I. None	A. Treat	1	rt-pa	cerebral ischemia	Thrombolytic treatment with rt-PA in the first 3 hours of cerebral ischemia reduces the risk of mortality or dependence at 3 months by 51%.
1489	C. Activation	E. Associate	0	metabotropic glutamate receptor 5	subarachnoid hemorrhage	Activation of metabotropic glutamate receptor 5 (mGluR5) provided neuroprotection in multiple central nervous system injury, but the roles of mGluR5 in subarachnoid hemorrhage (SAH) remain unclear.
1490	A.2 Under-expression	E. Associate	1	MCAD	heart failure	However, protein expression of MCAD and CPT-I was decreased concomitantly only in TG mice with criteria of heart failure.
1491	I. None	B. Target	1	HERG	arrhythmia	The human ether-a-go-go-related gene (HERG) cardiac K(+) channels are one of the representative pharmacological targets for development of drugs against cardiovascular diseases such as arrhythmia.
1492	D.1 Mutation	C. Cause	1	HERG	arrhythmia	Attenuation of repolarizing K+ current caused by mutations in HERG or channel block by common medications prolongs ventricular action potentials and increases the risk of arrhythmia and sudden death.
1493	I. None	E. Associate	0	CTMP	cerebral ischemia	We investigated the role of carboxy-terminal modulator protein (CTMP), an endogenous Akt inhibitor, in brain injury following focal cerebral ischemia in type 2 diabetic db/db mice and their control littermates non-diabetic db/+ mice.
1494	L.1 Up-regulation	C. Cause	1	SPHK1	coronary artery disease	Transforming Growth Factor β1 (TGF-β1) Appears to Promote Coronary Artery Disease by Upregulating Sphingosine Kinase 1 (SPHK1) and Further Upregulating Its Downstream TIMP-1.
1495	I. None	A. Treat	1	b-type natriuretic peptide	heart failure	Although short-term B-type natriuretic peptide (BNP) treatment has been shown to be effective for decompensated congestive heart failure, little is known about the effects of long-term BNP treatment in ventricular remodeling and heart failure in response to myocardial infarction.
1496	J. Inhibition	H. Benefit	1	AC5	chronic heart failure	These data indicate that selective AC5 inhibitors may be beneficial in chronic heart failure.
1497	D.1 Mutation	C. Cause	1	metavinculin	cardiomyopathy	Cardiomyopathy Mutations in Metavinculin Disrupt Regulation of Vinculin-Induced F-Actin Assemblies.
1498	I. None	A. Treat	1	brain natriuretic peptide	acute anterior myocardial infarction	Value of human brain natriuretic peptide in treatment of acute anterior myocardial infarction evaluated via three-dimensional speckle tracking imaging.
1499	A.1 Over-expression	G. Marker	1	CRP	cardiovascular disease	Minor elevations in CRP (>3 mg/L) are a nonspecific marker of systemic inflammation and predict the future onset of cardiovascular disease.
1500	A. Expression	E. Associate	1	MAP4K1	cerebral infarction	The expression of CDKN2B-AS1, BCL11A, and MAP4K1 was altered in lymphocytes extracted from patients with cerebral infarction.
1501	D.1 Mutation	E. Associate	0	methylenetetrahydrofolate reductase	coronary artery disease	We sought to investigate the association between the methylenetetrahydrofolate reductase (MTHFR) gene C677T mutation and the risk of coronary artery disease (CAD), myocardial infarction (MI) and venous thrombosis (VT) in a Chinese population in Taiwan.
1502	A.1 Over-expression	E. Associate	1	myostatin	myocardial infarction	Furthermore, following myocardial infarction, myostatin expression is upregulated in the cardiomyocytes surrounding the infarct area.
1503	J. Inhibition	A. Treat	1	thrombin	stroke	Dabigatran etexilate, a new oral direct thrombin inhibitor, is safe and effective in reducing risk of stroke among patients with atrial fibrillation.
1504	D.1 Mutation	C. Cause	1	LMNA	dilated cardiomyopathy	Mutations in the LMNA gene encoding lamins A and C by alternative splicing have been found to cause at least four different kinds of genetic disorders: autosomal dominant Emery-Dreifuss muscular dystrophy (EDMD2; MIM 181350); limb-girdle muscular dystrophy type 1B (LGMD1B; MIM 159001); dilated cardiomyopathy type 1A (CMD1A; MIM 115200); and familial partial lipodystrophy (FPLD; MIM 151660).
1505	D.1 Mutation	C. Cause	1	ethanolamine kinase	cardiomyopathy	Fly mutants that bear perturbations in phosphatidylethanolamine (PE) biosynthesis, such as the easily-shocked (eas) mutants defective in ethanolamine kinase, incurred aberrant activation of the sterol regulatory element binding protein (SREBP) pathway, thereby causing chronic lipogenesis and cardiac steatosis that culminates in the development of lipotoxic cardiomyopathy.
1506	J. Inhibition	A. Treat	1	NEP	cardiovascular disease	Thus neutral endopeptidase plays an important role in local kinin-modulated NO production in the coronary microcirculation and NEP inhibitors may be useful clinical tools in treatment of cardiovascular disease.
1507	A.2 Under-expression	E. Associate	0	protein S	stroke	One hundred forty-eight Caucasian infants and children (aged 0.5 to 16 years) with stroke and 296 age-matched controls from the same geographic areas as the patients were analyzed for increased lipoprotein (a) [Lp(a)] levels >30 mg/dL; for the presence of the factor V (FV) G1691A mutation, the prothrombin (PT) G20210A variant, and the TT677 genotype of methylenetetrahydrofolate reductase (MTHFR); and deficiencies of protein C, protein S, and antithrombin.
1508	I. None	C. Cause	1	urotensin II	heart failure	Urotensin II (UII) and urocortin (UCN) are potent contributors to the physiopathology of heart failure.
1509	J. Inhibition	H. Benefit	1	PDE3A	congestive heart failure	The classical phosphodiesterase 3A (PDE3A) inhibitors provide relaxation of the vasculature system via increasing the cellular level of cyclic adenosine monophosphate (cAMP) and proved to be useful in the management of congestive heart failure.
1510	A. Expression	E. Associate	1	osteocalcin	coronary atherosclerosis	This study tests the hypothesis that circulating mononuclear cells expressing osteocalcin (OCN) and bone alkaline phosphatase (BAP) are associated with distinct plaque tissue components in patients with early coronary atherosclerosis.
1511	D.1 Mutation	E. Associate	1	PON1	stroke	Sequence analysis of the PON1 gene from seventy stroke cases revealed a novel nonsense mutation at codon 32 in one stroke case, which was not detected in over 2500 unaffected individuals.
1512	A. Expression	E. Associate	1	CD40	dilated cardiomyopathy	Expression of costimulatory molecules B7-1, B7-2, and CD40 in the heart of patients with acute myocarditis and dilated cardiomyopathy.
1513	D.1 Mutation	E. Associate	0	methylenetetrahydrofolate reductase	ischemic stroke	The Factor V Leiden G1691A (Leiden V), the prothrombin G20210A and the methylenetetrahydrofolate reductase C677T (MTHFR C677T) mutations and the angiotensin-converting enzyme I/D (ACE I/D) and apolipoprotein E (APOE) genotypes were examined by the PCR technique in 689 ischemic stroke patients and 652 stroke-free controls.
1514	A.1 Over-expression	E. Associate	1	factor VIII	stroke	Heat stroke patients showed (i) significant prolongation of the prothrombin (PT), activated partial thromboplastin (aPTT) and thrombin times (TT) but normal reptilase time (RT); (ii) significant reduction in plasma levels of antithrombin III (AT-III), factor V, proteins C and S, plasminogen activator inhibitor (PAI) and platelet count; (iii) increase in plasma factor VIII, tissue plasminogen activator (t-PA) and serum FDP; (iv) no significant changes in plasma fibrinogen, plasminogen, alpha 2-antiplasmin and factors VII and X.
1515	D.5 Polymorphism	F. None	1	TLR5	stroke	TLR5 rs5744174 polymorphism may have no impact on the stroke risk, gene expression and inflammatory cytokines, but may influence the HDL-C serum level of IS patients in Chinese Han population.
1516	A.2 Under-expression	E. Associate	0	albuminuria	myocardial infarction	MR antagonism improves endothelial function in patients with CHF, reduces circulating biomarkers of cardiac fibrosis in CHF or following myocardial infarction, reduces blood pressure in resistant hypertension and decreases albuminuria in hypertensive and diabetic patients.
1517	D.1 Mutation	E. Associate	0	GLA	fabry disease	Using this method, we studied the relationship between urinary levels of total Gb3/creatinine excretion and four types of mutations in the GLA gene (missense, nonsense, frameshift, and splice-site defects) in 32 children and 78 adult patients with Fabry disease.
1518	J. Inhibition	C. Cause	1	estrogen receptor	cerebral ischemia	Previous work in our laboratory has provided evidence that acute, systemic administration of resveratrol is neuroprotective in a permanent model of cerebral ischemia, an effect that was blocked when animals received the non-selective estrogen receptor antagonist, ICI, 182,780.
1519	A. Expression	B. Target	1	MLCK	cardiomyopathy	Specifically targeting MLCK expression in the heart might, in the future, lead to promising therapies that counteract cardiomyopathy.
1520	A. Expression	E. Associate	1	brain natriuretic peptide	heart failure	Although brain natriuretic peptide (BNP) of myocardial origin is important in cardiovascular and renal function and as a marker of cardiac dysfunction, the expression of BNP in atrial and ventricular myocardium remains controversial both under normal conditions and in heart failure.
1521	M.2 Knock in	H. Benefit	1	fibroblast growth factor 9	myocardial infarction	Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction.
1522	A.2 Under-expression	H. Benefit	1	CHOP	myocardial infarction	By down-regulating GRP78, caspase-12 and CHOP expressions in myocardial cells in rat heart failure after myocardial infarction, atorvastatin treatment decreased the apoptosis of myocardial cells, suggesting the possible mechanism by which atorvastatin functions in protecting against heart failure.
1523	A.1 Over-expression	E. Associate	1	elastin	moyamoya disease	Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease.
1524	J. Inhibition	A. Treat	1	ACE	heart failure	Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort study.
1525	J. Inhibition	A. Treat	1	AT1	heart failure	Doses of heart failure medication did not differ significantly in patients with LVEDD >70 mm and WBCc >11 Gpt/l when compared to LVEDD >70 mm and WBCc ≤ 11 Gpt/l (percent of maximum doses: ß-blockers p=0.51, ACE inhibitors p=0.56, AT1 antagonists p=0.77, aldosterone antagonists p=0.35).
1526	L.1 Up-regulation	E. Associate	1	GRK2	heart failure	Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure.
1527	J. Inhibition	H. Benefit	1	TUG1	acute myocardial infarction	Suppression of lncRNA TUG1 may prevent myocardial I/R injury following acute myocardial infarction via inhibiting HMGB1 expression.
1528	J. Inhibition	H. Benefit	1	purinergic receptor P2X4	ischemic stroke	Neuroprotective and neuro-rehabilitative effects of acute purinergic receptor P2X4 (P2X4R) blockade after ischemic stroke.
1529	A.2 Under-expression	E. Associate	1	NF1	von hippel-lindau syndrome	Reduced or absent NF1 gene expression was documented in 7 of these 20 tumors (35%) including 1 of 4 sporadic tumors, 3 of 10 tumors from patients with multiple endocrine neoplasia (MEN) 2A, 2 of 4 tumors from patients with MEN2B, and 1 of 2 tumors from patients with von Hippel-Lindau syndrome.
1530	D.1 Mutation	C. Cause	1	NLRP3	myocardial infarction	The discovery of NLRP3 gene mutations in autoinflammatory diseases such as Muckle-Wells syndrome has led to the association of NLRs in the pathogenesis of many non-microbial diseases that include arthritis, neurodegenerative disorders, metabolic disorders (obesity and diabetes), cardiovascular disease (atherosclerosis, myocardial infarction), inflammatory bowel disease, kidney disease and hypersensitivity dermatitis.
1531	I. None	A. Treat	1	tpa	stroke	Other than thrombolysis in the acute phase of the disease by tissue plasminogen activator (tPA), which offers only a short window of treatment (~3 hours), an ideal stroke therapy is not available mainly because of limited understanding of the mechanisms of neuroregeneration and functional recovery in the chronic phase.
1532	I. None	A. Treat	1	tissue plasminogen activator	stroke	Trials testing intravenous recombinant tissue Plasminogen Activator suggest that it may be associated with slightly less hazard and more benefit when given up to six hours after stroke - death within the first ten days OR 1.24, 95% CI 0.85 to 1.81, death at the end of follow-up OR 1.16, 95% CI 0.94 to 1.44, dead or dependent at the end of follow-up OR 0.79, 95% CI 0.68 to 0.92.
1533	D.1 Mutation	E. Associate	0	LMNA	familial dilated cardiomyopathy	It is still not at all clear how defects in these nuclear membrane proteins are related to the phenotype, even less clear that LMNA mutations can also be associated with familial dilated cardiomyopathy with no weakness, and even familial partial lipodystrophy with diabetes mellitus and coronary heart disease!
1534	I. None	G. Marker	1	c-reactive protein	coronary atherosclerosis	Markers of coronary atherosclerosis, including brachial artery flow-mediated dilation, carotid intima-media thickness, and high-sensitivity C-reactive protein, were measured before GBS and 6, 12, and 24 months after GBS.
1535	D.1 Mutation	E. Associate	1	MYBPC3	hypertrophic cardiomyopathy	Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
1536	I. None	A. Treat	1	tissue plasminogen activator	stroke	Intravenous tissue plasminogen activator (t-PA) provided to carefully selected patients that can be treated within 3 hours of stroke onset results in improved outcome in these patients.
1537	I. None	A. Treat	1	tissue plasminogen activator	stroke	Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
1538	I. None	E. Associate	0	ARHGEF26	coronary artery disease	Phenome-wide association scanning showed that CCDC92 likely affects coronary artery disease through insulin resistance pathways, whereas experimental analysis suggests that ARHGEF26 influences the transendothelial migration of leukocytes.
1539	I. None	E. Associate	1	FGF23	cardiovascular disease	Better understanding of the most relevant pathophysiologic pathways for FGF23 may lead to therapeutic interventions against cardiovascular disease in patients with CKD.
1540	A. Expression	E. Associate	0	MPO	coronary artery disease	The aim of this study was to evaluate alterations in soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), matrix metalloproteinase-9 (MMP-9), plasminogen activator inhibitor-1 (PAI-1), and myeloperoxidase (MPO) levels, and their relation to insulin resistance in coronary artery disease (CAD) patients with stable and unstable angina (SAP, UAP).
1541	D.1 Mutation	C. Cause	0	plasminogen activator inhibitor 1	stroke	She was also homozygous for plasminogen activator inhibitor 1 (PAI-1) 4G/4G, which at present is a controversial stroke risk factor.
1542	L. Be regulated	H. Benefit	1	PTEN	coronary artery disease	MicroRNA-20a participates in the aerobic exercise-based prevention of coronary artery disease by targeting PTEN.
1543	I. None	A. Treat	1	β-blocker	myocardial infarction	Immediate β-blocker administration in the emergency setting is associated with a reduction of all-cause and cardiovascular mortality in patients with ST-segment elevation myocardial infarction and seems to be superior to a delayed β-blockade in our patient cohort.
1544	I. None	B. Target	1	PKM2	cardiovascular disease	In essence, PKM2 serves a previously unidentified role as a molecular integrator of metabolic dysfunction, oxidative stress and tissue inflammation and represents a novel therapeutic target in cardiovascular disease.
1545	G. Regulate	H. Benefit	1	csa	congestive heart failure	In animal models, inhibition of mPTP opening by either CsA or genetic ablation of CyP-D provides strong protection from both reperfusion injury and congestive heart failure.
1546	D.5 Polymorphism	E. Associate	1	LPL	coronary artery disease	We investigated the possibility that the DNA HindIII polymorphism of human lipoprotein lipase (LPL) is associated with the severity of coronary artery disease (CAD) determined by angiography in young patients who survived a myocardial infarction (MI).
1547	I. None	G. Marker	1	c-reactive protein	cardiovascular disease	Inflammatory markers, such as C-reactive protein (CRP), have been shown to predict future cardiovascular events in individuals with and without established cardiovascular disease (CVD).
1548	D.1 Mutation	E. Associate	1	HTRA1	cerebral small vessel disease	Characterization of Heterozygous HTRA1 Mutations in Taiwanese Patients With Cerebral Small Vessel Disease.
1549	J. Inhibition	A. Treat	1	angiotensin II	heart failure	[Current role of angiotensin II antagonists in the treatment of heart failure].
1550	J. Inhibition	A. Treat	1	renin	heart failure	Novel treatment strategy with direct renin inhibition against heart failure.
1551	I. None	E. Associate	0	HDL	ischaemic heart disease	We used linear regression to assess the strength of the association of ALDH2 variants with alcohol use, whether ALDH2 variants were independently associated with socio-economic position or other potential confounders and whether associations of ALDH2 variants with cardiovascular risk factors (systolic and diastolic blood pressure, HDL- and LDL-cholesterol, fasting glucose), triglycerides, body mass index, self reported cardiovascular disease, self-reported ischaemic heart disease, cognitive function (delayed 10-word recall and Mini Mental State Examination score) and liver function (alanine transaminase and aspartate transaminase) were fully mediated by alcohol use.
1552	A. Expression	E. Associate	1	KCNE2	acute myocardial infarction	Dynamic changes in HCN2, HCN4, KCNE1, and KCNE2 expression in ventricular cells from acute myocardial infarction rat hearts.
1553	I. None	E. Associate	0	CRP	transient ischemic attack	NT-proBNP and renin, but not CRP, are independent predictors of MI risk after stroke or transient ischemic attack, providing information additional to that provided by classic risk factors, and may enable more effective targeting of MI prevention strategies.
1554	J. Inhibition	H. Benefit	1	P2X4R	stroke	In summary, acute P2X4R inhibition protects against ischemic injury at both acute and chronic time-points after stroke.
1555	D.1 Mutation	E. Associate	1	MYBPC3	hypertrophic cardiomyopathy	We previously provided evidence for the feasibility of trans-splicing, exon skipping, and gene replacement in a mouse model of hypertrophic cardiomyopathy (HCM) carrying a mutation in MYBPC3, encoding cardiac myosin-binding protein C (cMyBP-C).
1556	I. None	A. Treat	1	brain natriuretic peptide	cardiac failure	Effectiveness and safety of recombinant human brain natriuretic peptide in the treatment of acute myocardial infarction in elderly in combination with cardiac failure.
1557	A. Expression	E. Associate	0	TTR	stroke	The unknown role of the carrier protein transthyretin (TTR) in mechanisms of functional recovery in the postischemic brain prompted us to study its expression following experimental stroke.
1558	H. Other	C. Cause	1	IRS2	heart failure	We recently demonstrated that insulin receptor substrates 1, 2 (IRS1, 2) are key components of insulin signaling and loss of IRS1 and IRS2 mediates insulin resistance, resulting in metabolic dysregulation and heart failure, which is associated with downstream Akt inactivation and in turn activation of the forkhead transcription factor Foxo1.
1559	I. None	B. Target	1	urotensin II	cardiovascular disease	Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease.
1560	I. None	G. Marker	1	brain natriuretic peptide	hypertrophic cardiomyopathy	Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
1561	A.1 Over-expression	H. Benefit	1	ABCA1	cardiovascular disease	Cav halts atherosclerosis by enhancing cholesterol efflux and increasing ABCA1 expression in macrophages and in exosomes, possibly through NF-κB and Akt signaling, which provides mechanistic insights regarding the beneficial effects of Cav on atherosclerotic cardiovascular disease.
1562	A.1 Over-expression	H. Benefit	1	HDL	cardiovascular disease	Early epidemiological studies, such as Framingham's, stated that increased HDL levels were associated with a significant decrease in relative risk for cardiovascular disease (CVD) mortality.
1563	A.2 Under-expression	E. Associate	1	STAMP2	carotid atherosclerosis	In MetS patients, especially women patients, STAMP2 expression was down-regulated in peripheral blood mononuclear cell, which was correlated with carotid atherosclerosis and cardiac adaptation.
1564	J. Inhibition	A. Treat	1	ACE	chronic heart failure	A great deal of research has demonstrated the benefits of treating patients with chronic heart failure with Angiotensin Converting Enzyme (ACE) inhibitors.
1565	A.1 Over-expression	E. Associate	0	TNF	heart failure	Similar changes in adenosine levels were found in 2 other models of heart failure, mice overexpressing calsequestrin and mice after chronic pressure overload, suggesting that the changes in adenosine-AR signaling were secondary to myocardial dysfunction rather than to TNF overexpression.
1566	D.1 Mutation	C. Cause	1	ACTA2	coronary artery disease	Mutations in ACTA2 are the most common genetic cause of thoracic aortic aneurysm, and are also the cause of other disorders, including Moyamoya disease, coronary artery disease and stroke as well as Multisystemic Smooth Muscle Dysfunction Syndrome.
1567	I. None	A. Treat	1	tissue plasminogen activator	stroke	Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator.
1568	I. None	E. Associate	0	leptin	coronary artery disease	Possible correlations between adiponectin, leptin, CD146, a novel adhesion molecule localized at the endothelial junction, and other markers of endothelial cell injury, von Willebrand factor, thrombomodulin, vascular cell adhesion molecule, and intracellular adhesion molecule, and markers of inflammation, tumor necrosis factor-alpha, interleukin-6, and high-sensitivity C-reactive protein in nondiabetic hemodialyzed patients with and without coronary artery disease were studied.
1569	I. None	E. Associate	1	occludin	cerebral ischemia	This study demonstrates the timing of TJ associated proteins claudin-5, occludin, and ZO-1 in light of BBB permeability associated with cerebral ischemia reperfusion, and suggests PKCδ pathway may participate in TJ barrier open and BBB leakage during reperfusion injury in a time-dependent manner.
1570	I. None	E. Associate	1	STAT1	cardiovascular disease	Many studies have revealed that signal transducer and activator of transcription 1 (STAT1) plays a significant role in cardiovascular disease.
1571	D.1 Mutation	C. Cause	1	GBE1	cardiomyopathy	The present findings extend previous studies indicating that truncating GBE1 mutations cause a spectrum of severe diseases ranging from generalized intrauterine hydrops to fatal perinatal hypotonia and fatal cardiomyopathy in the first months of life.
1572	G. Regulate	C. Cause	1	GRK2	heart failure	Cross-talk between hypertrophic signaling at the level of PKC and beta-AR signaling regulated by GRK2 may be an important mechanism in the transition from compensatory ventricular hypertrophy to heart failure.
1573	I. None	A. Treat	1	tissue plasminogen activator	stroke	Although many approaches have been tried in the attempt to reduce the devastating impact of stroke, tissue plasminogen activator for thromboembolic stroke is the only proved, effective acute stroke treatment to date.
1574	J. Inhibition	A. Treat	1	S1P	cerebral ischemia	These results suggest that inhibition of S1P signaling is a strategy to treat BBB impairment after cerebral ischemia and highlight the potential alternative use of probucol, a classical anti-hyperlipidemic drug, for emergency treatment of stroke.
1575	A. Expression	E. Associate	0	tissue plasminogen activator	cerebral infarction	To investigate the level of plasma tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI), 6-keto-prostaglandin F1 alpha(PGF1 alpha), thromboxane B2(TXB2), factor VIII related antigen (VIII R:Ag) in acute cerebral infarction (ACI) patients with different TCM syndrome-type and the therapeutical effect of activating blood stasis (ABS).
1576	G. Regulate	C. Cause	1	angiotensin II	stroke	Excess salt, via oxidative stress, accelerates stroke, and angiotensin II, via AT1 receptor, plays a pivotal role in brain superoxide production of SHRSP by excess salt.
1577	G. Regulate	C. Cause	1	AT1R	chronic heart failure	There is increasing evidence that pathological changes in the myocardium during chronic heart failure (CHF) are partly regulated through the activation of the renin-angiotensin system (RAS), an effect mediated by the angiotensin II type 1 receptor (AT1R).
1578	N.2 Decrease activity	F. None	1	CETP	cardiovascular disease	Although low CETP and high PLTP activity both result in higher concentrations of plasma HDL-cholesterol (HDL-C), there is no evidence that either of these changes is associated with a decrease in cardiovascular disease (CVD) in a general population.
1579	D.Genomic Alteration	C. Cause	1	ESR1	coronary artery disease	Sequence variants in the estrogen receptor alpha gene (ESR1) may alter the atheroprotective effects of estrogens, and be associated with the severity of coronary artery disease (CAD).
1580	N.2 Decrease activity	H. Benefit	0	phospholipase C beta 1	heart failure	We conclude that altered protein expression and stoichiometry of the major cardiomyocyte Ca2+ cycling proteins rather than reduced phospholipase C beta 1 activation may contribute to improved mechanical function produced by left ventricular assist device support in human heart failure.
1581	N.1 Increase activity	E. Associate	1	citrate synthase	chronic heart failure	Exercise training increased the citrate synthase activity and peripheral exercise capacity by 46% and 36%, respectively, in parallel with a two-fold increase in VEGF at both the mRNA (P = 0.03) and protein (P = 0.02) levels The increase in VEGF gene expression in response to exercise training indicates VEGF to be one possible mediator in exercise-induced angiogenesis and may therefore regulate an important and early step in adaptation to increased muscle activity in patient with chronic heart failure.
1582	I. None	G. Marker	0	chromogranin A	heart failure	The aim of this study was to evaluate the prognostic value of chromogranin A (CgA) and C-terminal endothelin-1 precursor fragment (CT-proET-1) in patients with acute destabilized heart failure.
1583	C. Activation	C. Cause	1	signal transducer and activator of transcription 3	intracerebral hemorrhage	Leukemia Inhibitory Factor Contributes to Reactive Astrogliosis via Activation of Signal Transducer and Activator of Transcription 3 Signaling after Intracerebral Hemorrhage in Rats.
1584	I. None	G. Marker	0	myeloperoxidase	chronic systolic heart failure	In a multicenter cohort of 1513 chronic systolic heart failure patients, we measured a contemporary biomarker panel consisting of high-sensitivity C-reactive protein, myeloperoxidase, B-type natriuretic peptide, soluble fms-like tyrosine kinase receptor-1, troponin I, soluble toll-like receptor-2, creatinine, and uric acid.
1585	I. None	C. Cause	1	c-reactive protein	cardiovascular disease	C-reactive protein (CRP), a biomarker of inflammation, has been associated with increased risk of developing cardiovascular disease.
1586	D.1 Mutation	F. None	1	prothrombin	cardioembolic stroke	The factor V Leiden mutation was over-represented in patients with cardioembolic stroke for trend, whereas the prothrombin 20210G-->A variant and the factor XIII polymorphism Val34Leu were not associated with stroke of any subtype.
1587	I. None	H. Benefit	1	activated protein C	stroke	Recombinant human activated protein C (rhAPC) has been found to be protective in severe sepsis and in animal models of stroke and spinal cord injury.
1588	I. None	A. Treat	1	tissue plasminogen activator	stroke	Since the only approved treatment of stroke is that of recombinant tissue plasminogen activator (rtPA) the models selected should be amenable to thrombolytic treatment.
1589	I. None	A. Treat	1	tissue-type plasminogen activator	acute myocardial infarction	Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
1590	D.Genomic Alteration	E. Associate	1	APOE	stroke	Association between APOE (the gene) alleles and stroke in this population may be altered due to interaction with other genetic effects.
1591	I. None	A. Treat	1	tissue-type plasminogen activator	ischemic stroke	Recombinant tissue-type plasminogen activator (rt-PA) improves outcomes for patients with acute ischemic stroke, but current approved use is limited to within 3 hours of symptom onset.
1592	I. None	E. Associate	1	norepinephrine	congestive heart failure	In certain cardiovascular disorders, such as congestive heart failure and ischemic heart disease, several endogenous regulators, including norepinephrine (NE) and endothelin-1 (ET-1), are released from various types of cell.
1593	A. Expression	E. Associate	0	CRP	vascular dementia	The following markers of inflammation: enzymatic activity of leukocyte elastase (LE), functional activity of alpha-1-proteinase inhibitor (α1-PI), levels of C-reactive protein (CRP) and interleukin-6 (IL-6) were measured in the blood plasma of patients with Alzheimer's disease (AD) and vascular dementia (VD).
1594	I. None	A. Treat	1	tissue plasminogen activator	ischaemic stroke	Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed for use within 3 h of acute ischaemic stroke.
1595	A.3 Splicing	E. Associate	1	TNNT2	dilated cardiomyopathy	Furthermore, we demonstrated that splicing of 4 key sarcomere genes, cardiac troponin T (TNNT2), cardiac troponin I (TNNI3), myosin heavy chain 7 (MYH7), and filamin C, gamma (FLNC), was significantly altered in ischemic cardiomyopathy and in dilated cardiomyopathy and aortic stenosis.
1596	A. Expression	E. Associate	0	TFI	atherosclerotic renal artery stenosis	Levels of FGF-23, Klotho, suPAR, plasminogen activator inhibitor (PAI)-1, tissue factor, and tissue factor pathway inhibitor (TFI) were measured in the inferior vena cava and renal vein of hypertensive patients with atherosclerotic renal artery stenosis (n=12) or age-matched participants with EH (n=12) and relatively preserved renal function.
1597	D.1 Mutation	C. Cause	1	LDL receptor	coronary artery disease	This result suggests the possibility that genetic variation at the LDL receptor locus or a closely linked locus on chromosome 19 may be responsible for metabolic alterations in ALP pattern B that account for a substantial proportion of the familial predisposition to coronary artery disease in the general population.
1598	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Angioedema has been reported during recombinant tissue plasminogen activator (rtPA) treatment of acute ischemic stroke, often with concomitant use of angiotensin I-converting enzyme inhibitor treatment.
1599	I. None	A. Treat	1	nerve growth factor	cerebral hemorrhage	Nerve growth factor in combination with Oxiracetam in the treatment of Hypertensive Cerebral Hemorrhage.
1600	I. None	E. Associate	0	APP	multi-infarct dementia	Since interleukin-1 (IL-1) is an APP gene promoter showing a progressive increase in body fluids in parallel with mental deterioration in AD patients, we have studied the effects of CDP-choline on cognition, several biological parameters, and IL-1 beta production in AD and multi-infarct dementia (MID) in order to elucidate whether this compound alone or in combination with other drugs is able to restore immune function and improve mental performance in senile dementia.
1601	D.1 Mutation	E. Associate	1	TET2	cardiovascular disease	Clonal hematopoiesis driven by somatic heterozygous TET2 loss is linked to malignant degeneration via consequent aberrant DNA methylation, and possibly to cardiovascular disease via increased cytokine and chemokine expression as reported in mice.
1602	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only available pharmacological therapy to improve the outcome of acute ischemic stroke.
1603	D.1 Mutation	C. Cause	1	TAZ	cardiomyopathy	Tafazzin is an enzyme that remodels saturated fatty acyl chains within CL to unsaturated fatty acyl chains, loss of function mutations in the TAZ gene encoding tafazzin are causal for the inherited cardiomyopathy Barth syndrome.
1604	I. None	A. Treat	1	tissue plasminogen activator	ischaemic stroke	Recombinant tissue plasminogen activator (tPA) thrombolysis is effective in treating acute ischaemic stroke, but may not be a viable option in developing countries.
1605	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Currently, the indication for thrombolytic therapy using intravenous recombinant tissue plasminogen activator (rt-PA) is restricted strictly to patients with acute ischemic stroke within 4.5 h of onset.
1606	I. None	A. Treat	1	TAFI	ischemic stroke	To investigate thrombin activatable fibrinolysis inhibitor (TAFI) in ischemic stroke and its relationship to fibrinolysis and inflammation, we investigated 32 patients with ischemic stroke during the acute phase and after 60 days.
1607	H. Other	C. Cause	1	prothrombin	cardiac insufficiency	The importance of prothrombin and factor V genetic-molecular alterations in thromboembolic pathology and of the activation of calcineurin phosphatase or other intracellular signal regulator molecules during cardiac insufficiency genesis is also discussed.
1608	A.1 Over-expression	E. Associate	1	osteoprotegerin	heart failure	Myocardial expression and circulating levels of osteoprotegerin are increased in heart failure.
1609	L. Be regulated	A. Treat	1	PRKAA1	coronary heart disease	Ginsenosides（Ra₁, Ra₂, Rb₁, Rb₂, Rg₁, Ro) bind these targets, PRKAA1, PRKAA2, NDUFA4, COX5B, UQCRC1, affect chemokines, non-alcoholic fatty liver, gonadotropin, carbon metabolism, glucose metabolism and other pathways to treat coronary heart disease indirectly.
1610	A. Expression	G. Marker	1	CXCL8	ischemic stroke	Furthermore, miR-4437 was suggested as a novel target for treating ischemic stroke, while the serum CXCL8 level could be a prognostic factor for ischemic stroke.
1611	H. Other	E. Associate	1	insulin	coronary artery disease	Metabolic syndrome, undiagnosed diabetes mellitus and insulin resistance are highly prevalent in urbanised South African blacks with coronary artery disease.
1612	A. Expression	C. Cause	1	NRBP2	dilated cardiomyopathy	The altered expression of autophagy-related genes participates in heart failure: NRBP2 and CALCOCO2 are associated with left ventricular dysfunction parameters in human dilated cardiomyopathy.
1613	A.2 Under-expression	C. Cause	1	MYBPC3	cardiomyopathy	We discovered that the hyperplastic to hypertrophic transition phase of mammalian heart development was altered in mice lacking MYBPC3 and this was the critical period for subsequent development of cardiomyopathy.
1614	M.2 Knock in	H. Benefit	1	VEGF	myocardial infarction	Angiogenesis in a rat model following myocardial infarction induced by hypoxic regulation of VEGF₁₆₅ gene-transfected EPCs.
1615	I. None	E. Associate	1	b-type natriuretic peptide	chronic heart failure	Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
1616	H. Other	F. None	1	insulin	ischemic heart disease	Adipocytokines, fat tissue derived factors with regulatory properties, are involved in the pathophysiology of atheromatous and metabolic illnesses such as: ischemic heart disease, insulin resistance, obesity, dyslipidemia and diabetes mellitus.
1617	I. None	B. Target	1	ABCA1	cardiovascular disease	Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment.
1618	I. None	E. Associate	1	neogenin	stroke	Toward the development of a treatment for stroke, we developed a human anti-RGMa antibody that also prevents Neogenin association with lipid rafts.
1619	I. None	A. Treat	1	coq10	myocardial infarction	This study was done to determine the effects of CoQ10 administration on cardiometabolic markers in overweight diabetic patients with stable myocardial infarction.
1620	I. None	B. Target	1	HDAC2	stroke	These data suggest that HDAC2 may represent the potential target for anti-stroke therapy and its selective inhibition may be a promising strategy for the protection of the penumbra tissue after ischemic stroke.
1621	D.5 Polymorphism	E. Associate	1	CYP2C19	stroke	In stratified analyses by CYP2C19 genotype and ESRS, HRs (95% CIs) of the clopidogrel-aspirin therapy for stroke recurrence were 1.00 (0.70~1.42), 0.63 (0.41~0.97), 0.62 (0.40~0.96), and 0.52 (0.31~0.88) among subgroups of LoFA carriers at low risk, LoFA carriers at high risk, LoFA noncarriers at low risk, and LoFA noncarriers at high risk, respectively, with p = 0.021 for interaction.
1622	I. None	A. Treat	1	botulinum toxin type A	stroke	To compare the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A plus an upper limb therapy programme with the upper limb therapy programme alone.
1623	H. Other	E. Associate	0	insulin	cardiovascular disease	DNA methylation from whole blood DNA was quantified using pyrosequencing at 5 CpG sites at the KCNQ1 locus in 510 individuals without diabetes from the 'Relationship between Insulin Sensitivity and Cardiovascular disease' (RISC) cohort.
1624	H. Other	H. Benefit	1	activated protein C	ischemic stroke	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1.
1625	M.1 Knock down	H. Benefit	1	TNNT2	dilated cardiomyopathy	By selectively targeting a pathogenic mutation (TNNT2 p.R173W) in patient-specific iPSC-derived cardiac myocytes, we demonstrated that the knockout strategy ameliorates the dilated cardiomyopathy phenotype in vitro.
1626	D.5 Polymorphism	G. Marker	1	APOC2	cardiovascular disease	The analyzed markers correspond to polymorphic sites in several candidate genes for cardiovascular disease including apolipopoteins and their receptors (APOA1, APOB, APOE, APOC1, APOC2, LPA, and LDLR), genes implied in the hemostasis regulation (Factor VII, alpha and beta-fibrinogen, alpha and beta platelet-integrin, tissue plasminogen activator, and plasminogen activator inhibitor-1), and the angiotensin converting enzyme gene.
1627	L. Be regulated	E. Associate	1	MMP9	ischemic stroke	This study aimed to explore potential new drugs in the treatment of ischemic stroke by Connectivity Map (CMap) and to determine the role of luteolin on ischemic stroke according to its effects on matrix metalloproteinase-9 (MMP9) and PI3K/Akt signaling pathway.
1628	D.1 Mutation	C. Cause	0	coxsackievirus B3	cardiomyopathy	To investigate the mechanisms by which restricted viral replication with low level expression of Coxsackieviral proteins may be able to induce cardiomyopathy, we generated transgenic mice which express a replication-restricted full-length Coxsackievirus B3 (CVB3) cDNA mutant (CVB3DeltaVP0) in the heart driven by the cardiac myocyte-specific myosin light chain-2v (MLC-2v) promoter.
1629	I. None	A. Treat	0	botulinum toxin type A	stroke	The results of modified ashworth score at different joints, pain score, barthel index showed no difference was found in the effectiveness of botulinum toxin type A compared with placebo in the treatment of the upper limb spasticity after stroke.
1630	A. Expression	E. Associate	0	RNF213	cerebral ischemia	However, information regarding the temporal and spatial expression patterns of the RNF213 gene under the condition of cerebral ischemia, which is one of characteristic pathologies associated with MMD, is currently limited.
1631	I. None	E. Associate	0	CRP	stroke	Higher D-dimer increased the risk of stroke and CHD independent of cardiovascular risk factors and CRP, with perhaps a stronger association for CHD versus stroke in blacks than whites.
1632	A.2 Under-expression	C. Cause	1	CASQ2	mitochondrial cardiomyopathy	Mitochondrial cardiomyopathy is associated with deleterious remodelling of cardiomyocyte Ca(2+) signalling that is partly due to the suppressed expression of the sarcoplasmic reticulum (SR) Ca(2+) buffer calsequestrin (CASQ2).
1633	I. None	A. Treat	0	EPO	subarachnoid haemorrhage	We investigated the in vivo effects of subcutaneously administered recombinant EPO on impaired cerebral blood flow (CBF) autoregulation after experimental subarachnoid haemorrhage (SAH).
1634	A. Expression	E. Associate	1	GAPDH	transient cerebral ischemia	In the present report we have investigated the concomitant changes in VEGF and glyceraldehyde dehydrogenase (GAPDH) mRNA expression in a model of permanent and transient cerebral ischemia.
1635	D.1 Mutation	F. None	1	MTHFR	myocardial infarction	FV Leiden, prothrombin 20210 variant, and MTHFR mutation are no risk factors for left ventricular thrombus in patients with myocardial infarction.The presence of multiple mutations did not influence the development and outcome of LV thrombus in patients with myocardial infarction
1636	D.5 Polymorphism	C. Cause	1	RANTES	cardiovascular disease	Three polymorphisms in the promoter region of the chemokine RANTES (-403G/A, -28G/C, In1.1T/C) are associated with a different expression of this chemokine as well as the occurrence of cardiovascular disease.
1637	D.5 Polymorphism	E. Associate	1	ALDH2	stroke	Previous studies have shown that polymorphisms at aldehyde dehydrogenase 2 (ALDH2) gene were independently associated with the risk of stroke.
1638	G. Regulate	E. Associate	1	TP	cerebral infarction	This study has shown a novel role of TP in microglia activation via the ERK signaling pathway, which provides insights for the management of neuroinflammation in diseases like cerebral infarction.
1639	J. Inhibition	A. Treat	0	ACE	coronary artery disease	The possible clinical benefit of ACE inhibition in atherosclerosis is currently being assessed in several large-scale trials with both surrogate and clinical outcome measures in high-risk patients with clinically manifest atherosclerosis, principally coronary artery disease.
1640	D.1 Mutation	E. Associate	0	GCKR	ischemic stroke	The present study was to determine the association of two single nucleotide polymorphisms (SNPs) in the glucokinase regulator gene (GCKR) and serum lipid levels, and the risk of coronary artery disease (CAD) and ischemic stroke (IS).
1641	D.1 Mutation	F. None	1	dystrophin	dilated cardiomyopathy	In a 24-year-old male with DMD due to the point mutation c.4213C>T (p.Gln1405X) in exon 30 of the dystrophin gene, cardiologic examination at the age of 23 years revealed asymptomatic severely reduced systolic dysfunction with a fractional shortening of 14% in the absence of dilated cardiomyopathy.
1642	I. None	E. Associate	1	translocator protein	stroke	The translocator protein (TSPO) is an important target for imaging focal neuroinflammation in diseases such as brain cancer, stroke and neurodegeneration, but current tracers for non-invasive imaging of TSPO have important limitations.
1643	I. None	E. Associate	0	PENK	chronic heart failure	In 2180 patients with HF of a large multicenter cohort (BIOSTAT-CHF [A Systems Biology Study to Tailored Treatment in Chronic Heart Failure]), the relationship between PENK and clinical variables, plasma and urinary biomarkers, and clinical end points was established.
1644	J. Inhibition	H. Benefit	1	ACE	heart failure	It is not known how the angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) attenuate heart failure (HF) in viable ischemic hearts.
1645	A. Expression	F. None	1	CRP	stroke	In multivariate regression analysis adjusting for age, sex, race/ethnicity, smoking history, hypertension, diabetes mellitus, recent neurologic symptoms (<120 days), CAD, PVD, myocardial infarction, stroke or transient ischemic attack, hypercholesterolemia, aspirin or nonsteroidal anti-inflammatory drug use, and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use, CRP level was independently associated with carotid stenosis (odds ratio [OR], 1.2; 95% confidence interval [CI], 1.1-1.5; P =.04), and LDL-C level was not (OR, 1.0; 95% CI, 0.98-1.01; P =.8).
1646	D.1 Mutation	E. Associate	0	TTR	restrictive cardiomyopathy	A 40-year-old man presented with initial symptoms of syncope caused by restrictive cardiomyopathy and autonomic nervous system impairment, but it was confirmed that he had a novel transthyretin (TTR) variant, aspartic acid-18 glutamic acid (Glu), and a de novo gene mutation.
1647	D.1 Mutation	C. Cause	1	selenoprotein N	multi-minicore disease	The genetic causes are diverse; central core disease is most often caused by mutations in ryanodine receptor 1 (RYR1), whereas multi-minicore disease is linked to pathogenic variants of several genes, including selenoprotein N (SELENON), RYR1 and titin (TTN).
1648	I. None	E. Associate	1	angiotensin II	dilated cardiomyopathy	Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2.
1649	G. Regulate	H. Benefit	0	LIF	stroke	The goal of this study was to determine whether LIF protects neurons during stroke by upregulating superoxide dismutase 3 (SOD3).
1650	I. None	F. None	1	c-reactive protein	cardiovascular disease	The purpose of this study was to assess whether increasing serum uric acid (UA) levels are related to cardiovascular disease (CVD) mortality, all-cause mortality, and incident (fatal and nonfatal) myocardial infarction (MI) in men from the general population taking into account C-reactive protein (CRP), a sensitive marker of systemic inflammation.
1651	D.1 Mutation	E. Associate	1	CYP4F2	stroke	Our results suggest that genetic variation in CYP4A11 and CYP4F2 alters susceptibility to stroke in the Han Chinese population.
1652	A.1 Over-expression	A. Treat	1	GDNF	stroke	These results imply that intrathecal injection of genetically engineered UCB-MC over-expressing therapeutic molecules (VEGF, GDNF, and NCAM) following cerebral blood vessel occlusion might represent a novel avenue for future research into treating stroke.
1653	A.2 Under-expression	E. Associate	0	asp	cerebral infarction	As compared with the model group, the high and medium dose GDLMI groups can significantly reduce the cerebral infarction rate and improve the symptoms of neurological impairment; increase SOD and GSH activity, reduce MDA and LA content in serum; increase Ca2+ concentration in cerebrospinal fluid and decrease the content of neurotransmitter Glu and Asp as well as CK-BB and LDH.
1654	J. Inhibition	A. Treat	1	MR	heart failure	Mineralocorticoid receptor (MR) blockade is effective in reducing total mortality and the incidence of heart failure in patients with systolic left ventricular dysfunction (SLVD) associated with chronic heart failure or post myocardial infarction.
1655	I. None	G. Marker	1	CRP	coronary artery disease	C-reactive protein (CRP) is proposed as a screening test for predicting risk and guiding preventive approaches in coronary artery disease (CAD).
1656	I. None	F. None	1	HDL	coronary atherosclerosis	Common genetic variants at the ARL15 locus are associated with plasma adiponectin, insulin and HDL cholesterol concentrations, obesity, and coronary atherosclerosis.
1657	L. Be regulated	C. Cause	1	AQP2	congestive heart failure	AQP2 is vasopressin regulated, it is the only family member to be implicated in human pathology, such as nephrogenic diabetes insipidus, congestive heart failure, hepatic cirrhosis, nephrotic syndrome or SIADH.
1658	D.1 Mutation	E. Associate	1	ATM	ataxia telangiectasia	Characterization of ATM mutations in 41 Nordic families with ataxia telangiectasia.
1659	A.2 Under-expression	H. Benefit	1	GLUT4	chronic heart failure	Compared with the AMI group, the ALLO group exhibited increased respiratory-chain enzyme activity, as well as increased PGC-1α and CPT-1 mRNA and protein expression, decreased MDA content, and decreased XO and GLUT4 mRNA and protein expression.ALLO improves myocardial energy metabolism in rats with chronic heart failure, which may result from the regulation of PGC-1α in the setting of glycolipid metabolism, enhancing the production of ATP.
1660	D.1 Mutation	E. Associate	1	LMNA	dilated cardiomyopathy	Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations.
1661	D.1 Mutation	E. Associate	1	ataxia telangiectasia mutated	ataxia telangiectasia	ATM (ataxia telangiectasia mutated), the gene mutated in ataxia telangiectasia, is related to a family of large phosphatidylinositol 3-kinase domain-containing proteins involved in cell cycle control and DNA repair.
1662	A. Expression	E. Associate	0	PKC	ventricular arrhythmia	Burst stimulus method was used to induce ventricular arrhythmia in perfused rabbit hearts; Real-time PCR was used to detect the mRNA expression of PKC in four different areas of ventricle.
1663	F.2 Methylation	E. Associate	0	MTHFD1	stroke	The diagnostic value of MTHFD1 methylation for stroke was also examined.
1664	A. Expression	E. Associate	1	RAGE	cerebral ischemia	Neuronal RAGE expression modulates severity of injury following transient focal cerebral ischemia.
1665	I. None	E. Associate	1	CREB	dilated cardiomyopathy	Taken together, these results implicate CREB as an important regulator of cardiac myocyte function and provide a genetic model of dilated cardiomyopathy which should facilitate studies of both the pathogenesis and therapy of this clinically important disorder.
1666	I. None	F. None	1	insulin	coronary heart disease	As lipoprotein(a) is an independent risk factor for the development of coronary heart disease we determined the effect on serum lipid and lipoprotein(a) levels of dietary fibre and of treatment with insulin in patients with diabetes mellitus type II.
1667	D.1 Mutation	E. Associate	0	HCN4	arrhythmogenic right ventricular dysplasia	It confirmed the involvement of HCN4 mutations in the combined bradycardia–myocardial non-compaction phenotype, and also suggested, for the first time, the involvement of PKP2, usually associated with arrhythmogenic right ventricular dysplasia, in ventricular non-compaction.
1668	J. Inhibition	A. Treat	1	vasopressin V2 receptor	congestive heart failure	Chronic hyponatremia due to disorders of volume regulation (congestive heart failure or cirrhosis) or to syndrome of inappropriate antidiuretic hormone release can be managed effectively with vasopressin V2 receptor antagonists, but there is no evidence that controlling the hyponatremia enhances survival associated with the underlying diseases.
1669	L.2 Down-regulation	A. Treat	1	HMGB1	ischemic heart disease	This protective effect is correlated with downregulation of HMGB1 and downstream proinflammatory cascades, which could be useful for the development of novel treatment for ischemic heart disease.
1670	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	He was diagnosed with acute ischemic stroke and treated with tissue plasminogen activator.
1671	L. Be regulated	H. Benefit	1	AIF	stroke	Thus, PARP inhibition is neuroprotective and regulates the ischemic nuclear translocation of AIF in stroke.
1672	A. Expression	G. Marker	1	b-type natriuretic peptide	heart failure	The expression of B-type natriuretic peptide, a marker of heart failure, was significantly increased by T3 and ameliorated by melatonin or vitamin E treatments.
1673	H. Other	E. Associate	0	angii	arrhythmia	We aimed to determine the role of p21-activated kinase 1 (Pak1), a downstream target in the AngII signaling cascade, in atrial electrophysiology and arrhythmia.
1674	A.1 Over-expression	C. Cause	1	interleukin 6	cardiovascular disease	Interleukin 6 (IL-6) is an inflammatory cytokine overexpressed in obese individuals that contributes to the development of diseases such as insulin resistance, type 2 diabetes, and cardiovascular disease.
1675	H. Other	E. Associate	1	insulin	stroke	Resistive training improves insulin sensitivity after stroke.
1676	H. Other	E. Associate	0	superoxide dismutase	cardiovascular injury	To elucidate the potential role of local renin-angiotensin system in aldosterone-induced cardiovascular injury, we investigated the effects of selective mineralocorticoid receptor (MR) antagonist eplerenone (EPL), angiotensin (Ang) II type 1 receptor antagonist candesartan (ARB), and superoxide dismutase mimetic tempol (TEM) on the development of hypertension, vascular injury, oxidative stress, and inflammatory-related gene expression in aldosterone-treated hypertensive rats.
1677	I. None	A. Treat	1	tissue plasminogen activator	stroke	Intravenous tissue plasminogen activator (tPA) is the only approved therapy for acute ischemic stroke, although only 2% of patients with stroke receive intravenous tPA nationally.
1678	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Intravenous tissue plasminogen activator and defibrinogenating agent are both now approved by the Food and Drug Administration for treatment of acute ischemic stroke within 3 h of symptom onset.
1679	D.1 Mutation	E. Associate	1	BAG3	dilated cardiomyopathy	The BAG3 gene variants in Polish patients with dilated cardiomyopathy: four novel mutations and a genotype-phenotype correlation.
1680	I. None	A. Treat	1	rt-pa	ischemic stroke	In this study, we examine risk factors and consequences of intravenous rt-PA for treatment of acute ischemic stroke.
1681	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	All acute ischemic stroke patients presenting between 11/2009 and 2/2011 eligible for tissue plasminogen activator therapy were screened and 56 enrolled.
1682	A.2 Under-expression	H. Benefit	1	myeloperoxidase	ischemic stroke	Trigonelline therapy confers neuroprotection by reduced glutathione mediated myeloperoxidase expression in animal model of ischemic stroke.
1683	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	The rates and extent of recovery in acute ischemic stroke (AIS) patients treated with intravenous tissue plasminogen activator (IV-tPA) remain highly variable.
1684	A. Expression	E. Associate	0	p21	heart failure	The expression of the CIP/KIP cyclin dependent kinase inhibitors p21, p27, p57 and the retinoblastoma protein was examined in acute (seen in brain dead transplant donors) and end-stage heart failure by Western blot analysis and compared to that seen in human and rat cardiac development.
1685	I. None	A. Treat	1	beta-blockers	congestive heart failure	Large, randomized, placebo-controlled studies have shown significant beneficial effects for several classes of drugs (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, aldosterone antagonists) in patients with congestive heart failure.
1686	A. Expression	E. Associate	0	leptin	stroke	It is unclear whether adiponectin, leptin, and resistin levels or the single-nucleotide polymorphisms of their encoding genes are independently associated with stroke risk.
1687	G. Regulate	E. Associate	1	sirtuin 3	cardiovascular disease	The mitochondrial deacetylase Sirt3 (Sirtuin 3) is critical in the regulation of metabolic and antioxidant functions which are associated with hypertension, and cardiovascular disease risk factors diminish Sirt3 level.
1688	A. Expression	E. Associate	1	NHE1	myocardial infarction	These results indicate that NHE1 expression decreased in response to extensive myocardial infarction only in non-infarcted myocardium.
1689	J. Inhibition	H. Benefit	1	angiotensin II	heart failure	Multiple studies have confirmed that angiotensin-converting enzyme (ACE) inhibitors, which block the formation of angiotensin II, lower blood pressure and also improve heart failure.
1690	I. None	A. Treat	1	tissue plasminogen activator	stroke	To determine the prevalence of the hyperdense middle cerebral artery sign (HMCAS) in an acute stroke population (treated with intravenous tissue plasminogen activator (tPA) within 90 minutes of stroke onset); to correlate the presence/absence of the sign with arteriographic findings; and to correlate the HMCAS with the volume of subsequent infarction.
1691	C. Activation	E. Associate	0	ACAT	coronary artery disease	To test the hypothesis whether low density lipoprotein (LDL) poor in cholesteryl ester from patients with coronary artery disease (CAD) express reduced capacity to regulate cellular sterol and lipoprotein metabolism, we compared the abilities of CAD-LDL and control-LDL to suppress receptor-mediated LDL degradation; activate acyl-CoA: cholesterol acyltransferase (ACAT); and regulate sterol synthesis rates in HL-60 promyelocytic leukemic cells.
1692	L. Be regulated	A. Treat	1	vasopressin V2 receptors	heart failure	Vaptans acting on the vasopressin V2 receptors (aquaretics) have attracted attention as a possible therapy for heart failure and polycystic kidney disease.
1693	A. Expression	E. Associate	0	MPO	unstable angina	The aim of this study was to evaluate alterations in soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), matrix metalloproteinase-9 (MMP-9), plasminogen activator inhibitor-1 (PAI-1), and myeloperoxidase (MPO) levels, and their relation to insulin resistance in coronary artery disease (CAD) patients with stable and unstable angina (SAP, UAP).
1694	A. Expression	E. Associate	1	TBX5	heart disease	[The mechanism of TBX5 abnormal expression in simple congenital heart disease].
1695	L. Be regulated	E. Associate	1	EPHA4	ischemic stroke	Our previous study indicated that microRNA 145 (miR-145) and its predicated target, erythropoietin-producing hepatoma (EPH) receptor A4 (EPHA4), was closely associated with ischemic stroke.
1696	H. Other	C. Cause	1	JAK2	cardiovascular disease	Thus, growth restriction alters specific targets in the JAK/STAT signalling pathway, with altered JAK2 and STAT3 potentially contributing to the increased risk of cardiovascular disease in the growth restricted males.
1697	I. None	G. Marker	1	cystatin C	coronary artery disease	Furthermore, evaluation of the feasibility of cathepsins as a diagnostic tool has revealed that the serum cathepsins S and L and the endogenous inhibitor cystatin C hold promise as biomarkers of coronary artery disease and aneurysm formation.
1698	I. None	B. Target	1	SR	stroke	The enzyme responsible for D-serine biosynthesis, serine racemase (SR), is therefore a promising target for treatment of neuropathologies related to glutamate receptor excitotoxicity, such as stroke or Alzheimer's disease.
1699	A.2 Under-expression	H. Benefit	1	TF	coronary artery disease	Inhibition of monocyte TF expression and attenuation of the persistent hypercoagulable state observed in cardiac transplant recipients during treatment with simvastatin may represent an important mechanism by which HMG-CoA reductase inhibitors protect against the development of transplant coronary artery disease.
1700	I. None	B. Target	1	ang2	cerebral ischemia	We propose that Ang2 represents a pertinent molecular target for the treatment of cerebral ischemia since acute brain damage may be limited by a pharmacological protection of the vascular compartment.
1701	J. Inhibition	A. Treat	1	ACE	ischaemic heart disease	Thus effective ACE inhibition impacts very positively on cardiovascular outcomes in patients with ischaemic heart disease, particularly in diabetic patients.
1702	D.1 Mutation	C. Cause	1	desmin	sudden cardiac death	The evaluation of risk of arrhythmia in familial forms of heart failure may benefit from genetic testing, as mutations in the genes encoding lamin A/C, desmin, and cardiac troponin T are associated with increased risk of sudden cardiac death.
1703	I. None	E. Associate	0	brdu	stroke	The mitotic marker BrdU was given on days 5 to 7, and TNF-alpha antibody or control protein was infused into the lateral ventricle of the ischemic hemisphere from day 8 to 14 after stroke.
1704	D.1 Mutation	C. Cause	1	chloramphenicol	cardiomyopathy	The mtDNA 16S rRNA chloramphenicol (CAP) resistance mutation was introduced into the mouse female germline and caused cataracts and rod and cone abnormalities in chimeras and neonatal lethal myopathy and cardiomyopathy in mutant animals.
1705	I. None	A. Treat	1	tissue plasminogen activator	embolic stroke	Thrombolytic therapy with recombinant tissue plasminogen activator may be safe and effective when there are no early computed tomographic findings within 3 hours from the onset of embolic stroke.
1706	L.1 Up-regulation	H. Benefit	1	BDNF	stroke	The oxygen-glucose deprivation in vitro model of stroke further demonstrated that "cold" rat splenocytes protected rat primary neurons by upregulating BDNF and IL-10.
1707	I. None	H. Benefit	1	tgf-beta1	cerebral ischemia	Taken as a whole, these results suggest that TGF-beta1 is an important neuroprotective factor that can reduce damage from a widearray of death-inducing agents/insults in vitro, as well as exert protection of the brain during cerebral ischemia.
1708	I. None	E. Associate	0	ALOX5AP	coronary artery disease	To assess the role of the leukotriene pathway in CVD pathogenesis, we performed genetic association studies of ALOX5AP and LTA4H in a family based study of early onset coronary artery disease (EOCAD) (GENECARD, 1,101 families) and in a non-familial dataset of EOCAD (CATHGEN, 656 cases and 405 controls).
1709	A. Expression	E. Associate	0	t-pa	ischemic stroke	Effects of nicotine treatment (4.5 mg/kg of nicotine-free base/day administered s.c. by osmotic minipumps for 14 days) on focal ischemic stroke and expression of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in cerebral microvessels were studied in rats in vivo using a reversible (1 h) middle cerebral artery occlusion model.
1710	I. None	H. Benefit	1	CGRP	arteriopathy	CGRP and endogenous E2 are independent protective factors in the development of coronary arteriopathy.
1711	D.1 Mutation	C. Cause	1	GLA	fabry disease	Fabry disease (OMIM 301500) is a rare X-linked recessive disorder caused by mutations in the alpha-galactosidase gene (GLA).
1712	D.1 Mutation	E. Associate	0	FGF16	heart disease	Identification of three novel FGF16 mutations in X-linked recessive fusion of the fourth and fifth metacarpals and possible correlation with heart disease.
1713	J. Inhibition	B. Target	1	CETP	coronary heart disease	Inhibition of CETP raises HDL cholesterol (good cholesterol) levels and reduces LDL cholesterol (bad cholesterol) levels, making it a promising drug target for the prevention and treatment of coronary heart disease.
1714	J. Inhibition	A. Treat	1	thrombin	stroke	Recently, the United States Food and Drug Administration approved the oral direct thrombin inhibitor dabigatran etexilate to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
1715	G. Regulate	H. Benefit	1	EPO	cardiomyopathy	Our results suggest that EPO exerts preventive cardioprotective effects on DOX-induced cardiomyopathy via anti-apoptotic pathways.
1716	I. None	E. Associate	1	lumican	carotid atherosclerosis	Circulating lumican was independently associated with carotid atherosclerosis plaque in essential hypertensive patients, indicating that SLRPs might be used as a promising molecular marker for atherosclerosis.
1717	A. Expression	E. Associate	0	chymase	ischemic heart disease	We address here whether Ang-(1-12) and chymase gene expression and activity are detected in the atrial appendages of 44 patients (10 females) undergoing heart surgery for the correction of valvular heart disease, resistant atrial fibrillation or ischemic heart disease.
1718	D.1 Mutation	E. Associate	1	SERPINE1	coronary atherosclerosis	Genetic variations of the serine proteinase inhibitor family E member 1 (SERPINE1) gene, which encodes plasminogen activator inhibitor 1, correlate with serum levels of its product and are associated with thrombophilia and coronary atherosclerosis.
1719	A. Expression	G. Marker	0	PRMT5	acute myocardial infarction	The purpose of this research is to determine whether the expression levels of the PRMT5 gene in peripheral blood can be used as a biomarker for predicting the risk of Acute Myocardial Infarction (AMI).
1720	A.1 Over-expression	E. Associate	1	CD63	ischemic stroke	The expressions of CD63 and P-selectin on platelets were significantly higher in patients with atherosclerotic ischemic stroke (n = 25) than in normal subjects (n = 24).
1721	A. Expression	E. Associate	0	epithelial cell adhesion molecule	ischemic stroke	Serum levels of D-dimer and EVs expressing markers for cancer cells (epithelial cell adhesion molecule [CD326]), tissue factor (TF [CD142]), endothelial cells (CD31+CD42b-), and platelets (CD62P) were measured using flow cytometry in (a) 155 patients with ischemic stroke and active cancer (116 - cancer-related, 39 - conventional stroke mechanisms), (b) 25 patients with ischemic stroke without cancer, (c) 32 cancer patients without stroke, and (d) 101 healthy subjects.
1722	L. Be regulated	E. Associate	0	NLRP3	coronary heart disease	This study aimed to identify the role of microRNA-22 (miR-22) in endothelial cell (EC) injury in coronary heart disease (CHD) by targeting NLRP3 through the inflammasome signaling pathway.
1723	D.1 Mutation	C. Cause	1	TET2	cardiovascular disease	Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease.
1724	I. None	A. Treat	1	beta-blocker	heart failure	Beta-blocker and positive inotropic therapies are currently viewed as alternative strategies for the management of severe heart failure patients.
1725	A.2 Under-expression	E. Associate	1	TCF7L2	coronary artery disease	Mice with a coronary artery disease-linked mutation in Wnt-coreceptor LRP6 exhibit vascular smooth muscle cell dedifferentiation and obstructive coronary artery disease, which are paradoxically associated with reduced TCF7L2 expression.
1726	J. Inhibition	A. Treat	1	thrombin	myocardial infarction	Heparin is currently the standard therapy, but we showed that the direct thrombin inhibitor bivalirudin may be an attractive alternative by causing less bleeding events, and a higher frequency of preprocedure thrombolysis in myocardial infarction (TIMI) 3 flow.
1727	I. None	B. Target	1	hsp20	stroke	These findings suggest that Hsp20 is a potential drug target for ischemia stroke treatment.
1728	J. Inhibition	A. Treat	1	angiotensin converting enzyme	cardiac failure	Combined inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin converting enzyme (ACE) is a candidate therapy for hypertension and cardiac failure.
1729	I. None	B. Target	1	NHE1	heart disease	Mitochondrial NHE1: a newly identified target to prevent heart disease.
1730	H. Other	B. Target	1	G6PD	cardiomyopathy	These findings demonstrate that dysregulation of G6PD activity is necessary and sufficient for maladaptive reductive stress and suggest a novel therapeutic target for abrogating R120GCryAB cardiomyopathy and heart failure in humans.
1731	I. None	B. Target	1	NADPH oxidase 4	cardiovascular disease	NADPH oxidase 4 (Nox4) as a major source of oxidative stress in the heart offers a new therapeutic target in cardiovascular disease.
1732	A. Expression	G. Marker	1	ANP	heart failure	The aim of this study was to evaluate in rats whether a wooden tube has any impact on cardiac morphology or on basal gene expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP); known markers of cardiac overload, hypertrophy and heart failure.
1733	D.1 Mutation	E. Associate	1	GLA	fabry disease	We detected one patient with a mutation in GLA associated with classical Fabry Disease (M290I), ten subjects carrying genetic variants of uncertain diagnosis (S126G, R118C, A143T), and a girl with the non-characterized variant F18Y, which was not previously described.
1734	J. Inhibition	A. Treat	1	thrombin	stroke	Data from randomized, Phase III clinical trials of the novel oral anticoagulants, dabigatran, a direct thrombin inhibitor, and rivaroxaban and apixaban, both factor Xa inhibitors, indicate these drugs are at least noninferior to warfarin for the prevention of stroke and systemic embolism.
1735	A. Expression	E. Associate	1	natriuretic peptides	heart failure	Yet the expression and serum levels of chromogranins and natriuretic peptides have been closely correlated with pathological cardiac hypertrophy and heart failure.
1736	J. Inhibition	A. Treat	1	ROMK	heart failure	Inhibitors of ROMK represent a target for novel diuretics for the treatment of hypertension and/or heart failure.
1737	I. None	C. Cause	1	leptin	coronary heart disease	Leptin, an adipocyte-derived protein, regulating food intake and metabolism has been implicated in the development of coronary heart disease.
1738	D.1 Mutation	E. Associate	1	LRP6	coronary artery disease	Mutations in the genes low-density lipoprotein (LDL) receptor-related protein-6 (LRP6) and myocyte enhancer factor 2A (MEF2A) were reported in families with coronary artery disease (CAD).
1739	I. None	E. Associate	0	angiotensin converting enzyme 2	myocardial infarction	Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study.
1740	D.1 Mutation	H. Benefit	1	BRG1	stroke	BRG1 variant rs1122608 on chromosome 19p13.2 confers protection against stroke and regulates expression of pre-mRNA-splicing factor SFRS3.
1741	A. Expression	E. Associate	0	basic fibroblast growth factor	myocardial infarction	The expression of basic fibroblast growth factor (bFGF) was first studied in 61 cases of early myocardial infarction.
1742	J. Inhibition	A. Treat	1	ACE	congestive heart failure	Captopril is an angiotensin converting enzyme (ACE) inhibitor which has been used extensively in the treatment of patients with hypertension and congestive heart failure.
1743	I. None	H. Benefit	1	adropin	coronary artery disease	Adropin is a newly-identified energy homeostasis protein with a potential protective effect against coronary artery disease (CAD).
1744	D.1 Mutation	C. Cause	1	LEMD2	cardiomyopathy	Characterization of a Unique Form of Arrhythmic Cardiomyopathy Caused by Recessive Mutation in LEMD2.
1745	M.3 Gene silencing	H. Benefit	1	apolipoprotein B	cardiovascular disease	Since previous studies have linked the genetic mutations of Apolipoprotein B (ApoB) to the low density lipoprotein (LDL) cholesterol levels, it can be believed that the knockdown of ApoB by siRNA silencing is a useful method to reduce the cardiovascular disease.
1746	J. Inhibition	A. Treat	1	ACE	heart failure	Post infarct heart failure: what to do in addition to ACE inhibition.
1747	I. None	A. Treat	1	tissue-type plasminogen activator	stroke	Stroke is a disease of aging affecting millions of people worldwide, and recombinant tissue-type plasminogen activator (r-tPA) is the only treatment approved.
1748	L. Be regulated	H. Benefit	1	ST2	acute myocardial infarction	LncRNA ANRIL knockdown relieves myocardial cell apoptosis in acute myocardial infarction by regulating IL-33/ST2.
1749	J. Inhibition	A. Treat	1	thrombin	stroke	Dabigatran etexilate is an oral direct thrombin inhibitor approved for prevention of stroke and systemic embolization in patients with nonvalvular atrial fibrillation and for the treatment of venous thromboembolism.
1750	J. Inhibition	A. Treat	1	angiotensin II	heart failure	Angiotensin II antagonists--therapeutic benefits spanning the cardiovascular disease continuum from hypertension to heart failure and diabetic nephropathy.
1751	I. None	H. Benefit	1	hepatocyte growth factor	ischemic heart disease	Some angiogenic factors, including hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF), have been reported to promote angiogenesis and improve myocardial perfusion in experimental models of ischemic heart disease.
1752	D.1 Mutation	C. Cause	1	SRSF2	ataxia telangiectasia	Here we report a chain of events triggered by multiple splicing factor mutations, especially high-risk alleles in SRSF2 and U2AF1, including elevated R-loops, replication stress, and activation of the ataxia telangiectasia and Rad3-related protein (ATR)-Chk1 pathway.
1753	J. Inhibition	A. Treat	1	thrombin	stroke	To ascertain the prevalence of overweight and obesity in patients with nonvalvular AF, their influence on adverse events, and the relation with anticoagulation control, we performed this post hoc analysis of the pooled Stroke Prevention using an Oral Thrombin Inhibitor in patients with atrial Fibrillation (SPORTIF) III and V data sets.
1754	D.1 Mutation	C. Cause	1	GAA	pompe disease	Pompe disease is caused by mutations in the gene encoding the lysosomal glycogen-metabolizing enzyme, acid-alpha glucosidase (GAA).
1755	J. Inhibition	A. Treat	1	ACE	heart failure	To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme (ACE) inhibition with captopril, the ELITE study compared losartan with captopril in older heart-failure patients.
1756	D.1 Mutation	C. Cause	1	transthyretin	cardiomyopathy	Hereditary ATTR amyloid cardiomyopathy is defined as the intramyocardial deposition of amyloid fibrils derived from the mutation of transthyretin (TTR).
1757	D.1 Mutation	C. Cause	1	KCNJ2	arrhythmia	Andersen-Tawil syndrome (ATS) is a rare arrhythmia disorder caused by a mutation in the KCNJ2 gene.
1758	L. Be regulated	E. Associate	1	GATA4	heart failure	Regulation of Cardiac Transcription Factor GATA4 by Post-Translational Modification in Cardiomyocyte Hypertrophy and Heart Failure.
1759	D.5 Polymorphism	E. Associate	0	phosphodiesterase 4D	ischemic stroke	Relationship of phosphodiesterase 4D (PDE4D) gene polymorphisms with risk of ischemic stroke: a hospital based case-control study.
1760	J. Inhibition	A. Treat	1	ACE	heart failure	Standard triple therapy for symptomatic heart failure consists of an angiotensin-converting enzyme (ACE) inhibitor, digoxin, and a diuretic.
1761	D.1 Mutation	E. Associate	0	MYH7	hypertrophic cardiomyopathy	Prevalence and Phenotypic Expression of Mutations in the MYH7, MYBPC3 and TNNT2 Genes in Families with Hypertrophic Cardiomyopathy in the South of Brazil: A Cross-Sectional Study.
1762	A. Expression	E. Associate	0	vwf	transient ischaemic attack	In a case-control study of 105 cases of transient ischaemic attack and minor ischaemic stroke, and 241 controls, data were available on levels of the haemostatic factors-von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI), tissue plasminogen activator (TPA) and factor VII (FVII).
1763	L. Be regulated	H. Benefit	1	DPP4	cerebral ischemia	MiR-29a protects against cerebral ischemia injury by targeting DPP4 through TGF-β signaling pathway.
1764	J. Inhibition	A. Treat	1	angiotensin converting enzyme	heart disease	Angiotensin converting enzyme (ACE) inhibitors are able to modify the actions of the renin-angiotensin system, and are indicated for the treatment of hypertension and heart disease.
1765	J. Inhibition	H. Benefit	1	SGLT2	heart failure	Areas covered: In this paper, the authors critically discuss the background, trial design, results and implications of a recent CVOT [NCT01730534; DECLARE-TIMI 58 study], which demonstrated that dapagliflozin was non-inferior to placebo in terms of major adverse cardiovascular events, and superior for the occurrence of hospitalization for heart failure (HF) and composite renal endpoints, thus confirming the cardiovascular benefit of sodium-glucose co-transporter-2 (SGLT2) inhibitors.
1766	L. Be regulated	C. Cause	1	SOCS3	stroke	In conclusion, induction of miR-3473b, which is likely targeted to SOCS3, contributes to stroke pathogenesis by enhancing post-stroke neuroinflammation injury.
1767	J. Inhibition	A. Treat	1	GPR4	myocardial infarction	Identification of a Potent and Selective GPR4 Antagonist as a Drug Lead for the Treatment of Myocardial Infarction.
1768	D.1 Mutation	C. Cause	1	transthyretin	cardiomyopathy	Mutation in the transthyretin (TTR) gene may clinically manifest as cardiomyopathy.
1769	D.1 Mutation	C. Cause	1	DNM2	centronuclear myopathy	Centronuclear myopathy with neonatal onset caused by a DNM2 mutation in the C-terminal part of the pleckstrin homology domain may have a favorable prognosis and follow a course similar to adult-onset centronuclear myopathy.
1770	A. Expression	E. Associate	1	natriuretic peptide	chronic heart failure	Understanding and making good use of changes in natriuretic peptide levels in chronic heart failure.
1771	A.1 Over-expression	E. Associate	1	tissue factor	heart failure	Neurohormonal activation does not explain elevated tissue factor expression in heart failure.
1772	A.1 Over-expression	H. Benefit	1	nerve growth factor	cerebral ischemia	Lettuce glycoside B ameliorates cerebral ischemia reperfusion injury by increasing nerve growth factor and neurotrophin-3 expression of cerebral cortex in rats.
1773	J. Inhibition	H. Benefit	1	TOR	cardiomyopathy	Previously, pharmacological studies using rapamycin have suggested a cardioprotective effect of TOR signaling inhibition on cardiomyopathy.
1774	A. Expression	E. Associate	0	toll like receptor 4	sudden cardiac death	To investigate the Toll like receptor 4 (TLR4) expression in the coronary atherosclerotic plaques in patients died from sudden cardiac death (SCD) or non SCD.
1775	L. Be regulated	E. Associate	1	ST2	heart failure	Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers.
1776	D.5 Polymorphism	C. Cause	1	XPF	ischemic stroke	These data indicate that XPF might play an important role in the pathophysiological process of ischemic stroke, and the 30028T/C polymorphism might be associated with ischemic stroke susceptibility in a Chinese Han population.
1777	I. None	B. Target	1	NAMPT	ischemic stroke	Most recently, studies have demonstrated several mechanisms by which NAMPT might serve as a therapeutic target against ischemic stroke, including cerebroprotection in the acute phase as well as vascular repair and neurogenesis in the chronic phase.
1778	I. None	B. Target	1	SMP30	heart failure	SMP30 has a cardio-protective role by anti-oxidative and anti-apoptotic effects in DOX-induced cardiotoxicity, and can be a new therapeutic target to prevent DOX-induced heart failure.
1779	A.1 Over-expression	E. Associate	0	ET	cerebral ischemia	We hypothesize that cerebral ischemia leads to enhanced expression of endothelin (ET), 5-hydroxytryptamine (5-HT), and angiotensin II (ANG II) receptors in the vascular smooth muscle cells.
1780	J. Inhibition	A. Treat	1	angiotensin converting enzyme	congestive heart failure	Orally active angiotensin converting enzyme (ACE) inhibitors have been successfully used in the treatment of congestive heart failure and hypertension.
1781	I. None	E. Associate	0	tumor necrosis factor alpha	acute myocardial infarction	The present work was undertaken to clarify the role of Tumor Necrosis Factor Alpha (TNF-alpha) in acute myocardial infarction (AMI).
1782	A.1 Over-expression	E. Associate	1	ITGA1	arrhythmogenic right ventricular cardiomyopathy	Kyoto Encyclopedia of Genes and Genomes and protein-protein interaction analyses determined the top 10 signaling pathways and found that the six hub proteins associated with the differentially expressed upregulated proteins (PRKAA1, DHPR, ACTB, desmin, ACTG1, and ITGA1) were all involved in hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and dilated cardiomyopathy.
1783	D.1 Mutation	C. Cause	1	PLN	dilated cardiomyopathy	Here we report that an inherited human dilated cardiomyopathy with refractory congestive heart failure is caused by a dominant Arg --> Cys missense mutation at residue 9 (R9C) in phospholamban (PLN), a transmembrane phosphoprotein that inhibits the cardiac sarcoplasmic reticular Ca2+-adenosine triphosphatase (SERCA2a) pump.
1784	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: an effective treatment for reperfusion injury following acute ischemic stroke in rats.
1785	A.1 Over-expression	G. Marker	1	vwf	stroke	Our study suggests that increased vWF levels and presence of HMWMs could be related to cerebrovascular disease and may represent useful biomarkers for stroke in AF.
1786	I. None	E. Associate	0	urotensin II	congestive heart failure	We hypothesized that increased pulmonary vascular pressure--one of the characteristics of congestive heart failure--directly regulates pulmonary endothelial vasoconstrictors (endothelin-1, urotensin II) and vasodilators (adrenomedullin, relaxin).
1787	I. None	F. None	1	fibrinogen	stroke	Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects.
1788	A. Expression	E. Associate	0	optic atrophy 1	ischemic heart disease	We sought to investigate the expression of this pathway along with the expression of mitochondrial biogenesis (PGC-1α [peroxisome proliferator-activated receptor-γ coactivator-1α]), dynamics (DRP-1 [dynamin-related protein 1], OPA-1 [optic atrophy 1], and MFN 2 [mitofusin 2]), and oxidative phosphorylation (citrate synthase and electron transport chain complexes) markers and COX IV (cytochrome C oxidase) activity in myocardium from patients with valvular or ischemic heart disease and heart failure with preserved ejection fraction (HFpEF) or heart failure with reduced ejection fraction (HFrEF).
1789	D.1 Mutation	C. Cause	1	MTHFR	coronary heart disease	The C677T mutation of the methylenetetrahydrofolate (MTHFR) gene is a nutrient-oriented, "eco" genetic mutation that is associated with elevated levels of homocysteine and an increased risk for coronary heart disease.
1790	A.1 Over-expression	E. Associate	1	parathyroid hormone	cardiovascular disease	Elevated parathyroid hormone (PTH) levels have been associated with cardiovascular disease risk factors and events.
1791	A.1 Over-expression	C. Cause	1	SOD1	stroke	Genetically modified mice (SOD1, SOD2) or rats that overexpress or are deficient in superoxide dismutase have provided strong evidence in support of the role of mitochondrial dysfunction and oxidative stress as determinants of neuronal death/survival after stroke and neurodegeneration.
1792	I. None	C. Cause	1	CRP	cardiovascular disease	CRP is an established risk factor of cardiovascular disease and a marker of low‑grade inflammation, typical of atherogenesis.
1793	I. None	E. Associate	1	c-reactive protein	heart disease	C-reactive protein (CRP), a nonspecific marker of inflammatory status, is associated with cardiovascular disease (CVD) risk factors and the late occurrence of heart disease in adults.
1794	A.2 Under-expression	H. Benefit	1	MMP9	ischemic stroke	Our study suggests that miR-212 promotes recovery function and vascular regeneration of EPCs through negative regulation of the Notch signaling pathway via downregulating expression of MMP9, thus provides a clinical theoretical basis for ischemic stroke therapy.
1795	D.1 Mutation	E. Associate	1	LMNA	dilated cardiomyopathy	Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy.
1796	L.2 Down-regulation	F. None	1	TRN	heart failure	Heart-specific overexpression of CSQ in transgenic mice (TG(CSQ)) was associated with heart failure, attenuation of SR Ca(2+) release, and downregulation of associated junctional SR proteins, e.g., TRN.
1797	A. Expression	H. Benefit	1	NGF	cerebral ischemia	Our data suggest that AST have the protective effects on focal cerebral ischemia in rats at the different reperfusion time points, the mechanism may be related to the antioxidation, regulated the expressions of iNOS, NGF and TrkA mRNA.
1798	G. Regulate	H. Benefit	1	anxa1	stroke	AnxA1 administration regulated platelet function directly (eg, via reducing thromboxane B2 and modulating phosphatidylserine expression) to promote cerebral protection post-I/RI and act as an effective preventative strategy for stroke by reducing platelet activation, aggregate formation, and cerebral thrombosis, a prerequisite for ischemic stroke.
1799	A. Expression	E. Associate	0	ANP	heart failure	To further characterize left ventricular remodeling during the progression of heart failure, we assessed left ventricular geometry, wall stress, and atrial natriuretic peptide (ANP) gene expression and protein content during control conditions, asymptomatic left ventricular dysfunction, and overt congestive heart failure (CHF).
1800	H. Other	E. Associate	0	insulin	cardiovascular disease	Moreover, since patients with cardiovascular disease and high levels of cholesterol are often treated with statins, we summarize recent data regarding effects on statins on glucose homeostasis and insulin secretion.
1801	J. Inhibition	E. Associate	1	vitamin K	ischemic stroke	Information on atrial fibrillation and vitamin K antagonistic treatment at admittance and at discharge was obtained for Greenlanders admitted to Queen Ingrid's Hospital in Nuuk with an ischemic stroke in 2011 or in 2012 with methods described in details elsewhere.
1802	J. Inhibition	H. Benefit	1	ACE	stroke	In the Heart Outcomes Prevention Evaluation (HOPE) Study, the angiotensin-converting enzyme (ACE) inhibitor ramipril was shown to significantly reduce the relative risk of stroke by 32% in high-risk cardiovascular patients (P < 0.001).
1803	J. Inhibition	A. Treat	0	adenosine A1 receptor	heart failure	The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment.
1804	J. Inhibition	E. Associate	0	insulin	heart failure	We hypothesized that cardiac accumulation of toxic lipid intermediates inhibits insulin signaling in advanced heart failure and that mechanical unloading of the failing myocardium corrects impaired cardiac metabolism.
1805	D.1 Mutation	E. Associate	1	NPPA	ischemic stroke	However, in logistic analysis for Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification of ischemic stroke, nonsynonymous rs5065 (STOP152Arg) and rs5067 in 3'UTR of NPPA, which were in complete linkage disequilibrium, showed significant associations with cardioembolic stroke.
1806	L.1 Up-regulation	E. Associate	1	pkc-alpha	myocardial infarction	These data demonstrate for the first time that in the remodeling heart after myocardial infarction, a subtype-selective regulation of the PKC isozymes occurs: The upregulation of PKC-alpha coincides with the development of hypertrophy, whereas the extensive upregulation of PKC-delta outlasts the process of developing hypertrophy and persists in the failing heart.
1807	D.1 Mutation	E. Associate	0	transthyretin	familial amyloid cardiomyopathy	Retrospective molecular detection of Transthyretin Met 111 mutation in a Danish kindred with familial amyloid cardiomyopathy, using DNA from formalin-fixed and paraffin-embedded tissues.
1808	D.1 Mutation	E. Associate	1	alpha-galactosidase A	fabry disease	Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
1809	I. None	E. Associate	1	tpa	myocardial infarction	When in 1947, Astrup and Permin reported that animal tissues contain fibrinokinase, a plasminogen activator, and when Pennica and colleagues (Pennica et al., 1983) cloned and expressed human tissue plasminogen activator (tPA) in Escherichia coli in 1983, they might did not realize how much their pioneer work would impact the life of millions of patients suffering from myocardial infarction or ischemic stroke.
1810	L. Be regulated	E. Associate	1	superoxide dismutase 2	heart failure	Publisher Correction: MicroRNAs regulating superoxide dismutase 2 are new circulating biomarkers of heart failure.
1811	I. None	E. Associate	1	myeloperoxidase	myocardial infarction	Dynamic evaluation of alkaline phosphatase and myeloperoxidase of leucocytes allows to assess the course of myocardial infarction and efficacy of its treatment.
1812	A.1 Over-expression	H. Benefit	1	occludin	stroke	Treatment of experimental stroke mice with isorhamnetin attenuated cerebral edema, improved blood-brain barrier function, and upregulated gene expression of tight junction proteins including occludin, ZO-1, and claudin-5.
1813	N.1 Increase activity	C. Cause	1	GRK5	heart failure	Moreover, the pathological involvement of Angiotensin-converting enzyme 1 (ACE1)/angiotensin II (Ang II)/angiotensin II type 1 (AT1) axis and beneficial ACE2/Ang (1-7)/Mas receptor axis also shows protective role via Gi βγ, during heart failure these receptors get desensitized or internalized due to increase in the activity of G-protein-coupled receptor kinase 2 (GRK2) and GRK5, responsible for phosphorylation of G-protein-mediated down regulatory signaling.
1814	A. Expression	E. Associate	1	CB2	stroke	In this study we have identified CB2 expressing cells that appear in the rat brain following stroke and hypoxic-ischemia.
1815	I. None	C. Cause	1	HSPB7	heart disease	Therefore, GATA4 and HSPB7 may act alone or together to regulate morphogenesis with relevance to congenital and acquired human heart disease.
1816	D.5 Polymorphism	E. Associate	0	APOE	vascular dementia	The APOE epsilon4 allele is an established risk factor for Alzheimer's disease, but reports of its association with vascular dementia (VaD) have been inconsistent.
1817	D.5 Polymorphism	E. Associate	0	NCX1	cardiovascular disease	We targeted CNRs of cardiovascular disease (CVD) candidate gene, Na(+)-Ca(2+) exchanger (NCX1) with polymorphism screening among CVD patients (n = 46) using DHPLC technology.
1818	I. None	F. None	1	β-blocker	myocardial infarction	Male patients with G genotype had a hazard ratio of 1.44 (1.11-2.33) for death when compared to the A genotype male patients (P = 0.048) after adjustment for age, baseline log-transformed N-terminal pro-B-type natriuretic peptide (NTproBNP), β-blocker and insulin treatment, QTc interval, history of myocardial infarction, and physical activity score.
1819	A. Expression	E. Associate	1	MYH7	hypertrophic cardiomyopathy	Intrinsic MYH7 expression regulation contributes to tissue level allelic imbalance in hypertrophic cardiomyopathy.
1820	A.1 Over-expression	E. Associate	1	CRP	coronary artery disease	Statins improve survival in patients with coronary artery disease, especially those with elevated C-reactive protein (CRP).
1821	J. Inhibition	H. Benefit	1	angiotensin converting enzyme	myocardial infarction	Angiotensin converting enzyme (ACE) inhibition after myocardial infarction is associated with an improvement in plasma fibrinolytic parameters.
1822	A. Expression	E. Associate	0	TBX5	heart disease	To explore the mechanism of TBX5 abnormal expression in simple congenital heart disease (CHD), 100 CHD venous blood, 50 CHD heart tissues, and 5 non-CHD heart tissues were involved in this study.
1823	H. Other	C. Cause	1	insulin	cardiovascular disease	Defects in insulin signaling are associated with abnormal endothelial cell function, which occurs commonly in cardiovascular disease.
1824	D.5 Polymorphism	E. Associate	0	LPA	cardiovascular disease	The analyzed markers correspond to polymorphic sites in several candidate genes for cardiovascular disease including apolipopoteins and their receptors (APOA1, APOB, APOE, APOC1, APOC2, LPA, and LDLR), genes implied in the hemostasis regulation (Factor VII, alpha and beta-fibrinogen, alpha and beta platelet-integrin, tissue plasminogen activator, and plasminogen activator inhibitor-1), and the angiotensin converting enzyme gene.
1825	A.1 Over-expression	G. Marker	1	fibrinogen	unstable angina	The elevation of fibrinogen and C-reactive protein in patients with unstable angina may be markers of ongoing plaque inflammation.
1826	J. Inhibition	A. Treat	1	MR	heart failure	In RALES, low doses of the mineralocorticoid receptor (MR) antagonist spironolactone, added to standard of care for severe heart failure, improved survival by 30% and lowered hospitalization by 35%.
1827	J. Inhibition	H. Benefit	0	TRP	stroke	The evidence reviewed here indicates that further investigation is needed to determine whether TRP channel inhibition can decrease damage or increase repair in stroke and other diseases affecting the white matter.
1828	J. Inhibition	H. Benefit	0	angiotensin II	myocardial infarct	Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.
1829	I. None	E. Associate	0	MTAP	coronary artery disease	Studies focusing on the association of gene methylthioadenosine phosphorylase (MTAP) with the risk of coronary artery disease (CAD) and myocardial infarction (MI) are limited.
1830	A. Expression	E. Associate	0	tumor necrosis factor alpha	cerebral ischemia	Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.
1831	D.1 Mutation	E. Associate	1	MYH7	hypertrophic cardiomyopathy	The electrocardiogram is a more sensitive indicator than echocardiography of hypertrophic cardiomyopathy in families with a mutation in the MYH7 gene.
1832	C. Activation	E. Associate	1	FVII	acute ischaemic heart disease	This report describes studies on the activation of coagulation factor VII (FVII) and the inhibition of the extrinsic coagulation pathway in acute ischaemic heart disease.
1833	I. None	E. Associate	1	transferrin receptor	cerebral infarction	Fabrication and evaluation a transferrin receptor targeting nano-drug carrier for cerebral infarction treatment.
1834	A.1 Over-expression	E. Associate	1	vwf	heart disease	Endocardial overexpression of vWF may occur during the process of atrial structural remodeling contributing to the thrombotic predilection of AF in association with underlying heart disease.
1835	A. Expression	E. Associate	1	CMP	myocardial infarction	It was found that assessments of the Hp and CMP levels as well as of mucoprotein heterogeneity make it possible to appraise the intensity of inflammatory reaction in myocardial necroses and thus facilitate the choice of differentiated antiinflammatory treatment of patients with myocardial infarction.
1836	I. None	A. Treat	1	tissue plasminogen activator	stroke	We applied an alternative drug delivery strategy, by injection of dexamethasone phosphate-containing liposomes in combination with recombinant tissue plasminogen activator (rtPA), in an experimental stroke model, and tested the hypothesis that this approach improves behavioral recovery and reduces lesion growth.
1837	D.1 Mutation	E. Associate	1	methylenetetrahydrofolate reductase	coronary heart disease	We examined the risk of coronary heart disease associated with homozygosity for the C677T mutation in the methylenetetrahydrofolate reductase gene.
1838	D.1 Mutation	C. Cause	1	DSG2	arrhythmogenic right ventricular cardiomyopathy	Our study reveals complex molecular interactions between DSG2 mutations and N-glycosylations of desmoglein-2, which may contribute to the molecular understanding of the patho-mechanisms associated with arrhythmogenic right ventricular cardiomyopathy.
1839	D.1 Mutation	C. Cause	1	TPM1	sudden cardiac death	In case of mutations Asp175Asn or Glu180Gly in TPM1, early detection of alterations in autonomic cardiac control could help to prevent sudden cardiac death in affected persons.
1840	J. Inhibition	B. Target	1	GRK2	heart failure	Recent advances in transgenic and gene therapy techniques have presented novel therapeutic strategies for management of heart failure via genetic manipulation of beta-AR signaling including the targeted inhibition of the beta-AR kinase (betaARK1 or GRK2).
1841	A.1 Over-expression	E. Associate	1	CD137	cerebral ischemia	Increased Peripheral CD137 Expression in a Mouse Model of Permanent Focal Cerebral Ischemia.
1842	I. None	G. Marker	0	CRP	myocardial infarction	We tested the predictive effect of markers of eosinophilic inflammation and C-reactive protein (CRP) on death from cardiovascular causes and nonfatal myocardial infarction over a 2.7-4.1-year follow-up period.
1843	A. Expression	E. Associate	1	PRKCA	heart failure	The haplotype carrying rs9909004 influences PRKCA expression in the heart and is associated with traits linked to heart failure, potentially affecting therapy of heart failure.
1844	I. None	H. Benefit	1	EGF	stroke	Combined therapy with epidermal growth factor (EGF) and growth hormone-releasing peptide 6 (GHRP-6) in stroke models has accumulated evidence of neuroprotective effects from several studies, but needs further support before clinical translation.
1845	L. Be regulated	B. Target	1	MBL	stroke	We propose that the superiority of rhC1-INH is due to its selective binding to MBL, which emerged as a novel target for stroke treatment.
1846	F.2 Methylation	E. Associate	0	ADORA2A	heart disease	We detected methylation differences in pathways related to heart disease, but also in genes with yet unknown function in DCM or heart failure, namely Lymphocyte antigen 75 (LY75), Tyrosine kinase-type cell surface receptor HER3 (ERBB3), Homeobox B13 (HOXB13) and Adenosine receptor A2A (ADORA2A).
1847	J. Inhibition	E. Associate	1	PDE5	heart disease	Marked disparity of microRNA modulation by cGMP-selective PDE5 versus PDE9 inhibitors in heart disease.
1848	A.2 Under-expression	E. Associate	1	ATM	ataxia telangiectasia	The ATR-CHEK1 pathway is upregulated and overactivated in Ataxia Telangiectasia (AT) cells, which lack functional ATM protein.
1849	H. Other	G. Marker	1	hsp70	cerebral ischemia	The induction of heat shock protein 70 (hsp70) mRNA is considered to be an important marker of cerebral ischemia injury, and c-fos may upregulate the expression of other genes related to the secondary injuries.
1850	L. Be regulated	E. Associate	1	CX3CR1	heart failure	These data suggest that FKN and its receptor, CX3CR1, modulate cardiovascular function at the level of the PVN and that the actions of FKN within this nucleus are altered in heart failure.
1851	A. Expression	E. Associate	1	GPER	ischemic stroke	Ischemic stroke increases membrane-bound G protein-coupled estrogen receptor (GPER) distribution and expression in the brain of male but not female mice.
1852	A. Expression	F. None	1	TSH	cardiovascular morbidity	EFT determination by TE does not seem to be a good marker of cardiovascular risk in SCH patients with serum TSH <10.0 mIU/L and no pre-existing cardiovascular morbidity.
1853	G. Regulate	H. Benefit	1	P4	stroke	We suggest that post-stroke infection exacerbates stroke outcomes and P4 exerts neuroprotective/modulatory effects through its systemic anti-inflammatory and BDNF regulatory actions.
1854	A.2 Under-expression	E. Associate	1	CD2	myocardial infarction	In myocardial infarction group, the mRNA expressions of six inhibitory receptors KIR2DL2, KIR3DL3, CD94, NKG2A, KLRB1, KLRG1, and eight activating receptors KIR2DS3, KIR2DS5, NKp30, NTB-A, CRACC, CD2, CD7 and CD96 were significantly down-regulated (P<0.05) compared with both angina patients and the controls.
1855	A. Expression	E. Associate	0	PON1	cardiovascular disease	In Experiment 1, morning plasma levels of the oxidative-stress biomarkers, thiobarbituric reactive substances (TBARS) and peroxides (PD), and of the antioxidant protective enzyme paraxonase-1 (PON1), were measured in OSA patients with and without cardiovascular disease (CVD) and in nonapneic controls after an overnight fasting.
1856	L.1 Up-regulation	E. Associate	1	neuroglobin	stroke	In a recent study, neuroglobin was ubiquitously expressed and up-regulated following stroke in the human brain.
1857	A.1 Over-expression	E. Associate	1	fibronectin	cerebral ischaemia	Here we report that ECM remodelling in the cerebrovasculature critically regulates IL-1-induced endothelial cell activation after cerebral ischaemia; Expression levels of ECM molecules associated with the cerebrovasculature, namely fibronectin (FN) and collagen IV (Col IV), strongly increased in brain blood vessels after middle cerebral artery occlusion (MCAo) in a time-dependent manner, reaching a peak of vascular expression 48 h after MCAo.
1858	L. Be regulated	E. Associate	1	TGFB1	cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy	Transforming growth factor beta 1 (TGFB1) is dysregulated in the hereditary SVD, CARASIL (cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy).
1859	A. Expression	E. Associate	1	orexin	chronic heart failure	Chronic heart failure alters orexin and melanin concentrating hormone but not corticotrophin releasing hormone-related gene expression in the brain of male Lewis rats.
1860	A.1 Over-expression	E. Associate	1	b-type natriuretic peptide	heart failure	Multiple regression analysis showed that age, left ventricular ejection fraction, left atrial diameter, structural heart disease, chronic atrial fibrillation, and heart failure symptoms were independently associated with elevated B-type natriuretic peptide levels.
1861	A.2 Under-expression	H. Benefit	1	c-reactive protein	cardiovascular disease	The use of statins in SLE reduced the serum lipid and high-sensitivity C-reactive protein levels, which suggests a role for the primary prevention of cardiovascular disease.
1862	D.5 Polymorphism	E. Associate	0	MYH7	dilated cardiomyopathy	Polymorphic microsatellite markers and single Nucleotide Polymorphisms were genotyped in 4 families of Newfoundland dogs segregating dilated cardiomyopathy for the genes encoding alpha-cardiac actin (ACTC), caveolin (CAVI), cysteine-rich protein 3 (CSRP3), LIM-domain binding factor 3 (LDB3), desmin (DES), lamin A/C (LMNA), myosin heavy polypeptide 7 (MYH7), delta-sarcoglycan (SGCD), troponin I (TNNTI3), troponin T (TNNT2), alpha-tropomyosin (TPMI), titin (TTN) and vinculin (VCL).
1863	J. Inhibition	H. Benefit	1	AQP4	stroke	Aquaporin 4 (AQP4) has been found to be the most important water channel in the brain, and its inhibition before inducing focal ischemia in an animal model of stroke proved to alleviate the pathology and improve clinical recovery.
1864	L. Be regulated	E. Associate	1	ASK1	ischemic stroke	We conclude that ASK1 is regulated in response to the early inflammation phase and regulates the differentiation of NSCs after inflammatory-inducing events, such as ischemic stroke.
1865	G. Regulate	E. Associate	1	TST	stroke	These data suggest that TST alters the expression of ephrin ligands in the CST after stroke.
1866	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Intravenous and intraarterial recombinant tissue plasminogen activator remains underutilized in the treatment of acute ischemic stroke, largely due to strict adherence to the concept of the therapeutic time window for administration.
1867	I. None	A. Treat	1	erythropoietin	ischemic stroke	Numerous preclinical findings and a clinical pilot study suggest that recombinant human erythropoietin (EPO) provides neuroprotection that may be beneficial for the treatment of patients with ischemic stroke.
1868	H. Other	C. Cause	1	HH	heart failure	In the absence of HH signaling, loss of coronary blood vessels led to tissue hypoxia, cardiomyocyte cell death, heart failure, and subsequent lethality.
1869	A.2 Under-expression	E. Associate	1	coq10	stroke	Noteworthy, CoQ10 deficiency is common in many surviving stroke patients as they are mostly prescribed statins for the secondary prevention of stroke incidence lifelong.
1870	I. None	A. Treat	1	tissue plasminogen activator	ischaemic stroke	Systemic thrombolysis with tissue plasminogen activator (tPA) is the only approved treatment for acute ischaemic stroke that improves functional outcome if given up to 4.5 h from symptom onset.
1871	J. Inhibition	E. Associate	1	ACE	acute myocardial infarction	Acute myocardial infarction in diabetes mellitus: lessons learned from ACE inhibition.
1872	L.1 Up-regulation	H. Benefit	1	HMOX1	cardiovascular disease	The upregulation of antioxidant enzyme heme oxygenase-1 (HMOX1) in endothelial cells is considered to be beneficial in cardiovascular disease.
1873	A. Expression	E. Associate	0	GRK3	dilated cardiomyopathy	To analyze these questions, we quantified the mRNA/protein expressions of six ARs (α(1A), α(1B), α(1D), β(1), β(2), and β(3)) and three GRKs (GRK2, GRK3, and GRK5) in left (LV) and right ventricle (RV) from four donors, 10 patients with ischemic cardiomyopathy (IC), 14 patients with dilated cardiomyopathy (DC), and 10 patients with nonischemic, nondilated cardiopathies (NINDC).
1874	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Baseline FMPP levels were measured in 186 consecutive acute ischemic stroke patients before tissue plasminogen activator treatment was administered.
1875	I. None	G. Marker	1	b-type natriuretic peptide	cardiomyopathy	Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
1876	G. Regulate	C. Cause	1	BMAL1	dilated cardiomyopathy	BMAL1 regulates mitochondrial fission and mitophagy through mitochondrial protein BNIP3 and is critical in the development of dilated cardiomyopathy.
1877	J. Inhibition	H. Benefit	1	LCN2	ischemic stroke	Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following ischemic stroke via inhibition of LCN2.
1878	F.1 Phosphorylation	E. Associate	1	LKB1	stroke	Phosphorylation of a major upstream regulator of AMPK, LKB1, was also induced in stroke brain.
1879	I. None	G. Marker	1	eosinophil cationic protein	coronary atherosclerosis	Eosinophil cationic protein: A new biomarker of coronary atherosclerosis.
1880	J. Inhibition	H. Benefit	1	PDE4	stroke	Nevertheless, recent investigations suggest PDE4 and PDE5 inhibitors to play a vital role in mitigating stroke symptoms by modulating signaling mechanisms in PDE pathway.
1881	I. None	A. Treat	1	tpa	ischemic stroke	The thrombolytic drug alteplase (tissue plasminogen activator or tPA) is the only treatment for acute ischemic stroke but its use is limited by several factors including short therapeutic window, selective efficacy, and subsequent haemorrhagic complications.
1882	D.1 Mutation	C. Cause	1	ACTA2	coronary artery disease	ACTA2 gene mutations cause a diversity of diffuse vasculopathies such as thoracic aortic aneurysms and dissections as well as occlusive vascular diseases, including premature coronary artery disease and ischemic stroke.
1883	A.1 Over-expression	H. Benefit	1	SOD1	cerebral ischemia	We have reported that overexpression of copper/zinc superoxide dismutase (SOD1) reduces apoptotic cell death by promoting the phosphatidylinositol 3-kinase (PI3-K)/Akt survival pathway after transient focal cerebral ischemia (tFCI).
1884	D.1 Mutation	C. Cause	1	ATM	ataxia telangiectasia	Ataxia telangiectasia (AT) is a chromosomal instability syndrome with autosomal recessive inheritance, it is caused by more than 500 mutations of the ATM gene, which is involved in the cellular response to DNA damage.
1885	A. Expression	E. Associate	1	t-pa	coronary artery disease	Patients with unstable coronary artery disease were randomly treated either with a combination therapy consisting of nitrates and calcium-channel blockers without or with addition of clinical grade heparin administered subcutaneously; in order to evaluate the effect of heparin treatment on the fibrinolytic system, tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) plasma levels were related to the clinical course of the disease.
1886	I. None	A. Treat	1	tissue plasminogen activator	stroke	Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
1887	G. Regulate	H. Benefit	1	GPR30	myocardial infarct	It suggested that GPR30 may improve cardiac function in female OVX mice by activating the PI3K/AKT pathway and reducing myocardial infarct size and fibrosis.
1888	D.1 Mutation	F. None	1	angiotensinogen	myocardial infarction	These genetic variants include: (1) angiotensin I converting enzyme deletion polymorphism in intron 16 (ACE I/D), reported to be associated with increased risk of myocardial infarction as well as left ventricular hypertrophy; (2) a point mutation in the angiotensinogen (Agt) gene resulting in a methionine to threonine substitution at residue 235 (M235T), reported to be associated with hypertension in Caucasians; and (3) an angiotensin receptor type I (ATR) A to C transition at bp 1166 (A1166C) which shows synergy with the deleterious effects of the ACE DD genotype in myocardial infarction.
1889	A.2 Under-expression	E. Associate	1	MYPT1	congestive heart failure	Congestive heart failure is associated with a decrease in LZ+ MYPT1 expression, which results in a decrease in the sensitivity to cGMP-mediated smooth muscle relaxation.
1890	I. None	A. Treat	0	tissue plasminogen activator	embolic stroke	In a rat embolic stroke (eMCAO) model, the effects of 100% normobaric hyperoxia (NBO) with delayed recombinant tissue plasminogen activator (tPA) administration on ischemic lesion size and safety were assessed by diffusion- and perfusion (PWI)-weighted magnetic resonance imaging.
1891	I. None	E. Associate	0	macrophage migration inhibitory factor	myocardial infarction	Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study.
1892	J. Inhibition	A. Treat	1	ACE	congestive heart failure	Angiotensin-I converting enzyme (ACE) inhibitors have provided a remarkable improvement in the treatment of patients with primary hypertension and congestive heart failure.
1893	L. Be regulated	H. Benefit	1	STAT1	ischemic stroke	These results suggest that paracrine factors inhibit p38 MAPK and JNK, and most likely by regulating their downstream targets, p53 and STAT1, to promote astrocyte survival associated with GFAP downregulation after ischemic stroke in vitro.
1894	D.1 Mutation	C. Cause	1	TNNT2	dilated cardiomyopathy	Dilated cardiomyopathy caused by a novel TNNT2 mutation-added value of genetic testing in the correct identification of affected subjects.
1895	I. None	C. Cause	1	ACTA2	coronary artery disease	The ACTA2 gene, which encodes the vascular smooth muscle cell (SMC)-specific isoform of alpha-actin, is known to cause TAADs and occlusive vascular diseases, including coronary artery disease and premature ischemic stroke.
1896	I. None	A. Treat	0	coenzyme Q10	heart failure	Coenzyme Q10 - A new player in the treatment of heart failure?
1897	D.1 Mutation	F. None	1	MYOZ1	familial dilated cardiomyopathy	Mutations in MYOZ1 as well as MYOZ2 encoding the calsarcins are not associated with idiopathic and familial dilated cardiomyopathy.
1898	I. None	A. Treat	1	tissue-type plasminogen activator	ischemic stroke	Although endovascular thrombectomy combined with recombinant tissue-type plasminogen activator is effective for treatment of acute ischemic stroke, regional disparities in implementation rates of those treatments have been reported.
1899	J. Inhibition	A. Treat	1	angiotensin converting enzyme	myocardial infarction	Orally active inhibitors of angiotensin converting enzyme (ACE) have made a major impact on the clinical therapy of hypertension, congestive cardiac failure and ventricular remodelling after myocardial infarction.
1900	D.1 Mutation	E. Associate	1	TTN	familial dilated cardiomyopathy	The prevalence of TTN mutations in patient with DCM, familial dilated cardiomyopathy (FDCM), and sporadic dilated cardiomyopathy (SDCM) was 0.17 (95% CI: 0.14-0.19), 0.23 (95% CI: 0.20-0.26), and 0.16 (95% CI: 0.12-0.21), respectively.
1901	G. Regulate	H. Benefit	1	SIRT1	heart failure	We investigated the mechanisms underlying resveratrol-mediated protection against heart failure in diabetic mice, with a focus on the role of sirtuin 1 (SIRT1) in regulating autophagic flux.
1902	I. None	B. Target	1	PLN	cardiomyopathy	Sarco(endo)plasmic reticulum Ca2+ ATPase and its regulatory protein phospholamban (PLN) are potential therapeutic targets for DMD cardiomyopathy owing to their key role in regulating intracellular Ca2+ cycling.
1903	J. Inhibition	H. Benefit	1	AT1R	heart failure	Blockade of AT1R signaling has been shown to alleviate hypertension and improve outcomes in patients with heart failure.
1904	J. Inhibition	H. Benefit	1	periostin	myocardial infarction	The inhibition of periostin by valsartan might especially contribute to its beneficial effects on cardiac remodeling after myocardial infarction.
1905	L. Be regulated	H. Benefit	1	ADAM17	acute myocardial infarction	MiR-26a-5p could target and regulate ADAM17, reduce the apoptosis of myocardial cells and the expression of inflammatory factors in acute myocardial infarction, and reduce the occurrence of oxidative stress.
1906	D.1 Mutation	E. Associate	1	factor V leiden	neonatal stroke	This patient, determined to be heterozygous for factor V Leiden, is the first reported case of neonatal stroke associated with this common mutation.
1907	A. Expression	C. Cause	1	hepcidin	intracerebral hemorrhage	Toll-Like Receptor 4/MyD88-Mediated Signaling of Hepcidin Expression Causing Brain Iron Accumulation, Oxidative Injury, and Cognitive Impairment After Intracerebral Hemorrhage.
1908	J. Inhibition	E. Associate	1	ASK1	cerebral ischemia	Taken together, we concluded that sodium orthovanadate could increase the tyrosine posphorylation of PTEN and further inhibit the activation of ASK1 via activating Akt during cerebral ischemia.
1909	J. Inhibition	A. Treat	1	ACE	dilated cardiomyopathy	This report describes a case of lisinopril overdose managed in part with an infusion of angiotensin II in a patient with dilated cardiomyopathy and reviews other literature reporting angiotensin-converting enzyme (ACE) inhibitor overdose.
1910	F.2 Methylation	E. Associate	1	peptidase M20 domain containing 1	stroke	After validating these data by MassArray Epityper, the promoter region of peptidase M20 domain containing 1 (PM20D1) gene was significantly hypermethylated in stroke patients.
1911	A.2 Under-expression	E. Associate	1	connexin 43	heart disease	Altered transcriptional control is likely to contribute to the down-regulation of connexin 43 (Cx43) expression observed in many forms of heart disease.
1912	I. None	A. Treat	1	tpa	stroke	Our aim was to correlate clinical recovery from stroke with the timing of arterial recanalization after therapy with intravenous tissue plasminogen activator (tPA).
1913	D.1 Mutation	E. Associate	1	TBX5	dilated cardiomyopathy	A novel TBX5 loss-of-function mutation associated with sporadic dilated cardiomyopathy.
1914	D.1 Mutation	C. Cause	1	GLA	stroke	Fabry disease (FD) is a multisystemic disorder with typical neurological manifestations such as stroke and small fiber neuropathy (SFN), caused by mutations of the alpha-galactosidase A (GLA) gene.
1915	J. Inhibition	A. Treat	1	P2Y12	coronary artery disease	Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
1916	I. None	B. Target	1	XO	heart failure	This review will summarize the recent evidence on XO as a novel and promising therapeutic target in heart failure.
1917	J. Inhibition	A. Treat	1	cyclic nucleotide phosphodiesterase	heart failure	Inhibitors of cyclic nucleotide phosphodiesterase (PDE) PDE3A have inotropic actions in human myocardium, but their long-term use increases mortality in patients with heart failure.
1918	D.1 Mutation	E. Associate	0	NEBL	cardiomyopathy	Since cardiomyopathies are commonly familial and because mutations in a single gene may result in variable phenotypes, we tested the hypothesis that NEBL mutations are associated with cardiomyopathy.
1919	D.1 Mutation	C. Cause	1	GYS1	sudden cardiac death	Identification of a novel mutation in GYS1 (muscle-specific glycogen synthase) resulting in sudden cardiac death, that is diagnosable from skin fibroblasts.
1920	J. Inhibition	A. Treat	1	angiotensin II	congestive heart failure	Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
1921	D.1 Mutation	E. Associate	0	MYL3	hypertrophic cardiomyopathy	In this study we have validated CAE-SSCP by 1) comparing detection by slab-gel based SSCP with CAE-SSCP of mutations in the MYH7, MYL2, and MYL3 genes encoding sarcomere proteins from patients suffering from hypertrophic cardiomyopathy; and 2) by constructing a series of 185 mutants having substitution mutations, as well as insertion/deletion mutations, or some combinations of these, in different sequence contexts in four exons and different positions relative to the end of the amplicon (three from the KCNQ1 gene, encoding a cardiac potassium channel, and one from the TNNI3 gene encoding cardiac troponin I).
1922	L.1 Up-regulation	C. Cause	1	osteopontin	heart failure	The most highly upregulated gene was osteopontin (47-fold increase; P=9.6×10(-45)), an inflammatory chemokine implicated in heart failure pathophysiology.
1923	N.1 Increase activity	E. Associate	1	PAI	coronary artery disease	Patients showed higher level of PAI activity, as well as plasma glucose, insulin, triglyceride, cholesterol and Apolipoprotein B levels than normal controls; highest values were observed with diabetic patients also affected by coronary artery disease.
1924	A.1 Over-expression	H. Benefit	1	BDNF	cerebral ischemia	EA combined with PGB can up-regulate the expression of BDNF and VEGF in the PVN of hypothalamus in cerebral ischemia rats, which might contribute to its effect in improving cerebral ischemia.
1925	G. Regulate	E. Associate	1	PDI	cardiovascular disease	In this review, we will discuss recent findings on the regulatory role of PDI in cardiovascular disease.
1926	J. Inhibition	E. Associate	0	PDE5	heart failure	Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure.
1927	A. Expression	E. Associate	0	sortilin	intracerebral hemorrhage	To observe the expressions of neurotrophin receptor homolog 2 (NRH2), nerve growth factor precursor (proNGF), sortilin and neurotrophin receptor p75 (p75NTR) in cerebral tissues around hematomas in the different periods after intracerebral hemorrhage, and explore their relationships to cell apoptosis.
1928	A. Expression	E. Associate	1	SAMSN1	myocardial infarction	In ST-segment elevation myocardial infarction (STEMI), a gene-by-gene analysis of the platelet gene expression identified five differentially expressed genes: FKBP5, S100P, SAMSN1, CLEC4E and S100A12.
1929	J. Inhibition	F. None	1	neprilysin	cardiac amyloidosis	Recent clinical trials with SGLT2 inhibitors, therapies targeting transthyretin cardiac amyloidosis, iron, angiotensin receptor blocker with neprilysin inhibition and newer mechanical circulatory support devices are very promising as practice changing new treatment strategies in prevention and treatment of heart failure.
1930	D.1 Mutation	C. Cause	1	MTHFR	stroke	Genotypic characteristics suggest that C(677)T MTHFR mutation confers a higher risk for stroke to both homozygous and heterozygous T allele carriers that cannot be ascribed solely to raised tHcy and/or lower folate status in CT subjects, nor to phenotypic expression of conventional risk factors for stroke.
1931	I. None	G. Marker	1	brain natriuretic peptide	heart failure	Brain natriuretic peptide (BNP) and the N-terminal fragment of the BNP precursor (NT-proBNP) are widely used as heart failure (HF) biomarkers.
1932	D.1 Mutation	F. None	1	HFE	coronary heart disease	In a population of moderately hypercholesterolaemic middle aged Scottish men who did not have any evidence of coronary heart disease at baseline, the presence of a C282Y mutation in the HFE gene did not predict the occurrence of coronary events over a mean follow up of 4.9 years.
1933	F.1 Phosphorylation	E. Associate	1	FHOD3	cardiomyopathy	In hearts of mice with LMNA mutation-induced cardiomyopathy, ERK1/2 mediated phosphorylation of FHOD3, an isoform highly expressed in cardiac tissue.
1934	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	To date, intravenous thrombolysis with tissue plasminogen activator up to 4.5 h after symptom onset is the only proven reperfusion therapy for acute ischemic stroke.
1935	D.1 Mutation	F. None	1	PIK3CA	sturge-weber syndrome	Numerous pathophysiogenetic mechanisms have been suggested such as venous dysplasia of the emissary veins in the intracranial circulation, neural crest alterations leading to alterations of autonomic perivascular nerves, mutation of the GNAO gene in the Sturge-Weber syndrome, PIK3CA mutation in malformative/overgrowth syndromes such as the Klippel-Trenaunay syndrome, and the twin-spotting phenomenon in phakomatosis pigmentovascularis.
1936	I. None	A. Treat	1	t-pa	myocardial infarction	Recently tissue plasminogen activator (t-PA) has been clinically applied to the thrombolytic therapy of myocardial infarction.
1937	A.1 Over-expression	E. Associate	1	platelet factor 4	myocardial infarction	In comparison with 44 healthy volunteers, the results have provided striking confirmation of 'hyperactive' platelets in the early phase of myocardial infarction expressed by the shorter bleeding time, increasing plasmatic beta-thromboglobulin, increased platelet factor 4 release and shorter heparin thrombin clotting time, and by the increased platelet sensitivity to threshold concentrations of adenosine diphosphate and collagen.
1938	L.1 Up-regulation	C. Cause	1	NCX	heart failure	Na(+) accumulation in the SERCA KO due to NCX upregulation and intracellular acidosis potentially play a role in the development of heart failure, by initiating a reinforcing cycle involving: a mismatch between ATP demand and supply; an increasingly compromised metabolism; a decreased pH(i); and, finally, an even greater [Na(+)](i) elevation.
1939	M.1 Knock down	E. Associate	1	p63	heart failure	Increased expression of cTnT and other marker genes was also observed in p63 knockdown human cardiac fibroblasts procured from patients undergoing procedures for heart failure.
1940	I. None	A. Treat	1	tissue plasminogen activator	embolic stroke	Tissue plasminogen activator may be of value for the immediate treatment of embolic stroke.
1941	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) is an effective treatment of acute ischemic stroke (AIS).
1942	J. Inhibition	E. Associate	1	TCR	dilated cardiomyopathy	The results show that anti-CD4 mAb is a powerful inhibitor of the early initiating events of T cell receptor (TCR) signal transduction in mouse autoimmune dilated cardiomyopathy.
1943	J. Inhibition	A. Treat	1	ACE	ischemic heart disease	The prognostic impact of NO resistance at vascular and platelet levels has been demonstrated in patients with ischemic heart disease, and it has been shown that a number of agents (angiotensin-converting enzyme [ACE] inhibitors, perhexiline, insulin, and possibly statins) ameliorate this anomaly.
1944	A. Expression	E. Associate	0	tissue plasminogen activator	ischemic cardiomyopathy	In this study explanted hearts of cardiac transplant recipients with ischemic cardiomyopathy and dilated cardiomyopathy, as well as control myocardial tissue, were investigated for expression of urokinase plasminogen activator, tissue plasminogen activator, urokinase plasminogen activator receptor, and plasminogen activator inhibitor 1 and 2.
1945	A.1 Over-expression	E. Associate	1	protein S	stroke	A decrease in functional antithrombin III and plasminogen and an increase in thrombin-antithrombin III complexes, total protein S, tissue plasminogen activator, plasminogen activator inhibitor and D-dimer were observed in the stroke group (p < 0.05).
1946	D.1 Mutation	C. Cause	1	GLA	fabry disease	Fabry disease (FD) is an X-linked lysosomal storage disorder caused by enzyme Alpha-Galactosidase A (α-Gal-A) deficiency, due mutations in GLA gene.
1947	I. None	A. Treat	1	tpa	ischemic stroke	Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
1948	J. Inhibition	A. Treat	1	thrombin	stroke	In the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, the direct thrombin inhibitor dabigatran etexilate was as an effective and safe as dose-adjusted warfarin for prevention of stroke in high-risk patients with atrial fibrillation.
1949	I. None	B. Target	1	GRK2	heart failure	Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade.
1950	A. Expression	E. Associate	1	omentin	coronary heart disease	Changes in omentin levels and its mRNA expression in epicardial adipose tissue in patients undergoing elective cardiac surgery: the influence of type 2 diabetes and coronary heart disease.
1951	I. None	G. Marker	1	myeloperoxidase	cardiovascular disease	Myeloperoxidase (MPO) has shown potential as a marker for cardiovascular disease.
1952	A. Expression	E. Associate	0	CD142	stroke	Serum levels of D-dimer and EVs expressing markers for cancer cells (epithelial cell adhesion molecule [CD326]), tissue factor (TF [CD142]), endothelial cells (CD31+CD42b-), and platelets (CD62P) were measured using flow cytometry in (a) 155 patients with ischemic stroke and active cancer (116 - cancer-related, 39 - conventional stroke mechanisms), (b) 25 patients with ischemic stroke without cancer, (c) 32 cancer patients without stroke, and (d) 101 healthy subjects.
1953	A. Expression	E. Associate	0	fibronectin	myocardial infarction	The expression of fibronectin in the repair process after myocardial infarction was studied using two protocols of coronary occlusion in the rabbit: a permanent occlusion or 3 h of occlusion followed by reperfusion (too late for salvage).
1954	A.1 Over-expression	E. Associate	1	CD137	stroke	Elevated plasma levels and monocyte-associated expression of CD137 ligand in patients with acute atherothrombotic stroke.
1955	I. None	F. None	1	TRPM4	heart failure	Evidence suggests that (a) upregulation of TRPC channels is involved in the development of cardiac hypertrophy and heart failure; (b) TRPC1, TRPC6, and TRPV2 play a role in the pathogenesis of cardiomyopathy associated with muscular dystrophy; (c) TRPC6 or TRPM4 is involved in the delayed after-depolarization; (d) TRPP2 is involved in the normal development of the interventricular and interatrial septa; and (e) neuronal TRPV1 acts as a detector of pain-producing stimuli.
1956	D.1 Mutation	C. Cause	1	ataxia telangiectasia mutated	ataxia telangiectasia	Ataxia telangiectasia (A-T), a rare autosomal recessive disorder characterized by progressive cerebellar degeneration and a greatly increased incidence of cancer among other symptoms, is caused by a defective or missing ataxia telangiectasia mutated (ATM) gene.
1957	J. Inhibition	A. Treat	1	angiotensin converting enzyme	heart failure	Chronic RAAS activation is an indirect or direct target of most effective pharmacological treatments in heart failure, such as beta-blockers, inhibitors of angiotensin converting enzyme, angiotensin receptor blockers, direct renin inhibitors, and mineralocorticoid receptor blockers.
1958	J. Inhibition	A. Treat	1	ACE	heart failure	Thus, long-term therapy with a combination of ACE inhibition and ET antagonism may provide a new approach for heart failure in humans.
1959	I. None	E. Associate	0	CRP	cardiovascular disease	In light of the associations among inflammatory biomarkers, obesity, platelet function, and cardiovascular disease, we sought to examine the relationships of C-reactive protein (CRP) and interleukin-6 (IL-6) to the expression of key inflammatory transcripts in platelets.
1960	D.1 Mutation	E. Associate	1	MTHFR	congenital heart disease	We present these cases and highlight the implications of MTHFR mutation in the management of complex congenital heart disease.
1961	I. None	C. Cause	1	tissue-type plasminogen activator	intracerebral hemorrhage	Thus far, recombinant tissue-type plasminogen activator (rtPA), the only approved treatment for acute ischemic stroke, increases the risk of intracerebral hemorrhage and is poorly efficient in disaggregating platelet-rich thrombi.
1962	J. Inhibition	A. Treat	1	ACE	heart failure	Although pharmacological therapy with angiotensin converting enzyme (ACE) inhibitors has proved to be effective in patients with heart failure (HF), the experimental basis of this effect has not yet been addressed.
1963	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Thrombolysis with recombinant tissue plasminogen activator (rt-PA) is currently the only approved acute therapy for ischemic stroke.
1964	I. None	B. Target	1	CX3CR1	coronary artery disease	The results suggest a coordinated mechanism for inflammatory cell accumulation in plaque and identify novel targets, such as CCR2 and CX3CR1, for potential drug development in coronary artery disease.
1965	I. None	E. Associate	0	fibrinogen	acute myocardial infarction	Studies on the functionality of newly synthesized fibrinogen after treatment of acute myocardial infarction with streptokinase, increase in the rate of fibrinopeptide release.
1966	I. None	G. Marker	1	MHRT	chronic heart failure	We concluded that circulating lncRNA MHRT might serve as a diagnostic and prognostic marker for chronic heart failure treatment.
1967	J. Inhibition	A. Treat	1	mineralocorticoid receptor	heart failure	Although antagonists of mineralocorticoid receptor (MR) have been widely used to treat heart failure, the underlying mechanisms are incompletely understood.
1968	J. Inhibition	A. Treat	1	ACE	cardiovascular morbidity	Today, angiotensins-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists have clearly demonstrated their efficacy in preventing target organ damage and in reducing cardiovascular morbidity and mortality in ischemic heart disease (IHD).
1969	J. Inhibition	A. Treat	1	PDE5	stroke	Sildenafil, a type 5 phosphodiesterase isoenzyme (PDE5) inhibitor with a short half-life, increases brain cyclic guanosine monophosphate (cGMP) levels and improves neurological functional recovery when administered after stroke.
1970	I. None	A. Treat	1	tpa	ischemic stroke	Late treatment with tissue plasminogen activator (tPA) leads to reperfusion injury and poor outcome in ischemic stroke.
1971	I. None	B. Target	1	NR1	psychiatric illness	The NMDAR contains a D-serine/glycine site on the NR1 subunit that may be a promising therapeutic target for psychiatric illness.
1972	D.1 Mutation	E. Associate	0	MTM1	myotubular myopathy	Specific findings of congenital myotubular myopathy and partial CMD, such as peripheral halo of muscle fibers, were demonstrated in biopsied muscle, and mutation of the myotubularin (MTM1) gene was identified.
1973	D.1 Mutation	E. Associate	0	prothrombin	ischemic stroke	We examined the prevalence of factor V Leiden, the prothrombin G20210A genotype, and the C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene in 100 patients (51 males and 49 females) who survived an ischemic stroke without a cardiac embolic source at an age < or = 45 years, and in 238 healthy control subjects from the same geographic area.
1974	F.1 Phosphorylation	E. Associate	1	prb	cerebral ischemia	We found that Cdc25A is activated in neurons undergoing ischemic stress mediated by hypoxia in vitro and global cerebral ischemia in rats in vivo We show that pharmacologic or genetic inhibition of Cdc25A activity protects neurons from delayed death in vitro and in vivo Downregulation of Cdc25A led to reduction in retinoblastoma tumor suppressor protein (pRb) phosphorylation.
1975	I. None	H. Benefit	1	interleukin-2	cardiovascular disease	Intriguingly, interleukin-2 has emerged as a common cytokine, which can be harnessed to upregulate both cell types, and also has important translational consequences as clinical trials are ongoing for its use in cardiovascular disease.
1976	L.2 Down-regulation	E. Associate	1	BRM	stroke	At 7 days post-transplantation, quantification of the fluorescent staining intensity in the cortex and striatum revealed significant upregulation of the endothelial marker RECA1 and a downregulation of the stroke-associated vasculome BRM, IKB, Foxf1, ITIH-5 and PMCA2 in the ipsilateral side of cortex and striatum of EPC-transplanted stroke animals relative to vehicle-treated stroke animals.
1977	H. Other	E. Associate	1	insulin	cardiovascular disease	Therefore, in patients with diabetes or insulin resistance, endothelial dysfunction may be a critical early target for preventing atherosclerosis and cardiovascular disease.
1978	L. Be regulated	C. Cause	1	tanis	cardiovascular disease	In addition, Tanis was postulated as a hepatic receptor for an inflammatory marker, serum amyloid A-1 (SAA1), which represents a risk factor for cardiovascular disease.
1979	I. None	G. Marker	0	ADM	myocardial infarction	Newly discovered circulating peptides, N-terminal pro-brain natriuretic peptide (N-BNP) and adrenomedullin (ADM), were examined for prediction of cardiac function and prognosis and compared with previously reported markers in 121 patients with myocardial infarction.
1980	I. None	H. Benefit	0	tissue plasminogen activator	myocardial infarction	Furthermore, data on late patency from the largest study, Global Utilization of Steptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO-I), failed to confirm independent benefits of an open infarct-related artery 1 year after myocardial infarction.
1981	J. Inhibition	A. Treat	1	CETP	cardiovascular disease	Inhibition of CETP raises HDL cholesterol and may potentially be used to treat cardiovascular disease.
1982	J. Inhibition	A. Treat	1	thrombin	stroke	Dabigatran, an oral direct thrombin inhibitor, is frequently used in treatment of venous thromboembolism and prevention of stroke in non-valvular atrial fibrillation.
1983	A. Expression	E. Associate	0	insulin	stroke	Nonfasting serum glucose and insulin concentrations and the risk of stroke.
1984	J. Inhibition	A. Treat	1	protein tyrosine phosphatase 1B	heart failure	Moreover, new approaches have been recently developed to specifically target the endothelial NO production, for example via inhibition of protein tyrosine phosphatase 1B, that may ultimately lead to new treatment of heart failure based on endothelial protection.
1985	J. Inhibition	A. Treat	1	PCSK9	cardiovascular disease	This secondary ad hoc analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial compared randomized treatments in 2 subgroups of patients with stable atherosclerotic cardiovascular disease currently receiving statin.
1986	I. None	H. Benefit	1	erythropoietin	cardiovascular morbidity	Partial correction of anaemia with recombinant human erythropoietin (epoetin) treatment has been recognized as a significant step forward in decreasing left ventricular mass and improving cardiovascular morbidity and mortality.
1987	A. Expression	E. Associate	0	fibrinogen	coronary heart disease	[Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations].
1988	J. Inhibition	A. Treat	1	P2Y12	TIA	We searched randomized trials evaluating clinical outcome with aspirin plus a P2Y12 inhibitor versus SAPT in patients with noncardioembolic stroke or TIA.
1989	A. Expression	E. Associate	1	GLAST	subarachnoid hemorrhage	In the present report, we demonstrate the different expression of EAAT4 and GLAST in the pathologic condition, neonatal subarachnoid hemorrhage.
1990	I. None	C. Cause	1	angiotensin II	cardiovascular disease	Aliskiren could therefore be used primarily with young patients, Caucasians, persons with ACEI intolerance, and also in diseases where angiotensin II is involved in the pathogenesis and the secondary prevention of cardiovascular disease.
1991	N.2 Decrease activity	E. Associate	1	CAT	stroke	BR postconditioning prevented the release of MnSOD from the mitochondria and reduced the activity of the total SOD and CAT if it is administrated short time after stroke.
1992	I. None	E. Associate	1	fibrinogen	cardiovascular disease	The impact of fibrinogen value, considered as a separate variable, on cardiovascular disease was comparable with the major risk factors, such as blood pressure, hematocrit, adiposity, cigarette smoking, and diabetes.
1993	D.1 Mutation	E. Associate	0	TIMM50	cardiomyopathy	Whole-exome sequencing identified compound heterozygous mutations in TIMM50 (c.[341G>A];[805G>A]) in a boy with West syndrome, optic atrophy, neutropenia, cardiomyopathy, Leigh syndrome, and persistent 3-MGA-uria.
1994	D.1 Mutation	E. Associate	0	FBN1	ventricular arrhythmia	Observational cohort study of ventricular arrhythmia in adults with Marfan syndrome caused by FBN1 mutations.
1995	J. Inhibition	A. Treat	1	factor xa	stroke	We aimed to determine whether the primary efficacy (stroke or systemic embolism) and safety (major bleeding and nonmajor clinically relevant bleeding) end points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation trial) differed among participants with WRF taking rivaroxaban and those taking warfarin.
1996	I. None	C. Cause	1	tissue plasminogen activator	intracerebral haemorrhage	The use of intravenous recombinant tissue plasminogen activator, alteplase, at a dose of 0.9 mg/kg is an effective treatment for patients with acute ischaemic stroke; this dose is also associated with high intracerebral haemorrhage rates.
1997	J. Inhibition	A. Treat	1	factor X	unstable angina	Heparins inhibit thrombin and factor X and therefore may have useful effects on arterial and venous thrombosis; they are effective in the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and in the prevention of myocardial infarction (MI) in patients with unstable angina.
1998	D.5 Polymorphism	E. Associate	1	CYP3A5	heart failure	Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.
1999	I. None	C. Cause	1	ANGPTL4	ischemic stroke	It has been found, however, that angiopoietin-like protein 4 (ANGPTL4), a protein expressed in vascular endothelial cells, plays a role in the pathophysiology of atherosclerosis and may therefore be involved in ischemic stroke.
2000	D.1 Mutation	C. Cause	1	PKP2	heart failure	One patient, heterozygous for a PKP2 nonsense mutation, developed severe heart failure and underwent cardiac transplantation.
2001	I. None	A. Treat	1	tissue plasminogen activator	stroke	American Heart Association/American Stroke Association guidelines recommend initiating treatment with IV tissue plasminogen activator (tPA) in acute ischemic stroke patients without suspected coagulopathy prior to availability of clotting results; however, little or no data support this practice.
2002	I. None	C. Cause	1	FABP4	coronary artery disease	Both clinical and experimental evidence have identified FABP4 as a relevant player in atherosclerosis and coronary artery disease, and it has been directly related to cardiac alterations such as left ventricular hypertrophy (LVH) and both systolic and diastolic cardiac dysfunction.
2003	A.1 Over-expression	C. Cause	1	tumor necrosis factor alpha	coronary artery disease	Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1.
2004	I. None	G. Marker	1	c-reactive protein	cardiovascular disease	C-reactive protein (CRP), a sensitive marker of inflammation, is an independent predictor of future cardiovascular disease (CVD), which is a major cause of death worldwide.
2005	A. Expression	E. Associate	0	HDL	coronary heart disease	To determine whether alterations in lipoprotein phospholipid composition might be an unrecognized factor that contributes to the unexplained acceleration of atherogenesis and the loss of sex-related protection from the development of coronary heart disease in women with insulin-dependent diabetes mellitus, we have estimated levels of neutral lipids, apolipoproteins (A-I, A-II, B), and free cholesterol (FC) in plasma and the four major phospholipid constituents of the very low-density lipoprotein + low-density lipoprotein and high-density lipoprotein (HDL) fractions in 12 ambulatory female patients with varying degrees of diabetic control.
2006	D.1 Mutation	E. Associate	1	NF1	heart disease	Prevalence, Type, and Molecular Spectrum of NF1 Mutations in Patients with Neurofibromatosis Type 1 and Congenital Heart Disease.
2007	I. None	H. Benefit	1	apocynin	stroke	The neuroprotective effects of apocynin have been investigated in numerous brain injury settings, such as stroke, traumatic brain injury (TBI), and epilepsy.
2008	D.1 Mutation	C. Cause	0	DST	arteriopathy	These neurological symptoms may also be due to DST gene mutation, although he has a concomitant diagnosis of CADASIL (cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy), a cerebral small-vessel arteriopathy, which thus complicates the genotype-phenotype interpretation.
2009	N.1 Increase activity	E. Associate	1	myeloperoxidase	myocardial infarction	The fact that increased myeloperoxidase activity and the enhanced response to Sudan black B persist through 14 days of the disease, coupled with a rise in neutrophil NAG activity on day 14, expands possibilities of myocardial infarction diagnosis.
2010	H. Other	C. Cause	1	insulin	cardiovascular disease	Chronic overnutrition and lack of physical activity result in excess deposition of adipose tissue and insulin resistance, which plays a key role in the pathophysiology of type 2 diabetes mellitus (DM2) and associated cardiovascular disease (CVD).
2011	I. None	G. Marker	1	c-reactive protein	coronary artery disease	Over the past few years, a flurry of data in the medical literature has strongly implicated C-reactive protein (CRP) as a marker of inflammation in coronary artery disease (CAD).
2012	A. Expression	G. Marker	1	BNP	heart failure	The expression of BNP correlated most closely with the expression of proenkephalin and follistatin 3, which may constitute additional heart failure markers.
2013	A. Expression	E. Associate	1	CD44	cerebral ischemia	In the present study, we demonstrated that the expression of CD44 mRNA was induced in a mouse model of cerebral ischemia.
2014	M.2 Knock in	A. Treat	1	FGF4	ischemic heart disease	Gene or protein therapy delivering VEGF, FGF2 or FGF4, as well as cell therapy using endothelial progenitor cells (EPCs), mesenchymal stem cells (MSCs) or induced pluripotent stem cells (iPSCs) have been developed as pro-angiogenic therapeutics for ischemic heart disease and peripheral vascular disease.
2015	A. Expression	E. Associate	0	BNIP3	cerebral ischemia	Expression of the gene encoding the pro-apoptotic BNIP3 protein and stimulation of hypoxia-inducible factor-1alpha (HIF-1alpha) protein following focal cerebral ischemia in rats.
2016	A.1 Over-expression	C. Cause	1	PTH	heart failure	Alterations in mineral metabolism, such as high phosphorus, high parathyroid hormone (PTH), and high fibroblast growth factor-23 (FGF-23) have been identified as potential risk factors for heart failure (HF).
2017	A. Expression	B. Target	1	MHRT	hypertensive heart disease	Our data reveal that the lncRNAs MHRT, FENDRR and CARMEN show distinct expression profiles in hypertensive patients and they possibly represent candidate therapeutic targets in hypertensive heart disease.
2018	N. Activity	E. Associate	1	parvalbumin	stroke	Reversed alterations of hippocampal parvalbumin and protein kinase C-gamma immunoreactivity after stroke in spontaneously hypertensive stroke-prone rats.
2019	H. Other	E. Associate	1	HDL	coronary artery disease	The efflux capacity of high-density lipoprotein (HDL) with cultured macrophages associates strongly and negatively with coronary artery disease status, indicating that impaired sterol efflux capacity might be a marker-and perhaps mediator-of atherosclerotic burden.
2020	I. None	H. Benefit	1	vps34	hypertrophic cardiomyopathy	Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy.
2021	M.2 Knock in	H. Benefit	1	CYP2J2	heart failure	Interestingly, transgenic (Tr) mice with cardiomyocyte-specific CYP2J2 expression were protected against heart failure compared with wild-type mice.
2022	H. Other	F. None	1	TBC1D1	heart failure	Mitochondrial respiratory capacity and substrate sensitivity to pyruvate and ADP were not altered by diet or TBC1D1 ablation, nor were markers of oxidative stress, or indexes of overt heart failure.
2023	I. None	E. Associate	1	inducible NO synthase	cardiovascular disease	In other animal models of cardiovascular disease, inflammatory alterations have been described that can contribute to microvascular endothelial dysfunction and reactive oxygen species, neutrophils, tumour necrosis factor-alpha, and inducible NO synthase are among the mediators that have been incriminated.
2024	A. Expression	H. Benefit	1	myelin basic protein	cerebral ischemia	The neuroprotective effect of picroside II via regulating the expression of myelin basic protein after cerebral ischemia injury in rats.
2025	I. None	H. Benefit	1	exendin-4	myocardial infarction	PEGylated exendin-4, a modified GLP-1 analog exhibits more potent cardioprotection than its unmodified parent molecule on a dose to dose basis in a murine model of myocardial infarction.
2026	I. None	E. Associate	1	c-reactive protein	coronary artery disease	C-reactive protein (CRP) has been implicated in the regulation of inflammation underlying coronary artery disease; however, little is known about the molecular mechanisms responsible for the expression of its pro- or anti-inflammatory activities.
2027	I. None	A. Treat	1	ADAMTS13	ischemic stroke	These data show for the first time a potent thrombolytic activity of ADAMTS13 in the setting of stroke, which might become useful in treatment of acute ischemic stroke.
2028	G. Regulate	A. Treat	1	EPO	ischemic stroke	These results provide evidence that low dose EPO treatment via MCAI provides neuroprotection following acute ischemic stroke by inhibiting the ER stress response.
2029	I. None	C. Cause	1	ACE	cardiovascular disease	Tissue angiotensin-converting enzyme (ACE) plays a central role in regulating processes that contribute to endothelial function and cardiovascular disease.
2030	N. Activity	E. Associate	0	tissue plasminogen activator	acute myocardial infarction	Plasma levels of tissue plasminogen activator (tPA) antigen, tPA activity and plasminogen activator inhibitor (PAI) activity were determined in 40 cases of acute myocardial infarction (AMI) at the onset and 2-4 weeks after the onset of the disease.
2031	D.5 Polymorphism	E. Associate	0	coagulation factor VII	myocardial infarction	[The coagulation factor VII gene polymorphisms in patients with myocardial infarction in Ningxia Hui and Han populations].
2032	D.1 Mutation	H. Benefit	0	APC	ischemic stroke	Using these strains, we determined whether or not recombinant murine signaling-selective APC mutants would reduce septic death or provide neuroprotection against ischemic stroke when mice carried PAR1-homozygous mutations that prevent cleavage at either R41 or R46.
2033	D.1 Mutation	E. Associate	1	MYH7	hypertrophic cardiomyopathy	The MYH7 tail domain mutation results in an inclusion body myopathy with an apparent absence of hypertrophic cardiomyopathy usually associated with mutations of this gene.
2034	D.1 Mutation	E. Associate	0	HFE	myocardial infarction	To test whether genetic haemochromatosis is associated with myocardial infarction, we determined the prevalence of three mutations in the HFE gene (Cys282Tyr, His63Asp and Ser65Cys) in a 2 : 1 case-control study including 177 patients who survived an acute myocardial infarction and 89 controls.
2035	J. Inhibition	A. Treat	1	ACE	heart failure	This 3-part discussion of captopril, the first oral angiotensin converting enzyme (ACE) inhibitor, focuses on the clinical use and superiority of this agent to standard treatments and the new observations that use can improve the overall poor survival associated with heart failure.
2036	A.1 Over-expression	E. Associate	1	FSTL1	heart failure	The aim of this work is to detect highly expressed genes: follistatin-related protein 1 (FSTL1) in heart failure within 30 minutes, using gold nanoparticles.
2037	H. Other	C. Cause	1	MD1	ventricular arrhythmia	Therefore, loss of MD1 exacerbated myocardial I/R injury and increased the susceptibility to ventricular arrhythmia, both of which are possibly related to the up-regulation of TLR4/NF-κB signaling pathway.
2038	A.1 Over-expression	F. None	1	PLC	ischemic heart disease	Hence, while CB2, PLC and PKC, ERK1/2, and eNOS are more strongly expressed in patients without ischemic heart disease, high CB1 and PKA expression is associated with low survival intracellular pathway activation and high iNOS activation in ischemic heart disease patients.
2039	D.1 Mutation	C. Cause	1	methylenetetrahydrofolate reductase	cardiovascular disease	A common mutation in methylenetetrahydrofolate reductase (MTHFR), a homocysteine metabolic pathway enzyme, has been associated with increased homocysteine levels and increased risk for premature cardiovascular disease.
2040	D.1 Mutation	E. Associate	1	MYBPC3	hypertrophic cardiomyopathy	Two novel mutations of the MYBPC3 gene identified in Chinese families with hypertrophic cardiomyopathy.
2041	A.2 Under-expression	E. Associate	1	CD94	myocardial infarction	In myocardial infarction group, the mRNA expressions of six inhibitory receptors KIR2DL2, KIR3DL3, CD94, NKG2A, KLRB1, KLRG1, and eight activating receptors KIR2DS3, KIR2DS5, NKp30, NTB-A, CRACC, CD2, CD7 and CD96 were significantly down-regulated (P<0.05) compared with both angina patients and the controls.
2042	A.1 Over-expression	E. Associate	0	CD18	ischemic stroke	The purpose of the present pilot study is to delineate whether the expression of leukocyte adhesion molecules, CD11a and CD18, are upregulated in patients with ischemic stroke and transient ischemic attack.
2043	J. Inhibition	H. Benefit	1	TRAF6	cardiomyopathy	Therefore, miR-23b improved sepsis-induced cardiomyopathy by attenuating the inflammatory response, suppressing apoptosis, and preventing NF-κB activation via targeted inhibition of TRAF6 and IκκB.
2044	A. Expression	C. Cause	1	ANRIL	coronary artery disease	Our thorough genomic characterization of 9p21.3 suggests common variants likely account for observed disease associations and provides further support for the hypothesis that complex regulatory variation affecting ANRIL and CDKN2B gene expression may contribute to increased risk for clinically apparent and subclinical coronary artery disease and aortic disease.
2045	I. None	G. Marker	1	growth differentiation factor-15	cardiovascular disease	Growth differentiation factor-15 (GDF-15) has been identified as a strong marker of cardiovascular disease; however, no data are available concerning the role of GDF-15 in the occurrence of organ dysfunction during coronary artery bypass grafting (CABG) associated with cardiopulmonary bypass (CPB).
2046	J. Inhibition	A. Treat	1	ACE	chronic congestive heart failure	Imidapril hydrochloride (imidapril) is a long-acting, non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor, which has been used clinically in the treatment of hypertension, chronic congestive heart failure (CHF), acute myocardial infarction (AMI), and diabetic nephropathy.
2047	A.1 Over-expression	E. Associate	1	FHOD1	dilated cardiomyopathy	Finally, we show that in contrast to FHOD3, FHOD1 shows increased expression levels in dilated cardiomyopathy, suggesting that the two formins play distinct roles and are differentially regulated in cardiomyocytes.
2048	I. None	G. Marker	1	copeptin	ischemic stroke	Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis.
2049	A.1 Over-expression	H. Benefit	1	HDL	cardiovascular disease	An acute dose of low calorie, high polyphenol cranberry beverage improved antioxidant status, while 8 week daily consumption reduced cardiovascular disease risk factors by improving glucoregulation, downregulating inflammatory biomarkers, and increasing HDL cholesterol.
2050	H. Other	E. Associate	1	von willebrand factor	acute myocardial infarction	Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction.
2051	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke.
2052	A. Expression	E. Associate	0	CAA	chronic heart failure	The purpose of this study was to examine the sarcoplasmic reticulum (SR) Ca(2+)-uptake and the expression of phospholamban (PLB) and Ca(2+)-ATPase (CAA) in left ventricular (LV) and right ventricular (RV) myocardium of 6 normal (NL) dogs and 6 dogs with chronic heart failure (HF).
2053	J. Inhibition	A. Treat	1	angiotensin converting enzyme	chronic heart failure	New agents for treating chronic heart failure include angiotensin converting enzyme (ACE) inhibitors, betablockers and phosphodiesterase inhibitors.
2054	A.1 Over-expression	E. Associate	1	HDL	coronary heart disease	Early identification of high Lp(a) levels may be of importance for two groups, (1) black females who have a 20% higher coronary heart disease mortality rate than white females in spite of significantly higher HDL levels; and (2) for black males and black females who have a prevalence of cerebrovascular disease twice as high as in whites.
2055	D.1 Mutation	E. Associate	1	MTM1	myotubular myopathy	MTM1 gene mutations in Japanese patients with the severe infantile form of myotubular myopathy.
2056	I. None	A. Treat	1	tissue plasminogen activator	stroke	Despite extensive research, treatments for clinical stroke are still limited only to the administration of tissue plasminogen activator and the recent introduction of mechanical thrombectomy, which can be used in only a limited proportion of patients due to time constraints.
2057	J. Inhibition	E. Associate	1	TWIST1	dilated cardiomyopathy	TWIST1 was repressed in patients with dilated cardiomyopathy by 43% (p=0.003), while Id1 expression was unchanged.
2058	L. Be regulated	H. Benefit	1	PDCD4	myocardial infarction	Overexpression of microRNA-145 protects against rat myocardial infarction through targeting PDCD4.
2059	D.1 Mutation	G. Marker	1	MYBPC3	cardiac failure	Therefore, 25 bp deletion in MYBPC3 may represent a genetic marker for cardiac failure in CAD patients from Southeast Asia.
2060	D.1 Mutation	F. None	1	alpha-galactosidase A	fabry disease	Lyso-Gb3 Indicates that the Alpha-Galactosidase A Mutation D313Y is not Clinically Relevant for Fabry Disease.
2061	J. Inhibition	E. Associate	1	PDE	cardiovascular injury	However, the PDE inhibitors acutely increased blood pressure and heart rate, whereas heart rate variability remained higher till the end of experiment and correlated well with markers of cardiovascular injury.
2062	M.2 Knock in	A. Treat	0	hepatocyte growth factor	heart failure	Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial.
2063	M.1 Knock down	C. Cause	1	BAG3	cardiomyopathy	BAG3 ablation in mice results in a lethal cardiomyopathy soon after birth and mutations of this gene have been associated with different cardiomyopathies including stress-induced Takotsubo cardiomyopathy (TTC).
2064	I. None	A. Treat	1	tissue-type plasminogen activator	ischemic stroke	Thrombolytic therapy of ischemic stroke with tissue-type plasminogen activator (tPA) improves clinical outcome which may, however, be partially offset by significant intracerebral bleeding (ICB).
2065	A.1 Over-expression	E. Associate	1	CD62P	ischemic stroke	Blood levels of ICAM-1 and CD62P expression in ischemic stroke patients were significantly higher than those in healthy subjects (P < 0.01).
2066	D.1 Mutation	H. Benefit	1	phospholamban	heart failure	Ablation or inhibition of phospholamban (PLN) has favorable effects in several genetic murine dilated cardiomyopathies, and we showed previously that a pseudophosphorylated form of PLN mutant (S16EPLN) successfully prevented progressive heart failure in cardiomyopathic hamsters.
2067	J. Inhibition	H. Benefit	1	ACE	acute myocardial infarction	Studies have shown that angiotensin converting enzyme (ACE) inhibition prevents left ventricular remodeling and cardiovascular events after an acute myocardial infarction.
2068	J. Inhibition	A. Treat	1	angiotensin converting enzyme	cardiac insufficiency	[Treatment of chronic congestive cardiac insufficiency with an orally active inhibitor of the angiotensin converting enzyme (Captopril)].
2069	D.1 Mutation	E. Associate	1	NEXN	heart failure	To evaluate the role of nexilin in human heart failure, we performed a genetic association study on individuals with dilated cardiomyopathy and found several mutations in NEXN associated with the disease.
2070	I. None	H. Benefit	1	CBX	cerebral ischemia	Our findings indicated that central microinjection of CBX has protective effect on against ischemic reperfusion injuries in a transient model of focal cerebral ischemia.
2071	I. None	G. Marker	1	BNP	heart failure	Brain natriuretic peptide (BNP) was a marker for heart failure and cardiac wall tension.
2072	A. Expression	E. Associate	0	ERBB1	ischemic heart disease	Human myocardial tissues were obtained from ischemic heart disease patients and normal control patients to compare ERBB1 expression.
2073	J. Inhibition	A. Treat	1	ACE	heart failure	Physicians can have a major impact on this disease by using effective agents for the treatment of heart failure (particularly angiotensin-converting enzyme [ACE] inhibitors and beta blockers), yet the actual clinical use of these drugs (especially the use of beta blockers by primary physicians) is disappointingly low.
2074	I. None	A. Treat	1	TTPA	myocardial infarct	[Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases].
2075	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) for acute ischemic stroke (AIS) is contraindicated in patient taking either Factor Xa inhibitors or direct thrombin inhibitors.
2076	J. Inhibition	H. Benefit	1	AQP4	ischemic stroke	Melatonin confers neuroprotection by protein kinase C mediated AQP4 inhibition in ischemic stroke.
2077	A. Expression	E. Associate	0	arginine vasopressin	intracerebral hemorrhage	Neurohypophysial arginine vasopressin (AVP) concentrations were determined by RIA in 9 patients with cerebral infarction, 11 patients with intracerebral hemorrhage, 5 patients with subarachnoid hemorrhage and 5 control subjects.
2078	L.2 Down-regulation	H. Benefit	1	P53	vascular dementia	Our previous work has demonstrated that piracetam inhibited the decrease in amino acid content induced by chronic hypoperfusion, ameliorated the dysfunction of learning and memory in a hypoperfusion rat model, down-regulated P53, and BAX protein, facilitated the synaptic plasticity, and may be helpful in the treatment of vascular dementia.
2079	D.5 Polymorphism	E. Associate	1	il-1ra	rheumatic heart disease	In the Brazilian population, the polymorphism of the IL-1ra gene is a relevant factor for rheumatic heart disease severity.
2080	A.2 Under-expression	H. Benefit	1	CAM	ventricular arrhythmia	Citrate can reduce myocardial cell apoptosis, alleviating ventricular arrhythmia and protecting the myocardium by reducing serum calcium ion concentration and downregulating caspase-3 and CAM expression.
2081	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Treatment with recombinant tissue plasminogen activator alters the microRNA expression profiles in mouse brain after acute ischemic stroke.
2082	L.1 Up-regulation	E. Associate	1	MMP9	cerebral ischemia	MiR-21 involve in ERK-mediated upregulation of MMP9 in the rat hippocampus following cerebral ischemia.
2083	A.2 Under-expression	E. Associate	1	GPR30	cerebral ischemia	The results of the present study revealed that downregulation of GPR30 expression may attenuate the neuroprotection of E2 within LTED conditions in rats post‑ovariectomy by leading to neuronal insensitivity to E2 neuroprotection following cerebral ischemia.
2084	E. Pathway	H. Benefit	1	IGF1R	cerebral ischemia	Based on our findings, GF1-induced activation of the IGF-1/IGF1R pathway to promote angiogenesis is an effective approach to alleviate cerebral ischemia, and GF1 is a potential agent that improves cerebrovascular function and promotes recovery from ischemic stroke.
2085	C. Activation	C. Cause	1	sulfonylurea receptor 1	subarachnoid hemorrhage	Sulfonylurea receptor 1 (Sur1) is a transmembrane protein that, when activated in the central nervous system, allows for unregulated sodium influx into cells, a process that has been linked to cytotoxic edema formation in ischemic stroke, subarachnoid hemorrhage, spinal cord injury, traumatic brain injury, and, most recently, brain metastases.
2086	E. Pathway	H. Benefit	1	JNK3	stroke	Taken together, our results implied that Akt-mediated phosphorylation of nNOS is involved in the neuroprotection of ATV against ischemic brain injury via suppressing JNK3 signaling pathway that provide a new experimental foundation for stroke therapy.
2087	A.1 Over-expression	H. Benefit	1	NMNAT1	ischemic stroke	In addition, NMNAT1 overexpression could reduce brain infarction size and improve behavioral outcomes in mice with ischemic stroke.
2088	I. None	G. Marker	1	CRP	cardiovascular disease	Serum C-reactive protein (CRP) has been identified in prospective epidemiological research as an independent risk marker for cardiovascular disease.
2089	I. None	G. Marker	1	CPK	myocardial infarction	Creatine phosphokinase (CPK) and creatine kinase-MB (CK-MB) have been used extensively as diagnostic markers for myocardial infarction and skeletal muscle injury.
2090	F.2 Methylation	E. Associate	0	PON2	cerebral infarction	This study explored the association of the promoter methylationof PON family genes (PON1, PON2 and PON3) with the risk of cerebral infarction.
2091	A.1 Over-expression	E. Associate	1	catalase	heart failure	Increased oxidative stress in human end-stage heart failure may result in a specific upregulation of catalase gene expression as a compensatory mechanism, whereas SOD and GPX gene expression remain unaffected.
2092	D.1 Mutation	C. Cause	1	NOTCH3	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	Mutations in the NOTCH3 gene are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary angiopathy leading to strokes and dementia.
2093	I. None	A. Treat	1	agalsidase beta	fabry disease	Fabry disease is a rare, X-linked, inherited lysosomal storage disorder that can be treated with the enzymes agalsidasealfa (Replagal) and agalsidase beta (Fabrazyme).
2094	I. None	E. Associate	1	HDL	myocardial infarction	The addition of HDL or either of its subfractions to the multivariate model substantially reduced the inverse association between alcohol intake and myocardial infarction, whereas the addition of the other plasma lipid measurements did not materially alter the relation.
2095	J. Inhibition	H. Benefit	1	cathepsin B	cerebral ischemia	Taken together, our results indicate that DMBC can offer neuroprotective effects against cerebral ischemia with an extended therapeutic window and its mechanism might be associated with inhibition of the cathepsin B activation.
2096	I. None	G. Marker	1	copeptin	heart failure	The main clinical scenarios where copeptin has been studied as a biomarker are: early rule-out of myocardial infarction in patients with acute chest pain, diagnosis of heart failure in patients with acute dyspnea and determining the prognosis of destabilized or chronic stable heart failure.
2097	A. Expression	E. Associate	1	ANP	pompe's disease	We conclude that the atrial myocytes in Pompe's disease maintain ANP expression, despite severe cytoplasmic vacuolization.
2098	A. Expression	E. Associate	1	BNP	heart failure	Preliminary evidence suggests that measuring the plasma concentration of BNP may be useful in fine tuning therapy for heart failure.
2099	I. None	B. Target	1	apelin	heart failure	These results associate apelin with a positive hemodynamic profile and suggest it as an attractive target for pharmacotherapy in the setting of heart failure.
2100	A.2 Under-expression	H. Benefit	1	b-type natriuretic peptide	heart failure	Furthermore, addition of DRIs to optimal heart failure treatment resulted in further reductions in B-type natriuretic peptide.
2101	D.1 Mutation	E. Associate	0	dystrophin	x-linked dilated cardiomyopathy	The goal of this study was to perform comprehensive mutation analysis of the dystrophin gene in patients with X-linked dilated cardiomyopathy (XLCM).
2102	D.1 Mutation	E. Associate	1	NOTCH3	cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy	NOTCH3 Gene Mutation in a Chilean Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Family.
2103	D.1 Mutation	C. Cause	1	LMNA	malouf syndrome	Malouf syndrome may be caused by heterozygous mutations in the lamin A/C (LMNA) gene.
2104	D.1 Mutation	E. Associate	1	TMEM43	arrhythmogenic right ventricular cardiomyopathy	A single report has associated mutations in TMEM43 (LUMA) with a distinctive form of arrhythmogenic right ventricular cardiomyopathy (ARVC).
2105	D.1 Mutation	C. Cause	1	MYL2	hypertrophic cardiomyopathy	Heterozygous missense mutations in MYL2 are known to cause dominant hypertrophic cardiomyopathy; however, none of the parents showed signs of cardiomyopathy.
2106	A. Expression	E. Associate	0	leukemia inhibitory factor receptor	heart failure	This study was designed to determine left ventricular expression of CT-1 and its glycoprotein 130 (gp130)/leukemia inhibitory factor receptor complex in human end-stage heart failure due to ischemic and dilated cardiomyopathy.
2107	D.1 Mutation	E. Associate	1	GATA6	congenital heart disease	Mutations in GATA6 have been previously associated with pancreatic agenesis and congenital heart disease.
2108	I. None	G. Marker	1	LCN2	stroke	Our results demonstrate that LCN2 is a neurotoxic factor secreted rapidly in response to cerebral ischaemia, suggesting its potential usage as an early stroke biomarker and a novel therapeutic target to reduce stroke-reperfusion injury.
2109	D.1 Mutation	E. Associate	1	PROC	neonatal stroke	We herewith present the first case of fetal ventriculomegaly and neonatal stroke associated with heterozygous PROC mutation.
2110	A. Expression	E. Associate	1	CXCR4	myocardial infarction	Expression of the chemokine receptor chemokine C-X-C motif receptor 4 (CXCR4) plays an important role in cancer metastasis, in autoimmune diseases, and during stem cell-based repair processes after stroke and myocardial infarction.
2111	D.1 Mutation	E. Associate	1	RBM20	dilated cardiomyopathy	Genetic variation in the alternative splicing regulator RBM20 is associated with dilated cardiomyopathy.
2112	J. Inhibition	A. Treat	1	GRK2	heart failure	Among the more-interesting information gained from these models is the finding that inhibition of a particular GRK - GRK2 or beta adrenergic receptor kinase 1 (betaARK1) - is a potential novel therapeutic strategy to improve function in the setting of heart failure.
2113	J. Inhibition	A. Treat	1	thrombin	stroke	The active control trials, SPORTIF III and SPORTIF V, compared the direct thrombin inhibitor ximelagatran to warfarin, where each was given as a treatment to prevent systemic embolism and stroke in patients with atrial fibrillation.
2114	D.1 Mutation	C. Cause	1	GLA	fabry disease	Fabry disease (FD) is a lysosomal storage disorder caused by enzyme α galactosidase A (α-Gal A) deficiency due to mutations in the galactosidase alpha (GLA) gene.
2115	F.2 Methylation	C. Cause	1	cyclin dependent kinase inhibitor 2B	coronary heart disease	Elevated methylation of cyclin dependent kinase inhibitor 2B contributes to the risk of coronary heart disease in women.
2116	J. Inhibition	A. Treat	1	thrombin	stroke	Data for warfarin compared against the new oral anticoagulants (OACs) in large phase III clinical trials of stroke prevention in atrial fibrillation (AF) are now available for the oral direct thrombin inhibitor, dabigatran etexilate, in 2 doses (150 mg twice daily [BID], 110 mg BID), and the oral Factor Xa inhibitors, rivaroxaban and apixaban.
2117	J. Inhibition	H. Benefit	1	GRK2	heart failure	A role for GRK3 in the pathogenesis of heart failure (HF) has not been investigated, but inhibition of its isozyme, GRK2, has been beneficial in several HF models.
2118	A.2 Under-expression	E. Associate	1	KIR3DL3	myocardial infarction	In myocardial infarction group, the mRNA expressions of six inhibitory receptors KIR2DL2, KIR3DL3, CD94, NKG2A, KLRB1, KLRG1, and eight activating receptors KIR2DS3, KIR2DS5, NKp30, NTB-A, CRACC, CD2, CD7 and CD96 were significantly down-regulated (P<0.05) compared with both angina patients and the controls.
2119	I. None	A. Treat	1	tpa	ischemic stroke	The aim of the present study was to examine the association between admission blood pressure and outcome in ischemic stroke patients treated with tissue plasminogen activator (tPA).
2120	J. Inhibition	H. Benefit	1	SGLT2	heart failure	In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms.
2121	D.1 Mutation	C. Cause	1	TTR	cardiomyopathy	We report the first American-Caucasian family with cardiomyopathy due to the TTR Ile122 mutation.
2122	I. None	B. Target	1	GRK2	heart failure	G protein-coupled receptor kinase 2 (GRK2) is a well-established therapeutic target for the treatment of heart failure.
2123	F.2 Methylation	E. Associate	1	AGTR1	coronary heart disease	A male-specific association between AGTR1 hypermethylation and coronary heart disease.
2124	I. None	C. Cause	1	adiponectin	coronary artery disease	Type 1 plasminogen activator inhibitor (PAI-1) and adiponectin are produced by adipocytes and are important in the progression of coronary artery disease (CAD).
2125	J. Inhibition	H. Benefit	1	angiotensin II	myocardial infarction	Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade.
2126	A. Expression	E. Associate	1	BDNF	stroke	A six-hr hypothermia treatment applied 45 min after stroke prevented depression and anxiety like behaviors examined at 6 weeks after stroke, as well as restored BDNF expression and oxytocin signaling.
2127	D.1 Mutation	C. Cause	1	GLA	fabry disease	Fabry disease (FD) is a multisystemic disorder with typical neurological manifestations such as stroke and small fiber neuropathy (SFN), caused by mutations of the alpha-galactosidase A (GLA) gene.
2128	I. None	G. Marker	0	MMP1	TIA	We set out to identify novel antibody biomarkers for TIA and CI, and detected matrix metalloproteinase 1 (MMP1), chromobox homolog 1 (CBX1), and chromobox homolog 5 (CBX5) as candidate antigens using serological identification of antigens by recombinant cDNA expression cloning (SEREX) and Western blotting to confirm the presence of serum antibodies against the antigens.
2129	L.1 Up-regulation	H. Benefit	1	ADM	chronic heart failure	Its levels are elevated in various diseases including chronic heart failure (CHF) and it has been suggested that the up-regulation of ADM in cardiac disease represents a protective mechanism.
2130	N.2 Decrease activity	E. Associate	1	thrombomodulin	carotid atherosclerosis	Our findings suggest that G-33A mutation reduces the thrombomodulin promoter activity and is associated with carotid atherosclerosis in younger subjects.
2131	L.1 Up-regulation	C. Cause	1	tpa	myocardial infarction	Upregulation in the fibrosis signaling cascade proteins such as fibroblast growth factor (FGF), urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and activation of matrix metalloproteinases (MMPs) are widely associated with the development of myocardial infarction, dilated cardiomyopathy, cardiac fibrosis and heart failure.
2132	N.1 Increase activity	E. Associate	1	PRMT1	heart disease	Additionally, PRMT1 activity is aberrantly upregulated in heart disease and cancer.
2133	L.2 Down-regulation	E. Associate	1	GFAP	ischemic stroke	These results suggest that paracrine factors inhibit p38 MAPK and JNK, and most likely by regulating their downstream targets, p53 and STAT1, to promote astrocyte survival associated with GFAP downregulation after ischemic stroke in vitro.
2134	F.2 Methylation	E. Associate	1	TLR1	heart disease	Multiple genes known or plausibly linked to heart development and post-natal heart disease were found to be differentially methylated in the blood DNA of newborns with TOF including: ABCB1, PPP2R5C, TLR1, SELL, SCN3A, CREM, RUNX and LHX9.
2135	D.1 Mutation	E. Associate	0	methylenetetrahydrofolate reductase	coronary artery disease	Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease.
2136	H. Other	C. Cause	1	AXL	carotid atherosclerosis	Carotid atherosclerosis (CA) is one of the most common causes of stroke, and recent studies suggest that pathways initiated by the interaction of the plasma vitamin K-dependent protein GAS6 with the tyrosine kinase receptors TYRO3, AXL and MERTK (TAM) may have a relevant role in atherogenesis.
2137	L. Be regulated	C. Cause	1	CXCR3	myocardial infarction	CXCL10, the chemokine with potent chemotactic activity on immune cells and other non-immune cells expressing its receptor CXCR3, has been demonstrated to involve in myocardial infarction, which was resulted from hypoxia/ischemia.
2138	I. None	E. Associate	1	tissue plasminogen activator	intracerebral haemorrhage	Symptomatic intracerebral haemorrhage occurred in 5.6% of 965 patients treated with tissue plasminogen activator in the SAINT cohorts.
2139	M.2 Knock in	A. Treat	0	placental growth factor	myocardial infarction	Three weeks after myocardial infarction, Sprague-Dawley rats in heart failure received intramyocardial injections of Ringer solution (control) or autologous myoblasts, unmodified or transfected with placental growth factor expression plasmid.
2140	A.1 Over-expression	E. Associate	1	CRP	heart failure	There is abundant evidence on inflammatory mechanisms in heart failure (HF) that are used for prognostication of the disease; however, data are lacking regarding the association between elevated cytokines, C-reactive protein (CRP), and cognition in HF.
2141	D.1 Mutation	E. Associate	1	F7	coronary atherosclerosis	[Polymorphic markers Ala455Val of the THBD gene and Arg353Gln of the F7 gene and association with unfavorable outcomes of coronary atherosclerosis in patients with a history of acute ischemic heart disease].
2142	D.1 Mutation	C. Cause	0	prothrombin	cerebral thrombosis	The aim of this study was to evaluate the significance of factor V (FV) G1691A, prothrombin G20210A, methylenetetrahydrofolate reductase (MTHFR) C677T, and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotypes in development of childhood cerebral thrombosis (CT).
2143	A.1 Over-expression	E. Associate	1	PAI	coronary artery disease	A decrease in the fibrinolytic potential, mainly due to an elevation of plasminogen activator inhibitor (PAI), has been described in patients with stable coronary artery disease and a previous myocardial infarction.
2144	J. Inhibition	A. Treat	0	neprilysin	right ventricular failure	Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure.
2145	M.2 Knock in	E. Associate	0	periostin	myocardial infarction	Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction.
2146	L. Be regulated	A. Treat	1	NOX2	ischemic stroke	Several microRNAs potentially targeting NOX2 and NOX4 genes displayed altered levels in hyperglycemic rats with the tMCAO model, suggesting their regulatory roles and targeting potentials for acute ischemic stroke treatment.
2147	H. Other	A. Treat	1	thrombin	stroke	Tissue-type plasminogen activator (t-PA) that interacts with thrombin for the lysis of thrombosis is widely used to treat stroke patients in early stage.
2148	A.1 Over-expression	C. Cause	1	TNF	heart disease	Further, increased levels of CCL3 create a scenario with abundant IFNγ and TNF, associated with cardiomyocyte injury, heart dysfunction and QTc prolongation, biomarkers of severity of Chagas' heart disease.
2149	A. Expression	H. Benefit	1	zona occludens 1	cerebral infarction	In a murine middle cerebral artery occlusion (MCAO) stroke model, administration of alogliptin ameliorated cerebral infarction and disruption of brain vascular permeability, and restored expression of the endothelial tight junction proteins occludin and zona occludens 1 (ZO-1).
2150	I. None	C. Cause	1	tissue-type plasminogen activator	intracerebral hemorrhage	In comparison with tissue-type plasminogen activator treatment, although urokinase treatment (5 x 10(5) IU/kg) improved neurological functions, it was associated with a systemic fibrinolytic state and a tendency to increase the incidence of intracerebral hemorrhage.
2151	A.1 Over-expression	C. Cause	1	plasminogen activator inhibitor 1	vascular dementia	For vascular dementia, the HR risk from high levels of all three hemostatic variables (fibrinogen, factor VIII, and plasminogen activator inhibitor 1) was 2.97 (P<0.001).
2152	I. None	E. Associate	1	kallikrein	acute myocardial infarction	Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
2153	I. None	G. Marker	1	CRP	cardiovascular disease	C-reactive protein (CRP) is a well-established, sensitive marker of systemic inflammation and the risk of cardiovascular disease.
2154	A.1 Over-expression	E. Associate	1	XPO1	ischemic cardiomyopathy	Transcriptomic signature of XPO1 was highly expressed and inversely related to left ventricular function in ischemic cardiomyopathy patients.
2155	D.1 Mutation	F. None	1	HFE	cardiomyopathy	Two siblings in a pedigree without cardiomyopathy were wild-type at the HFE C282Y locus; although the brother harboured a single copy of the 187C-->G (H63D) allele, segregation analysis showed that in neither sibling was the iron-storage disease linked to MHC Class I markers on chromosome 6p.
2156	E. Pathway	C. Cause	1	HMGB1	cerebral ischaemia	Our results for the first time provide evidence that NADPH oxidase-mediated HDAC4 and HDAC5 expression contributes to cerebral ischaemia injury via HMGB1 signalling pathway, suggesting that it is important to elucidate the role of individual HDACs within the brain, and the development of HDAC inhibitors with improved specificity is required to develop effective therapeutic strategies to treat stroke.
2157	A.1 Over-expression	C. Cause	1	CCL3	heart disease	Further, increased levels of CCL3 create a scenario with abundant IFNγ and TNF, associated with cardiomyocyte injury, heart dysfunction and QTc prolongation, biomarkers of severity of Chagas' heart disease.
2158	L. Be regulated	E. Associate	0	androgen receptor	myocardial infarction	We also review the latest research on redox balance and sexual dimorphism, with particular emphasis on the role of the natural antioxidant system glutathione (GSH) in the context of myocardial infarction, and the pro- and antioxidant effects of testosterone signaling via the androgen receptor (AR) on the heart.
2159	A. Expression	C. Cause	1	titin	dilated cardiomyopathy	Changes in titin isoform expression in heart failure patients with dilated cardiomyopathy significantly impact diastolic filling by lowering myocardial stiffness.
2160	D.1 Mutation	C. Cause	1	desmin	arrhythmia	The evaluation of risk of arrhythmia in familial forms of heart failure may benefit from genetic testing, as mutations in the genes encoding lamin A/C, desmin, and cardiac troponin T are associated with increased risk of sudden cardiac death.
2161	D.5 Polymorphism	F. None	1	TLR4	coronary atherosclerosis	We found that C/C genotype of the rs3804099 polymorphism within TLR2 gene and T/T genotype of the rs4711668 polymorphism within TREM-1 gene were significantly associated with severe coronary atherosclerosis while C allele of the rs5743551 polymorphism within TLR1 gene, A/G genotype of the rs4986790 polymorphism and C/T genotype of the rs4986791 polymorphism within TLR4 gene, and C allele of the rs3775073 polymorphism within TLR6 gene were significantly associated with severe noncoronary atherosclerosis.
2162	I. None	A. Treat	1	tpa	embolic stroke	We hypothesize that administration of an anti-vWF antibody (anti-vWF-Ab) may be used as adjunctive therapy with tissue plasminogen activator (tPA) to promote behavioral improvement following an embolic stroke.
2163	A. Expression	F. None	1	c-reactive protein	coronary artery disease	This association remained significant (P = 0.03) after excluding patients with contraindications to the use of beta-blockers, and adjusting for the probability of beta-blocker therapy (propensity score) and other clinical predictors of C-reactive protein concentration, including body mass index, high-density lipoprotein cholesterol level, family history of coronary artery disease, and angiographic severity.
2164	A.1 Over-expression	H. Benefit	1	GLUT4	myocardial infarction	Trimetazidine could improve the expression of GLUT4 mRNA and protein in diabetes complicating with myocardial infarction and inhibited myocardial fibrosis.
2165	C. Activation	E. Associate	1	mineralocorticoid receptor	chronic central serous chorioretinopathy	This formulation may be of interest for the local treatment of diseases involving overactivation of the mineralocorticoid receptor in the chorioretina such as chronic central serous chorioretinopathy.
2166	H. Other	C. Cause	1	insulin	cardiovascular disease	Recent evidence strongly argues for a pathogenic role of glucocorticoids and 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in obesity and the metabolic syndrome, a cluster of risk factors for atherosclerotic cardiovascular disease and type 2 diabetes mellitus (T2DM) that includes insulin resistance (IR), dyslipidaemia, hypertension and visceral obesity.
2167	L. Be regulated	H. Benefit	0	ANXA1	stroke	We investigated whether chloral hydrate preconditioning (CH) exerts neuroprotection via regulation of ANXA1 in stroke.
2168	D.1 Mutation	C. Cause	1	HFE	coronary heart disease	Moreover, several studies have suggested that HFE mutations may be involved in several age-related chronic diseases such as Alzheimer's disease (AD) and coronary heart disease, but apparently paradoxically also with longevity.
2169	I. None	H. Benefit	1	erythropoietin	ischemic stroke	Several drugs including erythropoietin and HMG-CoA reductase inhibitors (statins), antihypertensive (angiotensin modulators), antibiotics (minocycline) and antihyperglycemic drugs (thiazolidinediones) have been proved to provide vascular protection in patients with ischemic stroke.
2170	D.1 Mutation	E. Associate	1	TGFB3	mitral valve disease	We demonstrate that TGFB3 mutations are associated with significant cardiovascular involvement, including thoracic/abdominal aortic aneurysm and dissection, and mitral valve disease.
2171	J. Inhibition	A. Treat	1	CXCR4	myocardial infarction	Applications of the CXCR4 antagonists have heralded the era of cell-based therapy and opened a potential therapeutic horizon for many unmet medical needs such as kidney injury, ischemic stroke, cancer, and myocardial infarction.
2172	D.1 Mutation	F. None	1	TMEM43	ventricular arrhythmia	The most important parameters to consider when determining arrhythmic risk include electric instability, including the frequency of premature ventricular contractions and sustained ventricular arrhythmia; proband status; extent of structural disease; cardiac syncope; male sex; the presence of multiple mutations or a mutation in TMEM43; and the patient's willingness to restrict exercise and to eliminate participation in competitive or endurance exercise.
2173	I. None	A. Treat	1	tissue-type plasminogen activator	stroke	Thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-Pa) has been found to be beneficial to the outcome of patients who had a stroke.
2174	D.5 Polymorphism	E. Associate	0	APOE	cardiovascular disease	The analyzed markers correspond to polymorphic sites in several candidate genes for cardiovascular disease including apolipopoteins and their receptors (APOA1, APOB, APOE, APOC1, APOC2, LPA, and LDLR), genes implied in the hemostasis regulation (Factor VII, alpha and beta-fibrinogen, alpha and beta platelet-integrin, tissue plasminogen activator, and plasminogen activator inhibitor-1), and the angiotensin converting enzyme gene.
2175	A.2 Under-expression	E. Associate	1	SIRT3	myocardial infarction	Compared with those in the Sham group, the ejection fraction (EF) and fractional shortening (FS) in estrogen-deficient mice were significantly lowered, the myocardial fibrosis and myocardial apoptosis were clearly aggravated, and the SIRT3 expression was decreased at 28 days after myocardial infarction.
2176	D.5 Polymorphism	E. Associate	0	cytochrome P450 2C19	stroke	The Comparison of Triflusal and Clopidogrel Effects in Secondary Prevention of Stroke Based on Cytochrome P450 2C19 Genotyping (MAESTRO) study will investigate the effect of antiplatelet agents based on CYP2C19 polymorphisms in secondary prevention of ischemic stroke.
2177	A.1 Over-expression	E. Associate	1	GRP78	heart failure	In samples from failing human hearts, extensive splicing of XBP1 was observed along with increased expression of glucose-regulated protein of 78 kDa (GRP78), a target of spliced XBP1 (sXBP1), suggesting that the UPR was induced in heart failure in humans.
2178	I. None	F. None	1	cystatin C	heart failure	We evaluate whether cystatin C is associated with left ventricular hypertrophy, diastolic dysfunction, and systolic dysfunction among 818 outpatients with coronary artery disease who were free of clinical heart failure.
2179	G. Regulate	E. Associate	1	CHUK	heart disease	Other main drug targets such as GCK, CHUK and PRKAA2 indirectly regulated heart disease through many pathways; multiple disease-associated signaling pathways interfered with various heart diseases including coronary heart disease, myocardial ischemia and myocardial hypertrophy through influencing energy metabolism, enzyme activity and gene expression.
2180	I. None	A. Treat	1	tpa	ischemic stroke	Beneficial effects of IV tissue plasminogen activator (tPA) in acute ischemic stroke are strongly time-dependent.
2181	J. Inhibition	A. Treat	0	XO	cerebral ischemia	Recently, treatment of animals with the XD and XO inhibitor allopurinol or with free radical scavengers before cerebral ischemia has been shown to reduce brain injury.
2182	A.1 Over-expression	C. Cause	1	BNP	acute heart failure	KO mice showed significantly higher mortality because of a higher incidence of acute heart failure, which was associated with diminished water and sodium excretion and with higher cardiac levels of mRNAs encoding ANP, BNP, transforming growth factor-beta1, and type I collagen.
2183	J. Inhibition	C. Cause	0	tumor necrosis factor	ischemic heart disease	Data on the risk of ischemic heart disease in relation to therapy with tumor necrosis factor (TNF) antagonists (anti-TNF) are conflicting in patients with established RA and essentially lacking in those with early RA.
2184	G. Regulate	C. Cause	1	TXNIP	ischemic stroke	Taken together, these findings indicated that TXNIP aggravated the oxidative stress injury by regulating MAPK-Nrf2 axis in ischemic stroke.
2185	J. Inhibition	A. Treat	1	angiotensin converting enzyme	acute myocardial infarction	Effect of angiotensin converting enzyme inhibition after acute myocardial infarction in patients with arterial hypertension. TRACE Study Group, Trandolapril Cardiac Event.
2186	D.1 Mutation	E. Associate	0	MTHFR	stroke	The prevalence of homozygous gene mutation for MTHFR was higher among patients with stroke than control subjects, but this difference was not statistically significant.
2187	D.2 Rearrangement	E. Associate	1	alpha-galactosidase A	fabry disease	Fabry disease: detection of gene rearrangements in the human alpha-galactosidase A gene by multiplex PCR amplification.
2188	I. None	E. Associate	1	GLN	myocardial infarction	This review describes the relation of GLN to reduced glutathione metabolism and discusses the alteration of reduced glutathione metabolism under a variety of clinical conditions such as reperfusion injury, myocardial infarction, respiratory insufficiency, cancer, diabetes, liver disease, and clinical protein catabolism.
2189	J. Inhibition	A. Treat	1	neprilysin	heart failure with reduced ejection fraction	PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction.
2190	D.1 Mutation	E. Associate	1	ATM	ataxia telangiectasia	The Ataxia Telangiectasia Mutation (ATM) gene is mutated in the rare recessive syndrome Ataxia Telangiectasia (AT), which is characterized by cerebellar degeneration, immunodeficiency, and cancer predisposition.
2191	A.1 Over-expression	E. Associate	1	CRACC	angina	In myocardial infarction group, the mRNA expressions of six inhibitory receptors KIR2DL2, KIR3DL3, CD94, NKG2A, KLRB1, KLRG1, and eight activating receptors KIR2DS3, KIR2DS5, NKp30, NTB-A, CRACC, CD2, CD7 and CD96 were significantly down-regulated (P<0.05) compared with both angina patients and the controls.
2192	N.2 Decrease activity	E. Associate	1	CK	acute myocardial infarction	In this study, the E79G point mutation was identified in two acute myocardial infarction patients with muscle CK activity deficiency.
2193	A. Expression	E. Associate	0	PIK3R1	arrhythmia	Comparative analysis of changes in the status of expression of genes in the heart of rats induced by P-11 against the simulated in vivo arrhythmia identified 16 genes that reproducibly alter the level of expression.These genes encode the extracellular matrix proteins (glypican 1, Gpc1; tissue inhibitor of metalloproteinase 2, 3, Timp2, Timp 3); intracellular signaling molecules (rho GTPase activating protein 7, Dlc1; protein tyrosine phosphatase 4a1, Ptp4a1; phosphodiesterase 4D, PDE4D; PI3-kinase regulatory subunit alpha, PIK3R1; guanine nucleotide binding protein alpha 12, Gna12) and protein of intermediate junctions (junction plakoglobin, Jup), proteins involved in glycolysis (phosphofructokinase I, Pfk1) and hemostasis (tissue plasminogen activator, Plat), plasma membrane transporters (Solute carrier family 16, member 1, Slc16a1; ATPase, Na+/K+ transporting, Atp1a), and ets.
2194	G. Regulate	A. Treat	1	SFN	heart failure	However, due to its peculiar ability in Nrf2 activation, SFN is recognized as an activator of Nrf2 and recommended as a supplementation for prevention and/or treatment of disorders like neoplasm and heart failure.
2195	A. Expression	E. Associate	1	CXCL16	myocardial infarction	The CXCL16 level was up-regulated 3 days after myocardial infarction and returned to normal level at Day 28.
2196	L. Be regulated	E. Associate	1	glutamate	cerebral ischemia	Our data suggest that adenosine released during cerebral ischemia can activate inhibitory A(1) and stimulatory A(2A) receptors that down- or up-regulate the vesicular-like component of glutamate release.
2197	H. Other	H. Benefit	1	IRS1	cardiomyopathy	These results suggested that troxerutin protects against cardiomyopathy via alterations in NF‑κB, AKT and IRS1 signaling, in a rat model of type 2 diabetes.
2198	A.2 Under-expression	E. Associate	1	fibrinogen	cerebrovascular disease	From an analysis of results it was observed that of the four prothrombotic markers used, fibrinogen and factor VII showed a generic increase in comparison to coronary heart disease and cerebrovascular disease patients; this was paralleled by significant reduction of antithrombin III; differences were even more marked and significant in acute thrombo-occlusive (infarction, stroke) compared to functional forms (angina, TIA).
2199	M.1 Knock down	C. Cause	1	EAAC1	transient cerebral ischemia	EAAC1 gene deletion alters zinc homeostasis and exacerbates neuronal injury after transient cerebral ischemia.
2200	H. Other	E. Associate	1	VDAC1	cerebral ischemia	Overall, miR-224 inhibitor may prevent neuronal cell apoptosis by targeting SPG7 3'UTR and promote interaction SPG7 with VDAC1 after cerebral ischemia.
2201	I. None	E. Associate	0	CFTR	cardiomyopathy	The presence of the cystic fibrosis transmembrane conductance regulator (CFTR) in cardiac myocardia has prompted debate regarding possible defective ion channel-induced cardiomyopathy.
2202	A.1 Over-expression	E. Associate	1	PD-L1	heart failure	The subgroup of patients with acute coronary syndrome (ACS), which includes unstable angina pectoris, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction, showed a significant reduction of FOXP3 and PD-L1 expression on Tregs compared with the subgroup of patients with chronic coronary artery disease, comprising stable angina pectoris, silent myocardial ischemia, and ischemic heart failure, and the control group.
2203	A.1 Over-expression	F. None	1	calpastatin	cerebral ischemia	VGAT cleavage was also observed after transient middle cerebral artery occlusion in mice, a cerebral ischemia model, and following intrahippocampal injection of kainate, but no effect was observed in transgenic mice overexpressing calpastatin, a calpain inhibitor.
2204	A.2 Under-expression	E. Associate	1	UCP5	embolic stroke	UCP5 expression in the lesions was higher in multiple infarction cases than in embolic stroke cases.
2205	D.5 Polymorphism	F. None	1	PDGFD	ischaemic stroke	This study suggests that the polymorphism of rs7950273 in the PDGFD gene is not associated with ischaemic stroke in the Chinese Han population.
2206	L. Be regulated	E. Associate	1	LPP	heart failure	These findings suggest that LPP is regulated by a complex interplay between NO and mechanical cues and may play a role in heart failure induced by increased hemodynamic load.
2207	A.1 Over-expression	H. Benefit	1	NCX	heart failure	In early stage of heart failure, upregulated SERCA2a and NCX protein levels may be helpful for maintaining cardiac performance.
2208	C. Activation	G. Marker	1	CPK	myocardial infarction	[Diagnosis of myocardial infarction using activated serum creatine phosphokinase (CPK)].
2209	H. Other	E. Associate	1	CXCR3	myocardial infarction	CXCR3 signalling does not critically regulate cardiac remodelling and dysfunction following myocardial infarction.
2210	I. None	A. Treat	1	tissue plasminogen activator	stroke	Rehabilitation outcomes of stroke patients treated with tissue plasminogen activator.
2211	D.1 Mutation	C. Cause	1	ATM	ataxia telangiectasia	Biallelic mutations in ataxia-telangiectasia mutated (ATM), which encodes for a protein kinase, cause ataxia telangiectasia (A-T).
2212	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	We identified patients with a primary diagnosis of acute ischemic stroke who underwent treatment with intravenous recombinant tissue plasminogen activator and studied utilization rates and clinical outcomes: discharge to long-term facility (morbidity), in-hospital death (mortality), and intracranial hemorrhage.
2213	J. Inhibition	A. Treat	1	TRPV2	cardiomyopathy	Blockade of TRPV2 is a Novel Therapy for Cardiomyopathy in Muscular Dystrophy.
2214	A.1 Over-expression	E. Associate	1	SRF	congestive heart failure	To understand the effect of transcription regulation in modulating cardiac aging, we sought to study the role of serum response factor (SRF), a key transcription factor in the heart that is normally increased with senescence and also in congestive heart failure.
2215	L.1 Up-regulation	E. Associate	1	PENK	congestive heart failure	Following ACF severe congestive heart failure developed in all rats and was accompanied by up-regulation of DOR and PENK on mRNA as well as receptor proteins representing consecutive adaptations.
2216	I. None	B. Target	1	AVPR2	heart failure	Subsequently developed drugs targeting AVPR2 not only provide potential benefit to some patients with NDI, but are now used for much more common clinical applications as diverse as nocturnal enuresis and heart failure.
2217	I. None	B. Target	1	AQP4	stroke	We also examine the potential of AQP4 as a therapeutic target in edema associated with stroke.
2218	A.1 Over-expression	H. Benefit	1	BDNF	stroke	In a rat middle cerebral artery occlusion model of stroke, we found that intracerebroventricular pretreatment or oral posttreatment with 2'-FL significantly reduced brain infarction, mitigated microglial activation, improved locomotor activity, and upregulated brain-derived neurotrophic factor (BDNF) expression.
2219	D.1 Mutation	C. Cause	1	APP	intracerebral hemorrhage	A majority of mutations within the beta-amyloid region of the amyloid precursor protein (APP) gene cause inherited forms of intracerebral hemorrhage.
2220	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Although neurologists consider intravenous tissue plasminogen activator (tPA) to be standard of care in the treatment of patients with acute ischemic stroke, its use remains contentious within the broader medical community, and particularly among emergency physicians.
2221	D.1 Mutation	C. Cause	1	TNNI3	restrictive cardiomyopathy	Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy.
2222	D.1 Mutation	C. Cause	1	ALPK3	cardiomyopathy	Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric Cardiomyopathy.
2223	M.1 Knock down	H. Benefit	1	neuronal NOS	cerebral ischemia	Neuronal NOS knockout mice are resistant to global and focal cerebral ischemia, confirming a role for neuronal NO in cellular toxicity after stroke.
2224	A.1 Over-expression	E. Associate	1	ANP	myocardial infarction	Expression of myocardial alpha-skeletal actin, beta-MHC and ANP mRNA, or collagen I and III mRNA were higher at 3 weeks after myocardial infarction.
2225	I. None	C. Cause	1	angiotensin II	hypertrophic cardiomyopathy	However, the effects of GDF11 on Angiotensin II (ANG II)-induced hypertrophic cardiomyopathy and expression of markers for volume overload and hypertrophy such as ANP, BNP and beta-MHC, as well as the relationship between GDF11 and CCL11 in hypertrophic cardiomyopathy are unclear.
2226	D.1 Mutation	C. Cause	1	KCNJ2	cardiac arrhythmia	Loss of function mutations of KCNJ2 encoding Kir2.1 result in Andersen-Tawil syndrome, a disorder characterized by periodic paralysis, cardiac arrhythmia, and dysmorphic features.
2227	M.1 Knock down	C. Cause	1	METTL3	heart failure	Finally, cardiac-specific METTL3 knockout mice exhibit morphological and functional signs of heart failure with aging and stress, showing the necessity of RNA methylation for the maintenance of cardiac homeostasis.
2228	D.1 Mutation	E. Associate	0	DSC2	cardiomyopathy	This study aimed to evaluate the prevalence and type of mutations in the major desmosomal genes, Plakophilin-2 (PKP2), Desmoglein-2 (DSG2), and Desmocollin-2 (DSC2), in arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) patients.
2229	A. Expression	E. Associate	0	AQP4	cerebral hemorrhage	To investigate the effects of different atmosphere absolutes (ATA) of high-pressure oxygen (HPO) on brain tissue water content and Aquaporin-4 (AQP4) expression in rabbits with cerebral hemorrhage.
2230	A.1 Over-expression	E. Associate	1	CCR2	ischemic stroke	Activated microglia in ischemic stroke penumbra upregulate MCP-1 and CCR2 expression in response to lysophosphatidylcholine derived from adjacent neurons and astrocytes.
2231	I. None	A. Treat	1	tissue plasminogen activator	stroke	Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
2232	I. None	G. Marker	1	brain natriuretic peptide	cardioembolic stroke	Plasma brain natriuretic peptide as a surrogate marker for cardioembolic stroke.
2233	I. None	E. Associate	1	c-reactive protein	unstable angina	A statistically significant correlation exists between homocysteine serum levels and acute phase proteins (C-reactive protein, fibrinogen) in patients with unstable angina.
2234	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Therapeutic indications for recombinant tissue plasminogen activator therapy and endovascular therapy need to be assessed for patients with hyperacute ischemic stroke.
2235	D.1 Mutation	C. Cause	1	SMC1A	hypertrophic cardiomyopathy	Hypertrophic cardiomyopathy in a girl with Cornelia de Lange syndrome due to mutation in SMC1A.
2236	L.2 Down-regulation	E. Associate	1	CASC11	coronary artery disease	LncRNA CASC11 was downregulated in coronary artery disease and inhibits transforming growth factor-β1.
2237	L.1 Up-regulation	C. Cause	1	fibronectin	arteriopathy	Upregulation of fibronectin synthesis by interleukin-1 beta in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets.
2238	I. None	B. Target	1	RNPS1	ischemic stroke	Our study suggested that RNPS1 might be a potential therapeutic target for alleviating neuronal death in ischemic stroke.
2239	F.1 Phosphorylation	E. Associate	1	PLB	heart failure	The higher level of phosphorylation of PLB observed in the left ventricle of rabbits with heart failure is associated with a higher intrinsic kinase activity of the SR.
2240	I. None	B. Target	1	GRK2	cardiovascular disease	Therefore, targeting GRK2 by different strategies emerges as a potentially relevant approach to treat cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which are frequently interconnected and present as co-morbidities.
2241	E. Pathway	H. Benefit	1	STAT3	ischemic stroke	Xuesaitong May Protect Against Ischemic Stroke by Modulating Microglial Phenotypes and Inhibiting Neuronal Cell Apoptosis via the STAT3 Signaling Pathway.
2242	I. None	G. Marker	1	LRP8	myocardial infarction	A novel molecular diagnostic marker for familial and early-onset coronary artery disease and myocardial infarction in the LRP8 gene.
2243	F.2 Methylation	E. Associate	1	SREBF1	coronary artery disease	Genetic instrumental variable analysis of alterations in methylation at one of the 83 replicated CpGs, cg11024682 (intronic to sterol regulatory element binding transcription factor 1 [SREBF1]), demonstrated links to BMI, adiposity-related traits, and coronary artery disease.
2244	J. Inhibition	A. Treat	1	SGLT2	cardiovascular disease	In the cardiovascular outcome trials (CVOT) EMPA-REG OUTCOME, TECOS and SAVOR-TIMI 53, empagliflozin [sodium/glucose cotransporter 2 (SGLT2) inhibitor], sitagliptin and saxagliptin [both dipeptidyl peptidase 4 (DPP4) inhibitors] + standard of care (SoC) were compared to SoC in patients with type 2 diabetes and established cardiovascular disease (CVD).
2245	D.1 Mutation	C. Cause	1	KIF6	myocardial infarction	Confirming and extending previous reports, carriers of the 719Arg allele of KIF6 have 34% higher risk of myocardial infarction and 24% higher risk of CHD compared with noncarriers among 25,283 women from the WHS.
2246	L. Be regulated	H. Benefit	1	TUG1	acute myocardial infarction	Targeting TUG1, upregulating miR-132-3p, or inhibiting HDAC3 may benefit AMI treatment.NEW & NOTEWORTHY Increased production of reactive oxygen species (ROS) significantly contributed to the pathogenesis of acute myocardial infarction (AMI).
2247	I. None	A. Treat	1	tissue-type plasminogen activator	acute myocardial infarction	To delineate the role of plasmin inhibitors, especially the two molecular forms of alpha 2-antiplasmin (that is, the plasminogen-binding and the nonplasminogen-binding forms), in the control of systemic effects during thrombolytic therapy, the consumption of plasmin inhibitors and the degree of fibrinogen breakdown were studied in 35 patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA) or streptokinase.
2248	J. Inhibition	A. Treat	1	thrombin	myocardial infarction	In the HORIZONS-AMI trial, patients with acute ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) who were treated with the thrombin inhibitor bivalirudin had substantially lower 30-day rates of major haemorrhagic complications and net adverse clinical events than did patients assigned to heparin plus a glycoprotein IIb/IIIa inhibitor (GPI).
2249	I. None	G. Marker	1	mb	acute myocardial infarction	The results obtained indicate that the proposed immunosensor provides good sensitivity and simple operation for detecting acute myocardial infarction with Mb as a biomarker.
2250	I. None	A. Treat	1	annexin A2	embolic stroke	In a rat focal embolic stroke model, combination therapy with tPA and recombinant annexin A2 protein at 2 h post-ischemia decreased the effective dose required for tPA by four-fold and reduced brain infarction.
2251	A. Expression	E. Associate	0	CXCR4	congenital heart disease	We performed immunohistochemistry to determine the expression of progenitor cell markers (CD133 and c-Kit) and the major homing signal pathway stromal cell-derived factor-1 and its chemokine receptor (CXCR4) in lung tissue from patients with idiopathic PAH, familial PAH, and PAH associated with congenital heart disease.
2252	F.1 Phosphorylation	E. Associate	1	NR1	cerebral ischemia	Serotonin 5-hT1A receptor activation prevents phosphorylation of NMDA receptor NR1 subunit in cerebral ischemia.
2253	I. None	F. None	1	HDAC5	stroke	Unlike HDAC4, stroke did not alter nuclear localization of HDAC5.
2254	L.1 Up-regulation	H. Benefit	1	H19	acute myocardial infarction	Atorvastatin enhances the therapeutic efficacy of mesenchymal stem cells-derived exosomes in acute myocardial infarction via up-regulating long non-coding RNA H19.
2255	I. None	E. Associate	1	ASL	stroke	This highlights the usefulness of ASL and noninvasive perfusion biomarkers in stroke diagnosis and management.
2256	I. None	G. Marker	1	FGF23	cardiovascular disease	Fibroblast growth factor 23 (FGF23) is an intensively studied biomarker at the crossroads of cardiovascular disease, heart failure (HF) and chronic kidney disease.
2257	J. Inhibition	A. Treat	1	angiotensin converting enzyme	congestive heart failure	Sampatrilat is a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) under development for the treatment of hypertension and congestive heart failure.
2258	A.1 Over-expression	E. Associate	1	fibrinogen	vascular dementia	Higher levels of: factor (F)VII (SMD: 0.93; 95% CI: 0.60-1.26), fibrinogen (SMD: 1.53; 95% CI: 1.17-1.87), prothrombin fragment 1 and 2 (SMD: 0.64; 95% CI: 0.32-0.96), plasminogen activator inhibitor (SMD: 0.68; 95% CI: 0.26-1.10), D-dimer (SMD: 2.00; 95% CI: 1.59-2.40) and von Willebrand factor (VWF) (SMD: 1.68; 95% CI: 1.30-2.06) showed modest but significant associations with vascular dementia.
2259	J. Inhibition	H. Benefit	1	angiotensin II	heart failure	Reducing the effects of Angiotensin II (using an ACE inhibitor) has been shown to reduce the incidence of coronary events, sudden death, heart failure, renal damage, and fundal changes.
2260	J. Inhibition	A. Treat	1	vasopressin	heart failure	Lixivaptan is a non-peptide, orally-active vasopressin antagonist under development by American Home Products for the potential treatment of hyponatremia associated with diseases such as heart failure, liver cirrhosis and nephrotic syndrome.
2261	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	A 35-year-old man without any known medical history presented with an acute ischemic stroke and was initially treated with intravenous tissue plasminogen activator.
2262	D.1 Mutation	E. Associate	1	MTM1	myotubular myopathy	X-linked recessive myotubular myopathy (XLMTM) is a disorder associated with mutations in the myotubularin gene (MTM1) that usually affects boys, with transmission of the mutated allele from the mother.
2263	A.2 Under-expression	H. Benefit	1	c-reactive protein	heart failure	TZDs decrease plasma insulin levels, improve endothelial function, decrease vascular inflammation, and decrease C-reactive protein levels, effects that are potentially beneficial in patients with heart failure.
2264	D.1 Mutation	C. Cause	1	dystrophin	dilated cardiomyopathy	Dilated cardiomyopathy may be the only manifestation of dystrophin gene mutation in carriers.
2265	I. None	G. Marker	1	osteopontin	cardiovascular disease	Osteopontin (OPN) is an extracellular matrix protein that plays an integral role in myocardial remodelling and has previously been shown to be a valuable biomarker in cardiovascular disease.
2266	I. None	A. Treat	1	tpa	ischemic stroke	Tissue plasminogen activator (tPA) is the only approved thrombolytic therapy for acute ischemic stroke, yet many patients do not recanalize.
2267	I. None	A. Treat	1	thymomodulin	idiopathic myocarditis	The results suggest that treatment of idiopathic myocarditis and/or idiopathic dilated cardiomyopathy with interferon-alpha or thymomodulin induces an earlier and significantly superior clinical improvement than conventional treatment alone.
2268	I. None	B. Target	1	MMP3	stroke	Our findings point out MMP3 as a potential therapeutic target in hyperglycemic stroke.
2269	J. Inhibition	A. Treat	1	thrombin	embolic stroke	The concept was primarily established to justify and enable the conduct of the Embolic Stroke of Unknown Source (ESUS)-trials, such as RESPECT-ESUS (Randomized, Double-Blind, Evaluation in Secondary Stroke Prevention Comparing the Efficacy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate versus Acetylsalicylic Acid in Patients with Embolic Stroke of Undetermined Source) and NAVIGATE-ESUS (New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus aspirin to Prevent Embolism in Embolic Stroke of Undetermined Source).
2270	G. Regulate	E. Associate	1	phosphodiesterase 4D	stroke	Phosphodiesterase 4D (PDE4D), through the regulation of cyclic AMP, modulates inflammation and other processes that affect atherosclerosis and stroke.
2271	J. Inhibition	A. Treat	1	angiotensin converting enzyme	congestive heart failure	Among individuals with Type 2 diabetes and SMI identified from Maryland Medicaid data, we evaluated patient and service utilization factors associated with the prescription of HMG-CoA reductase inhibitors ("statins") for hyperlipidemia and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for chronic kidney disease, congestive heart failure, and hypertension.
2272	I. None	A. Treat	1	t-pa	acute myocardial infarction	Three thrombolytic agents are frequently used in the United States for treating patients with acute myocardial infarction: streptokinase, alteplase (tissue plasminogen activator [t-PA]), and anistreplase (anisoylated plasminogen-streptokinase activator complex [APSAC]).
2273	G. Regulate	E. Associate	1	MBP	aortic valve disease	Heart valves were primary sites for ERE activation by BPA and MBP, and transcriptomic analysis of microdissected heart tissues showed that both chemicals targeted several molecular pathways constituting biomarkers for calcific aortic valve disease (CAVD), including extra-cellular matrix (ECM) alteration.
2274	A.1 Over-expression	H. Benefit	1	GRP75	intracerebral hemorrhage	Overexpression of GRP75 inhibits inflammation in a rat model of intracerebral hemorrhage.
2275	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours?
2276	J. Inhibition	H. Benefit	1	SGLT2	heart failure	Recent large placebo-controlled trials of sodium glucose co-transporter 2 (SGLT2) inhibitors revealed desirable effects on heart failure (HF) and renal dysfunction; however, the mechanisms underlying these effects are unknown.
2277	D.1 Mutation	E. Associate	1	desmoplakin	carvajal syndrome	Novel desmoplakin mutations in familial Carvajal syndrome.
2278	D.1 Mutation	C. Cause	1	OPA3	dilated cardiomyopathy	We demonstrated conclusive genetic and functional evidence that the nonsense mutation c.343C>T in the bovine OPA3 gene causes the late-onset dilated cardiomyopathy in Red Holstein cattle.
2279	D.1 Mutation	C. Cause	1	dynamin 2	centronuclear myopathy	A new centronuclear myopathy phenotype due to a novel dynamin 2 mutation.
2280	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Despite the risk of intracranial hemorrhage, combination therapy with intravenous recombinant tissue plasminogen activator and intraarterial mechanical thrombolysis can be effective for treatment of acute ischemic stroke.
2281	D.1 Mutation	C. Cause	1	LMNA	dilated cardiomyopathy	We had encountered the case of membranous glomerulonephritis (MGN) with dilated cardiomyopathy due to LMNA gene mutation.
2282	I. None	H. Benefit	1	GH	myocardial infarction	In conclusion, GH and IGF-I had similar beneficial effects on systolic function and peripheral resistance after experimental myocardial infarction.
2283	I. None	A. Treat	0	insulin	myocardial infarction	Evaluation of glucose--insulin--potassium therapy in myocardial infarction.
2284	I. None	A. Treat	1	tissue plasminogen activator	ischemic stroke	Furthermore, in the mid 1990s we witnessed regulatory approval of intravenous recombinant tissue plasminogen activator for administration in acute ischemic stroke.
2285	H. Other	E. Associate	1	PTEN	ischemic stroke	We speculated that ischemic stroke induced neuronal PTEN degradation, hence enhanced GABAA receptor-medicated neuronal activity inhibition which could attenuate excitotoxicity and provide neuroprotection during the acute phase after stroke, while inhibiting long-term functional recovery and contributing to vascular cognitive impairment after stroke.
2286	D.1 Mutation	E. Associate	1	methylenetetrahydrofolate reductase	cardiovascular disease	The methylenetetrahydrofolate reductase C677T gene mutation is associated with hyperhomocysteinemia, cardiovascular disease and plasma B-type natriuretic peptide levels in Korea.
2287	J. Inhibition	A. Treat	1	AT2	heart failure	The common use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-2 receptor (AT2) antagonists in heart failure increases the risk of hyperkalaemia.
2288	F.2 Methylation	G. Marker	1	PON3	cerebral infarction	PON3 promoter methylation combined with HDL and UA could be used as potential biomarkers for the diagnosis of cerebral infarction.
2289	I. None	E. Associate	1	corticotropin releasing hormone	stroke	Corticotropin releasing hormone (CRH) and its family of related peptides are involved in regulating physiologic responses to multiple stressors, including stroke.
2290	A. Expression	G. Marker	1	macrophage migration inhibitory factor	myocardial infarction	We previously showed in patients with ST-segment elevated myocardial infarction (STEMI) that admission levels of macrophage migration inhibitory factor (MIF) predict infarct size.
2291	J. Inhibition	H. Benefit	1	angiotensin converting enzyme	myocardial infarction	Chronic renin-angiotensin system blockade by angiotensin converting enzyme inhibition in patients with moderate heart failure reduces the rate of myocardial infarction and reinfarction.
2292	A.2 Under-expression	E. Associate	1	glycogen debranching enzyme	ischemic stroke	Our study has identified that glycogen breakdown is impaired during ischemic stroke, the molecular basis of which includes reduced glycogen debranching enzyme expression level together with reduced glycogen phosphorylase and PKA activity.
2293	L. Be regulated	E. Associate	1	arginine vasopressin	heart failure	Background and objectives: Plasma arginine vasopressin (P-AVP) is regulated by the non-osmotic pathway in patients with heart failure (HF) and reduced ejection fraction.
2294	A.1 Over-expression	E. Associate	1	fibrinogen	coronary heart disease	High plasma levels of fibrinogen and plasminogen activator inhibitor (PAI-1) are reported to be correlated with coronary heart disease.
2295	L. Be regulated	H. Benefit	1	phosphatase and tensin homolog	acute myocardial infarction	MicroRNA-214 Inhibits Left Ventricular Remodeling in an Acute Myocardial Infarction Rat Model by Suppressing Cellular Apoptosis via the Phosphatase and Tensin Homolog (PTEN).
2296	L. Be regulated	E. Associate	1	NDRG3	cerebral ischemia	Let-7f Regulates the Hypoxic Response in Cerebral Ischemia by Targeting NDRG3.
2297	L.1 Up-regulation	E. Associate	1	CD18	ischemic stroke	Adhesive glycoproteins CD11a and CD18 are upregulated in the leukocytes from patients with ischemic stroke and transient ischemic attacks.
2298	I. None	A. Treat	1	tissue-type plasminogen activator	acute myocardial infarction	Indeed, clinicians worldwide have successfully utilized recombinant tissue-type plasminogen activator as first-line treatment of acute myocardial infarction for almost 2 decades.
2299	I. None	G. Marker	1	troponin	acute myocardial infarction	This review highlights recent advances and remaining uncertainties regarding the use of the most relevant cardiovascular biomarkers, namely high-sensitivity cardiac troponin and natriuretic peptides in established indications such as the early diagnosis of acute myocardial infarction and heart failure.
2300	A.1 Over-expression	E. Associate	1	ACE	heart failure	Furthermore, an up-regulation of myocardial ACE gene expression has been observed in patients with heart failure.
2301	I. None	B. Target	1	MLKL	stroke	These findings suggest MLKL is a new therapeutic target for neurological pathologies like stroke.
2302	D.1 Mutation	E. Associate	1	PHACTR1	myocardial infarction	Genome-wide association studies have showed that genetic variants in phosphatase and actin regulator 1 (PHACTR1) are associated with coronary artery disease and myocardial infarction.
2303	I. None	G. Marker	1	c-reactive protein	cardiovascular disease	B-type natriuretic peptide (BNP) and C-reactive protein (CRP) have been suggested to be prognostically relevant markers in patients with cardiovascular disease.
2304	D.1 Mutation	C. Cause	1	SMYD1	hypertrophic cardiomyopathy	A de novo mutation of SMYD1 (p.F272L) is responsible for hypertrophic cardiomyopathy in a Chinese patient.
2305	I. None	A. Treat	1	tpa	ischemic stroke	Hemorrhagic transformation (HT) after acute ischemic stroke is frequently detected using magnetic resonance imaging (MRI), in particular in patients treated with tissue plasminogen activator (tPA).
2306	D.1 Mutation	C. Cause	1	desmoplakin	carvajal syndrome	Carvajal syndrome may be due to mutations in the desmocollin-2, desmoplakin, or plakophilin-2 gene.
2307	J. Inhibition	E. Associate	0	PCSK9	myocardial infarction	Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction is unknown.
2308	A.1 Over-expression	E. Associate	1	neuropeptide K	heart disease	The patients with the most pronounced right heart disease had significantly higher (p less than .01) plasma levels of the tachykinins neuropeptide K and substance P as well as higher (p less than .001) urinary excretion of the serotonin metabolite 5-hydroxyindoleacetic acid.
2309	A.2 Under-expression	E. Associate	1	p62	ischemic stroke	After ischemic stroke, both diabetic and nondiabetic mice showed enhanced autophagosome formation and autophagic flux as demonstrated by increased expression of autophagy signals Beclin 1, microtubule-associated protein light-chain II (LC3-II), and decreased autophagy-specific substrate p62.
2310	I. None	A. Treat	1	t-pa	stroke	Ischemicstroke is a leading cause of death and disability in the United States, but recent advances in treatments [i.e., endovascular thrombectomy and tissue plasminogen activator (t-PA)] that target the stroke-causing blood clot, while improving overall stroke mortality rates, have had much less of an impact on overall stroke morbidity.
2311	I. None	A. Treat	1	tissue plasminogen activator	acute myocardial infarction	We describe an autopsy case of severe intracranial hemorrhage which occurred during the infusion of tissue plasminogen activator (t-PA) for acute myocardial infarction.
2312	J. Inhibition	A. Treat	1	ACE	heart failure	Angiotensin converting enzyme (ACE) inhibitors such as lisinopril, represent the front line pharmacological treatment for heart failure, which is characterised by marked left ventricular (LV) dilatation and hypertrophy.
2313	I. None	C. Cause	1	fibrinogen	stroke	In summary, nitrotyrosinated fibrinogen would be of pathophysiological interest in ischemic stroke due to both its impact on hemostasis - it impairs thrombolysis, the main target in stroke treatments - and its neurotoxicity that would contribute to the death of the brain tissue surrounding the infarcted area.
2314	L.1 Up-regulation	H. Benefit	1	omentin	chronic heart failure	YiQiFuMai powder injection ameliorates chronic heart failure through cross-talk between adipose tissue and cardiomyocytes via up-regulation of circulating adipokine omentin.
2315	N. Activity	E. Associate	1	SOD	ischaemic stroke	Therefore, the present review summarizes experimental data supporting a neuroprotective potential of H₂O₂ in ischaemic stroke that has been principally achieved by means of pharmacological and genetic strategies that modify either the activity or the expression of the superoxide dismutase (SOD), glutathione peroxidase (GPx) and CAT enzymes, which are key regulators of H₂O₂ metabolism.
2316	J. Inhibition	A. Treat	1	angiotensin converting enzyme	heart failure	In this trial, which was performed in patients with a high cardiovascular risk, it was investigated whether angiotensin II receptor blockade with telmisartan is equally effective as angiotensin converting enzyme (ACE) inhibition with ramipril and whether the combination oftelmisartan and ramipril (dual blockade) is more effective than ACE-inhibition alone to reduce cardiovascular morbidity and mortality and hospitalization for heart failure.
2317	A.2 Under-expression	H. Benefit	1	CRP	ischemic stroke	With the effects of improving hemorheology, decreasing acute phase reactive proteins such as CRP and fibrinogen, ameliorating endothelial cell function, HELP system may be a novel therapy for acute ischemic stroke.
2318	A. Expression	E. Associate	1	BNP	acute myocardial infarction	To investigate the effect of emergency percutaneous coronary interventional (PCI) treatment on plasma brain natriuretic peptide (BNP) levels and left ventricular remodeling in patients with acute myocardial infarction (AMI).
